NZ625973B2 - Influenza virus vaccines and uses thereof - Google Patents
Influenza virus vaccines and uses thereof Download PDFInfo
- Publication number
- NZ625973B2 NZ625973B2 NZ625973A NZ62597312A NZ625973B2 NZ 625973 B2 NZ625973 B2 NZ 625973B2 NZ 625973 A NZ625973 A NZ 625973A NZ 62597312 A NZ62597312 A NZ 62597312A NZ 625973 B2 NZ625973 B2 NZ 625973B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- seq
- polypeptides
- amino acid
- influenza
- sequence
- Prior art date
Links
- 241000712461 unidentified influenza virus Species 0.000 title description 88
- 229960005486 vaccine Drugs 0.000 title description 28
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 500
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 491
- 229920001184 polypeptide Polymers 0.000 abstract description 489
- 101710154606 Hemagglutinin Proteins 0.000 abstract description 419
- 101710093908 Outer capsid protein VP4 Proteins 0.000 abstract description 419
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 abstract description 419
- 101710176177 Protein A56 Proteins 0.000 abstract description 419
- 239000000185 hemagglutinin Substances 0.000 abstract description 416
- 235000001014 amino acid Nutrition 0.000 abstract description 258
- 229940024606 amino acid Drugs 0.000 abstract description 257
- 150000001413 amino acids Chemical class 0.000 abstract description 246
- 206010022000 influenza Diseases 0.000 abstract description 111
- 125000000539 amino acid group Chemical group 0.000 abstract description 74
- 125000001433 C-terminal amino-acid group Chemical group 0.000 abstract description 36
- 210000004899 c-terminal region Anatomy 0.000 abstract description 34
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 abstract description 16
- 229910052717 sulfur Inorganic materials 0.000 abstract description 15
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 abstract description 13
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 abstract description 13
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 abstract description 12
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 abstract description 11
- 235000009582 asparagine Nutrition 0.000 abstract description 11
- 229960001230 asparagine Drugs 0.000 abstract description 11
- 241001500351 Influenzavirus A Species 0.000 abstract description 9
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 abstract description 9
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 abstract description 9
- 239000004473 Threonine Substances 0.000 abstract description 9
- 235000003704 aspartic acid Nutrition 0.000 abstract description 9
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 abstract description 9
- 235000013922 glutamic acid Nutrition 0.000 abstract description 9
- 239000004220 glutamic acid Substances 0.000 abstract description 9
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 abstract description 9
- 206010069767 H1N1 influenza Diseases 0.000 abstract description 7
- 201000010740 swine influenza Diseases 0.000 abstract description 7
- 230000035772 mutation Effects 0.000 description 173
- 210000004027 cell Anatomy 0.000 description 153
- 108090000623 proteins and genes Proteins 0.000 description 95
- 125000003275 alpha amino acid group Chemical group 0.000 description 91
- 102000004169 proteins and genes Human genes 0.000 description 83
- 235000018102 proteins Nutrition 0.000 description 82
- 238000012217 deletion Methods 0.000 description 73
- 230000037430 deletion Effects 0.000 description 73
- 230000027455 binding Effects 0.000 description 61
- 150000007523 nucleic acids Chemical class 0.000 description 56
- 102000039446 nucleic acids Human genes 0.000 description 51
- 108020004707 nucleic acids Proteins 0.000 description 51
- 239000000203 mixture Substances 0.000 description 50
- 238000003776 cleavage reaction Methods 0.000 description 49
- 230000007017 scission Effects 0.000 description 49
- 230000004927 fusion Effects 0.000 description 48
- 238000000034 method Methods 0.000 description 45
- 230000002163 immunogen Effects 0.000 description 44
- 230000003053 immunization Effects 0.000 description 42
- 238000002649 immunization Methods 0.000 description 41
- 210000002966 serum Anatomy 0.000 description 40
- 241000712431 Influenza A virus Species 0.000 description 36
- 241000700605 Viruses Species 0.000 description 35
- 230000015572 biosynthetic process Effects 0.000 description 34
- 230000014509 gene expression Effects 0.000 description 34
- 239000013638 trimer Substances 0.000 description 33
- 108020004414 DNA Proteins 0.000 description 32
- 239000013604 expression vector Substances 0.000 description 31
- 230000004044 response Effects 0.000 description 31
- 238000002474 experimental method Methods 0.000 description 30
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 29
- 201000010099 disease Diseases 0.000 description 28
- 230000003472 neutralizing effect Effects 0.000 description 28
- 241000699670 Mus sp. Species 0.000 description 27
- 208000015181 infectious disease Diseases 0.000 description 25
- 239000013598 vector Substances 0.000 description 25
- 235000018417 cysteine Nutrition 0.000 description 23
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 23
- 230000028993 immune response Effects 0.000 description 23
- 101100107610 Arabidopsis thaliana ABCF4 gene Proteins 0.000 description 21
- 101100068078 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) GCN4 gene Proteins 0.000 description 21
- 238000003556 assay Methods 0.000 description 21
- 238000013461 design Methods 0.000 description 21
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 21
- 230000003993 interaction Effects 0.000 description 20
- 230000003834 intracellular effect Effects 0.000 description 20
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 19
- 230000000694 effects Effects 0.000 description 19
- 239000000178 monomer Substances 0.000 description 19
- 238000000746 purification Methods 0.000 description 19
- 108091035707 Consensus sequence Proteins 0.000 description 18
- 238000004422 calculation algorithm Methods 0.000 description 18
- 239000012528 membrane Substances 0.000 description 18
- 230000004048 modification Effects 0.000 description 18
- 238000012986 modification Methods 0.000 description 18
- 210000003205 muscle Anatomy 0.000 description 18
- 239000000523 sample Substances 0.000 description 18
- 241000713196 Influenza B virus Species 0.000 description 17
- 230000001965 increasing effect Effects 0.000 description 17
- 238000011282 treatment Methods 0.000 description 17
- 108010076504 Protein Sorting Signals Proteins 0.000 description 16
- 238000005829 trimerization reaction Methods 0.000 description 16
- 239000002671 adjuvant Substances 0.000 description 15
- 125000001165 hydrophobic group Chemical group 0.000 description 14
- 238000002965 ELISA Methods 0.000 description 13
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 13
- 238000001514 detection method Methods 0.000 description 13
- 230000002209 hydrophobic effect Effects 0.000 description 13
- 239000013642 negative control Substances 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 208000037797 influenza A Diseases 0.000 description 12
- 238000012545 processing Methods 0.000 description 12
- 238000010186 staining Methods 0.000 description 12
- 230000009385 viral infection Effects 0.000 description 12
- 230000003612 virological effect Effects 0.000 description 12
- 230000005847 immunogenicity Effects 0.000 description 11
- 230000001939 inductive effect Effects 0.000 description 11
- 208000037798 influenza B Diseases 0.000 description 11
- 230000001404 mediated effect Effects 0.000 description 11
- 230000002265 prevention Effects 0.000 description 11
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 10
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 10
- 108091005804 Peptidases Proteins 0.000 description 10
- 239000004365 Protease Substances 0.000 description 10
- 239000000427 antigen Substances 0.000 description 10
- 238000010790 dilution Methods 0.000 description 10
- 239000012895 dilution Substances 0.000 description 10
- 229910052739 hydrogen Inorganic materials 0.000 description 10
- 238000005728 strengthening Methods 0.000 description 10
- 238000001890 transfection Methods 0.000 description 10
- 238000001262 western blot Methods 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 102000036639 antigens Human genes 0.000 description 9
- 108091007433 antigens Proteins 0.000 description 9
- 239000003125 aqueous solvent Substances 0.000 description 9
- 239000000872 buffer Substances 0.000 description 9
- 229960003971 influenza vaccine Drugs 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 230000009467 reduction Effects 0.000 description 9
- 230000003014 reinforcing effect Effects 0.000 description 9
- 238000006467 substitution reaction Methods 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 238000002560 therapeutic procedure Methods 0.000 description 9
- 239000004471 Glycine Substances 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 230000013595 glycosylation Effects 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 230000003647 oxidation Effects 0.000 description 8
- 238000007254 oxidation reaction Methods 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 125000004434 sulfur atom Chemical group 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 7
- 230000001086 cytosolic effect Effects 0.000 description 7
- 210000003527 eukaryotic cell Anatomy 0.000 description 7
- 238000006206 glycosylation reaction Methods 0.000 description 7
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 6
- 101710139363 Mini-ribonuclease 3 Proteins 0.000 description 6
- 229910000831 Steel Inorganic materials 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 210000000987 immune system Anatomy 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 6
- 229960000310 isoleucine Drugs 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 230000001932 seasonal effect Effects 0.000 description 6
- 235000020183 skimmed milk Nutrition 0.000 description 6
- 239000010959 steel Substances 0.000 description 6
- 235000006576 Althaea officinalis Nutrition 0.000 description 5
- 239000004475 Arginine Substances 0.000 description 5
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 5
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 238000005520 cutting process Methods 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 230000000069 prophylactic effect Effects 0.000 description 5
- 238000002864 sequence alignment Methods 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 230000032258 transport Effects 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 241000701022 Cytomegalovirus Species 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
- 230000004988 N-glycosylation Effects 0.000 description 4
- 108010006232 Neuraminidase Proteins 0.000 description 4
- 102000005348 Neuraminidase Human genes 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000000368 destabilizing effect Effects 0.000 description 4
- 235000014304 histidine Nutrition 0.000 description 4
- 230000009545 invasion Effects 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 230000003362 replicative effect Effects 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 239000000277 virosome Substances 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241000272527 Mareca penelope Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 230000005875 antibody response Effects 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 239000003443 antiviral agent Substances 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 230000000120 cytopathologic effect Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 238000007499 fusion processing Methods 0.000 description 3
- 238000007429 general method Methods 0.000 description 3
- 125000000487 histidyl group Chemical class [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 3
- 238000000569 multi-angle light scattering Methods 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 238000001542 size-exclusion chromatography Methods 0.000 description 3
- 239000001488 sodium phosphate Substances 0.000 description 3
- 229910000162 sodium phosphate Inorganic materials 0.000 description 3
- 230000006641 stabilisation Effects 0.000 description 3
- 238000011105 stabilization Methods 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- 241000271566 Aves Species 0.000 description 2
- 102000000844 Cell Surface Receptors Human genes 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- -1 His Chemical compound 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 102000011931 Nucleoproteins Human genes 0.000 description 2
- 108010061100 Nucleoproteins Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 102000000447 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Human genes 0.000 description 2
- 108010055817 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Proteins 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 101710172711 Structural protein Proteins 0.000 description 2
- 239000012505 Superdex™ Substances 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 108020000999 Viral RNA Proteins 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 230000027645 antigenic variation Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 2
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 2
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 2
- 238000012575 bio-layer interferometry Methods 0.000 description 2
- 239000002981 blocking agent Substances 0.000 description 2
- 238000009933 burial Methods 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000010230 functional analysis Methods 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 230000034217 membrane fusion Effects 0.000 description 2
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 238000013081 phylogenetic analysis Methods 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000001323 posttranslational effect Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000012743 protein tagging Effects 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000008174 sterile solution Substances 0.000 description 2
- 238000012916 structural analysis Methods 0.000 description 2
- 230000008093 supporting effect Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 229960000814 tetanus toxoid Drugs 0.000 description 2
- 241000701447 unidentified baculovirus Species 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 241001136792 Alle Species 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 208000031504 Asymptomatic Infections Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- QCMYYKRYFNMIEC-UHFFFAOYSA-N COP(O)=O Chemical class COP(O)=O QCMYYKRYFNMIEC-UHFFFAOYSA-N 0.000 description 1
- 108010071134 CRM197 (non-toxic variant of diphtheria toxin) Proteins 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 208000034628 Celiac artery compression syndrome Diseases 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- ONIBWKKTOPOVIA-SCSAIBSYSA-N D-Proline Chemical compound OC(=O)[C@H]1CCCN1 ONIBWKKTOPOVIA-SCSAIBSYSA-N 0.000 description 1
- 229930182820 D-proline Natural products 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 101710146739 Enterotoxin Proteins 0.000 description 1
- 108010040721 Flagellin Proteins 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 241000702620 H-1 parvovirus Species 0.000 description 1
- 238000011993 High Performance Size Exclusion Chromatography Methods 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 241001500350 Influenzavirus B Species 0.000 description 1
- 102100027612 Kallikrein-11 Human genes 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
- 208000032420 Latent Infection Diseases 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 101710141347 Major envelope glycoprotein Proteins 0.000 description 1
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000282339 Mustela Species 0.000 description 1
- 241000282341 Mustela putorius furo Species 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000712464 Orthomyxoviridae Species 0.000 description 1
- 241000845082 Panama Species 0.000 description 1
- 241000702437 Parvovirus H3 Species 0.000 description 1
- 102000002508 Peptide Elongation Factors Human genes 0.000 description 1
- 108010068204 Peptide Elongation Factors Proteins 0.000 description 1
- 108010081690 Pertussis Toxin Proteins 0.000 description 1
- 206010035737 Pneumonia viral Diseases 0.000 description 1
- 102100037935 Polyubiquitin-C Human genes 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 101710152431 Trypsin-like protease Proteins 0.000 description 1
- 102400000700 Tumor necrosis factor, membrane form Human genes 0.000 description 1
- 101800000716 Tumor necrosis factor, membrane form Proteins 0.000 description 1
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 description 1
- 108010056354 Ubiquitin C Proteins 0.000 description 1
- 206010058874 Viraemia Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000010530 Virus Neutralization Effects 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 229940001007 aluminium phosphate Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 159000000013 aluminium salts Chemical class 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 150000001720 carbohydrates Chemical group 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000000978 circular dichroism spectroscopy Methods 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 230000005860 defense response to virus Effects 0.000 description 1
- 230000022811 deglycosylation Effects 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000037771 disease arising from reactivation of latent virus Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-N dithiophosphoric acid Chemical class OP(O)(S)=S NAGJZTKCGNOGPW-UHFFFAOYSA-N 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000000147 enterotoxin Substances 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 244000309457 enveloped RNA virus Species 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 229940124582 fever medication Drugs 0.000 description 1
- 238000012395 formulation development Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000005182 global health Effects 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 244000052637 human pathogen Species 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000001597 immobilized metal affinity chromatography Methods 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000002434 immunopotentiative effect Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000002887 multiple sequence alignment Methods 0.000 description 1
- 210000004898 n-terminal fragment Anatomy 0.000 description 1
- 238000001426 native polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229940023146 nucleic acid vaccine Drugs 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 229940124641 pain reliever Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007030 peptide scission Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 150000008298 phosphoramidates Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 102220075324 rs146331571 Human genes 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 108010061514 sialic acid receptor Proteins 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940124598 therapeutic candidate Drugs 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 239000000541 tocopherol-rich extract Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 208000009421 viral pneumonia Diseases 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1018—Orthomyxoviridae, e.g. influenza virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16151—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
Abstract
Discloses an influenza hemagglutinin stem domain polypeptide comprising (a) an H1 HA1 N-terminal segment comprising the amino acids 1-52, covalently linked by a linking sequence of 0-10 amino acid residues to an H1 5 HA1 C-terminal stem segment comprising the amino acids 321-end of HAl, and (b) an influenza hemagglutinin HA2 domain, wherein the C-terminal amino acid residue of the HA1 C-terminal stem segment is glutamine (Q), serine (S), threonine (T), asparagine (N), aspartic acid (D) or glutamic acid (E), and wherein one or more of the amino acids on position 406, 409, 413 and 416 have been changed into an amino acid selected from the group consisting of S,T,N,Q,R,H,K,D,E and G, and wherein the polypeptides comprise a disulphide bridge between the amino acids of position 324 and 436; wherein the polypeptide comprises hemagglutinin stem domains from HA of the influenza virus A/ Brisbane/59/2007(SEQ ID NO:1) or A/California/04/2009 (SEQ ID NO: 159), and wherein the numbering is based on the numbering of amino acids of the H1N1 influenza strain A/Brisbane/59/2007(SEQ ID NO:1); and an influenza hemagglutinin stem domain polypeptide comprising (a) an H3 HA1 N-terminal segment comprising the amino acids 1-61, covalently linked by a linking sequence of 0-10 amino acid residues to an H3 HA1 C-terminal stem segment comprising the amino acids 323-end of HA1, and (b) an influenza hemagglutinin HA2 domain wherein the C-terminal amino acid residue of the HA1 C-terminal stem segment is glutamine (Q), serine (S), threonine (T), asparagine (N), aspartic acid (D) or glutamic acid (E) and wherein one or more of the amino acids on position 40l, 408, 411, 415 and 418 have been changed into an amino acid selected from the group consisting of S,T,N,Q,R,H,K,D,E and G, and wherein the polypeptides comprise a disulphide bridge between the amino acids of position 326 and 438; wherein the polypeptide comprises HA domains of A/Wisconsin/67/2005 (SEQ ID NO: 89) or A/Hong Kong/1/1968 (SEQ ID NO: 121), and wherein the numbering is based on the numbering of amino acids of the H3N2 influenza strain A/Wisconsin/67/2005 (SEQ ID NO: 89); wherein the sequences are as defined in the complete specification. nfluenza hemagglutinin HA2 domain, wherein the C-terminal amino acid residue of the HA1 C-terminal stem segment is glutamine (Q), serine (S), threonine (T), asparagine (N), aspartic acid (D) or glutamic acid (E), and wherein one or more of the amino acids on position 406, 409, 413 and 416 have been changed into an amino acid selected from the group consisting of S,T,N,Q,R,H,K,D,E and G, and wherein the polypeptides comprise a disulphide bridge between the amino acids of position 324 and 436; wherein the polypeptide comprises hemagglutinin stem domains from HA of the influenza virus A/ Brisbane/59/2007(SEQ ID NO:1) or A/California/04/2009 (SEQ ID NO: 159), and wherein the numbering is based on the numbering of amino acids of the H1N1 influenza strain A/Brisbane/59/2007(SEQ ID NO:1); and an influenza hemagglutinin stem domain polypeptide comprising (a) an H3 HA1 N-terminal segment comprising the amino acids 1-61, covalently linked by a linking sequence of 0-10 amino acid residues to an H3 HA1 C-terminal stem segment comprising the amino acids 323-end of HA1, and (b) an influenza hemagglutinin HA2 domain wherein the C-terminal amino acid residue of the HA1 C-terminal stem segment is glutamine (Q), serine (S), threonine (T), asparagine (N), aspartic acid (D) or glutamic acid (E) and wherein one or more of the amino acids on position 40l, 408, 411, 415 and 418 have been changed into an amino acid selected from the group consisting of S,T,N,Q,R,H,K,D,E and G, and wherein the polypeptides comprise a disulphide bridge between the amino acids of position 326 and 438; wherein the polypeptide comprises HA domains of A/Wisconsin/67/2005 (SEQ ID NO: 89) or A/Hong Kong/1/1968 (SEQ ID NO: 121), and wherein the numbering is based on the numbering of amino acids of the H3N2 influenza strain A/Wisconsin/67/2005 (SEQ ID NO: 89); wherein the sequences are as defined in the complete specification.
Description
INFLUENZA VIRUS VACCINES AND USES THEREOF
INTRODUCTION
The invention relates to the field of medicine. Provided herein are influenza
hemagglutinin stem domain polypeptides, methods for providing hemagglutinin stem
domain polypeptides, compositions comprising the same, vaccines comprising the same and
methods of their use, in particular in the detection, prevention and/or treatment of influenza.
BACKGROUND
Influenza viruses are major human pathogens, causing a respiratory disease
(commonly referred to as “influenza” or “the flu”) that ranges in severity from sub-
clinical infection to primary viral pneumonia which can result in death. The clinical
effects of infection vary with the virulence of the influenza strain and the exposure,
history, age, and immune status of the host. Every year it is estimated that approximately
1 billion people worldwide undergo infection with influenza virus, leading to severe
illness in 3-5 million cases and an estimated 300,000 to 500,000 of influenza related
deaths. The bulk of these infections can be attributed to influenza A viruses carrying H1
or H3 hemagglutinin subtypes, with a smaller contribution from Influenza B viruses, and
therefore representatives of all three are included in the seasonal vaccine. The current
immunization practice relies on early identification of circulating influenza viruses to
allow for timely production of an effective seasonal influenza vaccine. Apart from the
inherent difficulties in predicting the strains that will be dominant during the next season,
antiviral resistance and immune escape also play a role in failure of current vaccines to
prevent morbidity and mortality. In addition to this the possibility of a pandemic caused
by a highly virulent viral strain originating from animal reservoirs and reassorted to
increase human to human spread, poses a significant and realistic threat to global health.
Influenza A viruses are widely distributed in nature and can infect a variety of birds
and mammals. Influenza viruses are enveloped RNA viruses that belong to the family of
Orthomyxoviridae. Their genomes consist of eight single-stranded RNA segments that code
for 11 different proteins, one nucleoprotein (NP), three polymerase proteins (PA, PB1, and
PB2), two matrix proteins (M1 and M2), three non-structural proteins (NS1, NS2, and PB1-
F2), and two external glycoproteins: hemagglutinin (HA) and neuraminidase (NA). The
viruses are classified on the basis of differences in antigenic structure of the HA and NA
proteins, with their different combinations representing unique virus subtypes that are
further classified into specific influenza virus strains. Although all known subtypes can be
found in birds, currently circulating human influenza A subtypes are H1N1 and H3N2.
Phylogenetic analysis has demonstrated a subdivision of hemagglutinins into two main
groups: inter alia the H1, H2, H5 and H9 subtypes in phylogenetic group 1 and inter alia
the H3, H4 and H7 subtypes in phylogenetic group 2.
The influenza type B virus strains are strictly human. The antigenic variation in
HA within the influenza type B virus strains is smaller than those observed within the
type A strains. Two genetically and antigenically distinct lineages of influenza B virus
are circulating in humans, as represented by the B/Yamagata/16/88 (also referred to as
B/Yamagata) and B/Victoria/2/87 (B/Victoria) lineages (Ferguson et al., 2003). Although
the spectrum of disease caused by influenza B viruses is generally milder than that caused
by influenza A viruses, severe illness requiring hospitalization is still frequently observed
with influenza B infection.
It is known that antibodies that neutralize the influenza virus are primarily
directed against hemagglutinin (HA). Hemagglutinin or HA is a trimeric glycoprotein
that is anchored to the viral coat and has a dual function: it is responsible for binding to
the cell surface receptor sialic acid and, after uptake, it mediates the fusion of the viral
and endosomal membrane leading to release of the viral RNA in the cytosol of the cell.
HA comprises a large head domain and a smaller stem domain. Attachment to the viral
membrane is mediated by a C-terminal anchoring sequence connected to the stem
domain. The protein is post-translationally cleaved in a designated loop to yield two
polypeptides, HA1 and HA2 (the full sequence is referred to as HA0). The membrane
distal head region is mainly derived from HA1 and the membrane proximal stem region
primarily from HA2 (.
The reason that the seasonal influenza vaccine must be updated every year is the
large variability of the virus. In the hemagglutinin molecule this variation is particularly
manifested in the head domain where antigenic drift and shift have resulted in a large
number of different variants. Since this is also the area that is immunodominant, most
neutralizing antibodies are directed against this domain and act by interfering with
receptor binding. The combination of immunodominance and large variation of the head
domain also explains why infection with a particular strain does not lead to immunity to
other strains: the antibodies elicited by the first infection only recognize a limited number
of strains closely related to the virus of the primary infection.
Recently, influenza hemagglutinin stem domain polypeptides, lacking all or
substantially all of the influenza hemagglutinin globular head domain, have been
described and used to generate an immune response to one or more conserved epitopes of
the stem domain polypeptide. It is believed that epitopes of the stem domain polypeptide
are less immunogenic than the highly immunogenic regions of a globular head domain,
thus the absence of a globular head domain in the stem domain polypeptide might allow
an immune response against one or more epitopes of the stem domain polypeptide to
develop (Steel et al., 2010). Steel et al. thus have created a new molecule by deleting
amino acid residue 53 to 276 of HA1 of the A/Puerto Rico/8/1934 (H1N1) and A/Hong
Kong/1968 (H3N2) strains from the HA primary sequence, and replacing this by a short
flexible linking sequence GGGG. Vaccination of mice with the H3 HK68 construct did
not elicit antisera that were cross-reactive with group 1 HAs. In addition, as shown in the
Examples below, the stem domain polypeptides were highly unstable and did not adopt
the correct conformation as proven by the lack of binding of antibodies that were shown
to bind to conserved epitopes in the stem region.
In addition, Bommakanti et al. (2010) described an HA2 based polypeptide
comprising amino acid residues 1-172 of HA2, a 7-amino acid linker (GSAGSAG),
amino acid residues 7-46 of HA1, a 6-amino acid linker GSAGSA, followed by residues
290-321 of HA1, with the mutations V297T, I300E, Y302T and C305T in HA1. The
design was based on the sequence of H3 HA (A/Hong Kong/1968). The polypeptide did
only provide cross-protection against another influenza virus strain within the H3 subtype
(A/Phil/2/82 but not against an H1 subtype (A/PR/8/34).
There thus still exists a need for a safe and effective universal vaccine that
stimulates the production of a robust, broadly neutralizing antibody response and that offers
protection against a broad set of current and future influenza virus strains (both seasonal
and pandemic), in particular providing protection against one or more influenza A virus
subtypes within phylogenetic group 1 and/or group 2, for effective prevention and therapy
of influenza.
It is an object of the present invention to go some way towards meeting this need
and/or to provide the public with a useful choice.
SUMMARY
Described herein are influenza hemagglutinin stem domain polypeptides, methods
for providing stem domain polypeptides, compositions comprising the same, vaccines
comprising the same and methods of their use.
In a first aspect, the present invention provides an influenza hemagglutinin stem
domain polypeptide comprising (a) an Hl HAl N-terminal segment comprising the amino
acids 1-52, covalently linked by a linking sequence of 0-10 amino acid residues to an H1
HAl C-terminal stem segment comprising the amino acids 321-end of HAl, and (b) an
influenza hemagglutinin HA2 domain, wherein the C-terminal amino acid residue of the
HAl C-terminal stem segment is glutamine (Q), serine (S), threonine (T), asparagine (N),
aspartic acid (D) or glutamic acid (E), and wherein one or more of the amino acids on
position 406, 409, 413 and 416 have been changed into an amino acid selected from the
group consisting of S,T,N,Q,R,H,K,D,E and G, and wherein the polypeptides comprise a
disulphide bridge between the amino acids of position 324 and 436; wherein the
polypeptide comprises hemagglutinin stem domains from HA of the influenza virus A/
Brisbane/59/2007(SEQ ID NO:1) or A/California/04/2009 (SEQ ID NO: 159), and
wherein the numbering is based on the numbering of amino acids of the H1N1 influenza
strain A/Brisbane/59/2007(SEQ ID NO:1).
In a second aspect, the present invention provides an influenza hemagglutinin
stem domain polypeptide comprising (a) an H3 HAl N-terminal segment comprising the
amino acids 1-61, covalently linked by a linking sequence of 0-10 amino acid residues to
an H3 HA1 C-terminal stem segment comprising the amino acids 323-end of HA1, and
(b) an influenza hemagglutinin HA2 domain wherein the C-terminal amino acid residue
of the HAl C-terminal stem segment is glutamine (Q), serine (S), threonine (T),
asparagine (N), aspartic acid (D) or glutamic acid (E) and wherein one or more of the
amino acids on position 40l, 408, 411, 415 and 418 have been changed into an amino acid
selected from the group consisting of S,T,N,Q,R,H,K,D,E and G, and wherein the
polypeptides comprise a disulphide bridge between the amino acids of position 326 and
438; wherein the polypeptide comprises HA domains of A/Wisconsin/67/2005 (SEQ ID
NO: 89) or A/Hong Kong/1/1968 (SEQ ID NO: 121), and wherein the numbering is
based on the numbering of amino acids of the H3N2 influenza strain
A/Wisconsin/67/2005 (SEQ ID NO: 89).
In a third aspect, the present invention provides a nucleic acid encoding the
polypeptide of the invention.
In a fourth aspect, the present invention provides an immunogenic composition
comprising the polypeptide of the invention, and/or a nucleic acid molecule of the
invention.
In a fifth aspect, the present invention provides the use of a polypeptide of the
invention, a nucleic acid described herein, and/or an immunogenic composition of the
invention in the manufacture of a medicament.
Also described are novel immunogenic polypeptides comprising an influenza
hemagglutinin stem domain and lacking the globular head, referred to as influenza
hemagglutinin (HA) stem domain polypeptides. The polypeptides are capable of inducing
an immune response when administered to a subject, in particular a human subject. The
polypeptides described herein present conserved epitopes of the membrane proximal stem
domain HA molecule to the immune system in the absence of dominant epitopes that are
present in the membrane distal head domain. To this end, part of the primary sequence of
the HA0 protein making up the head domain is removed and the remaining amino acid
sequence is reconnected, either directly or, in some embodiments, by introducing a short
flexible linking sequence (‘linker’) to restore the continuity of the amino acid chain. The
resulting sequence is further modified by introducing specific mutations that stabilize the
native 3-dimensional structure of the remaining part of the HA0 molecule. The
immunogenic polypeptides do not comprise the full-length HA1 and/or HA2 of an
influenza virus.
The influenza hemagglutinin stem domain polypeptides are based on HA of
influenza virus strains that are generally used for human influenza vaccine production. In
particular, the polypeptides are based on HA of influenza A viruses of the H1, H5 and/or
H3 subtype.
Also described are influenza hemagglutinin stem domain polypeptides comprising
(a) an influenza hemagglutinin HA1 domain that comprises an HAl N- terminal stem
segment, covalently linked by a linking sequence of 0-50 amino acid residues to an HA1
C- terminal stem segment, and (b) an influenza hemagglutinin HA2 domain, wherein the
hemagglutinin stem domain polypeptides are resistant to protease cleavage at the junction
between HA1 and HA2,and wherein one or more amino acids in the amino acid sequence
connecting the A helix and the helix CD of HA2 have been mutated as compared to a
wild-type influenza HA2 domain. Preferably, the HA1 and HA2 domain are derived from
an influenza A virus selected from the group consisting of the H1, H5 and H3 subtype.
The polypeptides described herein comprise one or more mutations in the HA2
amino acid sequence connecting the C-terminal residue of helix A to the N-terminal residue
of helix CD, as indicated in In certain embodiments, one or more hydrophobic
amino acids in said HA2 amino acid sequence have been substituted by hydrophilic amino
acids, such as polar and/or charged amino acids, or the flexible amino acid glycine (G).
In certain embodiments, the HA1 N- terminal stem segment comprises the amino
acids 1-x of HA1, and the HA1 C- terminal stem segment comprises the amino acids y-end
(i.e. C-terminal amino acid of HA1) of HA1. Thus, in certain embodiments, the deletion in
the HA1 segment comprises the amino acid sequence from the amino acid at position x+1
up to and including the amino acid at position y-1.In certain embodiments, the polypeptides
do not comprise the signal sequence. Thus in certain embodiments, the HA1 N-terminal
segment comprises the amino acid p-x of HA1, wherein p is the first amino acid of the
mature HA molecule (e.g. p=18 in case of SEQ ID NO: 1). The skilled person will be able
to prepare the polypeptides described herein without the signal peptides (e.g. amino acids 1-
17 of SEQ ID NO: 1). In certain embodiments, the polypeptides described herein contain
the intracellular sequences of HA and the transmembrane domain. In other embodiments,
the polypeptides of the invention do not comprise the intracellular sequences of HA and the
transmembrane domain. In certain embodiments, the intracellular and transmembrane
sequence, e.g. the amino acid sequence from position (or the equivalent of) 523, 524, 525,
526, 527, 526, 528, 529, or 530 of the HA2 domain to the C-terminus of the HA2 domain
has been removed.
The polypeptides described herein do not comprise the full length HA1.
In certain embodiments, the polyppetides are glycosylated.
In certain embodiments, the immunogenic polypeptides are substantially smaller
than HA0, preferably lacking all or substantially all of the globular head of HA. Preferably,
the immunogenic polypeptides are no more than 360, preferably no more than 350, 340,
330, 320, 310, 305, 300, 295, 290, 285, 280, 275, or 270 amino acids in length. In certain
embodiments, the immunogenic polypeptides are from about 250 to about 350, preferably
from about 260 to about 340, preferably from about 270 to about 330, preferably from
about 270 to about 330 amino acids in length.
In certain embodiments, the polypeptides further comprise one or more additional
mutations in the HA1 and/or HA2 domain, as compared to the amino acid sequence of the
HA on which the HA 1 and HA2 domains are based.
Described herein are methods for providing influenza hemagglutinin stem
polypeptides, comprising the general steps of:
(a) Providing an influenza HA0 amino acid sequence;
(b) Removing the cleavage site between HA1 and HA2;
(c) Removing the amino acid sequence of the globular head domain from the HA0
sequence, in particular the amino acid sequence starting from position x+1 to y-1;
(d) Introducing one or more mutations in the amino acid sequence connecting the C-
terminal residue of helix A to the N-terminal residue of helix CD; and
(e) Introducing one or more disulfide bridges in the HA stem domain polypeptide.
Polypeptides obtainable by such methods are also described herein.
In certain embodiments the polypeptides comprise the conserved stem domain
epitopes of the group 1 cross-neutralizing antibody CR6261 (as disclosed in
WO2008/028946) and/or of the antibody CR9114 (as described below and in the co-
pending application EP 11173953.8), an antibody capable of binding to and neutralizing
both group 1 and group 2 influenza A viruses, as well as influenza B viruses. It is thus
another aspect of the invention to provide HA stem domain polypeptides, wherein said
polypeptides bind to the antibody CR6261 and/or the antibody CR9114. In an embodiment,
the polypeptides do not bind to CR8057 (described in ), a monoclonal
antibody that binds to H3 influenza viruses only. In certain embodiments, the polypeptides
bind to the antibody CR8020, CR8043 and/or CR9114. The influenza hemagglutinin stem
domain polypeptides described herein are suitable for use in immunogenic compositions
(e.g. vaccines) capable of generating immune responses against a plurality of influenza
virus A and/or B strains. In an embodiment, the influenza hemagglutinin stem domain
polypeptides are capable of generating immune responses against influenza A virus strains
of phylogenetic group 1 and/or group 2, in particular against influenza virus strains of both
phylogenetic group 1 and group 2. In an embodiment, the polypeptides are capable of
generating an immune response against homologous influenza virus strains. In an
embodiment, the polypeptides are capable of generating an immune response against
heterologous influenza virus strains of the same and.or different subtypes. In a further
embodiment, the polypeptides are capable of generating an immune response to influenza
virus strains of both phylogenetic group 1 and group 2 and influenza B virus strains.
The polypeptides described herein may be used e.g. in stand alone therapy and/or
prophylaxis and/or diagnosis of a disease or condition caused by an influenza virus, in
particular a phylogenetic group 1 or 2 influenza A virus and/or an influenza B virus, or in
combination with other prophylactic and/or therapeutic treatments, such as (existing or
future) vaccines, antiviral agents and/or monoclonal antibodies.
Also described are nucleic acid molecules encoding the influenza HA stem domain
polypeptides. Also described are vectors comprising the nucleic acids encoding the
immunogenic polypeptides.
Also described are methods for inducing an immune response in a subject, the
method comprising administering to the subject a polypeptide and/or nucleic acid
molecule described herein.
Also described are immunogenic compositions comprising a polypeptide and/or a
nucleic acid moleculedescribed herein. The immunogenic compositions described herein
can be in any form that allows for the compositions to be administered to a subject, e.g.
mice, ferrets or humans. In a specific embodiment, the immunogenic compositions are
suitable for human administration. The polypeptides, nucleic acid molecules and
compositions may be used in methods of preventing and/or treating an influenza virus
disease and/or for diagnostic purposes. The compositions may further comprise a
pharmaceutically acceptable carrier or excipient. In certain embodiments, the compositions
described herein comprise, or are administered in combination with, an adjuvant.
Also described are polypeptides, nucleic acids and/or immunogenic compositions
for use as a vaccine. The disclosure in particular relates to immunogenic polypeptides,
nucleic acids, and/or immunogenic compositions for use as a vaccine in the prevention
and/or treatment of a disease or condition caused by an influenza virus A subtype of
phylogenetic group 1 and/or 2 and/or influenza B virus.
The various embodiments and uses of the polypeptides described herein will
become clear from the following detailed description of the invention.
BRIEF DESCRIPTION OF THE FIGURES
shows a model of the HA monomer in the pre-fusion state as present in the native
trimer. HA 1 is shown in light grey, HA2 is shown in dark grey. Helix A (an important
part of the epitope of CR6261) and helix CD (part of the trimer interface) are indicated,
as is the loop connecting these secondary structure elements.
Binding of monoclonal antibodies to full length HA and HA stem domain
polypeptides according to the invention as analyzed by FACS. A: Percentage of cells
positive after staining. B: mean fluorescence intensity. H1-Full-Length (SEQ ID NO: 1),
miniHA-cl1 (SEQ ID NO: 3), miniHA-cl1+2 (SEQ ID NO: 4), miniHA-cl1+3 (SEQ ID
NO: 5), miniHA-cl1+4 (SEQ ID NO: 6) miniHA-cl1+2+3 (SEQ ID NO: 7), miniHA-
cl1+2+3+4 (SEQ ID NO: 8).
Binding of monoclonal antibodies to full length HA and HA stem domain
polypeptides as analyzed by FACS. A: Percentage of cells positive after staining. B:
mean fluorescence intensity. H1-Full-Length (SEQ ID NO: 1), miniHA (SEQ ID NO: 2),
miniHA-cl1 (SEQ ID NO: 3)
Binding of serum antibodies to HEK293F expressed full length HA and
polypeptides of the invention. A: mean fluorescence intensity. B: Percentage of cells
positive after staining. H1-FL (SEQ ID NO: 1), CL1 (SEQ ID NO: 3), CL1+2 (SEQ ID
NO: 4) and CL1+4 (SEQ ID NO: 6). cM2 is a negative control.
Binding of monoclonal antibodies to full length HA and HA stem domain
polypeptides as analyzed by FACS. Top: Percentage of cells positive after staining.
Bottom: mean fluorescence intensity. H1-Full-Length (SEQ ID NO: 1), miniHA-cl1
(SEQ ID NO: 3), H1-mini1-cl11 (SEQ ID NO: 9), H1-mini2-cl11(SEQ ID NO: 10), H1-
mini3-cl11 (SEQ ID NO: 11),, H1-mini4-cl11 (SEQ ID NO: 12), H1-mini1-cl11+5 (SEQ
ID NO: 13), H1-mini2-cl11+5 (SEQ ID NO: 14), H1 mini3-cl11+5 (SEQ ID NO: 15),
and H1-mini4-cl11+5 (SEQ ID NO: 16).
Binding of serum antibodies to the ectodomain of Full length HA from A/Brisbane
59/2007 after i.m. immunization with DNA encoding HA A/Brisbane/59/2007 (SEQ ID
NO: 1), miniHA-cluster1 (SEQ ID NO: 3), Mini2-cluster11 (SEQ ID NO: 10), Mini1-
cluster11+5 (SEQ ID NO: 13), Mini2-cluster11+5 (SEQ ID NO: 14) and cM2 (consensus
M2 sequence) or gene gun immunization of DNA encoding HA A/Brisbane/59/2007
(SEQ ID NO: 1), Mini2-cluster11+5 (SEQ ID NO: 14) and cM2 (consensus M2
sequence). Panel A: 28 days after first immunization. Panel B: after 49 days of
immunization.
Binding of monoclonal antibodies to full length HA and HA stem domain
polypeptides as analyzed by FACS. Top: Percentage of cells positive after staining.
Bottom: mean fluorescence intensity. H1-Full-Length (SEQ ID NO: 1), miniHA (SEQ ID
NO: 2), H1-mini2-cl11+5 (SEQ ID NO: 14), H1-mini2-cl1 +5 (SEQ ID NO: 48), H1-
mini2-cl1+5+6 (SEQ ID NO: 46), H1-mini2-cl11+5+6 (SEQ ID NO: 47), H1-mini2-
cl1+5+6-trim (SEQ ID NO: 44), H1-mini2-cl1+5+6-GCN4 (SEQ ID NO: 45).
Binding of monoclonal antibodies to full length HA and HA stem domain
polypeptides as analyzed by FACS. A: Percentage of cells positive after staining. B:
mean fluorescence intensity.
Binding of monoclonal antibodies to full length HA and HA stem domain
polypeptides as analyzed by FACS. A: Percentage of cells positive after staining. B:
mean fluorescence intensity.
: Expression of Hong Kong/1/1968 based constructs on the cell surface.
: SDS-PAGE (A-D) and Western Blot (E-F) analysis of the purification of
several polypeptides of the invention. For the Western Blot an antibody directed against
the his-tag was used for detection.
: Binding of monoclonal antibody CR9114 (A), CR8020 (B) and polyclonal anti-
H1 HA serum (C) to several polypeptides of the invention as detected by Elisa.
: SDS-PAGE (A) ad Western Blot (B) analysis of the glycosylation of the
polypeptides of the invention. Upon deglycosylation diffuse bands are foused at the
expected molecular weight. For the Western Blot polyclonal serum directed against H1
HA was used for detection
: SEC-MALS analysis of polypeptides of the invention. Traces are labeled with
the SEQ ID NO.
FIG 15: A: Western Blot analysis of the supernatant of cells expressing SEQ ID NO:
145. For the Western Blot an antibody directed against the his-tag was used for detection
B: Binding of monoclonal antibody CR9114 (squares) , CR6261(circles), CR8020 (up
triangles) and FI6v3 (down triangles) to SEQ ID NO: 145 as detected by Elisa.
: Elution profile of the purification of SEQ ID NO: 145 from culture supernatant
on a His trap column. The polypeptide of the invention elutes at 100 (peak A) and 200
mM (peak B) imidazole, respectively.
: A-B: Elution profile of the purification of SEQ ID NO: 145 by size exclusion
chromatography (Superdex 200). Both peak A and B contain polypeptide of the
invention. C: Native PAGE analysis of fractions from the size exclusion chromatography.
The majority of the purified protein runs at amolecular weight consistent with a
monomeric form of the protein. D: SDS PAGE analysis of fractions from the size
exclusion chromatography.
: Time course of the IgG response towards the ectodomain of the homologous full
length protein as a result of the DNA immunization schedule described in this
application.
: IgG responses at week 7 after initial immunization for individual mice against
the ectodomain of the full length hemagglutinin from the homologous strain H1N1
A/Brisbane/59/2007 (A) and the heterologous strain H1N1 A/California/07/2009 (B).
Open symbols correspond to values below the limit of detection of the assay.
: IgG responses at week 7 after initial immunization for individual mice against
the ectodomain of the full length hemagglutinin from the homologous strain H1N1
A/Brisbane/59/2007 (A), the heterologous strain H1N1 A/California/07/2009 (B) the
heterosubtypic strain H5N1 A/Vietnam/1203/2004 (C) and the heterosubtypic strain
H3N2 A/Hong Kong/1/1968 (D). Open symbols correspond to values below the limit of
detection of the assay.
: FACS assay of stem domain polypeptides based on H3 HA. Mean fluorescence
intensity (A) and % positive cells (B) are shown.
: IgG responses at week 7 after inihtial immunization for individual mice against
the full length hemagglutinin from the homologous strain H1N1 A/Brisbane/59/2007
(panel A), the heterologous strain H1N1 A/California/07/2009 (panel B) and the
heterosubtypic strain H5N1 A/Vietnam/1203/2004 (panel C). Open symbols correspond
to values below the limit of detection of the assay.
: FACS analysis of binding of mAbs CR6261, CR9114, CR8020 and CR9020, as
well as polyclonal anti-H1 serum to Full length HA and corresponding polypeptides of
the invention. Top: Mean Fluorescence Intensity. Bottom: percentage positive cells. Solid
bars represent full length proteins, striped bars represent polypeptides of the invention.
Full length HA and the corresponding polypeptide of the invention derived from that
sequence have the same background color.
: Kaplan-Meier survival curves (A), weight changes (B) and median clinical
scores (C) for the influenza challenge experiment described in example 21.
: Alignment of H1N1 sequences selected according to example 22.
: FACS assay of stem domain polypeptides based on H1 HA selected according
example 22. Mean fluorescence intensity is shown.
: Kinetics of binding of Full length H1 HA (SEQ ID NO 149) in its trimeric and
monomeric form and s-H1-mini2-cluster1+5+6-GCN4(SEQ ID NO: 145) to immobilized
monoclonal antibody CR6261 (A), CR9114 (B) and CR8020 (C) as determined by
biolayer interferometry.
: Steady state titration of the binding of s-H1-mini2-cluster1+5+6-GCN4 (SEQ ID
NO: 145) to immobilized CR6261 (A) and CR9114 (B) followed by biolayer
interferometry.
: IgG response against the ectodomain of HA from A/Hong Kong/1/1968 at day
49 as determined by ELISA. Details of the experiment are described in example 24. Open
symbols correspond to values below the limit of detection of the assay.
: Kaplan-Meier survival curves (A), weight changes (B) and median clinical
scores (C) for the influenza challenge experiment described in example 24.
: FACS assay of stem domain polypeptides based on H1 HA selected according
example 25. Mean fluorescence intensity is shown.
: IgG response after 49 days against the ectodomain of HA as determined by HA
from A/Wisconsin/67/2005 (A), A/Hong Kong/1/1968 (B) and A/Perth/16/2009 (C).
Details of the experiment are described in example 26. Open symbols correspond to
values below the limit of detection of the assay.
: IgG response after 49 days against the ectodomain of HA from A/Hong
Kong/1/1968 as determined by ELISAs. Details of the experiment are described in
example 27. Open symbols correspond to values below the limit of detection of the assay.
: FACS assay of stem domain polypeptide based on H1 HA selected according
example 28. Mean fluorescence intensity is shown.
DEFINITIONS
Definitions of terms as used in the present disclosure are given below.
An amino acid according to the disclosure can be any of the twenty naturally
occurring (or ‘standard’ amino acids) or variants thereof, such as e.g. D-proline (the D-
enantiomer of proline), or any variants that are not naturally found in proteins, such as e.g.
norleucine. The standard amino acids can be divided into several groups based on their
properties. Important factors are charge, hydrophilicity or hydrophobicity, size and
functional groups. These properties are important for protein structure and protein–protein
interactions. Some amino acids have special properties such as cysteine, that can form
covalent disulfide bonds (or disulfide bridges) to other cysteine residues, proline that forms
a cycle to the polypeptide backbone, and glycine that is more flexible than other amino
acids. Table 5 shows the abbreviations and properties of the standard amino acids.
The term "amino acid sequence identity" refers to the degree of identity or similarity
between a pair of aligned amino acid sequences, usually expressed as a percentage. Percent
identity is the percentage of amino acid residues in a candidate sequence that are identical
(i.e., the amino acid residues at a given position in the alignment are the same residue) or
similar (i.e., the amino acid substitution at a given position in the alignment is a
conservative substitution, as discussed below), to the corresponding amino acid residue in
the peptide after aligning the sequences and introducing gaps, if necessary, to achieve the
maximum percent sequence homology. Sequence homology, including percentages of
sequence identity and similarity, are determined using sequence alignment techniques well-
known in the art, such as by visual inspection and mathematical calculation, or more
preferably, the comparison is done by comparing sequence information using a computer
program. An exemplary, preferred computer program is the Genetics Computer Group
(GCG; Madison, Wis.) Wisconsin package version 10.0 program, 'GAP' (Devereux et al.
(1984)).
"Conservative substitution" refers to replacement of an amino acid of one class is
with another amino acid of the same class. In particular embodiments, a conservative
substitution does not alter the structure or function, or both, of a polypeptide. Classes of
amino acids for the purposes of conservative substitution include hydrophobic (e.g. Met,
Ala, Val, Leu), neutral hydrophilic (e.g. Cys, Ser, Thr), acidic (e.g. Asp, Glu), basic (e.g.
Asn, Gln, His, Lys, Arg), conformation disrupters (e.g. Gly, Pro) and aromatic (e.g. Trp,
Tyr, Phe).
As used herein, the terms "disease" and "disorder" are used interchangeably to
refer to a condition in a subject. In some embodiments, the condition is a viral infection,
in particular an influenza virus infection. In specific embodiments, a term "disease" refers
to the pathological state resulting from the presence of the virus in a cell or a subject, or
by the invasion of a cell or subject by the virus. In certain embodiments, the condition is a
disease in a subject, the severity of which is decreased by inducing an immune response
in the subject through the administration of an immunogenic composition.
As used herein, the term "effective amount" in the context of administering a
therapy to a subject refers to the amount of a therapy which has a prophylactic and/or
therapeutic effect(s). In certain embodiments, an "effective amount" in the context of
administration of a therapy to a subject refers to the amount of a therapy which is
sufficient to achieve a reduction or amelioration of the severity of an influenza virus
infection, disease or symptom associated therewith, such as, but not limited to a reduction
in the duration of an influenza virus infection, disease or symptom associated therewith,
the prevention of the progression of an influenza virus infection, disease or symptom
associated therewith, the prevention of the development or onset or recurrence of an
influenza virus infection, disease or symptom associated therewith, the prevention or
reduction of the spread of an influenza virus from one subject to another subject , the
reduction of hospitalization of a subject and/or hospitalization length, an increase of the
survival of a subject with an influenza virus infection or disease associated therewith,
elimination of an influenza virus infection or disease associated therewith, inhibition or
reduction of influenza virus replication, reduction of influenza virus titer; and/or
enhancement and/or improvement of the prophylactic or therapeutic effect(s) of another
therapy. In certain embodiments, the effective amount does not result in complete
protection from an influenza virus disease, but results in a lower titer or reduced number
of influenza viruses compared to an untreated subject. Benefits of a reduction in the titer,
number or total burden of influenza virus include, but are not limited to, less severe
symptoms of the infection, fewer symptoms of the infection and a reduction in the length
of the disease associated with the infection.
The term “host”, as used herein, is intended to refer to an organism or a cell into
which a vector such as a cloning vector or an expression vector has been introduced. The
organism or cell can be prokaryotic or eukaryotic. Preferably, the host comprises isolated
host cells, e.g. host cells in culture. The term “host cells” merely signifies that the cells are
modified for the (over)-expression of the polypeptides described herein. It should be
understood that the term host is intended to refer not only to the particular subject organism
or cell but to the progeny of such an organism or cell as well. Because certain modifications
may occur in succeeding generations due to either mutation or environmental influences,
such progeny may not, in fact, be identical to the parent organism or cell, but are still
included within the scope of the term “host” as used herein.
The term “included” or “including” as used herein is deemed to be followed by the
words “without limitation”.
As used herein, the term "infection" means the invasion by, multiplication and/or
presence of a virus in a cell or a subject. In one embodiment, an infection is an "active"
infection, i.e., one in which the virus is replicating in a cell or a subject. Such an infection
is characterized by the spread of the virus to other cells, tissues, and/or organs, from the
cells, tissues, and/or organs initially infected by the virus. An infection may also be a
latent infection, i.e., one in which the virus is not replicating. In certain embodiments, an
infection refers to the pathological state resulting from the presence of the virus in a cell
or a subject, or by the invasion of a cell or subject by the virus.
Influenza viruses are classified into influenza virus types: genus A, B and C. The
term “influenza virus subtype” as used herein refers to influenza A virus variants that are
characterized by combinations of the hemagglutinin (H) and neuramidase (N) viral surface
proteins. According to the present disclosure influenza virus subtypes may be referred to by
their H number, such as for example “influenza virus comprising HA of the H3 subtype”,
“influenza virus of the H3 subtype” or “H3 influenza”, or by a combination of a H number
and an N number, such as for example “influenza virus subtype H3N2” or “H3N2”. The
term “subtype” specifically includes all individual “strains”, within each subtype, which
usually result from mutations and show different pathogenic profiles, including natural
isolates as well as man-made mutants or reassortants and the like. Such strains may also be
referred to as various “isolates” of a viral subtype. Accordingly, as used herein, the terms
“strains” and “isolates” may be used interchangeably. The current nomenclature for human
influenza virus strains or isolates includes the type (genus) of virus, i.e. A, B or C, the
geographical location of the first isolation, strain number and year of isolation, usually with
the antigenic description of HA and NA given in brackets, e.g. A/Moscow/10/00 (H3N2).
Non-human strains also include the host of origin in the nomenclature. The influenza A
virus subtypes can further be classified by reference to their phylogenetic group.
Phylogenetic analysis has demonstrated a subdivision of hemagglutinins into two main
groups: inter alia the H1, H2, H5 and H9 subtypes in phylogenetic group 1 (“group 1”
influenza viruses) and inter alia the H3, H4, H7 and H10 subtypes in phylogenetic group 2
(“group 2” influenza viruses).
As used herein, the term "influenza virus disease" refers to the pathological state
resulting from the presence of an influenza virus, e.g. an influenza A or B virus in a cell
or subject or the invasion of a cell or subject by an influenza virus. In specific
embodiments, the term refers to a respiratory illness caused by an influenza virus.
As used herein, the term "nucleic acid" is intended to include DNA molecules
(e.g., cDNA or genomic DNA) and RNA molecules (e.g., mRNA) and analogs of the
DNA or RNA generated using nucleotide analogs. The nucleic acid can be single-
stranded or double-stranded. The nucleic acid molecules may be modified chemically or
biochemically or may contain non-natural or derivatized nucleotide bases, as will be
readily appreciated by those of skill in the art. Such modifications include, for example,
labels, methylation, substitution of one or more of the naturally occurring nucleotides
with an analog, internucleotide modifications such as uncharged linkages (e.g., methyl
phosphonates, phosphotriesters, phosphoramidates, carbamates, etc.), charged linkages
(e.g., phosphorothioates, phosphorodithioates, etc.), pendent moieties (e.g., polypeptides),
intercalators (e.g., acridine, psoralen, etc.), chelators, alkylators, and modified linkages
(e.g., alpha anomeric nucleic acids, etc.). A reference to a nucleic acid sequence
encompasses its complement unless otherwise specified. Thus, a reference to a nucleic
acid molecule having a particular sequence should be understood to encompass its
complementary strand, with its complementary sequence. The complementary strand is
also useful, e.g., for anti-sense therapy, hybridization probes and PCR primers.
As used herein, in certain embodiments the numbering of the amino acids in HA
is based on the numbering of amino acids in HA0 of a wild type influenza virus, e.g. the
numbering of the amino acids of the H1N1 influenza strain A/Brisbane/59/2007 (SEQ ID
NO: 1). As used in the present invention, the wording “the amino acid at position “x” in
HA” thus means the amino acid corresponding to the amino acid at position x in HA0 of
the particular wild type influenza virus, e.g. A/Brisbane/59/2007 (SEQ ID NO: 1;
wherein the amino acids of the HA2 domain have been indicated in italics). It will be
understood by the skilled person that equivalent amino acids in other influenza virus
strains and/or subtypes can be determined by multiple sequence alignment (see e.g. Table
8). Note that, in the numbering system used throughout this application 1 refers to the N-
terminal amino acid of an immature HA0 protein (SEQ ID NO: 1). The mature sequence
starts e.g. on position 18 of SEQ ID NO: 1. In certain embodiments, the numbering of the
equivalent amino acids is based on the numbering of amino acids in H3 HA0, in
particular the numbering of the amino acids of the H3N2 influenza strain
A/Wisconsin/67/2005 (SEQ ID NO: 89).The equivalent amino acids in other H3 HA
sequences can be determined by alignment. It will be understood by the skilled person
that the leader sequence (or signal sequence) that directs transport of a protein during
production (e.g. corresponding to amino acids 1-17 of SEQ ID NO: 89), generally is not
present in the final polypeptide, that is e.g. used in a vaccine. In certain embodiments, the
polypeptides described herein thus comprise an amino acid sequence without the leader
sequence, i.e. the amino acid sequence is based on the amino acid sequence of HA0
without the signal sequence.
"Polypeptide" refers to a polymer of amino acids linked by amide bonds as is
known to those of skill in the art. As used herein, the term can refer to a single
polypeptide chain linked by covalent amide bonds. The term can also refer to multiple
polypeptide chains associated by non-covalent interactions such as ionic contacts,
hydrogen bonds, Van der Waals contacts and hydrophobic contacts. Those of skill in the
art will recognize that the term includes polypeptides that have been modified, for
example by post-translational processing such as signal peptide cleavage, disulfide bond
formation, glycosylation (e.g., N-linked glycosylation), protease cleavage and lipid
modification (e.g. S-palmitoylation).
"Stem domain polypeptide" refers to a polypeptide that comprises one or more
polypeptide chains that make up a stem domain of a naturally-occurring (or wild-type)
hemagglutinin (HA). Typically, a stem domain polypeptide is a single polypeptide chain
(i.e. corresponding to the stem domain of a hemagglutinin HA0 polypeptide) or two
polypeptide chains (i.e. corresponding to the stem domain of a hemagglutinin HAl
polypeptide in association with a hemagglutinin HA2 polypeptide). According to the
disclosure, a stem domain polypeptide comprises one or more mutations as compared to
the wild-type HA molecule, in particular one or more amino acid residues of the wild-
type HA may have been substituted by other amino acids, not naturally occurring on the
corresponding position in a particular wild-type HA. Stem domain polypeptides
according to the disclosure can furthermore comprise one or more linking sequences, as
described below.
The term “vector” denotes a nucleic acid molecule into which a second nucleic
acid molecule can be inserted for introduction into a host where it will be replicated, and
in some cases expressed. In other words, a vector is capable of transporting a nucleic acid
molecule to which it has been linked. Cloning as well as expression vectors are
contemplated by the term “vector”, as used herein. Vectors include, but are not limited to,
plasmids, cosmids, bacterial artificial chromosomes (BAC) and yeast artificial
chromosomes (YAC) and vectors derived from bacteriophages or plant or animal
(including human) viruses. Vectors comprise an origin of replication recognized by the
proposed host and in case of expression vectors, promoter and other regulatory regions
recognized by the host. Certain vectors are capable of autonomous replication in a host
into which they are introduced (e.g., vectors having a bacterial origin of replication can
replicate in bacteria). Other vectors can be integrated into the genome of a host upon
introduction into the host, and thereby are replicated along with the host genome.
As used herein, the term "wild-type" in the context of a virus refers to influenza viruses
that are prevalent, circulating naturally and producing typical outbreaks of disease.
The term “comprising” as used in this specification and claims means “consisting
at least in part of”. When interpreting statements in this specification, and claims which
include the term “comprising”, it is to be understood that other features that are additional
to the features prefaced by this term in each statement or claim may also be present.
Related terms such as “comprise” and “comprised” are to be interpreted in similar
manner.
DETAILED DESCRIPTION
Influenza viruses have a significant impact on global public health, causing millions
of cases of severe illness each year, thousands of deaths, and considerable economic losses.
Current trivalent influenza vaccines elicit a potent neutralizing antibody response to the
vaccine strains and closely related isolates, but rarely extend to more diverged strains
within a subtype or to other subtypes. In addition, selection of the appropriate vaccine
strains presents many challenges and frequently results in sub-optimal protection.
Furthermore, predicting the subtype of the next pandemic virus, including when and where
it will arise, is currently impossible.
Hemagglutinin (HA) is the major envelope glycoprotein from influenza A viruses
which is the major target of neutralizing antibodies. Hemagglutinin has two main functions
during the entry process. First, hemagglutinin mediates attachment of the virus to the
surface of target cells through interactions with sialic acid receptors. Second, after
endocytosis of the virus, hemagglutinin subsequently triggers the fusion of the viral and
endosomal membranes to release its genome into the cytoplasm of the target cell. HA
comprises a large ectodomain of ~500 amino acids that is cleaved by host- derived enzymes
to generate 2 polypeptides that remain linked by a disulfide bond. The majority of the N-
terminal fragment (HA1, 320-330 amino acids) forms a membrane-distal globular domain
that contains the receptor-binding site and most determinants recognized by virus-
neutralizing antibodies. The smaller C-terminal portion (HA2, ~180 amino acids) forms a
stem-like structure that anchors the globular domain to the cellular or viral membrane. The
degree of sequence homology between subtypes is smaller in the HA1 polypeptides (34% -
59% homology between subtypes) than in the HA2 polypeptide (51%- 80% homology).
The most conserved region is the sequence around the cleavage site, particularly the HA2
N- terminal 23 amino acids, which is conserved among all influenza A virus subtypes
(Lorieau et al., 2010). Part of this region is exposed as a surface loop in the HA precursor
molecule (HA0), but becomes inaccessible when HA0 is cleaved into HA1 and HA2.
Most neutralizing antibodies bind to the loops that surround the receptor binding site
and interfere with receptor binding and attachment. Since these loops are highly variable,
most antibodies targeting these regions are strain-specific, explaining why current vaccines
elicit such limited, strain-specific immunity. Recently, however, fully human monoclonal
antibodies against influenza virus hemagglutinin with broad cross-neutralizing potency
were generated. Functional and structural analysis have revealed that these antibodies
interfere with the membrane fusion process and are directed against highly conserved
epitopes in the stem domain of the influenza HA protein (Throsby et al., 2008; Ekiert et al.
2009, , ).
According to the present disclosure new HA stem domain polypeptides have been
designed containing these epitopes in order to create a universal epitope-based vaccine
inducing protection against a broad range of influenza strains. Essentially, the highly
variable and immunodominant part, i.e. the head domain, is first removed from the full
length HA molecule to create a stem domain polypeptide, also called mini-HA. In this
way the immune response will be redirected towards the stem domain where the epitopes
for the broadly neutralizing antibodies are located. The broadly neutralizing antibodies
mentioned above were used to probe the correct folding of the newly created molecules,
and to confirm the presence of the neutralizing epitopes.
The stem domain polypeptides described herein are capable of presenting the
conserved epitopes of the membrane proximal stem domain HA molecule to the immune
system in the absence of dominant epitopes that are present in the membrane distal head
domain. To this end, part of the primary sequence of the HA0 protein making up the head
domain is removed and reconnected, either directly or, in some embodiments, by
introducing a short flexible linking sequence (‘linker’) to restore the continuity of the
polypeptide chain. The resulting polypeptide sequence is further modified by introducing
specific mutations that stabilize the native 3-dimensional structure of the remaining part
of the HA0 molecule.
In a first aspect, the present invention thus provides an influenza hemagglutinin
stem domain polypeptide comprising (a) an Hl HAl N-terminal segment comprising the
amino acids 1-52, covalently linked by a linking sequence of 0-10 amino acid residues to an
H1 HAl C-terminal stem segment comprising the amino acids 321-end of HAl, and (b) an
influenza hemagglutinin HA2 domain, wherein the C-terminal amino acid residue of the
HAl C-terminal stem segment is glutamine (Q), serine (S), threonine (T), asparagine (N),
aspartic acid (D) or glutamic acid (E), and wherein one or more of the amino acids on
position 406, 409, 413 and 416 have been changed into an amino acid selected from the
group consisting of S,T,N,Q,R,H,K,D,E and G, and wherein the polypeptides comprise a
disulphide bridge between the amino acids of position 324 and 436; wherein the
polypeptide comprises hemagglutinin stem domains from HA of the influenza virus A/
Brisbane/59/2007(SEQ ID NO:1) or A/California/04/2009 (SEQ ID NO: 159), and wherein
the numbering is based on the numbering of amino acids of the H1N1 influenza strain
A/Brisbane/59/2007(SEQ ID NO:1).
In a second aspect, the present invention provides an influenza hemagglutinin stem
domain polypeptide comprising (a) an H3 HAl N-terminal segment comprising the amino
acids 1-61, covalently linked by a linking sequence of 0-10 amino acid residues to an H3
HA1 C-terminal stem segment comprising the amino acids 323-end of HA1, and (b) an
influenza hemagglutinin HA2 domain wherein the C-terminal amino acid residue of the
HAl C-terminal stem segment is glutamine (Q), serine (S), threonine (T), asparagine (N),
aspartic acid (D) or glutamic acid (E) and wherein one or more of the amino acids on
position 40l, 408, 411, 415 and 418 have been changed into an amino acid selected from the
group consisting of S,T,N,Q,R,H,K,D,E and G, and wherein the polypeptides comprise a
disulphide bridge between the amino acids of position 326 and 438; wherein the
polypeptide comprises HA domains of A/Wisconsin/67/2005 (SEQ ID NO: 89) or A/Hong
Kong/1/1968 (SEQ ID NO: 121), and wherein the numbering is based on the numbering of
amino acids of the H3N2 influenza strain A/Wisconsin/67/2005 (SEQ ID NO: 89).
Also described are polypeptides comprising (a) an influenza hemagglutinin HA1
domain that comprises an HA1 N- terminal stem segment, covalently linked by a linking
sequence of 0-50 amino acid residues to an HA1 C- terminal stem segment, and (b) an
influenza hemagglutinin HA2 domain, wherein on or more amino acids in the HA2 domain
have been mutated. In the polypeptides described herein, the HA2 domain thus comprises
one or more mutations as compared to the HA2 domain of a wild-type influenza
hemagglutinin on which the HA stem domain polypeptide is based.
The influenza hemagglutinin stem domain polypeptides are based on HA of
influenza A virus subtypes that are generally used in human influenza virus vaccines. In
preferred embodiments, the stem domain polypeptides are based on HA of an influenza
virus comprising HA of the H1, H5 and/or H3 subtype.
Also described are influenza hemagglutinin stem domain polypeptides comprising
(a) an influenza hemagglutinin HA1 domain that comprises an HAl N- terminal stem
segment, covalently linked by a linking sequence of 0-50 amino acid residues to an HA1
C- terminal stem segment, and (b) an influenza hemagglutinin HA2 domain, wherein the
hemagglutinin stem domain polypeptide is resistant to protease cleavage at the junction
between HA1 and HA2,and wherein one or more amino acids in the amino acid sequence
connecting the A helix and the helix CD of HA2 have been mutated as compared to a
wild-type influenza HA2 domain. Preferably, the HA1 and HA2 domain are derived from
an influenza A virus subtype selected from the group consisting of H1, H5 and H3.
The polypeptides described herein thus comprise one or more mutations in the HA2
amino acid sequence connecting the C-terminal residue of helix A to the N-terminal residue
of helix CD, as indicated in In certain embodiments, one or more hydrophobic
amino acids in said HA2 amino acid sequence have been substituted by hydrophilic amino
acids, such as polar and/or charged amino acids, or the flexible amino acid glycine (G).
The polypeptides described herein do not comprise the full length HA1.
In certain embodiments, the immunogenic polypeptides are substantially smaller
than HA0, preferably lacking all or substantially all of the globular head of HA. Preferably,
the immunogenic polypeptides are no more than 360, preferably no more than 350, 340,
330, 320, 310, 305, 300, 295, 290, 285, 280, 275, or 270 amino acids in length. In certain
embodiments, the immunogenic polypeptides are from about 250 to about 350, preferably
from about 260 to about 340, preferably from about 270 to about 330, preferably from
about 270 to about 330 amino acids in length.
In certain embodiments, the polypeptides further comprise one or more additional
mutations in the HA1 and/or HA2 domain, as compared to the amino acid sequence of the
HA of which the HA 1 and HA2 domains are derived.Thus, the stability of the stem
polypeptides is further increased.
According to the disclosure, the “HA1 N-terminal segment” refers to a polypeptide
segment that corresponds to the amino-terminal portion of the HA1 domain of an influenza
hemagglutinin (HA) molecule. In certain embodiments, the HA1 N-terminal polypeptide
segment comprises the amino acids from position 1 to position x of the HA1 domain,
wherein amino acid on position x is an amino acid residue within HA1. The term “HA1 C-
terminal segment” refers to a polypeptide segment that corresponds to the carboxy-terminal
portion of an influenza hemagglutinin HA1 domain. In certain embodiments, the HA1 C-
terminal polypeptide segment comprises the amino acids from position y to and including
the C-terminal amino acid of the HA1 domain, wherein the amino acid on position y is an
amino acid residue within HA1. According to the disclosure y is greater than x, thus a
segment of the HA1 domain between the HA1 N-terminal segment and the HA1 C-terminal
segment, i.e. between the amino acid on position x and the amino acid on position y of
HA1, has been deleted, and in some embodiments, replaced by a linking sequence.
In certain embodiments the HA1 N- terminal stem segment comprises the amino
acids 1-x of HA1, and the HA1 C- terminal stem segment comprises the amino acids y-end
of HA1. Thus, in certain embodiments, the deletion in the HA1 segment comprises the
amino acid sequence from the amino acid at position x+1 up to and including the amino
acid at position y-1.
In certain embodiments, the polypeptides do not comprise the signal sequence. Thus
in certain embodiments, the HA1 N-terminal segment comprises the amino acid p-x of
HA1, wherein p is the first amino acid of the mature HA molecule (e.g. p=18 in case of
SEQ ID NO: 1). The skilled person will be able to prepare the polypeptides described
herein without the signal peptides (e.g. amino acids 1-17 of SEQ ID NO: 1).In certain
embodiments, the polypeptides described herein contain the intracellular sequences of HA
and the transmembrane domain. In other embodiments, the polypeptides of the invention do
not comprise the intracellular sequences of HA and the transmembrane domain. In certain
embodiments, the intracellular and transmembrane sequence, e.g. the amino acid sequence
from position (or the equivalent of) 523, 524, 525, 526, 527, 526, 528, 529, or 530 of the
HA2 domain to the C-terminus of the HA2 domain has been removed.
According to the disclosure, the hemagglutinin stem domain polypeptides are
resistant to protease cleavage at the junction between HA1 and HA2. It is known to those
of skill in the art that the Arg (R) - Gly (G) sequence spanning HA1 and HA2 is a
recognition site for trypsin and trypsin-like proteases and is typically cleaved for
hemagglutinin activation. Since the HA stem domain polypeptides described herein
should not be activated, the influenza hemagglutinin stem domain polypeptides described
herein are resistant to protease cleavage. According to the disclosure, thus the protease
cleavage site is removed or the protease site spanning HA1 and HA2 is mutated to a
sequence that is resistant to protease cleavage.
In certain embodiments, the C- terminal amino acid residue of the HA1 C-
terminal stem segment is any amino acid other than arginine (R) or lysine (K). In certain
embodiments, the HA1 C-terminal amino acid is glutamine (Q), serine (S), threonine (T),
asparagine (N), aspartic acid (D) or glutamic acid (E). In certain embodiments, the C-
terminal amino acid residue of the HA1 C-terminal stem segment is glutamine (Q).
In certain embodiments, the polypeptides are glycosylated.
The influenza hemagglutinin stem domain polypeptides may be based on HA of any
naturally occurring influenza A hemagglutinin virus of a subtype that is used in human
influenza vaccines. Influenza A virus subtypes that are generally used in influenza vaccines
are influenza A viruses of the H1, H3 or H5 subtypes. With “based on” it is meant that the
N-terminal segments, and/or C-terminal segments of the HA1 domain and/or the HA2
domains have at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% amino
acid sequence identity with the corresponding N-terminal and/or C-terminal segments of
HA1 and/or the HA2 domains of any naturally occurring influenza hemagglutinin of a H1,
H3 and/or H5 subtype known to those of skill in the art or later discovered. In certain
embodiments, the influenza hemagglutinin stem domain polypeptides are based on an
influenza hemagglutinin of a group 1 influenza A virus. In certain embodiments, the
influenza hemagglutinin stem domain polypeptides are based on an influenza
hemagglutinin of a group 2 influenza A virus. In some embodiments, the influenza
hemagglutinin stem domain polypeptide is a hybrid or chimeric polypeptide that comprises
or consists of segments and/or domains from a plurality of influenza strains or subtypes.
For example, an influenza hemagglutinin stem domain polypeptide may comprise HA1 N-
terminal and HA1 C- terminal stem segments and/or HA2 domains from different influenza
A virus HA subtypes.
In certain embodiments, the polypeptides are based on H1 HA. In a particular
embodiment, the polypeptides comprise hemagglutinin stem domains from or based on HA
of an influenza A virus comprising HA of the H1 subtype, such as from the influenza virus
A/Brisbane/59/2007 (H1N1) (SEQ ID NO:1), as described below. It will be understood by
the skilled person that also other influenza A viruses comprising HA of the H1 subtype may
be used according to the disclosure. In certain embodiments, the polypeptides comprise
hemagglutinin stem domains based on HA of an influenza A H1 virus selected from Table
In certain embodiments, the polypeptides comprise a HA1 N-terminal polypeptide
segment comprising the amino acids from position 1 to position x of the H1 HA1 domain,
wherein x is any amino acid between the amino acid on position 46 and the amino acid on
position 60, such as the amino acid on position 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58,
or 59, preferably wherein x is 52, 53, 55 or 59. Preferably, the polypeptides comprise a
HA1 N-terminal segment without the signal sequence, i.e. a HA1 N-terminal segment
comprising the amino acids from position 18 (e.g. for H1 HA, such as SEQ ID NO: 1), or
an equivalent position in other H1 influenza virus strains, to position x of the HA1 domain.
In certain embodiments, the HA1 N-terminal segment thus comprises the amino acids from
position p (wherein p=18 for H1 HA in SEQ ID NO: 1 or an equivalent position on other
H1 HAs), to position x of the HA1 domain.
In certain embodiments, the HA1 C-terminal polypeptide segment comprises the
amino acids from position y to and including the C-terminal amino acid of the H1 HA1
domain, wherein y is any amino acid between the amino acid on positions 290 and the
amino acid on position 325 of H1 HA1, preferably wherein y is 291, 303, 318, or
321.According to the disclosure, the HA2 domain comprises one or more mutations in the
HA2 amino acid sequence connecting the C-terminal residue of helix A to the N-terminal
residue of helix CD (. In certain embodiments, one or more hydrophobic amino
acids in said HA2 amino acid sequence have been substituted by hydrophilic amino acids,
such as polar and/or charged amino acids. In certain embodiments (e.g. for H1 HA, such
as SEQ ID NO: 1), the HA2 amino acid sequence connecting the C-terminal residue of
helix A and the N-terminal residue of helix CD comprises the amino acid sequence
between residues 402-418 of influenza HA2. In certain embodiments, the HA2 amino
acid sequence connecting the C-terminal residue of helix A and the N-terminal residue of
helix CD comprises the amino acid sequence MNTQFTAVGKEFN(H/K)LE(K/R) (SEQ
ID NO: 17).
In certain embodiments, x is 59 and y is 291 .
In certain embodiments, x is 52 and y is 321.
In certain embodiments x is 53 and y is 303.
In certain embodiments x is 55 and y is 318.
In an embodiment, the amino acid sequence connecting the C-terminal residue of
helix A to the N-terminal residue of helix CD corresponds to the amino acid sequence
between the amino acid on position 402 and the amino acid on position 418 of HA2 of
SEQ ID NO: 1, wherein the polypeptides comprise one or more mutations in the amino
acid sequence spanning from amino acid 402 to 418 of SEQ ID NO: 1. The amino acid
sequence between residue 402-418 of influenza HA of serotype H1 comprises the amino
acid sequence MNTQFTAVGKEFN(H/K)LE(K/R) (SEQ ID NO: 17). In certain
embodiments, the amino acid sequence between residue 402-418 of influenza HA of
serotype H1 comprises the amino acid sequence
MNTQX TAX GKEX N(H/K)X E(K/R).
1 2 3 4
In certain embodiments the polypeptides thus comprise one or more of the
mutations in the H1 HA2 domain as indicated in Table 6. In certain embodiments, one or
more of the amino acids on position 406, 409, 413 and 416, i.e one or more of the amino
acids X , X , X and X have been mutated (numbering refers to SEQ ID NO: 1). In
1 2 3 4
certain embodiments, the amino acid on position 406, i.e. X has been changed into an
amino acid selected from the group consisting of S, T, N, Q, R, H, K, D, E, and G,
preferably S. In certain embodiments, the amino acid on position 409, i.e. X has been
changed into an amino acid selected from the group consisting of S, T, N, Q, R, H, K, D,
E, and G, preferably T, Q or G. In certain embodiments, the amino acid on position 413,
i.e. X3 has been changed into an amino acid selected from the group consisting of S, T,
N, Q, R, H, K, D, E, G, preferably S. In certain embodiments, the amino acid on position
416, i.e. X has been changed into an amino acid selected from the group consisting of S,
T, N, Q, R, H, K, D, E, G, preferably S. Combinations of these mutations are also
possible.
In certain embodiments, the HA1 N- terminal stem segment comprises the amino
acid residues 1-59 of HA1, and the HA1 C- terminal stem segment comprises the amino
acid residues 291-343 of HA1 wherein the amino acid on position 343, i.e. R343, has
been mutated and is an amino acid other than R, preferably glutamine (Q). In certain
embodiments, the HA1 N-terminal segment consists of the amino acid residues 1-59 of
HA1 and the HA1 C-terminal segment consists of the amino acid residues 291-343 of
HA1. It is noted that the numbering of the amino acids is based on the numbering of
amino acids in H1 HA0, in particular the numbering of the amino acids of the H1N1
influenza strain A/Brisbane/59/2007 (SEQ ID NO: 1). It is noted that since HA sequences
of different influenza subtypes/strains may have insertions or deletions in the head region
compared to each other the numbering is not always the same. The skilled person will be
able to determine the equivalent amino acid positions in HA sequences of different
influenza virus strains and/or subtypes by sequence alignment.
In certain embodiments, the HA1 N-terminal polypeptide segment does not
comprise the signal sequence. In preferred embodiments the HA1 N-terminal segment
comprises the amino acids from position 18 to position 59 of the HA1 domain. In certain
embodiments, the HA1 N-terminal segment consistis of the amino acids 18-59 of the
HA1 domain.
In some embodiments, the polypeptides described herein comprise one or more
further mutations, i.e. amino acid substitutions, in the HA1 domain and/or the HA2
domain. In certain embodiments, the HA1 domain thus further comprises one or more of
the following mutations: L58T, V314T and I316T. It is again noted that the numbering of
the amino acids is based on the numbering of amino acids in H1 HA0, in particular the
numbering of the amino acids of the H1N1 influenza strain A/Brisbane/59/2007 (SEQ ID
NO: 1). The skilled person will be able to determine the equivalent amino acids in HA of
other influenza H1 virusesand thus will be able to determine equivalent mutations.
In a specific embodiment, the HA1 domain comprises the mutations L58T,
V314T, and I316T, and the HA2 domain comprises one or more of the following
mutations: F406S, V409T, and L416S.
In certain embodiments, the HA1 domain further comprises the mutation K321C
and/or the HA2 domain further comprises one or more of the following mutations:
Q405C, F413C, E421C, and Y502S.
In a specific embodiment, the HA1 domain comprises the mutations L58T,
V314T, I316T, and K321C and the HA2 domain comprises the mutations: Q405C,
F406S, V409T, and L416S.
In a specific embodiment, the HA1 domain comprises the mutations L58T,
V314T, and I316T, and the HA2 domain comprises the mutations: F406S, V409T,
F413C, L416S and E421C.
In a specific embodiment, the HA1 domain comprises the mutations L58T,
V314T, and I316T, and the HA2 domain comprises the mutations: F406S, V409T,
L416S, and Y502S.
In a specific embodiment, the HA1 domain comprises the mutations L58T,
V314T, I316T, and K321C and the HA2 domain comprises the mutations: Q405C,
F406S, V409T, F413C, L416S and E421C.
In a specific embodiment, the HA1 domain comprises the mutations L58T,
V314T, I316T, and K321C and the HA2 domain comprises the mutations: Q405C,
F406S, V409T, F413C, L416S, E421C and Y502S.
In other embodiments, the HA2 domain further comprises one or more of the
mutations M420I and V421I, or equivalent mutations.
In a specific embodiment, the HA1 domain comprises the mutations L58T,
V314T, and I316T, and the HA2 domain comprises one or more of the following
mutations: F406S, V409T, L416S, M420I and V421I.
In certain embodiments, the HA1 N- terminal stem segment comprises the amino
acid residues 1-52 of HA1, preferably the amino acid residues 18-52 of HA1, and the
HA1 C- terminal stem segment comprises the amino acid residues 321-343 of HA1,
wherein the amino acid on position 343, i.e. R343, has been mutated and is an amino acid
other than R, preferably glutamine (Q), wherein the HA2 domain comprises the
mutations F406S, V409T, L416S, M420I and V421I. In certain embodiments, the HA1
N- terminal stem segment consists of the amino acid residues 1-52 of HA1, preferably the
amino acid residues 18-52 of HA1, and the HA1 C- terminal stem segment consists of the
amino acid residues 321-343 of HA1.
In certain embodiments, the HA1 N- terminal stem segment comprises the amino
acid residues 1-53 of HA1, preferably the amino acid residues 18-53 of HA1, and the
HA1 C- terminal stem segment comprises the amino acid residues 303-343 of HA1,
wherein the amino acid on position 343, i.e. R343, has been mutated and is an amino acid
other than R, preferably glutamine (Q). In certain embodiments, the HA1 N- terminal
stem segment consists of the amino acid residues 1-53 of HA1, preferably the amino acid
residues 18-53 of HA1, and the HA1 C- terminal stem segment consists of the amino acid
residues 303-343 of HA1. In a specific embodiment, the HA1 domain comprises the
mutations V314T and I316T, and the HA2 domain comprises one or more of the
following mutations: F406S, V409T, L416S, M420I and V421I. In a preferred
embodiment, the polypeptide comprises the amino acid sequence of SEQ ID NO: 11.
In certain embodiments, the HA1 N- terminal stem segment comprises the amino
acid residues 1-55 of HA1, preferably the amino acid residues 18-55 of HA1, and the
HA1 C- terminal stem segment comprises the amino acid residues 318-343 of HA1,
wherein the amino acid on position 343, i.e. R343, has been mutated and is an amino acid
other than R, preferably glutamine (Q). In certain embodiments, the HA1 N- terminal
stem segment consists of the amino acid residues 1-55 of HA1, preferably the amino acid
esidues 18-55 of HA1, and the HA1 C- terminal stem segment consists of the amino acid
residues 318-343 of HA1. In an embodiment, the HA2 domain comprises the mutations
F406S, V409T, L416S, M420I and V421I.
In certain embodiments, the polypeptides further comprise the mutation R324C
in the HA1 domain and T436C in the HA2 domain.
In a specific embodiment, the HA1 domain comprises the mutations L58T,
V314T, I316T, and R324C and the HA2 domain comprises one or more of the following
mutations: F406S, V409T, L416S, M420I, V421I and T436C.
In an embodiment, the HA1 domain comprises the mutation R324C, and the HA2
domain comprises the mutations F406S, V409T, L416S, M420I, V421I and T436C.
In another embodiment, the HA1 domain comprises the mutations V314T, I316T
and R324C, and the HA2 domain comprises one or more of the following mutations:
F406S, V409T, L416S, M420I, V421I and T436C.
In an embodiment, the HA1 domain comprises the mutation R324C, and the HA2
domain comprises the mutations F406S, V409T, L416S, M420I, V421I and T436C.
In certain embodiments, the polypeptides described herein contain the
intracellular sequences of HA and the transmembrane domain. In other embodiments, the
intracellular and transmembrane sequences, e.g. the amino acid sequence from position
(or the equivalent of) 523, 524, 525, 526, 527, 526, 528, 529, or 530 of the HA2 domain
to the C-terminus of the HA2 domain (numbering according to SEQ ID NO: 1) has been
removed. In certain embodiments, the polypeptides are further stabilized by introducing
a sequence known to form trimeric structures, i.e. AYVRKDGEWVLL (SEQ ID
NO:143) (‘foldon’ sequence), optionally connected through a linker. The linker may
optionally contain a cleavage site for processing afterwards according to protocols well
known to those skilled in the art. To facilitate purification of the soluble form a tag
sequence may be added, e.g. a his tag (HHHHHHH) connected via a short linker, e.g.
EGR. In some embodiments the linker and his-tag sequence are added without the foldon
sequence being present.
In certain embodiments, the amino acid sequence from position (or the equivalent
of) 530 of the HA2 domain to the C-terminus of the HA2 domain (numbering according
to SEQ ID NO: 1) has been removed. In certain embodiments, the intracellular and
transmembrane sequence have been replaced by the amino acid sequence
AGRHHHHHHH (SEQ ID NO: 81) or
SGRSLVPRGSPGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGHHHHHHH (SEQ ID
NO: 82).
In certain embodiments, the polypeptides selectively bind to the antibodies
CR6261 and/or CR9114. In an embodiment, the polypeptide does not bind to the
antibody CR8057. In an embodiment, CR6261 comprises a heavy chain variable region
comprising the amino acid sequence of SEQ ID NO: 20 and a light chain variable region
comprising the amino acid sequence of SEQ ID NO: 21; CR9114 comprises a heavy
chain variable region comprising the amino acid sequence of SEQ ID NO: 18 and a light
chain variable region comprising the amino acid sequence of SEQ ID NO: 19. In an
embodiment, CR8057 comprises a heavy chain variable region comprising the amino
acid sequence of SEQ ID NO: 22 and a light chain variable region comprising the amino
acid sequence of SEQ ID NO: 23.
As described above, the polypeptides comprise an influenza hemagglutinin HA1
domain that comprises an HA1 N- terminal stem segment that is covalently linked by a
linking sequence of 0- 50 amino acid residues to the HA1 C- terminal stem segment. The
linking sequence does not occur in naturally occurring, or wild-type, HA. In certain
embodiments, the linker is a peptide that comprises one amino acid residue, two or less
amino acid residues, three or less amino acid residues, four or less amino acid residues, five
or less amino acid residues, ten or less amino acid residues, 15 or less amino acid residues,
or 20 or less amino acid residues or 30 or less amino acid residues or 40 or less amino acid
residues or 50 or less amino acid residues. In a specific embodiment, the linking sequence
is a sequence selected from the group consisting of G, GS, GGG, GSG, GSA, GSGS,
GSAG, GGGG, GSAGS, GSGSG, GSAGSA, GSAGSAG, and GSGSGSG.
Also described are methods to provide the polypeptides described herein, in
particular to provide the H1 HA stem domain polypeptide described herein, as well as the
polypeptides obtainable or obtained by these methods. In certain embodiments, the methods
comprise the steps of:
(a) Providing an influenza HA0 amino acid sequence, in particular an influenza HA0 amino
acid sequence of serotype H1;
(b) Removing the cleavage site between HA1 and HA2, preferably by mutating the C-
terminal amino acid of HA1 into an amino acid other that arginine (R) or lysine (K);
(c) Removing the amino acid sequence of the globular head domain from the HA0
sequence; This is done by deleting a segment of the HA1 domain between amino acid on
position x and an amino acid on position y, and reconnecting the N-terminal segment
(spanning from amino acid on position 1 to and including amino acid on position x of
HA1) and the C-terminal segment of HA1 (spanning from amino acid y to the C-terminal
amino acid of HA1), thus obtained, optionally through a linking sequence of 0-50 amino
acids. In certain embodiments, x is an amino acid on any position between positions 46 and
60, preferably the amino acid on position 52, 53, 55 or 59 of HA1 and wherein y is an
amino acid on any position between positions 290 and 325, preferably an amino acid on
position 291, 303, 318, or 321 of HA1. Again, the numbering used refers to SEQ ID NO:1.
It will be understood by the skilled person that the leader sequence (or signal sequence) that
directs transport of a protein during production (e.g. corresponding to amino acids 1-17 of
SEQ ID NO: 1), generally will not be present in the final polypeptide, that is e.g. used in a
vaccine. In certain embodiments, the polypeptides described herein thus comprise a HA1
N-terminal segment without the leader sequence.
(d) Increasing the stability of the pre-fusion conformation and destabilizing the post-fusion
conformation of the modified HA, preferably by introducing one or more mutations in the
amino acid sequence connecting the C-terminal residue of helix A to the N-terminal residue
of helix CD, preferably in the amino acid sequence spanning from amino acid 402-418 of
SEQ ID NO: 1 in particular comprising the amino acid sequence of
MNTQFTAVGKEFN(H/K)LE(K/R) (SEQ ID NO: 17). The mutations preferably comprise
the substitution of hydrophobic amino acid residues into hydrophilic amino acid residues.
(e) Introducing one or more disulfide bridges in the HA stem domain polypeptide.
According to the disclosure, removal of the cleavage site between HA1 and HA2
can be achieved by mutation of R (in a small number of cases K) to Q at the P1 position
(see e.g. Sun et al, 2010 for an explanation of the nomenclature of the cleavage site
(position 343 in SEQ ID NO: 1). A mutation to Q is preferred but S, T, N, D or E are
alternatives.
Removal of the head domain can be achieved, e.g. by deleting amino acids 53 to
320 from SEQ ID NO; 1, or at equivalent positions in HA from other influenza viruses.
Equivalent positions can be easily determined by those skilled in the art by aligning the
sequences using a suitable algorithm such as e.g. Clustal or Muscle. The remaining parts
of the sequence can be joined directly, or alternatively a flexible linker can be
introduced. Linker sequences can be 1 to 50 amino acids in length. Preferred are flexible
linkers of limited length (smaller or equal to 10 amino acids), e.g. GGG, GGGG, GSA,
GSAG, GSAGSA, GSAGSAG or similar. The length of the deletion can also be varied,
e.g. by starting the deletion at (the equivalent of) position (x), e.g. at position 54, 55, 56,
57 or 58, or to increase the length of the deletion, by cutting at position.47, 48, 49, 50,
51, or 52. Similarly, the last amino acid to be deleted can be at (the equivalent of)
position (y), such as 315, 316, 317, 318 or 319, or to increase the length of the deletion at
(the equivalent of) position 321, 322, 323, 324, or 325. It is important to realize that
changes in the length of the deletion can be in part compensated for by matching the
length of the linker sequence, i.e. a larger deletion can be matched with a longer linker
and vice versa. These polypeptides are also encompassed by the present disclosure.
According to thepresent disclosure, the solubility of the loop between the A-helix
and the CD helix is increased. This loop is formed by (the equivalent of) residues 402 to
418 in H1 A/Brisbane/59/2007 (SEQ ID NO: 1). Thus, the stability of the pre-fusion
conformation is increased and the post-fusion conformation of the modified HA is
destabilized. This loop is highly conserved in H1 sequences, as can be seen in table 6
below. This can for example be achieved by replacing the amino acids I, L, F or V in
said loop with hydrophilic counterparts. Equivalent position can be easily determined by
those skilled in the art by aligning the sequences using a suitable algorithm such as e.g.
Clustal or Muscle. Mutations to glycine destabilize the post-fusion conformation since
the high flexibility of this amino acid leads to a decrease in stability of the post-fusion
helix to be formed by this part of the HA sequence. The consensus sequence describing
the loop between residue 402-418 of influenza HA of serotype H1 is (SEQ ID NO: 17)
MNTQFTAVGKEFN(H/K)LE(K/R) . In polypeptides described herein the amino acid at
positions 406, 409, 413 and/or 416 (or their equivalent, as determined from a sequence
alignment ) is a polar (S,T,N,Q), charged (R,H,K,D,E) or flexible (G) amino acid.
Combinations of mutations at these sites are also possible, for example F406S, V409T,
L416S.. In some cases a mutation to restore the consensus amino acid is preferred, e.g.
where V or M is at position 404 (to T), V at 408 (to A) or 410 (to G) or I at 414 (to N);
the incidence of sequences with these particular amino acids is very low. An overview of
the mutations described above that characterize polypeptides described herein is given in
table 6.
According to thepresent disclosure, one or more disulfide bridges are introduced
in the stem domain polypeptides, preferably between amino acids of (or the equivalent
of) position 324 and 436 in H1 A/Brisbane/59/2007. Equivalent positions can be easily
determined by those skilled in the art by aligning the sequences using a suitable
algorithm such as Clustal, Muscle etc. Engineered disulfide bridges are created by
mutating at least one (if the other is already a cysteine), but usually two residues that are
spatially close into cysteine, that will spontaneously or by active oxidation form a
covalent bond between the sulfur atoms of these residues.
The native HA exists as a trimer on the cell surface. Most of the interactions
between the individual monomers that keep the trimer together are located in the head
domain. After removal of the head the tertiary structure is thus destabilized and therefore
reinforcing the interactions between the monomers in the truncated molecule will
increase the stability. In the stem domain trimerization is mediated by the formation of a
trimeric coiled coil motif. By strengthening this motif a more stable trimer can be
created. According to the present disclosure, a consensus sequence for the formation of a
trimeric coiled coil, e.g. IEAIEKKIEAIEKKIE (SEQ ID NO: 83), may be introduced in
a polypeptide described herein at (the equivalent of) position 418 to 433. In certain
embodiments, the sequence MKQIEDKIEEIESKQ (SEQ ID NO: 84), derived from
GCN4 and also known to trimerize is introduced at (the equivalent of) position 419-433.
In certain embodiments, the trimer interface is stabilized by modifying M420, L423,
V427, G430 into isoleucine.
In certain embodiments, the polypeptides described herein contain the
intracellular sequences of H1 HA and the transmembrane domain. In other embodiments,
the intracellular and transmembrane sequences, e.g. the amino acid sequence from
position (or the equivalent of) 523, 524, 525, 526, 527, 526, 528, 529, or 530 of the HA2
domain to the C-terminus of the HA2 domain (numbering according to SEQ ID NO: 1)
has been removed to produce a soluble polypeptide following expression in cells. In
certain embodiments, the polypeptides are further stabilized by introducing a sequence
known to form trimeric structures, i.e. AYVRKDGEWVLL (SEQ ID NO: 80),
optionally connected through a linker. The linker may optionally contain a cleavage site
for processing afterwards according to protocols well known to those skilled in the art.
To facilitate purification of the soluble form a tag sequence may be added, e.g. a his tag
(HHHHHHH) connected via a short linker, e.g. EGR. In some embodiments the linker
and his-tag sequence are added without the foldon sequence being present. In certain
embodiments, the intracellular and transmembrane sequence have been replaced by the
amino acid sequence AGRHHHHHHH (SEQ ID NO: 97) or
SGRSLVPRGSPGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGHHHHHHH (SEQ ID
NO: 82).
Applicants have previously identified broadly neutralizing antibodies isolated
from primary human B-cells from vaccinated individuals some of which were specific
for group 1 (e.g. CR6261, as described in ) and some of which were
specific for group 2 influenza viruses (e.g. CR8020 as described in ).
Detailed analysis of the epitopes of these monoclonal antibodies has revealed the reason
for the lack of cross-reactivity of these specific antibodies. In both cases the presence of
glycans in group 1 or group 2 HA molecules on different positions at least partly
explained the fact that the antibodies are group-specific. With the identification of
CR9114-like antibodies that cross-react with many group 1 and 2 HA molecules, as
described below, it has become clear that it is possible for the human immune system to
elicit very broad neutralizing antibodies against influenza viruses. However, given the
need for a yearly vaccination scheme these antibodies are apparently not, or only to a
very low extent elicited following infection or vaccination with (seasonal) influenza
viruses of subtypes H1 and/or H3. In certain embodiments, the present disclosure thus
describes polypeptides that present the stem region of HA in a conformational correct
manner so that the epitopes that elicit the broadly neutralizing antibodies are presented to
the immune system in the absence of immune dominant variable regions. Since it is
known that the pattern of glycans differs between H1 and H3 HA, and that this
difference may lead to more group restricted antibody response, in different
embodiments the polypeptides described herein are based on group 2 HA molecules (e.g.
HA of the H3). As shown in Example 3, below, the in vitro neutralizing capacity of
CR9114 is higher on H1 subtypes compared to H3 subtypes. Therefore, it is
hypothesized that the epitope of CR9114 is more accessible on H1 compared to H3 HA
molecules which could be due to a glycan on N38 in HA1 common to many group 2 HA
subtypes. Without wishing to be bound to this theory, it may be reasoned that if a
polypeptide described herein is based on H1, the resulting antibodies are more likely to
be hindered by the glycan on N38 on group 2 HA molecules and thus be somewhat less
active on group 2 influenza viruses. Therefore, to enable elicitation of broadly
neutralizing antibodies that act on both group 1 and group 2 influenza viruses with good
activity, in certain embodiments the stem domain polypeptides described herein are
based on H3 HA subtypes.
Humans are frequently infected with seasonal influenza viruses comprising HA of
the H1or H3 subtype. Apparently despite the exposure to these influenza viruses, broadly
neutralizing antibodies are not often raised in the natural situation. One of the reasons for
this, besides the presence of the variable head region in HA, might be that the exposure to a
new subtype that is closely related to the one seen previously somehow makes the response
less broad. It thus may be preferred to expose the individual to a more unrelated subtype
sequence. Therefore, in yet another embodiment, the stem domain polypeptides described
herein are based on HA of a group 2 subtype that does contain an asparagine (N) on
position 38 in HA1 (N38), and that is not an H3 subtype.
In certain embodiments, the polypeptides are based on an influenza A virus
subtype. In certain embodiments, the polypeptides are not based on H7 HA.
As described above, polypeptides described herein are not only designed based
on parental HA sequences from influenza vaccine virus subtypes of group 1 (such as e.g.
H1 and H5), but can also based on HA sequences of influenza subtypes from group 2, in
particular influenza virus subtypes of group 2 that are used for influenza vaccines, such as
H3. According to the disclosure, polypeptides were constructed that conserve the epitope
of CR8020 and CR8043 because these antibodies are capable of neutralizing a wide range
of group 2 strains (WO2010/130636). In these polypeptides, the beta-sheet at the bottom
of the stem region and its surroundings should be as conserved as possible since this is
the region were CR8020 and CR8043 bind to H3 HA.
In certain embodiments, the HA domains are of a H3 subtype, preferably of
A/Wisconsin/67/2005 (SEQ ID NO: 89), or A/Hong Kong/1/1968 (SEQ ID NO: 121). It
will be understood by the skilled person that also other influenza A viruses comprising HA
of the H3 subtype may be used according to the present disclosure.
In certain embodiments, the polypeptides comprise, or consist of, a HA1 N-
terminal polypeptide segment comprising the amino acids from position 1 to position x of
the H3 HA1 domain, preferably the amino acids from position p to position x of the HA1
domain, wherein x is any amino acid between the positions 56 and 69, such as 57, 58, 59,
60, 61, 62, 63, 64, 65, 66, 67 or 68, of H3 HA1, preferably wherein x is 61, 62, 63 or 68. In
certain embodiments, the HA1 C-terminal polypeptide segment comprises the amino acids
from position y to and including the C-terminal amino acid of the H3 HA1 domain, wherein
y is any amino acid between and including the positions 292 and 325, of H3 HA1,
preferably wherein y is 293, 306, 318 or 323.
In certain embodiments, the HA domains are of a H3 subtype, preferably
A/Wisconsin/67/2005 (SEQ ID NO: 89), or A/Hong Kong/1/1968 (SEQ ID NO: 121).
According to the disclosure, the head domain has been removed by deleting a
large part of the HA1 sequence and reconnecting the N- and C-terminal sequences
through a short linker. The deletion can vary in length, but it is preferred that the last
residue of the N-terminal sequence of HA1 and the first residue of the C-terminal
sequence are spatially close together to avoid introducing strain through the linking
sequence. In H3 sequence deletions can be introduced at (the equivalent positions of)
S62-P322, S63-P305 and T64-T317. Equivalent positions can be easily determined by
those skilled in the art by aligning the sequences using a suitable algorithm such as e.g.
Clustal or Muscle. The remaining parts of the sequence can be joined directly or
alternatively a flexible linker can be introduced. Linker sequences can be 1 to 50, amino
acids in length. Preferred are flexible linkers of limited length (smaller or equal to 10
amino acids), e.g. GGG, GGGG, GSA, GSAG, GSAGSA, GSAGSAG or similar. The
length of the deletion can also be varied, e.g. by decreasing the number of residues in the
deletion by starting at (the equivalent of) position 63, 64, 65, 66, 67, or to increase the
length of the deletion, by cutting at position 57, 58, 59, 60 or 61. Similarly, the last
amino acid to be deleted can be at (the equivalent of) position 317, 318, 319, 320 or 321,
or to increase the length of the deletion at (the equivalent of) position 323, 324, 325, 326,
or 327. It is important to realize that changes in the length of the deletion can be in part
compensated for by matching the length of the linker sequence, i.e. a larger deletion can
be matched with a longer linker and vice versa. These polypeptides are also included in
the disclosure.
In certain embodiments x is 61 and y is 323.
In certain embodiments, x is 62 and y is 306.
In certain embodiments x is 63 and y is 318.
In certain embodiments, x is (the equivalent of) position 62, 63, 64, 65, 66, or
position 56, 57, 58, 59 or 60.
In certain embodiments, y is (the equivalent of) position 306, 318, 319, 320, 321 or
322, or (the equivalent of) position 324, 325, 326, 327, or 328.
In an embodiment, the amino acid sequence connecting the C-terminal residue of
helix A to the N-terminal residue of helix CD corresponds to the amino acid sequence
between the amino acid on position 400 and the amino acid on position 420 of HA2 of
SEQ ID NO: 89, or the amino acid residues on equivalent positions in other H3 virus
strains, wherein the polypeptides comprise one or more mutations in the amino acid
sequence connecting the C-terminal residue of helix A to the N-terminal residue of helix
CD, i.e. the amino acid sequence spanning from amino acid 400-420 of SEQ ID NO: 89,
or equivalent amino acid residues in other H3 influenza virus strains.
In certain embodiments, the amino acid sequence connecting the C-terminal residue
of helix A to the N-terminal residue of helix CD of influenza HA of serotype H3 comprises
the amino acid sequence of SEQ ID NO: 104.
According to the idisclosure, the polypeptides comprise one or more mutations in
the amino acid sequence connecting the C-terminal residue of helix A to the N-terminal
residue of helix CD. In certain embodiments, the polypeptides comprise one or more
mutations of Table 8, or equivalent mutations in other influenza virus strains of the H3
subtype.
According to the disclosure, the cleavage site between HA1 and HA2 has been
removed. In certain embodiments, the removal of the cleavage site at position 345
(numbering refers to SEQ ID NO: 89) has been mutated (R345Q) to prevent the
formation of HA1 and HA2 from HA0. Optionally residue 347 to 351 (IFGAI, part of the
fusion peptide) can additionally be deleted to minimize the exposure of hydrophobic
residues to the aqueous solvent. The positive charge at the cleavage is 100% conserved in
H3 and this mutation can therefore be applied in all sequences.
The deletion of the head domain leaves the B-loop between residues 400 to 420
now exposed to the aqueous solvent. In H3 HAs this loop is highly conserved (see table
9). The consensus sequence is: 401 I(E/G)KTNEKFHQIEKEFSEVEGR 421 (SEQ ID
NO: 104; numbering refers to SEQ ID NO: 89). To increase the solubility of this loop
for the polypeptides described herein in the pre-fusion conformation and destabilize the
post-fusion conformation some hydrophobic residues have to be modified into polar
(S,T,N,Q), charged amino acids (R,H,K,D,E), or flexibility has to be increased by
mutation to G. Specifically mutations at positions 401, 408, 411, 415, 418, (numbering
refers to SEQ ID NO: 89) will contribute to the stability of a polypeptide described
herein.
To stabilize the pre-fusion conformation of polypeptides described herein a
covalent bond between two parts distant in the primary sequences but close in the folded
pre-fusion conformation is introduced To this end a disulfide bridge may be engineered in
the polypeptides described herein a, preferably between (the equivalent of) position 326
and 438 in H3 A/Wisconsin/67/2005 (SEQ ID NO: 89). Equivalent positions can be
easily determined by those skilled in the art by aligning the sequences using a suitable
algorithm such as Clustal, Muscle etc. Engineered disulfide bridges are created by
mutating at least one (if the other is already a cysteine), but usually two residues that are
spatially close into cysteine, that will spontaneously or by active oxidation form a
covalent bond between the sulfur atoms of these residues. An alternative cysteine bridge
can be created between (the equivalent of) position 334 and 393 in H3
A/Wisconsin/67/2005 (SEQ ID NO: 89) by mutation of these residues into cysteine. In
some cases the cysteine at (the equivalent of) position 321 is modified into a glycine to
avoid formation of unwanted disulfide bridges.
In certain embodiments, the polypeptides comprise one or more of the following
mutations: F408S, I411T, F415S, V418G, I401R, K326C, S438C, T334C, I393C,
C321G.
The native HA exists as a trimer on the cell surface. Most of the interactions
between the individual monomers that keep the trimer together are located in the head
domain. After removal of the head the tertiary structure is thus destabilized and therefore
reinforcing the interactions between the monomers in the truncated molecule will
increase the stability. In the stem domain trimerization is mediated by the formation of a
trimeric coiled coil motif. By strengthening this motif a more stable trimer can be
created. A consensus sequence for the formation of a trimeric coiled coil,
IEAIEKKIEAIEKKIEAIEKK, is introduced at (the equivalent of) position 421 to
441.To avoid interference with the formation of the disulfide bridge between positions
326 and 438 an alternative shorter sequence IEAIEKKIEAIEKKI at (the equivalent of)
positions 421 to 435 was also used. An alternative is to introduce the sequence
RMKQIEDKIEEIESKQKKIEN, derived from GCN4 and known to trimerize, at
position 421-441 or the shorter sequence RMKQIEDKIEEIESK at position 421 to 435.
The polypeptides described herein may contain the intracellular sequences of HA
and the transmembrane domain so that the resulting polypeptides are presented on the cell
surface when expressed in cells. In other embodiments, the cytoplasmic sequence and the
transmembrane sequence from (the equivalent of) position 522 to the C-terminus is
removed so that a secreted (soluble) polypeptide is produced following expression in
cells. Optionally some additional residues can be included in the soluble protein by
deleting the sequence from (the equivalent of) 523, 524, 525, 526, 527, 528 or 529. The
soluble polypeptide can be further stabilized by introducing a sequence known to form
trimeric structures, i.e. AYVRKDGEWVLL (SEQ ID NO: 143)(‘foldon’ sequence),
optionally connected through a linker. The linker may optionally contain a cleavage site
for processing afterwards according to protocols well known to those skilled in the art. To
facilitate purification of the soluble form a tag sequence may be added, e.g. a his tag
(HHHHHHH) connected via a short linker, e.g. EGR. In some embodiments the linker
and his-tag sequence are added without the foldon sequence being present.
According to the present disclosure, the amino acid sequence from position 530
(numbering according to SEQ ID NO: 1) to the C-terminal amino acid of the HA2
domain may be removed and replaced by the following sequences: EGRHHHHHHH
(SEQ ID NO: 81), or
SGRSLVPRGSPGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGHHHHHHH (SEQ ID
NO: 82).
In certain embodiments the HA1 N- terminal stem segment does not comprise the
signal sequence. It will be understood by the skilled person that the leader sequence (or
signal sequence) that directs transport of a protein during production (e.g. corresponding
to amino acids 1-17 of SEQ ID NO: 89), generally will not be present in the final
polypeptide, that is e.g. used in a vaccine. In certain embodiments, the polypeptides
according to the disclosure thus comprise an amino acid sequence without the leader
sequence.
According to the disclosure, the polypeptides are not based on HA molecules of
Influenza B. The influenza type B virus strains are strictly human. The antigenic variation
in HA within the influenza type B virus strains is smaller than those observed within the
type A strains. Two genetically and antigenically distinct lineages of influenza B virus are
circulating in humans, as represented by the B/Yamagata/16/88 (also referred to as
B/Yamagata) and B/Victoria/2/87 (B/Victoria) lineages (Ferguson et al., 2003). Although
the spectrum of disease caused by influenza B viruses is generally milder than that caused
by influenza A viruses, severe illness requiring hospitalization is still frequently observed
with influenza B infection.
According to the present disclosure polypeptides are described that mimic the
specific epitopes of CR6261 and CR9114, and that can be used as immunogenic
polypeptides, e.g. to elicit cross-neutralizing antibodies when administered in vivo, either
alone, or in combination with other prophylactic and/or therapeutic treatments. With
“cross-neutralizing antibodies”, antibodies are meant that are capable of neutralizing at
least two, preferably at least three, four, or five different subtypes of influenza A viruses
of phylogenetic group1, and/or at least two, preferably at least three, four, or five
different subtypes of influenza A viruses of phylogenetic group 2, and/or at least two,
different subtypes of influenza B viruses, in particular at least all virus strains that are
neutralized by CR6261 and CR9114.
The polypeptides described herein do not comprise the full length HA1. In certain
embodiments, the immunogenic polypeptides are substantially smaller than HA0,
preferably lacking all or substantially all of the globular head of HA. Preferably, the
immunogenic polypeptides are no more than 360, preferably no more than 350, 340, 330,
320, 310, 305, 300, 295, 290, 285, 280, 275, or 270 amino acids in length. In an
embodiment, the immunogenic polypeptide is from about 250 to about 350, preferably from
about 260 to about 340, preferably from about 270 to about 330, preferably from about 270
to about 330 amino acids in length.
In certain embodiments, the polypeptides selectively bind to the antibodies
CR6261 and/or CR9114. In an embodiment, the polypeptide does not bind to the
antibody CR8057. In an embodiment, CR6261 comprises a heavy chain variable region
comprising the amino acid sequence of SEQ ID NO: 20 and a light chain variable region
comprising the amino acid sequence of SEQ ID NO: 21; CR9114 comprises a heavy
chain variable region comprising the amino acid sequence of SEQ ID NO: 18 and a light
chain variable region comprising the amino acid sequence of SEQ ID NO: 19. In an
embodiment, CR8057 comprises a heavy chain variable region comprising the amino
acid sequence of SEQ ID NO: 22 and a light chain variable region comprising the amino
acid sequence of SEQ ID NO: 23.
As described above, the polypeptides comprise an influenza hemagglutinin HA1
domain that comprises an HA1 N- terminal stem segment that is covalently linked by a
linking sequence of 0- 50 amino acid residues to the HA1 C- terminal stem segment. The
linking sequence does not occur in naturally occurring, or wild-type, HA. In certain
embodiments, the linker is a peptide that comprises one amino acid residue, two or less
amino acid residues, three or less amino acid residues, four or less amino acid residues, five
or less amino acid residues, ten or less amino acid residues, 15 or less amino acid residues,
or 20 or less amino acid residues or 30 or less amino acid residues or 40 or less amino acid
residues or 50 or less amino acid residues. In a specific embodiment, the linking sequence
is a sequence selected from the group consisting of G, GS, GGG, GSG, GSA, GSGS,
GSAG, GGGG, GSAGS, GSGSG, GSAGSA, GSAGSAG, and GSGSGSG.
Also described are methods to provide the polypeptides described herein, in
particular to provide the amino acid sequence of the HA stem domain polypeptide
according to the invention, as well as the polypeptides obtainable or obtained by these
methods. In certain embodiments, the methods comprise the steps of:
- Providing an influenza HA0 amino acid sequence, e.g. an influenza HA0 sequence of
serotype H1, H5 or H3;
- Removing the cleavage site between HA1 and HA2, preferably by mutating the C-
terminal amino acid of HA1 into an amino acid other that arginine (R) or lysine (K);
- Removing the amino acid sequence of the globular head domain from the HA0 sequence;
This is done by deleting a segment of the HA1 domain between amino acid on position x
and an amino acid on position y, and reconnecting the N-terminal segment (spanning from
amino acid on position 1 to and including amino acid on position x of HA1) and the C-
terminal segment of HA1 (spanning from amino acid y to the C-terminal amino acid of
HA1), thus obtained, optionally through a linking sequence of 0-50 amino acids.
- Increasing the stability of the pre-fusion conformation and destabilizing the post-fusion
conformation of the modified HA, preferably by introducing one or more mutations in the
amino acid sequence connecting the C-terminal residue of helix A to the N-terminal residue
of helix CD, preferably in the amino acid sequence spanning from amino acid 402-418 of
H1 HA, in particular comprising the amino acid sequence of
MNTQFTAVGKEFN(H/K)LE(K/R) (SEQ ID NO: 17) or
I(E/G)KTNEKFHQIEKEFSEVEGR 421 (SEQ ID NO: 104) for H3 HA. The mutations
preferably comprise the substitution of hydrophobic amino acid residues into hydrophilic
amino acid residues.
- Introducing one or more disulfide bridges in the HA stem domain polypeptide.
According to the disclosure, removal of the cleavage site between HA1 and HA2
can be achieved by mutation of R (in a small number of cases K) to Q at the P1 position
(see e.g. Sun et al, 2010 for an explanation of the nomenclature of the cleavage site
(position 343 in SEQ ID NO: 1). A mutation to Q is preferred but S, T, N, D or E are
alternatives.
Removal of the head domain can be achieved, e.g. by deleting amino acids 53 to
320 from SEQ ID NO; 1. Equivalent positions can be easily determined by those skilled
in the art by aligning the sequences using a suitable algorithm such as e.g. Clustal or
Muscle. The remaining parts of the sequence can be joined directly, or alternatively a
flexible linker can be introduced. Linker sequences can be 1 to 50 amino acids in length.
Preferred are flexible linkers of limited length (smaller or equal to 10 amino acids), e.g.
GGG, GGGG, GSA, GSAG, GSAGSA, GSAGSAG or similar. The length of the
deletion can also be varied, e.g. by starting the deletion at (the equivalent of) position
(x), e.g. at position 54, 55, 56, 57 or 58, or to increase the length of the deletion, by
cutting at position.47, 48, 49, 50, 51, or 52. Similarly, the last amino acid to be deleted
can be at (the equivalent of) position (y), such as 315, 316, 317, 318 or 319, or to
increase the length of the deletion at (the equivalent of) position 321, 322, 323, 324, or
325. It is important to realize that changes in the length of the deletion can be in part
compensated for by matching the length of the linker sequence, i.e. a larger deletion can
be matched with a longer linker and vice versa. These polypeptides are also
encompassed by the disclosure.
According to the disclosure, the solubility of the loop between the A-helix and the
CD helix is increased. This loop is formed by (the equivalent of) residues 402 to 418 in
H1 A/Brisbane/59/2007 (SEQ ID NO: 1). Thus, the stability of the pre-fusion
conformation is increased and the post-fusion conformation of the modified HA is
destabilized. This loop is highly conserved in H1 sequences, as can be seen in table 6
below. This can for example be achieved by replacing the amino acids I, L, F or V in
said loop with hydrophilic counterparts. Equivalent position can be easily determined by
those skilled in the art by aligning the sequences using a suitable algorithm such as e.g.
Clustal or Muscle. Mutations to glycine destabilize the post-fusion conformation since
the high flexibility of this amino acid leads to a decrease in stability of the post-fusion
helix to be formed by this part of the HA sequence. The consensus sequence describing
the loop between residue 402-418 of influenza HA of serotype H1 is (SEQ ID NO: 17)
MNTQFTAVGKEFN(H/K)LE(K/R) . In certain polypeptides described herein the
amino acid at positions 406, 409, 413 and/or 416 (or their equivalent, as determined from
a sequence alignment ) is a polar (S,T,N,Q), charged (R,H,K,D,E) or flexible (G) amino
acid. Combinations of mutations at these sites are also possible, for example F406S,
V409T, L416S as in SEQ ID NO: 10 and SEQ ID NO: 14. In some cases a mutation to
restore the consensus amino acid is preferred, e.g. where V or M is at position 404 (to T),
V at 408 (to A) or 410 (to G) or I at 414 (to N); the incidence of sequences with these
particular amino acids is very low. An overview of the mutations described above that
characterize polypeptides of the invention is given in tables 6.
According to the disclosure, one or more disulfide bridges are introduced in the
stem domain polypeptides, preferably between amino acids of (or the equivalent of)
position 324 and 436 in H1 A/Brisbane/59/2007: SEQ ID NOs: 13-16. Equivalent
positions can be easily determined by those skilled in the art by aligning the sequences
using a suitable algorithm such as Clustal, Muscle etc. Engineered disulfide bridges are
created by mutating at least one (if the other is already a cysteine), but usually two
residues that are spatially close into cysteine, that will spontaneously or by active
oxidation form a covalent bond between the sulfur atoms of these residues.
Polypeptides obtainable by said method are also part of the disclosure.
The native HA exists as a trimer on the cell surface. Most of the interactions
between the individual monomers that keep the trimer together are located in the head
domain. After removal of the head the tertiary structure is thus destabilized and therefore
reinforcing the interactions between the monomers in the truncated molecule will
increase the stability. In the stem domain trimerization is mediated by the formation of a
trimeric coiled coil motif. By strengthening this motif a more stable trimer can be
created. According to the disclosure, a consensus sequence for the formation of a
trimeric coiled coil, IEAIEKKIEAIEKKIE (SEQ ID NO: 83), may be introduced in a
polypeptide of the invention at (the equivalent of) position 418 to 433. In certain
embodiments, the sequence MKQIEDKIEEIESKQ (SEQ ID NO: 84), derived from
GCN4 and known to trimerize is introduced at (the equivalent of) position 419-43. In
certain embodiments, the trimer interface is stabilized by modifying M420, L423, V427,
G430 into Isoleucine.
In certain embodiments, the polypeptides comprise an amino acid sequence selected
from the group consisting of SEQ ID NO: 3-16, SEQ ID NO: 44-53, SEQ ID NO: 111-114,
SEQ ID NO: 119-120, SEQ ID NO: 125, 126, 130, SEQ ID NO: 144-175 and SEQ ID NO:
177-187.
In certain embodiments, the polypeptides are selected from the group consisting of
SEQ ID NO: 45, SEQ ID NO; 113 and SEQ ID NO: 130.
It will be understood by the skilled person that the leader sequence (or signal
sequence) that directs transport of a protein during production (e.g. corresponding to amino
acids 1-17 of SEQ ID NO: 1 ), is not present in the final polypeptide, that is e.g. used in a
vaccine. In certain embodiments, the polypeptides according to the disclosure thus
comprise an amino acid sequence without the leader sequence.
The influenza hemagglutinin stem domain polypeptides can be prepared
according to any technique deemed suitable to one of skill, including techniques
described below.
Thus, the immunogenic polypeptides described herein may be synthesized as DNA
sequences by standard methods known in the art and cloned and subsequently expressed, in
vitro or in vivo, using suitable restriction enzymes and methods known in the art. Also
described are nucleic acid molecules encoding the above described polypeptides. Also
described are vectors comprising the nucleic acids encoding the polypeptides of the
invention. In certain embodiments, a nucleic acid molecule described herein is part of a
vector, e.g. a plasmid. Such vectors can easily be manipulated by methods well known to
the person skilled in the art, and can for instance be designed for being capable of
replication in prokaryotic and/or eukaryotic cells. In addition, many vectors can directly or
in the form of an isolated desired fragment there from be used for transformation of
eukaryotic cells and will integrate in whole or in part into the genome of such cells,
resulting in stable host cells comprising the desired nucleic acid in their genome. The vector
used can be any vector that is suitable for cloning DNA and that can be used for
transcription of a nucleic acid of interest. When host cells are used it is preferred that the
vector is an integrating vector. Alternatively, the vector may be an episomally replicating
vector.
The person skilled in the art is capable of choosing suitable expression vectors, and
inserting the nucleic acid sequences of the invention in a functional manner. To obtain
expression of nucleic acid sequences encoding polypeptides, it is well known to those
skilled in the art that sequences capable of driving expression can be functionally linked to
the nucleic acid sequences encoding the polypeptide, resulting in recombinant nucleic acid
molecules encoding a protein or polypeptide in expressible format. In general, the promoter
sequence is placed upstream of the sequences that should be expressed. Many expression
vectors are available in the art, e.g. the pcDNA and pEF vector series of Invitrogen,
pMSCV and pTK-Hyg from BD Sciences, pCMV-Script from Stratagene, etc, which can be
used to obtain suitable promoters and/or transcription terminator sequences, polyA
sequences, and the like. Where the sequence encoding the polypeptide of interest is
properly inserted with reference to sequences governing the transcription and translation of
the encoded polypeptide, the resulting expression cassette is useful to produce the
polypeptide of interest, referred to as expression. Sequences driving expression may include
promoters, enhancers and the like, and combinations thereof. These should be capable of
functioning in the host cell, thereby driving expression of the nucleic acid sequences that
are functionally linked to them. The person skilled in the art is aware that various promoters
can be used to obtain expression of a gene in host cells. Promoters can be constitutive or
regulated, and can be obtained from various sources, including viruses, prokaryotic, or
eukaryotic sources, or artificially designed. Expression of nucleic acids of interest may be
from the natural promoter or derivative thereof or from an entirely heterologous promoter
(Kaufman, 2000). Some well-known and much used promoters for expression in eukaryotic
cells comprise promoters derived from viruses, such as adenovirus, e.g. the E1A promoter,
promoters derived from cytomegalovirus (CMV), such as the CMV immediate early (IE)
promoter (referred to herein as the CMV promoter) (obtainable for instance from pcDNA,
Invitrogen), promoters derived from Simian Virus 40 (SV40) (Das et al, 1985), and the like.
Suitable promoters can also be derived from eukaryotic cells, such as methallothionein
(MT) promoters, elongation factor 1a (EF-1a) promoter (Gill et al., 2001), ubiquitin C or
UB6 promoter (Gill et al., 2001), actin promoter, an immunoglobulin promoter, heat shock
promoters, and the like. Testing for promoter function and strength of a promoter is a
matter of routine for a person skilled in the art, and in general may for instance encompass
cloning a test gene such as lacZ, luciferase, GFP, etc. behind the promoter sequence, and
test for expression of the test gene. Of course, promoters may be altered by deletion,
addition, mutation of sequences therein, and tested for functionality, to find new,
attenuated, or improved promoter sequences. According to the present disclosure, strong
promoters that give high transcription levels in the eukaryotic cells of choice are preferred.
The constructs may be transfected into eukaryotic cells (e.g. plant, fungal, yeast or
animal cells) or suitable prokaryotic expression systems like E. coli using methods that are
well known to persons skilled in the art. In some cases a suitable ‘tag’ sequence (such as for
example, but not limited to, a his-, myc-, strep-, or flag-tag) or complete protein (such as for
example, but not limited to, maltose binding protein or glutathione S transferase) may be
added to the sequences described herein to allow for purification and/or identification of the
polypeptides from the cells or supernatant. Optionally a sequence containing a specific
proteolytic site can be included to afterwards remove the tag by proteolytic digestion.
Purified polypeptides can be analyzed by spectroscopic methods known in the art
(e.g. circular dichroism spectroscopy, Fourier Transform Infrared spectroscopy and NMR
spectroscopy or X-ray crystallography) to investigate the presence of desired structures like
helices and beta sheets. ELISA, Octet and FACS and the like can be used to investigate
binding of the polypeptides described herein to the broadly neutralizing antibodies
described before (CR6261, CR9114, CR8057). Thus, polypeptides described herein having
the correct conformation can be selected.
Also described are immunogenic compositions comprising a therapeutically
effective amount of at least one of the polypeptides and/or nucleic acids described herein.
In certain embodiments, the compositions comprise polypeptides comprising hemagglutinin
stem domains from (or based on) HA of one influenza subtype, e.g. based on HA of an
influenza virus comprising HA of e.g. a H1 or H7 subtype. In certain embodiments, the
compositions comprise polypeptides comprising hemagglutinin stem domains based on HA
of two or more different influenza subtypes, e.g. compositions comprising both
polypeptides comprising hemagglutinin stem domains based on HA of the H1 subtype and
polypeptides comprising hemagglutinin stem domains based on HA of the H7 subtype.
The immunogenic compositions preferably further comprise a pharmaceutically
acceptable carrier. In the present context, the term "pharmaceutically acceptable" means
that the carrier, at the dosages and concentrations employed, will not cause unwanted or
harmful effects in the subjects to which they are administered. Such pharmaceutically
acceptable carriers and excipients are well known in the art (see Remington's
Pharmaceutical Sciences, 18th edition, A. R. Gennaro, Ed., Mack Publishing Company
; Pharmaceutical Formulation Development of Peptides and Proteins, S. Frokjaer and
L. Hovgaard, Eds., Taylor & Francis [2000]; and Handbook of Pharmaceutical Excipients,
3rd edition, A. Kibbe, Ed., Pharmaceutical Press [2000]). The term "carrier" refers to a
diluent, adjuvant, excipient, or vehicle with which the composition is administered. Saline
solutions and aqueous dextrose and glycerol solutions can e.g. be employed as liquid
carriers, particularly for injectable solutions. The exact formulation should suit the mode of
administration. The polypeptides and/or nucleic acid molecules preferably are formulated
and administered as a sterile solution. Sterile solutions are prepared by sterile filtration or
by other methods known per se in the art. The solutions can then be lyophilized or filled
into pharmaceutical dosage containers. The pH of the solution generally is in the range of
pH 3.0 to 9.5, e.g. pH 5.0 to 7.5.
Also described are methods for inducing an immune response in a subject, the
method comprising administering to a subject, a polypeptide, nucleic acid molecule and/or
immunogenic composition as described above. A subject according to the disclosure
preferably is a mammal that is capable of being infected with an infectious disease-causing
agent, in particular an influenza virus, or otherwise can benefit from the induction of an
immune response, such subject for instance being a rodent, e.g. a mouse, a ferret, or a
domestic or farm animal, or a non-human-primate, or a human. Preferably, the subject is a
human subject. Also described are methods for inducing an immune response to an
influenza virus hemagglutinin (HA), in particular of a group 1 and/or group 2 influenza A
virus, such as an influenza virus comprising HA of the H1, H2, H3, H4, H5, H7 and/or H10
subtype, and/or of an influenza B virus, in a subject utilizing the polypeptides, nucleic acids
and/or immunogenic compositions described herein. In some embodiments, the immune
response induced is effective to prevent and/or treat an influenza virus infection caused
group 1 and/or group 2 influenza A virus subtypes and/or influenza B viruses. In some
embodiments, the immune response induced by the polypeptides, nucleic acids and/or
immunogenic compositions described herein is effective to prevent and/or treat an influenza
A and/or B virus infection caused by two, three, four, five or six subtypes of influenza A
and/or B viruses.
Since it is well known that small proteins and/or nucleic acid molecules do not
always efficiently induce a potent immune response it may be necessary to increase the
immunogenicity of the polypeptides and/or nucleic acid molecules by adding an adjuvant.
In certain embodiments, the immunogenic compositions described herein comprise, or are
administered in combination with, an adjuvant. The adjuvant for administration in
combination with a composition described herein may be administered before,
concomitantly with, or after administration of said composition. Examples of suitable
adjuvants include aluminium salts such as aluminium hydroxide and/or aluminium
phosphate; oil-emulsion compositions (or oil-in-water compositions), including squalene-
water emulsions, such as MF59 (see e.g. WO 90/14837); saponin formulations, such as for
example QS21 and Immunostimulating Complexes (ISCOMS) (see e.g. US 5,057,540;
WO 90/03184, WO 96/11711, , ); bacterial or microbial
derivatives, examples of which are monophosphoryl lipid A (MPL), 3-O-deacylated MPL
(3dMPL), CpG-motif containing oligonucleotides, ADP-ribosylating bacterial toxins or
mutants thereof, such as E. coli heat labile enterotoxin LT, cholera toxin CT, pertussis toxin
PT, or tetanus toxoid TT, Matrix M (Isconova). In addition, known immunopotentiating
technologies may be used, such as fusing the polypeptides described herein to proteins
known in the art to enhance immune response (e.g. tetanus toxoid, CRM197, rCTB,
bacterial flagellins or others) or including the polypeptides in virosomes, or combinations
thereof. Other non-limiting examples that can be used are e.g. disclosed by Coffman et al.
(2010).
In an embodiment, the influenza hemagglutinin stem domain polypeptides described
herein are incorporated into viral-like particle (VLP) vectors. VLPs generally comprise a
viral polypeptide(s) typically derived from a structural protein(s) of a virus. Preferably, the
VLPs are not capable of replicating. In certain embodiments, the VLPs may lack the
complete genome of a virus or comprise a portion of the genome of a virus. In some
embodiments, the VLPs are not capable of infecting a cell. In some embodiments, the VLPs
express on their surface one or more of viral (e.g., virus surface glycoprotein) or non-viral
(e.g., antibody or protein) targeting moieties known to one skilled in the art.
In a specific embodiment, the polypeptide described herein is incorporated into a
virosome. A virosome containing a polypeptide described herein may be produced using
techniques known to those skilled in the art. For example, a virosome may be produced by
disrupting a purified virus, extracting the genome, and reassembling particles with the viral
proteins (e.g., an influenza hemagglutinin stem domain polypeptide) and lipids to form lipid
particles containing viral proteins.
Also described are the above-described polypeptides, nucleic acids and/or
immunogenic compositions for inducing an immune response in a subject against
influenza HA, in particular for use as a vaccine. The influenza hemagglutinin stem
domain polypeptides, nucleic acids encoding such polypeptides, or vectors comprising
such nucleic acids or polypeptides described herein thus may be used to elicit neutralizing
antibodies against influenza viruses, for example, against the stem region of influenza
virus hemagglutinin. Also described are polypeptides, nucleic acids, and/or imunogenic
compositions as described above for use as a vaccine in the prevention and/or treatment
of a disease or condition caused by an influenza A virus of phylogenetic group 1 and/or
phylogenetic group 2 and/or an influenza B virus. In an embodiment, the vaccine may be
used in the prevention and/or treatment of diseases caused by two, three, four, five, six or
more different subtypes of phylogenetic group 1 and/or 2 and/or influenza B viruses. The
polypeptides described herein may be used after synthesis in vitro or in a suitable cellular
expression system, including bacterial and eukaryotic cells, or alternatively, may be
expressed in vivo in a subject in need thereof, by expressing a nucleic acid coding for the
immunogenic polypeptide. Such nucleic acid vaccines may take any form, including
naked DNA, plasmids, or viral vectors including adenoviral vectors.
Administration of the polypeptides, nucleic acid molecules, and/or immunogenic
compositions described herein can be performed using standard routes of administration.
Non-limiting examples include parenteral administration, such as intravenous, intradermal,
transdermal, intramuscular, subcutaneous, etc, or mucosal administration, e.g. intranasal,
oral, and the like. The skilled person will be capable to determine the various possibilities
to administer the polypeptides, nucleic acid molecules, and/or immunogenic compositions
according to the disclosure, in order to induce an immune response. In certain
embodiments, the polypeptide, nucleic acid molecule, and/or immunogenic composition (or
vaccine) is administered more than one time, i.e. in a so-called homologous prime-boost
regimen. In certain embodiments where the polypeptide, nucleic acid molecule, and/or
immunogenic composition is administered more than once, the administration of the second
dose can be performed after a time interval of, for example, one week or more after the
administration of the first dose, two weeks or more after the administration of the first dose
, three weeks or more after the administration of the first dose, one month or more after the
administration of the first dose, six weeks or more after the administration of the first dose,
two months or more after the administration of the first dose, 3 months or more after the
administration of the first dose, 4 months or more after the administration of the first dose,
etc, up to several years after the administration of the first dose of the polypeptide, nucleic
acid molecule, and/or immunogenic composition. It is also possible to administer the
vaccine more than twice, e.g. three times, four times, etc, so that the first priming
administration is followed by more than one boosting administration. In other
embodiments, the polypeptide, nucleic acid molecule, and/or immunogenic composition
described herein is administered only once.
The polypeptides, nucleic acid molecules, and/or immunogenic compositions may
also be administered, either as prime, or as boost, in a heterologous prime-boost regimen.
Also described are methods for preventing and/or treating an influenza virus disease
in a subject utilizing the polypeptides, nucleic acids and/or compositions described herein.
In a specific embodiment, a method for preventing and/or treating an influenza virus
disease in a subject comprises administering to a subject in need thereof an effective
amount of a polypeptide, nucleic acid and/or immunogenic composition, as described
above. A therapeutically effective amount refers to an amount of the polypeptide, nucleic
acid, and/or composition as defined herein, that is effective for preventing, ameliorating
and/or treating a disease or condition resulting from infection by a group 1 or 2 influenza A
virus, and/or an influenza B virus. Prevention encompasses inhibiting or reducing the
spread of influenza virus or inhibiting or reducing the onset, development or progression of
one or more of the symptoms associated with infection by an influenza virus. Ameloriation
as used in herein may refer to the reduction of visible or perceptible disease symptoms,
viremia, or any other measurable manifestation of influenza infection.
Those in need of treatment include those already inflicted with a condition resulting
from infection with a group 1 or a group 2 influenza A virus, or an influenza B virus, as
well as those in which infection with influenza virus is to be prevented. The polypeptides,
nucleic acids and/or compositions described herein thus may be administered to a naive
subject, i.e., a subject that does not have a disease caused by influenza virus infection or has
not been and is not currently infected with an influenza virus infection, or to subjects that
already are and/or have been infected with an influenza virus.
In an embodiment, prevention and/or treatment may be targeted at patient groups
that are susceptible to influenza virus infection. Such patient groups include, but are not
limited to e.g., the elderly (e.g. ≥ 50 years old, ≥ 60 years old, and preferably ≥ 65 years
old), the young (e.g. ≤ 5 years old, ≤ 1 year old), hospitalized patients and patients who
have been treated with an antiviral compound but have shown an inadequate antiviral
response.
In another embodiment, the polypeptides, nucleic acids and/or immunogenic
compositions may be administered to a subject in combination with one or more other
active agents, such as existing, or future influenza vaccines, monoclonal antibodies and/or
antiviral agents, and/or antibacterial, and/or immunomodulatory agents. The one or more
other active agents may be beneficial in the treatment and/or prevention of an influenza
virus disease or may ameliorate a symptom or condition associated with an influenza virus
disease. In some embodiments, the one or more other active agents are pain relievers, anti-
fever medications, or therapies that alleviate or assist with breathing.
Dosage regimens of the polypeptides and/or nucleic acid molecules described herein
can be adjusted to provide the optimum desired response (e.g., a therapeutic response). A
suitable dosage range may for instance be 0.1-100 mg/kg body weight, preferably 1-50
mg/kg body weight, preferably 0.5-15 mg/kg body weight. The precise dosage of the
polypeptides and/or nucleic acid molecules to be employed will e.g. depend on the route of
administration, and the seriousness of the infection or disease caused by it, and should be
decided according to the judgment of the practitioner and each subject's circumstances. For
example, effective doses vary depending target site, physiological state of the patient
(including age, body weight, health), and whether treatment is prophylactic or therapeutic.
Usually, the patient is a human but non-human mammals including transgenic mammals
can also be treated. Treatment dosages are optimally titrated to optimize safety and
efficacy.
The polypeptides described herein may also be used to verify binding of monoclonal
antibodies identified as potential therapeutic candidates. In addition, the polypeptides of the
invention may be used as diagnostic tool, for example to test the immune status of an
individual by establishing whether there are antibodies in the serum of such individual
capable of binding to the polypeptide described herein. Also described are an in vitro
diagnostic method for detecting the presence of an influenza infection in a patient said
method comprising the steps of a) contacting a biological sample obtained from said patient
with a polypeptide described herein; and b) detecting the presence of antibody-antigen
complexes.
The polypeptides described herein may also be used to identify new binding
molecules or improve existing binding molecules, such as monoclonal antibodies and
antiviral agents.
The invention is further illustrated in the following examples and figures. The
examples are not intended to limit the scope of the invention in any way.
EXAMPLES
Example 1: Identification of a novel group 1 and group 2 cross-neutralizing antibody:
CR9114
Peripheral blood was collected from normal healthy donors by venapuncture in
EDTA anti-coagulation sample tubes. scFv phage display libraries were obtained
essentially as described in , which is incorporated by reference herein.
Selection was performed against recombinant hemagglutinin (HA) of influenza A
subtype H1 (A/New Caledonia/20/99), H3 (A/Wisconsin/67/2005), H4 (A/Duck/Hong
Kong/24/1976), H5 (A/Chicken/Vietnam/28/2003), H7 (A/Netherlands/219/2003) and
H9 (A/HongKong/1073/99). Two consecutive rounds of selections were performed
before isolation of individual single-chain phage antibodies. After the second round of
selection, individual E.coli colonies were used to prepare monoclonal phage antibodies.
Selected supernatants containing single-chain phage antibodies that were obtained in the
screenings described above were validated in ELISA for specificity, i.e. binding to
different HA antigens. For this purpose, baculovirus expressed recombinant H1 (A/New
Caledonia/20/99), H3 (A/Wisconsin/67/2005), H5 (A/Vietnam/1203/04) H7
(A/Netherlands/219/2003), and B (B/Ohio/01/2005) HAs (Protein Sciences, CT, USA)
were coated to Maxisorp ELISA plates. Of the single-chain phage antibodies that were
obtained, single-chain phage antibody SC09-114 was shown to specifically bind
recombinant influenza A H1, H3, H5, H7 and influenza B HA. Binding and specificity of
SC09-114 was validated by FACS analysis. For this purpose, full-length recombinant
influenza A subtypes H1 (A/New Caledonia/20/1999), H3 (A/Wisonsin/67/2005) and H7
(A/Netherlands/219/2003) HAs were expressed on the surface of PER.C6 cells. SC09-
114 was shown to specifically bind to influenza A subtypes H1, H3 and H7 HA. Heavy
and light chain variable regions of the scFv were cloned as described before (WO
2008/028946). The resulting expression constructs encoding the human IgG1 heavy and
light chains were transiently expressed in combination in 293T cells and supernatants
containing the human IgG1 antibody CR9114 were obtained and produced using standard
purification procedures. The amino acid sequence of the CDRs of the heavy and light
chains of CR9114 are given in Table 1. The nucleotide and amino acid sequences and of
the heavy and light chain variable regions are given below.
Example 2: Cross-binding reactivity of CR9114
CR9114 was validated in ELISA for binding specificity, i.e. binding to different
HA antigens. For this purpose, baculovirus expressed recombinant H1 (A/New
Caledonia/20/1999), H3 (A/Wisconsin/67/2005), H5 (A/Vietnam/1203/04, H7
(A/Netherlands/219/2003) and H9 (A/HongKong/1073/99) HA’s (Protein Sciences, CT,
USA) were coated to Maxisorp ELISA plates. As a control, an unrelated IgG CR4098
was used. CR114 was shown to have heterosubtypic cross-binding activity to all the
recombinant HAs tested. See Table 2.
Additionally, the antibody was tested for heterosubtypic binding by FACS
analysis. For this purpose, full-length recombinant influenza A subtypes H1 (A/New
Caledonia/20/1999), H3 (A/Wisonsin/67/2005) and H7 (A/Netherlands/219/2003) HAs
were expressed on the surface of PER.C6 cells. The cells were incubated with CR9114
for 1 hr followed by three wash steps with PBS+0.1%BSA. Bound antibody was detected
using PE conjugated anti-human antibody. As a control, untransfected PER.C6 cells were
used. CR9114 showed cross-binding activity to influenza A subtypes H1, H3 and H7 HA
but not wild-type PER.C6 cells. See Table 2.
Example 3: Cross-neutralizing activity of CR9114
In order to determine whether CR9114 was capable of blocking multiple influenza
A strains, additional in vitro virus neutralization assays (VNA) were performed. The
VNA were performed on MDCK cells (ATCC CCL-34). MDCK cells were cultured in
MDCK cell culture medium (MEM medium supplemented with antibiotics, 20 mM
Hepes and 0.15% (w/v) sodium bicarbonate (complete MEM medium), supplemented
with 10% (v/v) fetal bovine serum). The H1 (A/WSN/33, A/New Caledonia/20/1999,
A/Solomon Islands/IVR-145 (high-growth reassortant of A/Solomon Islands/3/2006),
A/Brisbane/59/2007, A/NYMC/X-181 (high-growth reassortant of
A/California/07/2009), H2 (A/Env/MPU3156/05), H3 (A/Hong Kong/1/68,
A/Johannesburg/33/94, A/Panama/2000/1999, A/Hiroshima/52/2005,
A/Wisconsin/67/2005 and A/Brisbane/10/2007), H4 (A/WF/HK/MPA892/06), H5 (PR8-
H5N1-HK97 (6:2 reassortant of A/Hong Kong/156/97 and A/PR/8/34) and A/Eurasian
Wigeon/MPF461/07), H6 (A/Eurasian Wigeon/MPD411/07), H7 (NIBRG-60 (6:2
reassortant of A/Mallard/Netherlands/12/2000) and PR8-H7N7-NY (7:1 reassortant of
A/New York/107/2003 (H7N7) and A/PR/8/34)), H8 (A/Eurasian Wigeon/MPH571/08)
H9 (A/Hong Kong/1073/99 and A/Chick/HK/SSP176/09), H10 (A/Chick/Germany/N/49)
and H14 (PR8-H14N5 (6:2 reassortant of A/mallard/Astrakhan/263/1982 (H14N5) and
A/PR/8/34)) strains which were used in the assay were all diluted to a titer of 5,7 x10
TCID50/ml (50% tissue culture infective dose per ml), with the titer calculated according
to the method of Spearman and Karber. The IgG preparations (200 μg/ml) were serially
2-fold diluted (1:2 - 1:512) in complete MEM medium in quadruplicate wells. 25 μl of
the respective IgG dilution was mixed with 25 μl of virus suspension (100 TCID50/25 μl)
and incubated for one hr at 37°C. The suspension was then transferred in quadruplicate
onto 96-well plates containing confluent MDCK cultures in 50 μl complete MEM
medium. Prior to use, MDCK cells were seeded at 3x10 cells per well in MDCK cell
culture medium, grown until cells had reached confluence, washed with 300-350 μl PBS,
pH 7.4 and finally 50 μl complete MEM medium was added to each well. The inoculated
cells were cultured for 3-4 days at 37°C and observed daily for the development of
cytopathogenic effect (CPE). CPE was compared to the positive control.
CR9114 was shown to have heterosubtypic cross-neutralizing activity to
representative strains of all tested influenza A subtypes H1, H2, H3, H4, H5, H6, H7, H8,
H9 and H10 viruses. See Table 3.
Example 4: Design of a stem domain polypeptide comprising the conserved stem domain
epitopes of CR6261 and CR9114 based on H1 HA
Fully human monoclonal antibodies against influenza virus hemagglutinin with
broad cross-neutralizing potency were identified previously. CR6261 (as described in
) was shown to have broadly cross-neutralizing activity against
influenza A viruses of phylogenetic group 1. In addition, CR9114, described above, has
been shown to be able to bind to and neutralize influenza A viruses of both phylogenetic
group 1 and 2, as well as influenza B viruses. Functional and structural analysis have
revealed that these antibodies interfere with the membrane fusion process and are
directed against highly conserved epitopes in the stem domain of the influenza HA
protein (Throsby et al.(2008); Ekiert et al. (2009) WO2008/028946, and co-pending
application no. EP11173953.8).
In the research that led to the present invention, new molecules comprising the
stem domains of HA containing these epitopes were designed in order to create universal
epitope-based immunogenic polypeptides that can be used, e.g. as a vaccine inducing
protection against a broad range of influenza strains. Essentially, the highly variable and
immunodominant part, i.e. the head domain is first removed from the full length HA
molecule to create a HA stem-domain polypeptide, also referred to as “mini-HA”. In this
way the immune response will be redirected towards the stem domain where the epitopes
for the broadly neutralizing antibodies are located. The antibodies CR6261 and CR9114
are used to probe the correct folding of the newly created molecules, and to confirm the
presence of the neutralizing epitopes.
The polypeptides of this invention thus present the conserved epitopes of the
membrane proximal stem domain HA molecule to the immune system in the absence of
dominant epitopes that are present in the membrane distal head domain. To this end, part
of the primary sequence of the HA0 protein making up the head domain is removed and
reconnected, either directly or by introducing a short flexible linking sequence (‘linker’)
to restore the continuity of the chain. The resulting sequence is further modified by
introducing specific mutations that stabilize the native 3-dimensional structure of the
remaining part of the HA0 molecule.
The function of the HA molecule in the virus is binding to the cell surface
receptor sialic acid and, after uptake in endosomes, mediating the fusion of viral and
endosomal membranes leading to release of the viral RNA into the cell. An essential step
in the fusion process is a large conformational change of the HA molecule that rearranges
the secondary structure elements of the molecule so that the fusion peptide becomes
exposed. Consequently, two conformations (pre- and post-fusion) of the HA molecule
exist that are very different in terms in their tertiary structure. Since the viral HA protein
is primarily exposed to the immune system in the pre-fusion state, it is important to make
sure that the polypeptide of the invention adopts this conformation. This requirement can
be met by stabilizing the pre-fusion conformation and at the same time destabilizing the
post-fusion conformation. This stabilization/destabilization is a necessity since the pre-
fusion conformation is metastable and adopting the post-fusion conformation results in a
stable conformation, i.e. a low energy minimum (Chen et al, 1995).
In this example, HA from H1N1 A/Brisbane/59/2007 (SEQ ID NO: 1) is taken as
the primary (or wild-type) sequence to create the polypeptides of the invention.
In a first step, polypeptides of the invention are constructed by removing HA1
sequences between positions 59 and 291 (the numbering refers to the position in the HA0
sequence, as shown in SEQ ID NO: 1. In certain embodiments, the HA1 part comprises
the amino acids 18-343 and the HA2 part the amino acid residues 344-565; since SEQ ID
NO: 1 comprises the signal peptide, and the HA1 part starts at position 18). This results
in the removal of residues 60 to 290 of HA0. These residues were replaced by a GGGG
linking sequence. Next, the accessible surface area of each residue in both the pre- and
post-fusion conformation was calculated with the aid of Brugel (Delhaise et al., 1984).
The degree of exposure and burial of each residue was determined as described in
Samantha et al (2002), wherein was focused on residues that are exposed in the pre-
fusion conformation and get buried in the post-fusion conformation. Further analysis of
these residues indicated that some of these amino acid residues can be mutated in such a
way that the mutation does not have an effect on the pre-fusion conformation but
destabilizes the post-fusion conformation. These residues have in general a hydrophobic
side chain and are involved in the formation of the coiled coil in the post-fusion
conformation. Mutating these amino acid residues to a hydrophilic amino acid will
disturb the coiled coil properties – the contacts between the helices in a coiled coil are in
general hydrophobic – and hence destabilize the post-fusion conformation.
Following this reasoning, in the HA2 part of the sequence some mutations were
introduced: Phe 406 to Ser (F406S), Val 409 to Thr (V409T), Leu 416 to Ser (L416S)
and Tyr 502 to Ser (Y502S). These are mutations that remove a hydrophobic residue
from the surface of HA. It should be noted that mutation of L416 to either S or T also
introduces a consensus N-glycosylation site (consensus sequence is NX(S/T).
Glycosylation at this position will further increase solubility of this region. In addition,
Leu 58 was mutated to Thr (L58T), Val 314 to Thr (V314T) and Ile 316 to Thr (I316T);
these mutations are all in the HA1 domain, i.e. the part of the sequence corresponding to
HA1 after cleavage of the native HA0 chain. The latter two mutations maintain the beta-
branch of the side chain but remove a hydrophobic residue from the surface. As will be
shown below some of these mutations were introduced in all variants, others were tested
in separate polypeptides to investigate whether the mutations influence each other in an
undesirable manner.
To increase the stability of the polypeptides, two disulfide bridges were
investigated to lock HA in the pre-fusion conformation. The disulfide bridges are formed
between residues which are spatially at an appropriate distance from each other (in the
full length HA molecule) and which have their C-beta atom already at the correct position
to form a disulfide bridge. The first disulfide bridge proposed is between position 321
(HA1 domain) and position 405 (HA2 domain). Within the HA2 domain, a disulfide
bridge was created between positions 413 and 421.
Since cleavage of HA at position R343 is an essential step for the conformational
change to be able to take place, in the polypeptides of the invention the cleavage site was
removed by introducing a mutation of Arg (R) to a Gln (Q). Another solution according
to the invention is to change Arg into a Gln and to delete residues 345 to 350, a small part
of the fusion peptide of HA2. Removal of these (hydrophobic) sequence will further
stabilize the polypeptide.
In certain embodiments, the polypeptides of the invention contain the intracellular
sequences of HA and the transmembrane domain. In other embodiments, the cytoplasmic
sequence and the transmembrane sequence from position (or the equivalent thereof) 523,
524, 525, 526, 526, 527, 528, 529, or 530 of HA2 to the C-terminus of HA2 (numbering
according to SEQ ID NO: 1) were removed so that a secreted (soluble) polypeptide was
produced following expression in cells, which can be used e.g. in a vaccine. The soluble
polypeptide was further stabilized by introducing a sequence known to form trimeric
structures, i.e. AYVRKDGEWVLL (SEQ ID NO: 143), optionally connected through a
linker. The linker may optionally contain a cleavage site for processing afterwards
according to protocols well known to those skilled in the art. To facilitate purification of
the soluble form a tag sequence may be added, e.g. a his tag (HHHHHHH) connected via
a short linker, e.g. EGR. In some embodiments the linker and his-tag sequence are added
without the foldon sequence being present. According to the present invention, the amino
acid sequence from position 530 (numbering according to SEQ ID NO: 1) to the C-
terminal amino acid of the HA2 domain was removed and replaced by the following
sequences:
EGRHHHHHHH (SEQ ID NO: 81), comprising a short linker and his tag, or
SGRSLVPRGSPGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGHHHHHHH (SEQ ID
NO: 82), comprising a thrombin cleavage site, trimerization domain, and his tag.
The mutations described above were grouped into clusters according to their
function and location in the 3-dimensional structure of the HA stem polypeptides. All
polypeptides contain H1 HA sequence 1-59 and 291-565 and the R343Q mutation, with
the following additional mutations: L58T, V314T, I316T, F406S, V409T, L416S (SEQ
ID NO: 3; named cluster 1). In addition variants were made that have additional
mutations:
Cluster 2: K321C, Q405C (SEQ ID NO: 4)
Cluster 3: F413C, E421C (SEQ ID NO: 5)
Cluster 4: HA2 Y502S (SEQ ID NO: 6)
Furthermore two variants were made that contained the cluster 1 sequence and in
addition the mutations of cluster 2 and 3 (SEQ ID NO: 7) or cluster 2, 3 and 4 (SEQ ID
NO: 8).
The genes encoding the above protein sequences were synthesized and cloned into
expression vector pcDNA2004 using methods generally known to those skilled in the art.
For reasons of comparison the full length sequence (SEQ ID NO: 1) was included in the
experiment as well as the sequence described by Steel et al (2010) (H1-PR8-dH1; SEQ
ID NO: 24), which is based on the H1N1 A/Puerto Rico/8/1934 sequence.
HEK293F (Invitrogen) suspension cells (10 cells/ml, 30 ml) were transfected
with the expression vectors (1 µg/ml) using 40 µl 293transfectin as the transfection agent
and allowed to further propagate for 2 days. Cells were harvested, aliquotted (0.3 ml,
approximately 3*10 cells) and aliquots were treated with either polyclonal serum raised
against H1 HA to probe expression or a HA-specific monoclonal antibody (5
microgram/ml) and a secondary antibody used for staining. The cells were then analyzed
by fluorescence associated cell sorting (FACS) for expression of the membrane attached
HA stem domain polypeptides of the invention using polyclonal serum raised against H1
HA to probe expression. A panel of monoclonal antibodies of known specificity that bind
the full length protein (e.g. CR6261 and CR9114) were used to probe for the presence of
conserved epitopes and, by inference, correct folding of the full length HA and the mini-
HA polypeptides of the invention. Results are expressed as percentage positive cells and
mean fluorescence intensity and are shown in
The results show that all constructs are expressed on the cell surface since the
reaction with the polyclonal serum (anti-H1 poly) results in 75% or higher of all cells
analyzed being positive compared to ca 4% for non-transfected cells. This is confirmed
by the values of the mean fluorescence intensity (MFI), which is similar for all constructs
after treatment with polyclonal serum. Control experiments in the absence of IgG, using
only the labeled anti-Human IgG or an irrelevant mAb are all negative. Both the
A/Brisbane/59/2007 and A/Puerto Rico/8/1934 full length HA proteins are recognized by
monoclonal antibodies CR6261, CR6254, CR6328 (all known to bind and neutralize H1
HA; Throsby et al. (2008), ), CR9114 (described above), CR8001
(binds to H1 HA, but does not neutralize H1; described in WO2010/130636), but not
CR8057 (binds only to some H3 strains, also described in WO2010/130636) and CR6307
(Throsby et al. (2008), ).
Considering the discontinuous and conformational character of the CR6261
epitope (Ekiert et al. 2009) it is concluded that both full length proteins are present in
their native 3-dimensional conformation. For the newly designed polypeptides of the
invention that are tested in this experiment the same pattern of recognition by the panel of
monoclonal antibodies was observed: binding by CR6261, CR6254, CR6328, CR9114
and CR8001 but not CR6307 and CR8057. This is most evident in the data on the
percentage positive cells, but is also observed in the mean fluorescence intensity data.
Best results are obtained with miniHA-cluster1 both with respect to % cells positive as
well as mean fluorescence intensity.
Adding further modifications, such as the above described disulfide bridges
(cluster 2 and 3) and the Y502S mutation of cluster 4 (or combinations of these, resulted
in decreased percentages of positive cells and lower mean intensities. The construct
described by Steel et al. (2010) (SEQ ID NO: 24) which contains the deletion of the head
domain, but lacks further modifications is not recognized above background level by any
of the antibodies used in this experiment. Therefore, it is concluded that after DNA
transfection this protein is not displayed in the native 3-dimensional conformation that it
has in HA.
The results described above point towards the importance of cluster 1 mutations
increasing the hydrophilic character of the loop formed by residues 402 to 418 connecting
the A-helix and the long backbone helix (CD) of the HA-molecule and the surrounding
area. To further establish the beneficial effect the mutations of cluster1 on the stability
and folding of the polypeptides of the invention miniHA (SEQ ID NO: 2; polypeptide
according to Steel, but based on A/Brisbane) and miniHA_cluster1 (polypeptide
according to the invention; SEQ ID NO: 3) were compared in a separate experiment
(.
Whereas about 60% of cells transfected with miniHA-cluster1 is positive after
binding of CR6261, CR6254, CR6328 and CR9114, transfection with miniHA
(polypeptide according to Steel, but based on A/Brisbane; SEQ ID NO: 2) leads to values
very close to background level (1-3%). We conclude that the mutations of cluster1
contribute favorably to proper folding and stability of the polypeptides according to the
present invention, as compared to unmodified miniHA protein (SEQ ID NO: 2) that lacks
these mutations.
Steel et al. created a new molecule by deleting amino acid residue 53 to 276 of
HA1 of the H1 A/Puerto Rico/8/1934 and H3 HK68 strain from the primary sequence,
and replacing this by a short flexible linker. As shown in this Example this results in a
highly unstable molecule that does not adjust the correct conformation, as proven by the
lack of binding of antibodies that were previously shown to bind to conserved epitopes in
the stem region. The incorrect folding is caused by solvent exposure of a large area that is
normally shielded by the globular head in the full length HA molecule. Since this area is
hydrophobic in nature the molecule is no longer stable and therefore adaptations are
necessary.
Exchange of hydrophobic residues for hydrophilic residues as has been done in
the polypeptides of the invention counteracts this effect and stabilizes the HA stem
domain polypeptides. Further stabilization of the native 3-dimensional fold of the stem
domain is achieved by introducing disulfide bridges at appropriate locations to closely
connect residues that are spatially close in the native tertiary structure but separated in the
primary structure.
Example 5: Immunogenicity of HA stem domain polypeptides of Example 4
In order to assess the immunogenicity of the stem domain polypeptides mice were
immunized with the expression vectors encoding full length H1 from A/Brisbane/59/2007
(SEQ ID NO: 1), miniHA-cluster1 (SEQ ID NO: 3), miniHA-cluster1+2 (SEQ ID NO:
4) and miniHA- cluster1+4 (SEQ ID NO:6). For reasons of comparison the miniHA
design by Steel et al. (2010) (mini-PR8; SEQ ID NO: 24) and the corresponding full
length protein HA from A/Puerto Rico/8/1934 were also included in the experiment. An
expression vector encoding for cM2 was also included as a negative control.
Groups of 4 mice (BALB\c) were immunized with 50 µg construct + 50 µg
adjuvant (pUMCV1-GM-CSF) i.m. on day 1, 21 and 42. On day 49 a final bleed was
performed and serum collected. The sera were analyzed by FACS assay. HEK293F
(Invitrogen) suspension cells (10 cell/ml, 30 ml) were transfected with the expression
vectors (1 microgram/ml) using 40 microliter 293transfectin as the transfection agent and
allowed to further propagate for 2 days. Cells were harvested, aliquotted (0.3 ml,
approximately 3*10 cells) and aliquots were treated with the construct-specific sera,
stained with secondary antibodies and analyzed by fluorescence associated cell sorting.
The results are shown in
As expected, the cM2-specific serum (negative control) recognizes cM2, but none
of the full-length HA or stem domain polypeptides as evidenced by the % positive cells
and MFI. In contrast, the full length HA-specific serum stains cells expressing the
corresponding full length HA (SEQ ID NO: 1), but also miniHA-cluster1 (SEQ ID NO:
3) , miniHA-cluster1+2 (SEQ ID NO:4) and miniHA-cluster1+4(SEQ ID NO:6) , albeit
at a lower level (ca 40% positive cells versus ca 80% for full length, MFI ca 1000 versus
ca 7000 for full length). The reverse is also true: sera specific for miniHA-cluster1 (SEQ
ID NO: 3), miniHA-cluster1+2 (SEQ ID NO:4) and miniHA-cluster1+4(SEQ ID NO:6)
recognize cells expressing the corresponding construct as well as the full length HA (SEQ
ID NO: 1). The results are summarized in Table 4, below.
In contrast to the result above for miniHA-cluster1(SEQ ID NO: 3) , miniHA-
cluster1+2 (SEQ ID NO:4) and miniHA-cluster1+4(SEQ ID NO:6), the serum obtained
from mice immunized with the full length PR8 did not bind very well to cells transfected
with H1-PR8-dH1 (SEQ ID NO:24). Percentage cells positive was around 20%,
compared to 40-50% for the miniHA-cluster1 (SEQ ID NO: 3) and miniHA-cluster 1+2
(SEQ ID NO: 4). The results are also reflected in the observed in the mean fluorescent
intensity which is barely above background level.
In conclusion, the data show that polypeptides of the invention are capable of
inducing an immune response directed towards full length HA. In particular
modifications in the region between residue 402 and 418 (numbering according to SEQ
ID NO: 1) is important to create a stable molecule.
Example 6: Preparation of second generation of stem domain polypeptides
The mean fluorescence intensities for the stem domain polypeptides described in
Example 4 are in all cases lower than observed for the corresponding full length proteins;
in fact the best design, miniHA-cluster 1 (SEQ ID NO: 3), has an intensity that is in the
order of 10% of the mean intensity of the full length construct after binding with
monoclonal antibodies. This indicates that the expression and/or folding of the stem
domain polypeptides on the cells surface is lower than observed for the full length
proteins and that the designs can be further improved. The results obtained from the first
generation show that improvement of the first generation constructs is possible and
therefore a second round of design was initiated.
The polypeptides described in Example 4 were based on the same deletion of the
HA0 chain, i.e. residues L60 to K290 (mini1; numbering refers to position in the full
length HA0 from H1N1 A/Brisbane/59/2007; SEQ ID NO: 1). This approach creates a
long unstructured loop that is now no longer attached to the head domain. It was reasoned
that this loop is not contributing to the overall protein stability and can be shortened
considerably without affecting folding of the other parts of the polypeptide. Three
additional deletions were designed and replaced with a GGGG linker sequence as before
and combined with the mutations of cluster1 described above. The deletions are S53 to
P320 (mini2), H54 to I302 (mini3), G56 to G317 (mini4). Additional modifications were
introduced identical to cluster 1 above (L58T, V314T, I316T, F406S, V409T, L416S).
Some of the residues belonging to this cluster are part of the deleted sequences and can
therefore no longer be modified (see below). Furthermore, two additional mutations were
created in the long helix C that forms a trimeric coiled-coil in the pre-fusion state. It is
well known in the art that trimeric coiled coils are stabilized by Ile at positions 420 a and
d of the heptad repeat sequence that is the hallmark of this structural motif (Suzuki et al.,
(2005); Woolfson et al. (2005)). This knowledge was applied by introducing Ile at
positions 420 (M420I) and 427 (V427I). The combination of these two mutations and the
mutations of cluster 1 were designated cluster11; for clarification the combinations are
listed below:
Mini1: deletion L60 to K290 cluster11: M420I, V427I, L58T, V314T, I316T,
F406S, V409T, L416S
Mini2: deletion S53 to P320 cluster11: M420I, V427I, F406S, V409T, L416S
Mini3: deletion H54 to I302 cluster11: M420I, V427I, V314T, I316T, F406S,
V409T, L416S
Mini4: deletion G56 to G317 cluster11: M420I, V427I, F406S, V409T, L416S
To further stabilize the pre-fusion state of the stem domain polypeptides an
additional disulfide bridge was introduced between position 324 and 436 (cluster 5:
R324C, T436C) and combined with the different deletion mutants. The following
combinations were synthesized and tested for binding in the FACS assay as described
above:
Mini1-cluster11 (SEQ ID NO: 9)
Mini2-cluster11 (SEQ ID NO: 10)
Mini3-cluster11 (SEQ ID NO: 11)
Mini4-cluster11 (SEQ ID NO: 12)
Mini1-cluster11+5 (SEQ ID NO: 13)
Mini2-cluster11+5 (SEQ ID NO: 14)
Mini3-cluster11+5 (SEQ ID NO: 15)
Mini4-cluster11+5 (SEQ ID NO: 16)
For reasons of comparison miniHA-cluster1 (SEQ ID NO:3) was also included in
the experiment. The results are shown in
In all cases the stem domain polypeptides were present on the cell surface after
transfection of expression vectors into HEK293F cells, as evidenced by the percentage of
positive cells (90% or larger) after treatment with polyclonal anti-H1 serum.
All HA stem domain polypeptides in this experiment were recognized by
CR6261, CR6254, CR6328 and CR9114, but not CR8057; the latter is expected since this
mAb is specific for H3 HA. There are, however, clear differences in the percentages of
cells positive and MFI for the different antibodies. The best characterized antibody is
CR6261, of which the epitope is known in detail. The epitope is discontinuous and
conformational, and binding of this antibody can therefore be regarded as a stringent test
of correct folding of the HA stem domain polypeptides. CR9114 is broadly neutralizing,
covering strains from both group 1 and 2 (Table 3). Of the epitopes of CR6328 and
CR6254 less details are known, but based on the higher values that are found for %
positive cells and MFI, as well as a smaller spread in the data, binding of these antibodies
seems to be a less sensitive probe of correct folding than CR6261.
Comparing the percentage positive cells (taking into account the data for all
antibodies) Mini1 to 4 constructs can be ranked (highest to lowest %).
Mini2 > Mini1 > Mini4 > Mini3 for combinations with cluster11 and
Mini2 > Mini1 = Mini4 > Mini3 for combinations with cluster11+5
This ranking is also reflected in the data on the MFI, and leads to the conclusion that the
deletion of the Mini2 construct, S53 to P320, leads to the highest level of proteins
displayed on the cell surface in the correct conformation from this set.
Comparing MiniHA-cluster1 (SEQ ID NO: 3) with mini1-cluster11 (SEQ ID NO:
9), the additional mutations M420I, V427I do not seem to lead to additional stabilization
of the construct; if anything, they lead to lower percentages of positive cells and MFI
values, but the differences are small.
The introduction of disulfide bridge R324C, T436C (cluster 5) leads to an
increase of correctly folded protein on the cell surface for mini2-cluster11 (SEQ ID NO:
10) and mini4-cluster11 (SEQ ID NO: 12), but minimal or no improvement for mini1-
cluster11 (SEQ ID NO: 9) and mini3-cluster11 (SEQ ID NO: 11). The best results overall
are obtained with mini2-cluster11+5 (SEQ ID NO: 14). This is in particular evident from
the MFI values which for this construct are ca 50% of the value for the full length
construct.
In certain embodiments, the polypeptides of the invention contain the intracellular
sequences of HA and the transmembrane domain. In other embodiments, the cytoplasmic
sequence and the transmembrane sequence from position (or the equivalent thereof) 523,
524, 525, 526, 526, 527, 528, 529, or 530 of HA2 to the C-terminus of HA2 (numbering
according to SEQ ID NO: 1) is removed, and optionally replaced by introducing a
sequence known to form trimeric structures, i.e. AYVRKDGEWVLL (SEQ ID NO:
143), optionally connected through a linker. The linker may optionally contain a
cleavage site for processing afterwards according to protocols well known to those
skilled in the art. To facilitate purification of the soluble form a tag sequence may be
added, e.g. a his tag HHHHHHH connected via a short linker, e.g. EGR. According to
the present invention, the amino acid sequence from position 530 (numbering according
to SEQ ID NO: 1) to the C-terminal amino acid of the HA2 domain was removed and
replaced by SEQ ID NO: 81 or SEQ ID NO: 82.
Example 7: Immunogenicity of second generation HA stem domain polypeptides
In order to assess the immunogenicity of the stem domain polypeptides of
Example 6, mice were immunized with the expression vectors encoding full length H1
from A/Brisbane/59/2007 (SEQ ID NO: 1), miniHA-cluster1 (SEQ ID NO: 3), Mini2-
cluster11 (SEQ ID NO: 10), Mini1-cluster11+5 (SEQ ID NO: 13), Mini2-cluster11+5
(SEQ ID NO: 14). An expression vector encoding for cM2 was also included as a
negative control.
Groups of 4 mice (BALB\c) were immunized with 50 µg construct + 50 µg
adjuvant (pUMCV1-GM-CSF) i.m. on day 1, 21 and 42. On day 49 a final bleed was
performed and serum collected. Full length HA0 (SEQ ID NO: 1), negative control cM2
and Mini2-cluster11+5 (SEQ ID NO: 14) were also administered to separate groups of
mice by gene gun, using ca 10 µg construct + ca. 2µg adjuvant (pUMCV1-GM-CSF) and
the same immunization scheme. The sera were analyzed by Elisa using the recombinant
ectodomain of the full length HA from A/Brisbane/59/2007 strain (obtained from Protein
Sciences Corporation, Meriden, CT, USA) as the antigen. In short, 96 wells plates were
coated with 50 ng HA overnight at 4 C, followed by incubation with block buffer (100
ml PBS, pH 7.4 + 2% skim milk) for 1h at room temperature. Plates were washed with
PBS + 0.05% Tween-20, and 100 ml of a 2-fold dilution series in block buffer, starting
from a 20 fold dilution of the serum is added. Bound antibody is detected using HRP –
conjugated goat-anti-mouse IgG, using standard protocols well-established in the art.
Titers are compared to a standard curve using mAb 3AH1 InA134 (Hytest, Turku,
Finland) to derive Elisa units/ml (EU/ml).
Results of the Elisa after 28 and 49 days are shown in Figure 6A and B,
respectively. Serum obtained form mice immunized with DNA encoding Mini2-
cluster11+5 (SEQ ID NO: 14) exhibit clear binding to the ectodomain full length HA
after 28 and 49 days after immunization using the gene gun and also after 49 days when
immunized IM. For Mini2-cluster11 (SEQ ID NO: 10) and Mini1-cluster11+5 (SEQ ID
NO: 13) a response was detected for 1 out of 4 mice, whereas for miniHA-cluster1 (SEQ
ID NO: 3) no binding was detected.
In conclusion, the data show that polypeptides of the invention are capable of
inducing an immune response directed towards full length HA. In particular
modifications in the region between residue 402 and 418 (numbering according to SEQ
ID NO: 1), deletion S53 to P320 in combination with disulfide bridge R324C, T436C are
important to create a stable molecule.
Example 8: Preparation of third generation stem domain polypeptides
To further improve the design of the stem domain polypeptides a third round of
design was implemented. An additional mutation to increase hydrophilicity of surfaces
buried in the full length HA, but not the stem domain polypeptides was introduced at
position 413, F413G (numbering according to SEQ ID NO: 1), and named cluster 6. This
cluster was combined with the deletion of mini-2 (S53 to P320), the disulfide bridge of
cluster 5 (R324C, T436C) and the mutations of either cluster 1 (i.e. F406S, V409T,
L416S; SEQ ID NO: 46) or cluster 11 (M420I, V427I, F406S, V409T, L416S; SEQ ID
NO: 47). The combination of the mini-2 deletion (S53 to P320) with cluster 1 (F406S,
V409T, L416S) and cluster 5 (R324C, T436C) is also included in this experiment for
reference (SEQ ID NO: 48).
The native HA exists as a trimer on the cell surface. Most of the interactions
between the individual monomers that keep the trimer together are located in the head
domain. After removal of the head the tertiary structure is thus destabilized and therefore
reinforcing the interactions between the monomers in the truncated molecule will
increase the stability. In the stem domain trimerization is mediated by the formation of a
trimeric coiled coil motif. By strengthening this motif a more stable trimer can be
created. According to the invention, a consensus sequence for the formation of a trimeric
coiled coil, IEAIEKKIEAIEKKIE (SEQ ID NO: 83), is introduced in a polypeptide of
the invention at (the equivalent of) position 418 to 433 (SEQ ID NO: 44) in H1
A/Brisbane/59/2007 (numbering according to SEQ ID NO: 1). An alternative is to
introduce the sequence MKQIEDKIEEIESKQ (SEQ ID NO: 84), derived from GCN4
and known to trimerize, at position 419-433 (SEQ ID NO: 45).
In the case of the stem domain polypeptides described by SEQ ID NO: 44 to SEQ
ID NO: 48 all proteins were present on the cell surface after transfection of expression
vectors into HEK293F cells, as evidenced by the percentage of positive cells (90% or
larger) after treatment with polyclonal anti-H1 serum. The results are shown in Figure 7.
All HA stem domain polypeptides in this experiment, with the exception of
miniHA (SEQ ID NO: 2), were recognized by CR6261, CR6328 and CR9114, but not
CR8020; the latter is expected since this mAb is specific for H3 HA. The percentage
positive cells is around 80% for the stem domain polypeptides using CR6261, CR6328
and CR9114 for staining, with the exception of miniHA, which is only recognized by the
polyclonal anti-H1 serum. Again, this is indicative of a lack of proper folding of this
particular construct. There are, however, clear differences in the MFI for the different
antibodies. The best characterized antibody is CR6261, of which the epitope is known in
detail. The epitope is discontinuous and conformational, and binding of this antibody can
therefore be regarded as a stringent test of correct folding of the HA stem domain
polypeptides. CR9114 is broadly neutralizing, covering strains from both group 1 and 2
(Table 3). Of the epitope of CR6328 less details are known but in binding experiments on
full length HA competition with CR6261 is observed.
The MFI for H1-mini2-cl11+5 (SEQ ID NO: 14), H1-mini2-cl1+5 (SEQ ID NO:
48), H1-mini2-cl1+5+6 (SEQ ID NO: 46) and H1-mini2-cl11+5+6 (SEQ ID NO: 47) are
very similar, irrespective of the monoclonal antibody that is used in the experiment. The
inclusion of the consensus trimerization domain (SEQ ID NO: 44) reduces the MFI by a
factor 3 to 4 compared to the equivalent sequence without the trimerization domain (i.e.
H1-mini2-cluster1+5+6; SEQ ID 46), but the result is still clearly better than in the
absence of modifications to the stem polypeptide after deletion of the head domain (cf
miniHA results). The addition of the GCN4 trimerization sequence (SEQ ID NO: 45)
increases the MFI to levels comparable to the full length protein.
Example 9: Design of further stem domain polypeptides comprising the conserved stem
domain epitopes of CR6261 and CR9114
Polypeptides of the invention designed following the the procedure described
above can be further modified to increase the stability. Such modifications can be
introduced to enhance the formation of trimeric forms of the polypeptides of the
invention over monomeric and/or dimeric species. As described above, the native HA
exists as a trimer on the cell surface. Most of the interactions between the individual
monomers that keep the trimer together are located in the head domain. After removal of
the head the tertiary structure is thus destabilized and therefore reinforcing the
interactions between the monomers in the truncated molecule will increase the stability.
In the stem domain trimerization is mediated by the formation of a trimeric coiled coil
motif. By strengthening this motif a more stable trimer can be created.
According to the invention, a consensus sequence for the formation of a trimeric
coiled coil, IEAIEKKIEAIEKKIE (SEQ ID NO; 83), was introduced in a polypeptide of
the invention at (the equivalent of) position 418 to 433 (SEQ ID NO: 44) in H1
A/Brisbane/59/2007 (numbering according to SEQ ID NO: 1). Alternatively
IEAIEKKIEAIEKKI (SEQ ID NO: 85) can be introduced at 419-433 (SEQ ID NO: 49)
or IEAIEKKIEAIEKK (SEQ ID NO: 86) at 420-433 (SEQ ID NO: 50). An alternative is
to introduce the sequence MKQIEDKIEEIESKQ (SEQ ID NO: 84) derived from GCN4
and known to trimerize, at position 419-433 (SEQ ID NO: 45). Alternatively
MKQIEDKIEEIESK (SEQ ID NO: 87) can be introduced at position 420-433 (SEQ ID
NO: 51 ) or RMKQIEDKIEEIESKQK (SEQ ID NO: 88) at position 417-433 (SEQ ID
NO: 52). Similarly, the trimer interface is strengthened by modifying M420, L423,
V427, G430 into Isoleucine. (SEQ ID NO: 53).
Alle peptides were shown to bind CR9114 and CR6261.
In certain embodiments, the polypeptides of the invention do not contain the
signal sequence and/or the intracellular sequences and the transmembrane domain of HA,
as described earlier.
Example 10: Design of a stem domain polypeptide comprising the conserved stem
domain epitopes of CR6261 and CR9114 based on H7 HA
The procedure described above to design polypeptides of the invention was also
be applied to H7. In this example the design of a polypeptide of the invention on the basis
of serotype H7 is described. HA of the H7 influenza virus
A/Mallard/Netherlands/12/2000 (SEQ ID NO: 31) was used as the parental sequence, but
those skilled in the art will understand that the use of other H7 sequences would have
been equally possible because the sequences are well conserved, in particular in the stem
region.
The first modification in the sequence is the removal of the cleavage site at
position 339 (numbering refers to SEQ ID NO: 31 by mutating R to Q (R339Q) to
prevent the formation of HA1 and HA2 from HA0. Optionally residue 341 to 345
(LFGAI, part of the fusion peptide) can additionally be deleted to minimize the exposure
of hydrophobic residues to the aqueous solvent. The positive charge at the cleavage is
100% conserved in H7 and this mutation can therefore be applied in all sequences.
The second modification is the removal of the head domain by deleting a large
part of the HA1 sequence and reconnecting the N- and C-terminal sequences through a
short linker. The deletion can vary in length, but it is preferred that the last residue of the
N-terminal sequence of HA1 and the first residue of the C-terminal sequence are
spatially close together to avoid introducing strain through the linking sequence. In H7
sequences deletions can be introduced at (the equivalent positions of) R53-P315 (mini2;
SEQ ID NO: 33) in H7 A/Mallard/Netherlands/12/2000 (SEQ ID NO: 31). Equivalent
positions can be easily determined by those skilled in the art by aligning the sequences
using a suitable algorithm such as e.g. Clustal or Muscle. The remaining parts of the
sequence can be joined directly or alternatively a flexible linker can be introduced.
Linker sequences can be 1 to 50 amino acids in length. Preferred are flexible linkers of
limited length (smaller or equal to 10 amino acids), e.g. GGG, GGGG, GSA, GSAG,
GSAGSA, GSAGSAG or similar.
SEQ ID NO: 40 describes such a polypeptide of the invention containing deletion
T54-C314 (mini5; SEQ ID NO: 40). The deletions described above ensure that the
unstructured regions formed by residues 280 – 310 are also removed; this is beneficial to
the overall stability of the polypeptides of the invention. A similar effect was observed
for polypeptides of the invention derived from a H1 sequence (see above).
The deletion of the head domain leaves the loop between residues 394 to 414
now exposed to the aqueous solvent. In H7 HA’s this loop is highly conserved (see table
7). The consensus sequence is: LI (E/D/G) KTNQQFELIDNEF (N/T/S) E (I/V) E (Q/K)
(SEQ ID NO: 32).
To increase the solubility of this loop in the pre-fusion conformation and
destabilize the post-fusion conformation some hydrophobic residues were modified into
polar (S,T,N,Q), charged amino acids (R,H,K,D,E), or flexibility was increased by
mutation to G. Specifically mutations at positions 402, 404, 405, 409, 412 (numbering
refers to SEQ ID NO: 31) will contribute to the stability of a polypeptide of the invention.
For positions F402 and F409 mutation to S is preferred but other polar (T,N,Q),
charged (R,H,K,D,E) and highly flexible amino acids (G) will have the same effect. For
position 404 (96% L), mutation to N or S is preferred; the latter amino acid also occurs
naturally, albeit at low frequency, and mutation of this position is in those cases
unnecessary. Other polar (T, Q), charged (R,H,K,D,E) and highly flexible amino acids
(G) will have the same effect. For position 405 (99% I) mutation to T or D is preferred. D
also occurs naturally and mutation of this position is then unnecessary. Other polar (S, N,
Q), charged (R, H, K, ) and highly flexible amino acids (G) will have the same effect. For
position 412 (I or V) mutation to N is preferred but other polar (S, T, Q), charged (R, H,
K, D, E) or flexible (G) residues are also possible. So polypeptides contain at least one of
the mutations described above. Combinations of more than one mutationhave also been
applied, as shown for example in SEQ ID NOs: 34-39 and 41-43.
To stabilize the pre-fusion conformation of polypeptides of the invention a
covalent bond between two parts distant in the primary sequences but close in the folded
pre-fusion conformation was introduced. To this end a disulfide bridge was engineered in
the polypeptides of the invention a, preferably between (the equivalent of) position 319
and 432 in H7 A/Mallard/Netherlands/12/2000 (SEQ ID NO: 36-39, 42, 43). Equivalent
positions can be easily determined by those skilled in the art by aligning the sequences
using a suitable algorithm such as Clustal, Muscle etc. Engineered disulfide bridges are
created by mutating at least one (if the other is already a cysteine), but usually two
residues that are spatially close into cysteine, that will spontaneously or by active
oxidation form a covalent bond between the sulfur atoms of these residues.
As described above, the native HA exists as a trimer on the cell surface. Most of
the interactions between the individual monomers that keep the trimer together are
located in the head domain. After removal of the head the tertiary structure is thus
destabilized and therefore reinforcing the interactions between the monomers in the
truncated molecule will increase the stability. In the stem domain trimerization is
mediated by the formation of a trimeric coiled coil motif. By strengthening this motif a
more stable trimer can be created. It is well known in the art that trimeric coiled coils are
stabilized by Ile at positions a and d of the heptad repeat sequence that is the hallmark of
this structural motif. Here this knowledge was applied by introducing Ile at (the
equivalent of) positions 419, 423, 426 and 430 (SEQ ID NO: 38, 43). Alternatively a
consensus sequence for the formation of a trimeric coiled coil, EAIEKKIEAI, is
introduced at (the equivalent of) position 417 to 426 (SEQ ID NO: 39).
These sequences (SEQ ID NO: 33-43) were subjected to the Fluorescence
Associated Cell Sorting assay described above. However, no binding of monoclonal
antibodies CR8020, CR8043, CR9114 or CR8957 could be detected. We conclude that
these sequences do not present the epitopes of these antibodies and consequently the
proteins as present on the cell-membrane are not folded into their native 3-dimensional
structure.
Example 11: Design of stem domain polypeptides comprising the conserved stem domain
epitopes of CR8020, CR8043 and CR9114 based on H3 HA
In a first step, a sequence representing a polypeptide of the invention was
constructed analogously as described by Steel and coworkers (Steel et al 2010) using HA
from H3 A/Wisconsin/67/2005 as the parental sequence (SEQ ID NO: 89). The head of
HA is removed by deletion of a part of HA1 from amino acid D69 to amino acid K292 .
These residues can be replaced by 3 or 4 Gly. The 4 Gly linker was tested by Steel
and coworkers and gave good results of expression and was adopted here to create mini-
H3 (SEQ ID NO: 90). To prevent cleavage of the polypeptide chain, a normal post-
translational processing step for the full length HA protein, the cleavage site at position
345 (arginine) was mutated into a glutamine (R345Q).
Next, the accessible surface area of each residue in both the constructed mini-HA
and the post-fusion conformation was calculated with the aid of Brugel. The degree of
exposure and burial of each residue was determined as described in Samantha and
coworkers (Samantha et al., 2002). It was focused on residues which are exposed in the
pre-fusion conformation and get buried in the post-fusion conformation. Further analysis
of these residues indicates that some of them can be modified in such a way that the
mutation does not have an effect on the pre-fusion but destabilizes the post-fusion
conformation. In general these residues have a hydrophobic side chain and are involved
in the formation of the coiled coil in the post-fusion conformation. Mutation of these
residues to include a hydrophilic side-chain will disturb the coiled coil properties – the
contacts between the helices in a coiled coil are in general hydrophobic – and hence
destabilize the post-fusion conformation. Residues that go from exposed in pre-fusion to
buried in the post-fusion conformation and that are expected to have a destabilizing effect
on the latter conformation after mutation are L397, I401 and L425 (numbering according
to SEQ ID NO: 89). Here L397K and I401T are included.
The loop (B-loop, residues 401 to 420) that connects helix A (residue 383 to 400)
with the central helix CD (residues 421 to 470) changes conformation upon adopting the
post-fusion state; it becomes helical and is part of an extended trimeric coiled coil. To
stabilize the pre-fusion loop conformation of this linker and/or to destabilize its post-
fusion conformation it was reasoned that it should be sufficient to mutate all residues that
are involved in formation of the core of the coiled coil. For position N405 several
mutations are designed, in particular residues carrying a negative charge (Asp and Glu,
N405D, N405E) since this extra charge will reinforce the ionic network observed in the
prefusion conformation. A mutation to the neutral Ala (N405A) is also included in this
study. We also mutated Phe 408 to Thr, His 409 to Ser and Val 418 to Ser (numbering
according to SEQ ID NO: 89; F408T, H409S, V418S) to further increase the solubility of
the newly exposed surface after removal of the head domain.
Five disulfide bridges were designed to lock HA in the pre-fusion conformation.
These bridges are formed between residues which are spatially at an appropriate distance
from each other and which have their Cb atoms already at the correct position to form a
disulfide bridge. They are introduced between positions 320 and 406 (A320C, E406C;
numbering according to SEQ ID NO: 89), 326 and 438 (K326C, S438C) and between
415 and 423 (F415C, Q423C). The first two are cross-links between HA1 and HA2 parts
of the chain, whereas the last covalently connects the top of the B-loop together. The
K326C, S438C disulfide bridge is accompanied by mutation of Asp 435 to Ala (D435A).
Disulfide bridges F347C/N461C and S385C/L463C were taken from the paper by
Bommakanti et al (2010) and also used in this study.
To remove newly exposed hydrophobic residues form the solvent several
additional mutations are designed. The Ile at position 67 (numbering according to SEQ
ID NO: 89) is mutated to a Thr (I67T). This mutation maintains the beta-branch of the
side chain but removes a hydrophobic residue from the surface. The same can be said for
the mutation of Ile 298 to Thr (I298T). Another mutation is introduced at position 316,
isoleucine in the native sequence. Intuitively, one would propose to mutate this residue to
a Thr to maintain the beta-branch but remove the hydrophobicity from the surface.
However, this mutation would result in the introduction of an extra N-glycosylation site
(position 314 is an Asn) and therefore a mutation to Gln is introduced (I316Q).
Gly 495 was also mutated to Glu (G495E). This mutation is designed to introduce
an ionic bridge since there is a positive charge in the surrounding. Nature already
provided some H3 strains with a Glu at this position.
An important residue of HA is position 345 (Arg) since this is the position where
the protease cleavage occurs to render the protein fusion competent. Mutation of this Arg
to a Gln (R345Q) prevents cleavage from occurring thereby locking the protein in the
pre-fusion state.
The mutations described above were clustered as described below:
Cluster 1: I67T, I98T, I316Q, F408T, H409S, V418S
Cluster 2: A320C, E406C
Cluster 3 K326C , D435A, S438C
Cluster 4 L397K, I401T
Cluster 5 N405D or N405E or N405A
Cluster 6 F415C, Q423C
Cluster 7 G495E
Cluster 8 F347C, S385C, N461C, L463C
To arrive at the polypeptides of the invention, the clusters were combined with the
deletion D69 to K292 and the R345Q mutation according to the scheme described below
H3 Mini-HA cluster 1 (SEQ ID NO: 91)
H3 Mini-HA cluster 1+2 (SEQ ID NO: 92)
H3 Mini-HA cluster 1+3 (SEQ ID NO: 93)
H3 Mini-HA cluster 1+4 (SEQ ID NO: 94)
H3 Mini-HA cluster 1+5 N405A (SEQ ID NO: 95)
H3 Mini-HA cluster 1+5 N405D (SEQ ID NO: 96)
H3 Mini-HA cluster 1+5 N405E (SEQ ID NO: 97)
H3 Mini-HA cluster 1+6 (SEQ ID NO: 98)
H3 Mini-HA cluster 1+7 (SEQ ID NO: 99)
H3 Mini-HA cluster 1+2+3+4+5+6+7-N405E (SEQ ID NO: 100)
H3 Mini-HA cluster 1+2+3+4+5+6+7-N405A (SEQ ID NO: 101)H3 Mini-HA cluster
1+2+3+4+5+6+7-N405D (SEQ ID NO: 102)
H3 Mini-HA cluster 1+8 (SEQ ID NO: 103).
The genes encoding the above protein sequences were synthesized and cloned into
expression vector pcDNA2004 using methods generally known to those skilled in the art.
For reasons of comparison the full length HA sequence of H3 A/Wisconsin/67/2005 was
included in the experiment, as well as the full length HA sequence of H1
A/Brisbane/59/2007 containing the cleavage site mutation R343Q.
HEK293F (Invitrogen) suspension cells (10 cells/ml, 30 ml) were transfected
with the expression vectors (1 µg/ml) using 40 µl 293transfectin as the transfection agent
and allowed to further propagate for 2 days. Cells were harvested, aliquotted (0.3 ml,
approximately 3*10 cells) and aliquots were treated with either polyclonal serum raised
against H3 HA (Protein Sciences Corp, Meriden, CT, USA) to probe expression or a HA-
specific monoclonal antibody (5 microgram/ml) and a secondary antibody used for
staining. The cells were then analyzed by fluorescence associated cell sorting (FACS) for
expression of the membrane attached HA stem domain polypeptides of the invention
using polyclonal serum raised against H3 HA or H1 HA to probe expression. A panel of
monoclonal antibodies of known specificity that bind the full length protein (CR8020,
CR8043 and CR9114) were used to probe for the presence of conserved epitopes and, by
inference, correct folding of the full length HA and the mini-HA polypeptides of the
invention. Monoclonal antibody CR6261 (known not to bind to H3 HA’s) and CR8057
(binds to the head domain of HA from A/Wisconsin/67/2005) were also included in the
experiment. Results are expressed as percentage positive cells and are shown in
The results show that all constructs are expressed on the cell surface since the
reaction with the H3 polyclonal serum results in 80-90% of all cells analyzed being
positive for H3-based sequences and more than 50% for the Full length H1 sequence
compared to below 4% for non-transfected cells. Using the anti-H1 polyclonal 60-70% of
all cells are positive, except for the full length H1 sequence that approaches 100%.
Control experiments in the absence of IgG, using only the labeled anti-Human or anti-
rabbit IgG are all negative. Both the A/Wisconsin/67/2005 and the A/Brisbane/59/2007
full length HA proteins are recognized by monoclonal antibody CR9114, known to be
capable of neutralizing both strains. A/Wisconsin/67/2005 full length HA further binds
CR8020, CR8043, and CR8057 (binds only to some H3 strains, described in
WO2010/130636), but not CR6261 (Throsby et al. (2008), ). For full
length HA from A/Brisbane/59/2007 the reverse is true: it does bind to CR6261 but not
CR8020, CR8043 and CR8057.
The polypeptides as described in SEQ ID NO: 91 to SEQ ID NO: 103 are not
capable of binding to CR8020, CR8043 and CR9114 in any of the cases as evidenced by
the lack of signals above background in It was therefore concluded that these
sequences do not present the epitopes of these antibodies and consequently that the
proteins as present on the cell-membrane are not folded into their native 3-dimensional
structure.
Example 12: Design of further stem domain polypeptides comprising the conserved stem
domain epitopes of CR8020, CR8043 and CR9114 based on H3 HA
In this example the design of further polypeptides of the invention on the basis of
serotype H3 is described. HA of the H3 influenza virus A/Wisconsin/67/2005 (SEQ ID
NO: 89 ) and A/Hong Kong/1/1968 (SEQ ID NO: 121) were used as the parental
sequence.
The first modification in the sequence is the removal of the cleavage site at
position 345 (numbering refers to SEQ ID NO: 89 by mutating R to Q (R345Q) to
prevent the formation of HA1 and HA2 from HA0. Optionally residue 347 to 351
(IFGAI, part of the fusion peptide) can additionally be deleted to minimize the exposure
of hydrophobic residues to the aqueous solvent. The positive charge at the cleavage is
100% conserved in H3 and this mutation can therefore be applied in all sequences.
The second modification is the removal of the head domain by deleting a large
part of the HA1 sequence and reconnecting the N- and C-terminal sequences through a
short linker. The deletion can vary in length, but it is preferred that the last residue of the
N-terminal sequence of HA1 and the first residue of the C-terminal sequence are
spatially close together to avoid introducing strain through the linking sequence. In H3
sequence deletions can be introduced at (the equivalent positions of) S62-P322 (mini2;
SEQ ID NO: 105), S63-P305 (mini3; SEQ ID NO: 119) and T64-T317 (mini4; SEQ ID
NO: 120. Equivalent positions can be easily determined by those skilled in the art by
aligning the sequences using a suitable algorithm such as e.g. Clustal or Muscle. The
remaining parts of the sequence can be joined directly or alternatively a flexible linker
can be introduced. Linker sequences can be 1 to 50, amino acids in length. Preferred are
flexible linkers of limited length (smaller or equal to 10 amino acids), e.g. GGG, GGGG,
GSA, GSAG, GSAGSA, GSAGSAG or similar. The length of the deletion can also be
varied, e.g. by decreasing the number of residues in the deletion by starting at (the
equivalent of) position 63, 64, 65, 66, 67, or to increase the length of the deletion, by
cutting at position 57, 58, 59, 60 or 61. Similarly, the last amino acid to be deleted can be
at (the equivalent of) position 317, 318, 319, 320 or 321, or to increase the length of the
deletion at (the equivalent of) position 323, 324, 325, 326, or 327. It is important to
realize that changes in the length of the deletion can be in part compensated for by
matching the length of the linker sequence, i.e. a larger deletion can be matched with a
longer linker and vice versa. These polypeptides are also included in the invention.
The deletion of the head domain leaves the B-loop between residues 400 to 420
now exposed to the aqueous solvent. In H3 HAs this loop is highly conserved (see table
9). The consensus sequence is: 401 I(E/G)KTNEKFHQIEKEFSEVEGR 421 (SEQ ID
NO: 104; numbering refers to SEQ ID NO: 89). To increase the solubility of this loop for
the polypeptides of the invention in the pre-fusion conformation and destabilize the post-
fusion conformation some hydrophobic residues have to be modified into polar
(S,T,N,Q), charged amino acids (R,H,K,D,E), or flexibility has to be increased by
mutation to G. Specifically mutations at positions 401, 408, 411, 415, 418, (numbering
refers to SEQ ID NO: 89) will contribute to the stability of a polypeptide of the invention.
For positions F408 and F415 mutation to S is preferred but other polar (T,N,Q),
charged (R,H,K,D,E) and highly flexible amino acids (G) will have the same effect. For
position 411 (I), mutation to T is preferred; Other polar (S, N, Q), charged (R,H,K,D,E)
and highly flexible amino acids (G) will have the same effect and are therefore also
included in the invention. For position 418 (V) mutation to G is preferred. Other polar (S,
T, N, Q), charged (R, H, K, D, E) will have the same effect and are therefore also
included in the invention. For position 401 (I) mutation to R is preferred but other polar
(S, T, N, Q), charged (H, K, D, E) or flexible (G) residues are also possible. So
polypeptides of the invention contain at least one of the mutations described above.
Combinations of more than one mutation are also possible, as shown for example in SEQ
ID NOs 123-127 and 129-131.
To stabilize the pre-fusion conformation of polypeptides of the invention a
covalent bond between two parts distant in the primary sequences but close in the folded
pre-fusion conformation is introduced To this end a disulfide bridge is engineered in the
polypeptides of the invention a, preferably between (the equivalent of) position 326 and
438 in H3 A/Wisconsin/67/2005 (SEQ ID NO: 89). Equivalent positions can be easily
determined by those skilled in the art by aligning the sequences using a suitable algorithm
such as Clustal, Muscle etc. Engineered disulfide bridges are created by mutating at least
one (if the other is already a cysteine), but usually two residues that are spatially close
into cysteine, that will spontaneously or by active oxidation form a covalent bond
between the sulfur atoms of these residues. An alternative cysteine bridge can be created
between (the equivalent of) position 334 and 393 in H3 A/Wisconsin/67/2005 (SEQ ID
NO: 89) by mutation of these residues into cysteine. In some cases the cysteine at (the
equivalent of) position 321 is modified into a glycine to avoid formation of unwanted
disulfide bridges.
The native HA exists as a trimer on the cell surface. Most of the interactions
between the individual monomers that keep the trimer together are located in the head
domain. After removal of the head the tertiary structure is thus destabilized and therefore
reinforcing the interactions between the monomers in the truncated molecule will
increase the stability. In the stem domain trimerization is mediated by the formation of a
trimeric coiled coil motif. By strengthening this motif a more stable trimer can be
created. A consensus sequence for the formation of a trimeric coiled coil,
IEAIEKKIEAIEKKIEAIEKK, is introduced at (the equivalent of) position 421 to
441.To avoid interference with the formation of the disulfide bridge between positions
326 and 438 an alternative shorter sequence IEAIEKKIEAIEKKI at (the equivalent of)
positions 421 to 435 was also used. An alternative is to introduce the sequence
RMKQIEDKIEEIESKQKKIEN, derived from GCN4 and known to trimerize, at
position 421-441 or the shorter sequence RMKQIEDKIEEIESK at position 421 to 435.
The polypeptides of the invention may contain the intracellular sequences of HA
and the transmembrane domain so that the resulting polypeptides are presented on the cell
surface when expressed in cells. In other embodiments, the cytoplasmic sequence and the
transmembrane sequence from (the equivalent of) position 522 to the C-terminus is
removed so that a secreted (soluble) polypeptide is produced following expression in
cells. Optionally some additional residues can be included in the soluble protein by
deleting the sequence from (the equivalent of) 523, 524, 525, 526, 527, 528 or 529. The
soluble polypeptide can be further stabilized by introducing a sequence known to form
trimeric structures, i.e. AYVRKDGEWVLL (SEQ ID NO: 143)(‘foldon’ sequence),
optionally connected through a linker. The linker may optionally contain a cleavage site
for processing afterwards according to protocols well known to those skilled in the art. To
facilitate purification of the soluble form a tag sequence may be added, e.g. a his tag
(HHHHHHH) connected via a short linker, e.g. EGR. In some embodiments the linker
and his-tag sequence are added without the foldon sequence being present.
An important residue of HA is position 345 (Arg) since this is the position where
the protease cleavage occurs to render the protein fusion competent. Mutation of this Arg
to a Gln (R345Q) prevents cleavage from occurring thereby locking the protein in the
pre-fusion state.
The mutations described above were clustered as described below:
Cluster 9 F408S, I411T, F415S
Cluster 10 V418G
Cluster 11 I401R
Cluster 12 K326C, S438C
Cluster 13 T334C, I393C
Cluster 14 C321G
GCN4 RMKQIEDKIEEIESKQKKIEN at position 421 to 441
or RMKQIEDKIEEIESK at position 421 to 435
tri IEAIEKKIEAIEKKIEAIEKK at position 421 to 441
or IEAIEKKIEAIEKKI at positions 421 to 435
Using the sequence of full length HA from H3N2 A/Wisconsin/67/2005 as
starting point the clusters described above were combined with the S62-P322 deletion
(mini2; SEQ ID NO: 105) to arrive at polypeptides of the invention
SEQ ID NO: 105: H3-mini2
SEQ ID NO: 106: H3-mini2-cl9+10
SEQ ID NO: 107: H3-mini2-cl9+11
SEQ ID NO: 108: H3-mini2-cl9+10+11
SEQ ID NO: 109: H3-mini2-cl9+10+11-tri (tri sequence at position 421-441)
SEQ ID NO: 110: H3-mini2-cl9+10+11-GCN4 (GCN4 sequence at position 421-441)
SEQ ID NO: 111: H3-mini2-cl9+10+11+12
SEQ ID NO: 112: H3-mini2-cl9+10+12
SEQ ID NO: 113: H3-mini2-cl9+10+11+12-GCN4 (short GCN4 sequence at position
421-435)
SEQ ID NO: 114: H3-mini2-cl9+10+11+12-tri (short tri sequence at position 421-435)
SEQ ID NO: 115: H3-mini2-cl9+13
SEQ ID NO: 116: H3-mini2-cl9+10+11+13
SEQ ID NO: 117: H3-mini2-cl9+10+11+13-GCN4 (GCN4 sequence at position 421-
441)
SEQ ID NO: 118: H3-mini2-cl9+10+11+13-tri (tri sequence at position 421-441)
In addition the deletions S63-P305 (mini3) and T64-T317 (mini4) were combined
with clusters 9, 10, 11 and 14 to create the polypeptides of the invention
SEQ ID NO: 119: H3-mini3-cl9+10+11+12+14
SEQ ID NO: 120: H3-mini4-cl9+10+11+12+14
Using the sequence of full length HA from H3N2 A/Hong Kong/1/1968 as
starting point the clusters described above were combined with the S62-P322 deletion to
arrive at polypeptides of the invention
SEQ ID NO: 121: H3 Full length A/Hong Kong/1/1968
SEQ ID NO: 122: HK68 H3m2-cl9
SEQ ID NO: 123: HK68 H3m2-cl9+10
SEQ ID NO: 124: HK68 H3m2-cl9+10+11
SEQ ID NO: 125: HK68 H3m2-cl9+10+12
SEQ ID NO: 126: HK68 H3m2-cl9+10+11+12
SEQ ID NO: 127: HK68 H3m2-cl9+10+11+13
SEQ ID NO: 128: HK68 H3m2-cl9+10+11+12-tri (short tri sequence at position 421-
435)
SEQ ID NO: 129: HK68 H3m2-cl9+10+11+13-tri (tri sequence at position 421-441)
SEQ ID NO: 130: HK68 H3m2-cl9+10+11+12-GCN4 (short GCN4 sequence at position
421- 435)
SEQ ID NO: 131: HK68 H3m2-cl9+10+11+13-GCN4 (GCN4 sequence at position 421-
441).
The genes encoding the above protein sequences were synthesized and cloned into
expression vector pcDNA2004 using methods generally known to those skilled in the art.
For reasons of comparison the full length HA sequence of H3 A/Wisconsin/67/2005
and/or H3 A/Hong Kong/1/1968 was included in the experiment.
HEK293F (Invitrogen) suspension cells (10 cells/ml, 30 ml) were transfected
with the expression vectors (1 µg/ml) using 40 µl 293transfectin as the transfection agent
and allowed to further propagate for 2 days. Cells were harvested, aliquotted (0.3 ml,
approximately 3*10 cells) and aliquots were treated with either polyclonal serum raised
against H3 HA (Protein Sciences Corp, Meriden, CT, USA) to probe expression or a HA-
specific monoclonal antibody (5 microgram/ml) and a secondary antibody used for
staining. The cells were then analyzed by fluorescence associated cell sorting (FACS) for
expression of the membrane attached HA stem domain polypeptides of the invention
using polyclonal serum raised against H3 HA or H1 HA to probe expression. A panel of
monoclonal antibodies of known specificity that bind the full length protein (CR8020,
CR8043 and CR9114) were used to probe for the presence of conserved epitopes and, by
inference, correct folding of the full length HA and the mini-HA polypeptides of the
invention. Monoclonal antibody CR6261 (known not to bind to H3 HAs ) and CR8057
(binds to the head domain of HA from A/Wisconsin/67/2005) were also included in the
experiments. Results are expressed as percentage positive cells and are shown in
for H3 HA of A/Wisconsin/67/2005 based sequences and for H3 HA of A/Hong
Kong/1/1968 based sequences.
The results show that all A/Wisconsin/67/2005 based constructs ( are
expressed on the cell surface since the reaction with the H3 polyclonal serum results in ca
80% or more of all cells analyzed being positive compared to below 5% for non-
transfected cells. Control experiments in the absence of IgG, using only the labeled anti-
Human or anti-rabbit IgG are all negative. The A/Wisconsin/67/2005 full length HA is
recognized by monoclonal antibodies CR8020, CR8043, CR8057 (binds only to some H3
strains, described in WO2010/130636) and CR9114 known to be capable of binding to
this protein, but not by mAb CR6261. In contrast, most of the stem domain polypeptides
are not recognized by CR8020, CR8043 or CR9114 with some notable exceptions.
Polypeptides comprising the cluster 12 mutation were recognized by CR8020 and/or
CR8043. H3-mini2-cl9+10+11+12 (SEQ ID NO: 111), H3-mini2-cl9+10+12(SEQ ID
NO: 112), H3-mini2-cl9+10+11+12-GCN4 (SEQ ID NO: 113) and H3-mini2-
cl9+10+11+12-tri (SEQ ID NO: 114) exhibit recognition by CR8020 (% percentage
positive cells ranging from ca 10 to 60) and CR8043 (40 to 70%) (indicated by arrows).
Of the 4 positive constructs H3-mini2-cl9+10+11+12-GCN4 (SEQ ID NO: 113) exhibits
the largest responses in this assay. The same results are obtained from the Mean
fluorescence intensity that is shown in panel B (. H3-mini2-cl9+10+11+12 (SEQ
ID NO: 111), H3-mini2-cl9+10+12(SEQ ID NO: 112), H3-mini2-cl9+10+11+12-GCN4
(SEQ ID NO: 113) and H3-mini2-cl9+10+11+12-tri (SEQ ID NO: 114) exhibit mean
fluorescence intensity well above background after exposure to CR8020 and CR8043 and
staining, with the highest responses for H3-mini2-cl9+10+11+12-GCN4 (SEQ ID NO:
113). None of the polypeptides based on HA from A/Wisconsin/67/2005 is capable of
recognizing CR9114.
Figure 10 shows that all A/Hong Kong/1/1968 based constructs () are
expressed on the cell surface since the reaction with the H3 polyclonal serum for most
constructs results in ca 40-60% of all cells analyzed being positive compared to below
5% for non-transfected cells. Control experiments in the absence of IgG, using only the
labeled anti-Human or anti-rabbit IgG are all negative. The percentage positive cells for
the Full length protein from A/Hong Kong/1/1968 after treatment with the polyclonal
serum is low (ca 10%), but strong signals obtained from the binding of CR8020, CR8043
and CR9114 indicate that the protein is present on the cell surface. CR8057 does not
recognize A/Hong Kong/1/1968 based sequences, only the Full length protein from
A/Wisconsin/67/2005. Four constructs (containing the cluster 12 mutation) are
recognized by CR8020 and CR8043, i.e. HK68 H3m2-cl9+10+12 (SEQ ID NO: 125),
HK68 H3m2-cl9+10+11+12 (SEQ ID NO: 126), HK68 H3m2-cl9+10+11+12-tri (SEQ
ID NO: 128 containing the shortened tri sequence at position 421-435) and HK68 H3m2-
cl9+10+11+12-GCN4 (SEQ ID NO: 130, containing the short GCN4 sequence at position
421- 435), as indicated by the % positive cells (15% or higher) and MFI clearly above
background. The strongest signals (MFI) are obtained for HK68 H3m2-cl9+10+11+12-
GCN4 (SEQ ID NO:130); this stem domain polypeptide construct also shows a
detectable binding to CR9114.
In conclusion we have shown that following the method described above stem
domain polypeptides of the invention can be obtained for serotypes of group 2, in
particular influenza A viruses of the H3 subtype.
Example 13: Design, expression and partial purification of soluble stem domain
polypeptides comprising the conserved stem domain epitopes
In certain embodiments, the polypeptides of the invention contain the intracellular
sequences of HA and the transmembrane domain so that the resulting polypeptides are
presented on the cell surface when expressed in cells. In other embodiments, the
cytoplasmic sequence and the transmembrane sequence from position (or the equivalent
of) 523, 524, 525, 526, 527, 528, 529 or 530 to the C-terminus of HA2 (numbering
according to SEQ ID NO: 1) was removed so that expression in cells results in secreted
(soluble) polypeptide which can be used e.g. in a vaccine. The soluble polypeptide can
further be stabilized by introducing a sequence known to form trimeric structures (also
known as ‘foldon’), i.e. AYVRKDGEWVLL (SEQ ID NO: 143) optionally connected
through a linker (e.g GSGYIPEAPRDGQAYVRKDGEWVLLSTFL). The linker may
optionally contain a cleavage site for processing following purification according to
protocols well known to those skilled in the art. To facilitate purification of the soluble
form a tag sequence may be added, e.g. a histidine-tag (six or seven consecutive
Histidines) connected via a short linker, e.g. EGR. In some embodiments the linker and
the histidine-tag are added without the foldon sequence being present.
According to the present invention the amino acid sequence from position 530 of
the full length HA from H1N1 A/Brisbane/59/2007 (numbering according to SEQ ID
NO: 1) to the C-terminal amino acid of the HA2 domain was removed and replaced by
the following sequences EGRHHHHHHH (SEQ ID NO: 81) comprising a short linker
and a histidine tag. This exchange was applied to SEQ ID NO: 44: H1-mini2-
cluster1+5+6-trim (resulting in SEQ ID NO 144: s-H1-mini2-cluster1+5+6-trim), SEQ
ID NO: 45: H1-mini2-cluster1+5+6-GCN4 (resulting in SEQ ID NO: 145: s-H1-mini2-
cluster1+5+6-GCN4), SEQ ID NO: 46: mini2-cluster1+5+6 (A/Brisbane/59/2007)
(resulting in SEQ ID NO: 146: s-H1-mini2-cluster1+5+6), SEQ ID NO: 47: mini2-
cluster11+5+6 (A/Brisbane/59/2007) (resulting in SEQ ID NO: 147: s-H1-mini2-
cluster11+5+6), SEQ ID NO: 48: mini2-cluster1+5 (A/Brisbane/59/2007) (resulting in
SEQ ID NO: 148: s-H1-mini2-cluster1+5).
Similarly, for reasons of comparison the exchange was applied to the SEQ ID NO
1: H1 Full length (A/Brisbane/59/2007) and in addition the HA cleavage site was
impaired by modifying Arginine 343 to a Glutamine (R343Q mutation) to yield SEQ ID
NO: 149: s-H1 Full length R343Q). Furthermore two polypeptides of the invention were
created with a different linker between the N-terminal and C-terminal parts of HA1: s-
H1-mini2-cluster1+5+6-nl (SEQ ID NO:150) and s-H1-mini2-cluster1+5+6-nl2 (SEQ ID
NO: 151).
The genes encoding the above protein sequences were synthesized and cloned into
expression vector pcDNA2004neo using methods generally known to those skilled in the
art. HEK293F (Invitrogen) suspension cells were transfected with the expression vectors
using \ 293transfectin as the transfection agent following protocols well known in the art
and allowed to further propagate for 7 days. Cells were separated from the culture
medium by centrifugation and discarded, while the supernatant containing the soluble
polypeptides of the invention was collected for further processing. The supernatant was
purified by immobilized metal affinity chromatography on a Ni-NTA column to bind the
His-tagged polypeptides of the invention to the resin and the flow-through was collected.
The column was washed with 3-10 column volumes 20 mM sodium phosphate pH 7.4,
500 mM NaCl, 10 mM imidazole (‘wash’), 5-15 column volumes 20 mM sodium
phosphate pH 7.4, 500 mM NaCl, 100 mM imidazole (‘stringent wash’) and eluted with
mM sodium phosphate pH 7.4, 500 mM NaCl, 500 mM imidazole. In individual cases
buffer compositions or used volumes were adapted to increase purity or yield, or a linear
gradient was used instead of a step gradient. Fractions were collected throughout and
analyzed on SDS-PAGE and Western blot, using a polyclonal anti-H1 HA serum for
detection (see figure 11a-h). Results indicate a clear enrichment of the polypeptides of the
invention in the eluates compared to the starting materials.
In order to confirm proper folding and functionality of the purified polypeptides
of the invention the preparations were tested for binding of monoclonal antibody
CR9114. To this end a monoclonal antibody capable of binding a His-tag (6 or 7
consecutive histidines) at the C-terminus of a protein was coated on a standard 96 well
plate by applying 100 microliter of a 1 mg/ml antibody solution to each well and
incubating for overnight at 4 °C. After removal of excess solution and washing, the plate
was blocked with 150 microliter of a 2% skimmed milk solution for 1h at room
temperature. After removal of the blocking agent and washing, 100 microliter of a 1
mg/ml solution of the polypeptides of the invention, as well as the ectodomain of the
corresponding Full length protein (SEQ ID NO: 149) was added and incubated for 2h at
room temperature. After removal of excess polypeptides of the invention mAb CR9114,
mAb CR8020 (negative control) or polyclonal serum raised against H1 HA in rabbits
(positive control) was added at concentrations varying between 2 and 20 mg/ml and
incubated for 2h at room temperature. Binding was detected through HRP- conjugated
anti-human antibody using protocols well known in the art.
The results (fig 12) show that monoclonal antibody CR9114 is binding to the
purified soluble polypeptides of the invention as well as to the full length ectodomain
(Figure 12a), whereas monoclonal antibody CR8020 does not (Figure 12b). Polyclonal
anti-H1 serum also binds to the polypeptides of the invention and the full length
ectodomain in a very similar manner (Figure 12c). It is thus concouded that the broadly
neutralizing epitope of CR9114 is preserved in the polypeptides of the invention, and
taking into account the discontinuous and conformational nature of this epitope, that the
stem domain is properly folded and adopts a three-dimensional conformation equal or
very similar to the conformation in the native full length HA.
The preparations of the polypeptides of the invention were inhomogeneous in size
as determined from the SDS-PAGE and Western blot results. We hypothesized that the
variation is due to variation in protein glycosylation patterns between individual protein
molecules. To confirm this, small aliquots of the protein preparations were treated with 3
units of N-glycosidase F (an enzyme that removes N-linked carbohydrate moieties from
Asparagine residues) for 18h at 37 C and analyzed by SDS-PAGE and Western Blot.
The results (Figure 13a and 13b) show that treatment with the N-glycosidase focuses the
diffuse bands of the polypeptides of the invention to a single band at the expected
molecular weight calculated from the amino acid sequence. This is clear evidence that the
observed size inhomogeneity indeed arises from variation in glycosylation patterns.
The preparations of the polypeptides of the invention were further characterized
by HP-SEC. To this end approximately 40 mg of the polypeptides of the invention in a
volume between 43 and 63 ml (concentration of polypeptide between 0.64 and 0.93
mg/ml) was applied to a Tosoh TSK-gel G2000 SWxl column connected to a multi-angle
light scattering detector. Results are shown in figure 14. The main peak (retention time ca
8 minutes) arises from the polypeptides of the invention, and is well separated from the
larger species, indicating that further purification can be achieved. Based on the data of
the multi-angle light scattering detector the main peaks correspond to a molecular species
with molecular weight between 50 and 80 kiloDalton (see table 9) depending on the
polypeptide of the invention under study. In light of the size inhomogeneity and variety in
polypeptide glycosylation described above, as well as the dependence of the results on
the hydrodynamic shape of the molecules, these numbers should be taken as an indication
only.
Example 14: Expression and partial purification of a soluble stem domain polypeptide
comprising the conserved stem domain epitope of monoclonal antibodies CR9114,
CR6261 and FI6v3
In order to obtain a highly pure preparation of a polypeptide of the invention,
HEK293F cells were transfected with expression vector pcDNA2004 containing the gene
encoding s-H1-mini2-cluster1+5+6-GCN4 (SEQ ID NO: 145). It will be understood by
the skilled person that the leader sequence (or signal sequence) that directs transport of a
protein during production (corresponding to amino acids 1-17 of SEQ ID NO: 145) will
not be present in the secreted final polypeptide. To this end, 1.0* 10 vc/mL were seeded
by spinning down HEK293F cells (Invitrogen) at 300 g for 5 min and resuspending in
300 mL pre-warmed Freestyle medium per SF1000. This culture was incubated for 1
hour at 37 °C, 10% CO at 110 rpm in a multitron incubator. After 1 hour the plasmid
DNA was pipetted in 9.9 mL Optimem medium to a concentration of 1.0 μg/mL in the
300 mL culture volume. In parallel 440 μL 293fectin was pipetted in 9.9 mL Optimem
medium and incubated for 5 minutes at room temperature. After 5 minutes the plasmid
DNA/Optimem mix was added to the 293fectin /Optimem mix and incubated at room
temperature for 20 minutes. After the incubation the plasmid DNA/293fectin mix was
added drop wise to the cell suspension. The transfected cultured was incubated at 37 °C,
% CO and 110 rpm in a multitron incubator. At day 7 cells were separated from the
culture medium by centrifugation (30 minutes at 3000 g), while the supernatant
containing the soluble polypeptides of the invention was filtrated over a 0.2 μm bottle top
filter for further processing.
To verify the presence of the polypeptide of the invention a small aliquot of the
supernatant was analyzed by Western Blot, using a monoclonal antibody directed against
the his-tag for detection (Figure 15a). Several bands were observed at an apparent
molecular weight between 37 and 50 kDa, which is close to or above the calculated
molecular weight based on the amino acid composition of the protein. The size
inhomogeniety is caused by variation in glycosylation patterns, since earlier experiments
have shown that treatment of this protein with N-glycosidase F to remove attached N-
linked glycans from the protein results in focusing of the band at the expected molecular
weight.
The presence of the broadly neutralizing epitopes on the polypeptide of the
invention was confirmed by ELISA, using broadly neutralizing antibodies CR6261,
CR9114 and FI6v3 as probes. For reasons of comparison monoclonal antibody CR8020
was also included as a negative control in the experiment; this antibody is capable of
binding to HA molecules from group 2 viruses (e.g. H3 and H7 HA), but not from group
1 (e.g. H1 and H5 HA). To this end a monoclonal antibody capable of binding a His-tag
(6 or 7 consecutive histidines ) at the C-terminus of a protein was coated on a standard 96
well plate by applying 100 microliter of a 1 mg/ml antibody solution to each well and
incubation overnight at 4 °C. After removal of excess solution and washing, the plate was
blocked with 150 microliter of a 2% skimmed milk solution for 1h at room temperature.
After removal of the blocking agent and washing, 100 microliter of the supernatant was
added and incubated for 2h at room temperature. After removal of excess polypeptides of
the invention mAb CR9114 was added, in a 1:2 dilution series starting at a 5mg/ml
concentration, and incubated for 2h at room temperature. Binding was detected through
HRP- conjugated anti-human antibodies using protocols well known in the art. Clear
binding of CR9114, FI6v3 and to a lesser extent CR6261 to the polypeptide of the
invention is observed, whereas no response is observed for CR8020 indicating that the
observed binding is specific for the monoclonal antibodies tested (Figure 15b).
For purification purposes 250 ml of culture supernatant was applied to a 5 ml
His-trap column, washed with 75 ml wash buffer (20 mM TRIS, 500 mM NaCl, pH 7.8),
and eluted with a step-wise gradients of imidazole ( 10, 50, 100, 200, 300 and 500 mM in
wash buffer). The chromatogram (fig. 16) exhibits multiple peaks, with the polypeptides
of the invention eluting at 100 mM imidazole (peak A) and 200 mM imidazole (peak B).
Both peaks were collected, concentrated, and applied to a size exclusion column for
further purification (Superdex 200). Elution profiles are shown in figure 17a and 17b.
Fractions were collected and analyzed on SDS-PAGE (Figure 17c and d). Fraction 3
derived from both peak A and B contain highly pure polypeptide of the invention. The
final yield was ca 10 mg/ml of culture supernatant. Purified batches are free of endotoxin
(dosing at 5mg/kg; < 1 EU/mg); Chromogenic LAL) and bioburden is below 1
CFU/50µg.
Example 15. Design of a stem domain polypeptide comprising the conserved stem domain
epitope of CR9114 based on Influenza B HA
The procedure described above to design polypeptides of the invention was also
applied to Influenza B. In this Example, polypeptides of the invention on the basis of HA
sequences taken from virus strains of both known lineages, i.e. B/Florida/4/2006
(B/Yamagata lineage) and B/Malaysia/2506/2004 (B/Victoria lineage) are described.
Those skilled in the art will understand that the use of other Influenza B HA sequences is
also possible because the sequences are well conserved, in particular in the stem region.
Therefore polypeptides derived from other Influenza B HA sequences according to the
description below are also encompassed by the invention.
The first modification in the HA sequence of B/Florida/4/2006 was the removal of
the cleavage site at position 361 (numbering refers to SEQ ID NO: 132) by mutating R
(or in a limited number of cases K) to Q (R361Q) to prevent the formation of HA1 and
HA2 from HA0. Optionally residue 363 to 367 (GFGAI, part of the fusion peptide) can
additionally be deleted to minimize the exposure of hydrophobic residues to the aqueous
solvent. The positive charge at the cleavage is 100% conserved in HA from Influenza B
and this mutation can therefore be applied in all sequences.
The second modification is the removal of the head domain by deleting a large
part of the HA1 sequence and reconnecting the N- and C-terminal sequences through a
short linker. The deletion can vary in length, but it is preferred that the last residue of the
N-terminal sequence of HA1 and the first residue of the C-terminal sequence are
spatially close together to avoid introducing strain through the linking sequence. In B
sequences deletions can be introduced at (the equivalent positions of) P51-I336 (m2;
SEQ ID NO: 133) in B/Florida/4/2006 (SEQ ID NO:132). Equivalent positions can be
easily determined by those skilled in the art by aligning the sequences using a suitable
algorithm such as e.g. Clustal or Muscle. The remaining parts of the sequence can be
joined directly or alternatively a flexible linker can be introduced. Linker sequences can
be 1 to 50 amino acids in length. Preferred are flexible linkers of limited length (smaller
or equal to 10 amino acids), e.g. GGG, GGGG, GSA, GSAG, GSAGSA, GSAGSAG or
similar.
SEQ ID NO: 133 describes such a polypeptide of the invention containing
deletion P51-I332 (m2; SEQ ID NO: 133). The deletions described above ensure that
the unstructured regions formed by residues between P51 and N58 and between E306
and I337 are also removed; this is beneficial to the overall stability of the polypeptides of
the invention. A similar effect was observed for polypeptides of the invention derived
from a H1 sequence (see above).
The deletion of the head domain leaves the loop between residues 416 to 436
now exposed to the aqueous solvent. In B HA’s this loop is highly conserved (see table
). The consensus sequence is: LSELEVKNLQRLSGAMDELHN.
To increase the solubility of this loop in the pre-fusion conformation and
destabilize the post-fusion conformation some hydrophobic residues were modified into
polar (S,T,N,Q), charged amino acids (R,H,K,D,E), or flexibility has to be increased by
mutation to G. Specifically mutations at positions 421, 424, 427, 434 (numbering refers
to SEQ ID NO: 132) will contribute to the stability of a polypeptide of the invention.
For positions V421 and L427 mutation to T is preferred but other polar (S,N,Q),
charged (R,H,K,D,E) and highly flexible amino acids (G) will have the same effect. For
position 424, mutation to S is preferred. Other polar (N, T, Q), charged (R,H,K,D,E) and
highly flexible amino acids (G) will have the same. For position L434 mutation to G is
preferred. Other polar (S, T, N, Q), charged (R, H, K, D, E) will have the same effect.
Polypeptides containing at least one of the mutations described above were made.
Combinations of more than one mutation are also possible, as shown for example in SEQ
ID NOs: 134-136.
To stabilize the pre-fusion conformation of polypeptides of the invention a
covalent bond between two parts distant in the primary sequences but close in the folded
pre-fusion conformation was introduced. To this end a disulfide bridge is engineered in
the polypeptides , preferably between (the equivalent of) position K340 and S454 in HA
from B/Florida/4/2006 (SEQ ID NO: 134-136). Equivalent positions can be easily
determined by those skilled in the art by aligning the sequences using a suitable algorithm
such as Clustal, Muscle etc. Engineered disulfide bridges are created by mutating at least
one (if the other is already a cysteine), but usually two residues that are spatially close
into cysteine, that will spontaneously or by active oxidation form a covalent bond
between the sulfur atoms of these residues.
In the stem domain trimerization is mediated by the formation of a trimeric coiled
coil motif. By strengthening this motif a more stable trimer can be created. Sequences
supporting the formation of a trimeric coiled coil derived from GCN4 are introduced at
(the equivalent of) position 436 to 452 RRMKQIEDKIEEILSKI (SEQ ID NO: 135), or
alternatively RMKQIEDKIEEILSKI at position 436 to 451 (SEQ ID NO: 136).
The same procedure was followed for HA from B/Malaysia/2506/2004 (SEQ ID
NO: 137) to provide polypeptides. Compared to HA from B/Florida/4/2006 this HA has
an additional asparagine residue inserted at position 178 as can be readily seen in an
alignment of the two sequences. Consequently the cleavage site is at position 362, and
the corresponding mutation to prevent cleavage is R362Q. The deletion to remove the
head region of in this case is for example P51 to I337 (m2; SEQ ID NO: 138). Again the
remaining parts of the sequence can be joined directly or alternatively a flexible linker
can be introduced. Linker sequences can be 1 to 50 amino acids in length. Preferred are
flexible linkers of limited length (smaller or equal to 10 amino acids), e.g. GGG, GGGG,
GSA, GSAG, GSAGSA, GSAGSAG or similar. .
SEQ ID NO:138 describes such a polypeptide containing deletion P51-I332 (m2;
SEQ ID NO: 138). The deletions described above ensure that the unstructured regions
formed by residues between P51 and N58 and between E307 and I338 are also removed;
this is beneficial to the overall stability of the polypeptides of the invention. A similar
effect was observed for polypeptides of the invention derived from a H1 sequence (see
above).
The deletion of the head domain leaves the loop between residues L420 to H436
now exposed to the aqueous solvent. In B HA’s this loop is highly conserved (see table
x). The consensus sequence is: LSELEVKNLQRLSGAMDELHN.
To increase the solubility of this loop in the pre-fusion conformation and
destabilize the post-fusion conformation some hydrophobic residues were modified into
polar (S,T,N,Q), charged amino acids (R,H,K,D,E), or flexibility has to be increased by
mutation to G. Specifically mutations at positions 422, 425, 428, 435 (numbering refers
to SEQ ID NO: 137) were tested.
For positions V422 and L428 mutation to T is preferred but other polar (S,N,Q),
charged (R,H,K,D,E) and highly flexible amino acids (G) will have the same effect. For
position 425, mutation to S is preferred. Other polar (N, T, Q), charged (R,H,K,D,E) and
highly flexible amino acids (G) will have the same. For position L435 mutation to G is
preferred. Other polar (S, T, N, Q), charged (R, H, K, D, E) will have the same.
Polypeptides containinf at least one of the mutations described above were made.
Combinations of more than one mutation are also possible, as shown for example in SEQ
ID NOs: 139-141.
To stabilize the pre-fusion conformation of polypeptides of the invention a
covalent bond between two parts distant in the primary sequences but close in the folded
pre-fusion conformation is introduced. To this end a disulfide bridge is engineered in the
polypeptides of the invention a, preferably between (the equivalent of) position K341 and
S455 in HA from B/Malaysia/2506/2004 (SEQ ID NO: 139-141). Equivalent positions
can be easily determined by those skilled in the art by aligning the sequences using a
suitable algorithm such as Clustal, Muscle etc. Engineered disulfide bridges are created
by mutating at least one (if the other is already a cysteine), but usually two residues that
are spatially close into cysteine, that will spontaneously or by active oxidation form a
covalent bond between the sulfur atoms of these residues.
As described above, the native HA exists as a trimer on the cell surface. Most of
the interactions between the individual monomers that keep the trimer together are
located in the head domain. After removal of the head the tertiary structure is thus
destabilized and therefore reinforcing the interactions between the monomers in the
truncated molecule will increase the stability. In the stem domain trimerization is
mediated by the formation of a trimeric coiled coil motif. By strengthening this motif a
more stable trimer can be created. Sequences supporting the formation of a trimeric
coiled coil derived from GCN4 are introduced at (the equivalent of) position 437 to 453
RRMKQIEDKIEEILSKI (SEQ ID NO: 135), or alternatively RMKQIEDKIEEILSKI at
position 437 to 452 (SEQ ID NO: 136).
The polypeptides based on influenza B hemagglutinin, SEQ ID NO: 133-136 and
138-141 were tested for the presence of the epitope of CR9114 by Fluorescence
Associated C ell Sorting as described above. However, no binding of mAb CR9114 was
observed for these constructs.
Example 16: Immunogenicity of third generation HA stem domain polypeptides
In order to assess the immunogenicity of the stem domain polypeptides mice were
immunized with the expression vectors encoding full length H1 from A/Brisbane/59/2007
(SEQ ID NO: 1), Mini3- cluster11 (SEQ ID NO: 11), Mini2-cluster11+5 (SEQ ID NO:
14), mini2-cluster1+5 (SEQ ID NO: 48), mini2-cluster1+5+6 (SEQ ID NO: 46), mini2-
cluster1+5+6-GCN4 (SEQ ID NO: 45) and mini2-cluster1+5+6-nl (SEQ ID NO: 152).
An expression vector encoding for cM2 was also included as a negative control.
Groups of 4 mice (BALB\c) were immunized with 50 µg construct + 50 µg
adjuvant (pUMCV1-GM-CSF) i.m. on day 1, 21 and 42. On day 49 a final bleed was
performed and serum collected. The sera were analyzed by Elisa using the recombinant
ectodomains of the full length HA from the A/Brisbane/59/2007 and the
A/California/07/2009 strains (obtained from Protein Sciences Corporation, Meriden, CT,
USA) as the antigen. In short, 96 wells plates were coated with 50 ng HA overnight at 4
oC, followed by incubation with block buffer (100 µl PBS, pH 7.4 + 2% skim milk) for
1h at room temperature. Plates were washed with PBS + 0.05% Tween-20, and 100 µl of
a 2-fold dilution series in block buffer, starting from a 20 fold dilution of the serum is
added. Bound antibody is detected using HRP –conjugated goat-anti-mouse IgG, using
standard protocols well-established in the art. Titers are compared to a standard curve
using mAb 3AH1 InA134 (Hytest, Turku, Finland) to derive Elisa units/ml (EU/ml).
The time course of the IgG response towards the ectodomain of the homologous
full length protein induced by the immunization schedule described above are shown in
figure 18. A high response can already be observed for the mice immunized with DNA
(SEQ ID NO: 1) encoding the full length protein after 4 weeks. The response is increased
by a boost injection, as shown from the increased titer at 7 weeks. Immunization with
DNA encoding polypeptides of the invention mini2-cluster11+5 (SEQ ID NO: 14),
mini2-cluster1+5 (SEQ ID NO: 48), mini2-cluster1+5+6 (SEQ ID NO: 46), mini2-
cluster1+5+6-GCN4 (SEQ ID NO: 45) and mini2-cluster1+5+6-nl (SEQ ID NO: 152)
leads to intermediate titers that are further increased upon a booster immunization as
evidenced from titers at week 7. Immunization with DNA encoding Mini3-cluster11
(SEQ ID NO: 11) and negative control cM2 do not result in a detectable response in this
assay.
Figure 19 exhibits the IgG responses at week 7 after inihtial immunization for
individual mice against the ectodomain of the full length hemagglutinin from the
homologous strain H1N1 A/Brisbane/59/2007 (panel A) and the heterologous strain
H1N1 A/California/07/2009. Antibodies induced by DNA encoding polypeptides of the
invention DNA encoding polypeptides of the invention mini2-cluster11+5 (SEQ ID NO:
14), mini2-cluster1+5 (SEQ ID NO: 48), mini2-cluster1+5+6 (SEQ ID NO: 46), mini2-
cluster1+5+6-GCN4 (SEQ ID NO: 45) and mini2-cluster1+5+6-nl (SEQ ID NO: 152)
bind equally well to the ectodomain of hemagglutinin dreived from the homologous and
heterologous strain. In contrast, immunization with DNA encoding the full length protein
(SEQ ID NO: 1) results in high titers against the homologous hemagglutinin (more than
an order of magnitude higher than titers observed for immunization with DNA encoding
the polypeptides of the invention), but in low titers against the ectodomain of the
heterologous hemagglutinin. Immunization with DNA encoding Mini3-cluster11 (SEQ
ID NO: 11) and negative control cM2 do not result in a detectable response aganst either
of the hemagglutinin ectodomains in this assay.
In conclusion, antibodies raised against the polypeptides of the invention mini2-
cluster11+5 (SEQ ID NO: 14), mini2-cluster1+5 (SEQ ID NO: 48), mini2-cluster1+5+6
(SEQ ID NO: 46), mini2-cluster1+5+6-GCN4 (SEQ ID NO: 45) and mini2-
cluster1+5+6-nl (SEQ ID NO: 152) are capable of recognizing full length hemagglutin.
Their epitopes necessarily are located on the hemaglutinin stem domain and are
conserved between the full length hemagglutinins from H1N1 A/Brisbane/59/2007 and
H1N1 A/California/07/2009.
Example 17: Immunogenicity of third generation HA stem domain polypeptide mini2-
cluster1+5+6-GCN4
In order to further assess the immunogenicity of the stem domain polypeptides of
the invention mice were immunized once with the expression vector encoding mini2-
cluster1+5+6-GCN4 (SEQ ID NO: 45) (prime) and boosted twice with purified protein s-
H1-mini2-cluster1+5+6-GCN4 (SEQ ID NO: 145) at three week intervals. For reasons of
comparison, separate groups were immunized three times at three week intervals
immunization with the expression vectors encoding mini2-cluster1+5+6-GCN4 (SEQ ID
NO: 45) as well as full length H1 from A/Brisbane/59/2007 (SEQ ID NO: 1). An
expression vector encoding for cM2 was also included as a negative control.
Groups of 4 mice (BALB\c) were immunized intramuscularly (i.m.) with 1000 µg
construct encoding mini2-cluster1+5+6-GCN4 (SEQ ID NO: 45) + 100 µg adjuvant
(pUMCV1-GM-CSF) on day 1 and with s-H1-mini2-cluster1+5+6-GCN4 (SEQ ID NO:
145; 100 µg purified protein) adjuvanted with 10 µg Matrix-M on day 21 and 42. One
nd rd nd rd
group received 2 and 3 immunization s.c., whereas another received 2 and 3
immunizations i.m.. A third group was again primed with 100 µg construct encoding
mini2-cluster1+5+6-GCN4 (SEQ ID NO: 45) + 100 µg adjuvant (pUMCV1-GM-CSF)
on day 1 as above and received booster immunizations on day 21 and 41 of s-H1-mini2-
cluster1+5+6-GCN4 (SEQ ID NO: 145; 100 µg purified protein) adjuvanted with
Montanide ISA-720 (1:1 v/v). For comparison, groups of 4 mice (BALB\c) were
immunized i.m. on day 1, 21 and 42 with 100 µg construct encoding mini2-cluster1+5+6-
GCN4 (SEQ ID NO: 45), full length H1 from A/Brisbane/59/2007 (SEQ ID NO: 1) or
cM2, adjuvanted with 100 µg adjuvant (pUMCV1-GM-CSF).
On day 49 a final bleed was performed and serum collected. The sera were
analyzed by ELISA using the recombinant full length HA from the H1N1
A/Brisbane/59/2007, H1N1 A/California/07/2009, H5N1 A/Vietnam/1203/2004 and
H3N2 A/Hong Kong//1968 strains (obtained from Protein Sciences Corporation,
Meriden, CT, USA) as the antigen. In short, 96 wells plates were coated with 50 ng HA
overnight at 4 C, followed by incubation with block buffer (100 ml PBS, pH 7.4 + 2%
skim milk) for 1h at room temperature. Plates were washed with PBS + 0.05% Tween-20,
and 100 ml of a 2-fold dilution series in block buffer, starting from a 20 fold dilution of
the serum is added. Bound antibody is detected using HRP –conjugated goat-anti-mouse
IgG, using standard protocols well-established in the art. Titers are compared to a
standard curve composed of a serial dilution of a mouse monoclonal antibody binding to
the HA antigen and expressed as ELISA units per ml (EU/ml). Figure 20 exhibits the IgG
responses at week 7 after initial immunization for individual mice against the ectodomain
of the full length hemagglutinin from the homologous strain H1N1 A/Brisbane/59/2007
(panel A), the heterologous strain H1N1 A/California/07/2009 (panel B) the
heterosubtypic strain H5N1 A/Vietnam/1203/2004 (panel C) and the heterosubtypic
strain H3N2 A/Hong Kong/1/1968 (panel D). Antibodies induced by immunization with
DNA encoding the polypeptide of the invention mini2-cluster1+5+6-GCN4 (SEQ ID NO:
45) are capable of recognizing the HA of H1N1 A/Brisbane/59/2007, H1N1
A/California/07/2009 and to a lesser extent H5N1 A/Vietnam/1203/2004. Antibodies
elicited by immunization with DNA encoding the full length H1 from
A/Brisbane/59/2007 (SEQ ID NO: 1) recognize the homologous protein very well, but
the heterologous HA from H1N1 A/California/07/2009, and heterosubtypic HA from
H5N1 A/Vietnam/1203/2004 much less so, as is evidenced by the lower titers in figure
17B and C. The group of mice immunized with DNA encoding mini2-cluster1+5+6-
GCN4 (SEQ ID NO: 45; prime) followed by booster immunizations with s-H1-mini2-
cluster1+5+6-GCN4 (SEQ ID NO: 145) protein exhibit high titers aginst the ectodomains
of HA derived from homologous H1N1 A/Brisbane/59/2007, heterologous H1N1
A/California/07/2009 and heterosubtypic H5N1 A/Vietnam/1203/2004.
Figure 20D exhibits the IgG responses at week 7 against the ectodomain of HA
from H3N2 A/Hong Kong/1/1968. Unlike mini2-cluster1+5+6-GCN4 (SEQ ID NO: 45)
and s-H1-mini2-cluster1+5+6-GCN4 (SEQ ID NO: 145) that are derived from HA of
H1N1 A/Brisbane/59/2007, a strain that belongs to Influenza group 1, H3N2 A/Hong
Kong/1/1968 belongs to Influenza group 2 and is therefore phylogenetically distant from
the parent sequence used to design the polypeptides of the invention used in this
experiment. Immunizing three times with DNA encoding mini2-cluster1+5+6-GCN4
(SEQ ID NO: 45) or full length HA from H1N1 A/Brisbane/59/2007 (SEQ ID NO: 1)
does not result in IgG levels detectable by ELISA against this antigen. In contrast, the
immunization with DNA encoding mini2-cluster1+5+6-GCN4 (SEQ ID NO: 45)
followed by two booster immunizations with purified protein s-H1-mini2-cluster1+5+6-
GCN4 (SEQ ID NO: 145) results in high titers against HA from H3N2 A/Hong
Kong/1/1968. This result is obtained independent from the immunization route used (i.e.
intramuscular vs subcutaneous) or the adjuvant added to the protein boost immunizations
(Matrix-M or Montanide ISA-720).
In conclusion, immunization with polypeptides of the invention can elicit IgG’s
that are capable of recognizing HA from a broad range of influenza strains, including
homologous, heterologous, and heterosubtypic strains from influenza group 1 as well as a
strain form influenza group 2. In contrast immunization with the full length HA results in
high titers against HA of the homologous strains, reduced titers against heterologous and
heterosubtypic strains and IgG levels below the limit of detection for the strain from
influenza group 2.
Example 18: Design of further stem domain polypeptides comprising the conserved stem
domain epitopes of CR6261 and CR9114
Polypeptides of the invention designed following the the procedure described
above can be further modified to increase the stability. Such modifications can be
introduced to enhance the formation of trimeric forms of the polypeptides of the
invention over monomeric and/or dimeric species. As described, the native HA exists as
a trimer on the cell surface. Many of the interactions between the individual monomers
that keep the trimer together are located in the head domain. After removal of the head
the tertiary structure is thus destabilized and therefore reinforcing the interactions
between the monomers in the truncated molecule will increase the stability of the
trimeric form. trimerization is mediated by the formation of a trimeric. By strengthening
the coiled coil motif in the stem domain a more stable trimer form can be achieved.
According to the invention, a consensus sequence for the formation of a trimeric
coiled coil, IEAIEKKIEAIEKKIE (SEQ ID NO: 83), is introduced in a polypeptide of
the invention at (the equivalent of) position 418 to 433 (SEQ ID NO: 44) in H1
A/Brisbane/59/2007 (numbering according to SEQ ID NO: 1). Alternatively
IEAIEKKIEAIEKKI (SEQ ID NO: 85) can be introduced at 419-433 (SEQ ID NO: 49)
or IEAIEKKIEAIEKK (SEQ ID NO: 86) at 420-433 (SEQ ID NO: 50). An alternative is
to introduce the sequence MKQIEDKIEEIESKQ (SEQ ID NO: 84), derived from GCN4
and known to trimerize, at position 419-433 (SEQ ID NO: 45). Alternatively
MKQIEDKIEEIESK (SEQ ID NO: 87) can be introduced at position 420-433 (SEQ ID
NO: 51 ) or RMKQIEDKIEEIESKQK (SEQ ID NO: 88) at position 417-433 (SEQ ID
NO: 52). Similarly, the trimer interface might be strengthened by modifying M420,
L423, V427, G430 into Isoleucine (SEQ ID NO: 53).
In certain embodiments, the polypeptides of the invention contain the intracellular
sequences of H1 HA and the transmembrane domain. In other embodiments, the
cytoplasmic sequence and the transmembrane sequence from position (or the equivalent
thereof) 523, 524, 525, 526, 526, 527, 528, 529, or 530 of HA2 to the C-terminus of HA2
(numbering according to SEQ ID NO: 1) is removed so that a secreted (soluble)
polypeptide is produced. The soluble polypeptide can be further stabilized as described
above.
Description Linker variants
The genes encoding the above protein sequences (SEQ ID NO: 44 to 46; SEQ ID
NO: 49 to 53 and SEQ ID NO: 152-157 were synthesized and cloned into expression
vector pcDNA2004 using methods generally known to those skilled in the art. For
reasons of comparison an expression vector encoding the full length sequence (SEQ ID
NO: 1) as well as cM2 was included in the experiment
HEK293F (Invitrogen) suspension cells (10 cells/ml, 30 ml) were transfected
with the expression vectors (1 µg/ml) using 40 µl 293-transfectin as the transfection agent
and allowed to further propagate for 2 days. Cells were harvested; aliquotted (0.3 ml,
approximately 3*10 cells) and aliquots were treated with either polyclonal serum raised
against H1 HA to probe expression or a HA-specific monoclonal antibody (5
microgram/ml) and a secondary antibody used for staining. The cells were then analyzed
by fluorescence associated cell sorting (FACS) for expression of the membrane attached
HA stem domain polypeptides of the invention using polyclonal serum raised against H1
HA to probe expression. A panel of monoclonal antibodies of known specificity that bind
the full length protein (CR6261, CR9114, CR9020 and CR8020) were used to probe for
the presence of conserved epitopes and, by inference, correct folding of the full length
HA and the mini-HA polypeptides of the invention. Results are expressed as percentage
positive cells and mean fluorescence intensity and are shown in FIG 21.
Results show that all tested variants are expressed on the cell surface as evidenced
by the positive response from the polyclonal anti-H1 serum. H3 HA specific antibody
CR8020 does not recognize any of the constructs included in the experiment, whereas
CR9020, which binds to the head domain of H1 HA’s only clearly recognizes the full
length protein. All polypeptides of the invention, as well as the full length protein are
recognized by CR6261 and CR9114, indicating that the correspondent epitopes are
present in the polypeptides of the invention in the same conformation as in the wilde type
protein . Among the polypeptides of the invention with an additional trimerization motif
included in helix CD (see , SEQ ID NO: 45, 51 and 52 containing the GCN4-
derived sequences SEQ ID NO: 84, 87 and 88, respectively result in an equal or higher
responses (MFI) than SEQ ID NO: 44, 49 and 50, containing the consensus trimerization
sequences of SEQ ID NO: 83, 85 and 86.
The variation in the composition of the linker connecting amino acids 52 and 321
(numbering refers to SEQ ID NO: 1) in the polypeptides of the invention does not lead to
major changes in the recognition of monoclonal antibodies CR6261 and CR9114. The
largest change is observed when GGGG in SEQ ID NO: 46 is replaced with HNGK,
resulting in SEQ ID NO: 152, which leads to a somewhat lower response to CR6261, but
does not affect the response to CR9114. Removing the linker and introducing amino
acids 53-56 of SEQ ID NO: 1 (SHNG), i.e. creating a polypeptide of the invention
without a linker in SEQ ID NO: 46 (resulting in SEQ ID NO: 153), SEQ ID NO: 45
(resulting in SEQ ID NO: 154) or SEQ ID NO: 50 (resulting in SEQ ID NO: 155) does
not impact the response in the FACS assay, indicating that the linker sequence is not
critical.
SEQ ID NO: 156 is derived from SEQ ID NO: 46 by introducing mutations
I337N, I340N and F352Y, whereas SEQ ID NO: 157 contains an additional mutation at
position 353, i.e. I353N. These mutations do not lead to an improved response to CR6261
and CR9114 in the FACS assay shown in FIG 21.
In certain embodiments, the polypeptides of the invention contain the intracellular
sequences of HA and the transmembrane domain. In other embodiments, the cytoplasmic
sequence and the transmembrane sequence from position (or the equivalent thereof) 523,
524, 525, 526, 526, 527, 528, 529, or 530 of HA2 to the C-terminus of HA2 (numbering
according to SEQ ID NO: 1) is removed, and optionally replaced by introducing a
sequence known to form trimeric structures, i.e. AYVRKDGEWVLL (SEQ ID NO: 143),
optionally connected through a linker. The linker may optionally contain a cleavage site
for processing afterwards according to protocols well known to those skilled in the art. To
facilitate purification of the soluble form a tag sequence may be added, e.g. a His tag
HHHHHHH connected via a short linker, e.g. EGR. According to the present invention,
the amino acid sequence from position 530 (numbering according to SEQ ID NO: 1) to
the C-terminal amino acid of the HA2 domain was removed and replaced by SEQ ID NO:
81 or SEQ ID NO: 82.
Example 19: Immunogenicity of third generation HA stem domain polypeptides
In order to assess the immunogenicity of the stem domain polypeptides mice were
immunized with the expression vectors encoding full length H1 from A/Brisbane/59/2007
(SEQ ID NO: 1), Mini3- cluster11 (SEQ ID NO: 11), Mini2-cluster11+5 (SEQ ID NO:
14), mini2-cluster1+5+6 (SEQ ID NO: 46), mini2-cluster1+5+6-GCN4 (SEQ ID NO:
45), mini2-cluster1+5+6-nl (SEQ ID NO: 152), mini2-cluster1+5+6-nl2 (SEQ ID NO:
153), mini2-cluster1+5+6-nl2s-GCN4 (SEQ ID NO: 154), mini2-cluster1+5+6-GCN4t2
(SEQ ID NO: 51), mini2-cluster1+5+6-GCN4t3 (SEQ ID NO: 52), mini2-
cluster1+5+6+12 (SEQ ID NO: 156) and mini2-cluster1+5+6+12+13 (SEQ ID NO: 157).
An expression vector encoding for cM2 was also included as a negative control.
Groups of 4 mice (BALB\c) were immunized with 100 µg construct + 100 µg
adjuvant (pUMCV1-GM-CSF) i.m. on day 1, 21 and 42. On day 49 a final bleed was
performed and serum collected. The sera were analyzed by ELISA using recombinant full
length HA from the H1N1 A/Brisbane/59/2007, H1N1 A/California/07/2009 and H5N1
A/Vietnam/1203/2004 strains (obtained from Protein Sciences Corporation, Meriden, CT,
USA) as the antigen. In short, 96 wells plates were coated with 50 ng HA overnight at 4
C, followed by incubation with block buffer (100 ml PBS, pH 7.4 + 2% skim milk) for
1h at room temperature. Plates were washed with PBS + 0.05% Tween-20, and 100 ml of
a 2-fold dilution series in block buffer, starting from a 50 fold dilution of the serum is
added. Bound antibody is detected using HRP –conjugated goat-anti-mouse IgG, using
standard protocols well-established in the art. Titers are compared to a standard curve
composed of a serial dilution of a mouse monoclonal antibody binding to the HA antigen
and expressed as ELISA units per ml (EU/ml).
Figure 22 exhibits the IgG responses at week 7 after inihtial immunization for
individual mice against the full length hemagglutinin from the homologous strain H1N1
A/Brisbane/59/2007 (panel A), the heterologous strain H1N1 A/California/07/2009
(panel B) and the heterosubtypic strain H5N1 A/Vietnam/1203/2004 (panel C).
Antibodies induced by immunization with DNA encoding polypeptides of the invention
Mini2-cluster11+5 (SEQ ID NO: 14), mini2-cluster1+5+6 (SEQ ID NO: 46), mini2-
cluster1+5+6-GCN4 (SEQ ID NO: 45), mini2-cluster1+5+6-nl (SEQ ID NO: 152),
mini2-cluster1+5+6-nl2 (SEQ ID NO: 153), mini2-cluster1+5+6-nl2s-GCN4 (SEQ ID
NO: 154), mini2-cluster1+5+6-GCN4t2 (SEQ ID NO: 51), mini2-cluster1+5+6-GCN4t3
(SEQ ID NO: 52), mini2-cluster1+5+6+12 (SEQ ID NO: 156) and mini2-
cluster1+5+6+12+13 (SEQ ID NO: 157) bind equally well to the ectodomain of
hemagglutinin derived from the homologous H1N1 A/Brisbane/59/2007 and
heterologous H1N1 A/California/07/2009 strain (Figure 22A and B). Highest titers are
observed for mini2-cluster1+5+6-GCN4 (SEQ ID NO: 45), mini2-cluster1+5+6-GCN4t2
(SEQ ID NO: 51) and mini2-cluster1+5+6-nl2s-GCN4 (SEQ ID NO: 154). In contrast,
immunization with DNA encoding the full length protein (SEQ ID NO: 1) results in high
titers against the homologous hemagglutinin (more than an order of magnitude higher
than titers observed for immunization with DNA encoding the polypeptides of the
invention), but in low titers against the ectodomain of the heterologous hemagglutinin
(more than an order of magnitude). Immunization with DNA encoding Mini3-cluster11
(SEQ ID NO: 11) and negative control cM2 do not result in a detectable response against
either of the hemagglutinin ectodomains in this assay.
The titers against the ectodomain of the heterosubtypic hemaglutinin from H5N1
A/Vietnam/1203/2004 (Figure 22C) indicate a clear response for mini2-cluster1+5+6-
GCN4t2 (SEQ ID NO: 51). Observable titers are also obtained for 2 out of 4 mice after
immunization with DNA encoding mini2-cluster1+5+6-GCN4 (SEQ ID NO: 45) and for
1 out of 4 mice for mini2-cluster1+5+6-nl (SEQ ID NO: 152), mini2-cluster1+5+6-nl2
(SEQ ID NO: 153), mini2-cluster1+5+6-nl2s-GCN4 (SEQ ID NO: 154). Surprisingly, we
also find detectable titers after immunization with DNA encoding Mini3- cluster11 (SEQ
ID NO 11) and Mini2-cluster11+5 (SEQ ID NO: 14). The former construct did not
induce any detectable antibody titers against homologous and heterologous H1 HA,
whereas the latter induced only moderate responses (Figure 22A and B). Comparison of
the sequences of all constructs in this experiment and H5 HA point towards a putative
linear epitope located at the membrane distal end of the long CD helix (see figure 1). The
methionine to isoleucine mutation at position 175 in SEQ ID NO: 11 and position 156 in
SEQ ID NO: 14 results in linear sequence ERRIENLNKK (position 172 to 181 in SEQ
ID NO: 11; position 153 to 162 in SEQ ID NO: 14). This sequence is also present in HA
from H5N1 A/Vietnam/1203/2004, but not in the HA from H1N1 A/Brisbane/59/2007
and H1N1 A/California/07/2009, where the corresponding sequences are
ERRMENLNKK and EKRIENLNKK, respectively.
In conclusion, antibodies raised against the polypeptides of the invention mini2-
cluster11+5 (SEQ ID NO: 14), mini2-cluster1+5+6 (SEQ ID NO: 46), mini2-
cluster1+5+6-GCN4 (SEQ ID NO: 45), mini2-cluster1+5+6-nl (SEQ ID NO: 152),
mini2-cluster1+5+6-nl2 (SEQ ID NO: 153), mini2-cluster1+5+6-nl2s-GCN4 (SEQ ID
NO: 154), mini2-cluster1+5+6-GCN4t3 (SEQ ID NO: 52), mini2-cluster1+5+6-GCN4t2
(SEQ ID NO: 51), mini2-cluster1+5+6+12 (SEQ ID NO: 156) and mini2-
cluster1+5+6+12+13 (SEQ ID NO: 157) are capable of recognizing full length
hemagglutin. The epitopes of these antibodies must be located on the hemaglutinin stem
domain and are conserved between the full length hemagglutinins from H1N1
A/Brisbane/59/2007 and H1N1 A/California/07/2009. Antibodies elicited through
immunization with DNA encoding mini2-cluster1+5+6-GCN4t2 (SEQ ID NO: 51), and
to a lesser extent mini2-cluster11+5 (SEQ ID NO: 14), mini2-cluster1+5+6-GCN4 (SEQ
ID NO: 45), mini2-cluster1+5+6-nl (SEQ ID NO: 152), mini2-cluster1+5+6-nl2 (SEQ
ID NO: 153), mini2-cluster1+5+6-nl2s-GCN4 (SEQ ID NO: 154) and mini2-
cluster1+5+6+12 (SEQ ID NO: 156) are also able to recognize the ectodomain of HA
from H5N1 A/Vietnam/1203/2004. Polypeptide of the invention Mini3- cluster11 (SEQ
ID NO: 11) is capable of inducing antibodies that recognize from H5N1
A/Vietnam/1203/2004.
Example 20. General method to design of stem domain polypeptides comprising the
conserved stem domain epitopes of CR6261 and CR9114
On the basis of the results described above a general method is defined to create a
polypeptide of the invention from an influenza virus HA0 sequence, in particular from an
influenza HA0 sequence of serotype H1. The method comprises the steps:
1. Removal of the cleavage site between HA1 and HA2. This can be achieved by
mutation of R (in a small number of cases K) to Q at the P1 position (see e.g. Sun et
al, 2010 for an explanation of the nomenclature of the cleavage site (position 343 in
SEQ ID NO: 1). A mutation to Q is preferred but S, T, N, D or E are alternatives.
2. Removal of the head domain by deleting amino acids 53 to 320 from SEQ ID NO: 1,
or at equivalent positions in HA from other influenza viruses. Equivalent positions
can be easily determined by those skilled in the art by aligning the sequences using
suitable algorithms such as e.g. Clustal or Muscle. The remaining parts of the
sequence can be joined directly or alternatively by introducing a flexible linker.
Linker sequences can be 1 to 50 amino acids in length. Preferred are flexible linkers
of limited length (smaller or equal to 10 amino acids), e.g. GGG, GGGG, GSA,
GSAG, GSAGSA, GSAGSAG or similar. The length of the deletion can also be
varied, e.g. by starting the deletion at (the equivalent of) position 54, 55, 56, 57 or
58, or to increase the length of the deletion, by cutting at position 47, 48, 49, 50, 51,
or 52. Similarly, the last amino acid to be deleted can be at (the equivalent of)
position 315, 316, 317, 318 or 319, or to increase the length of the deletion at (the
equivalent of) position 321, 322, 323, 324, or 325. It is important to realize that changes
in the length of the deletion can be in part compensated for by matching the length of
the linker sequence, i.e. a larger deletion can be matched with a longer linker and
vice versa. These polypeptides are also encompassed by the invention.
3. Increasing the solubility of the loop (between the A-helix and the CD helix) formed
by (the equivalent of) residues 402 to 418 in H1 A/Brisbane/59/2007 (SEQ ID NO:
1) to increase the stability of the pre-fusion conformation and destabilize the post-
fusion conformation of the modified HA. This loop is highly conserved in H1
sequences, as can be seen in table 6 below. This can for example be achieved by
replacing I, L, F or V residues in said loop with hydrophilic counterparts. Equivalent
positions can be easily determined by those skilled in the art by aligning the
sequences using a suitable algorithm such as e.g. Clustal or Muscle. Mutations to
glycine destabilize the post-fusion conformation since the high flexibility of this
amino acid leads to a decrease in stability of the post-fusion helix to be formed by
this part of the HA sequence. The consensus sequence describing the loop between
residue 402-418 of influenza HA of serotype H1 is (SEQ ID NO: 17)
MNTQFTAVGKEFN(H/K)LE(K/R). In polypeptides of the invention the amino acid
at positions 406, 409, 413 and/or 416 (or their equivalent, as determined from a
sequence alignment ) is a polar (S,T,N,Q), charged (R,H,K,D,E) or flexible (G)
amino acid. It should be noted that mutation of L416 to either S or T also introduces
a consensus N-glycosylation site (consensus sequence is NX(S/T)). Glycosylation of
the Asparagine this position will further increase the solubility of this region.
Combinations of mutations at these sites are also possible, for example F406S,
V409T, L416S as in SEQ ID NO: 10 and SEQ ID NO: 14. In some cases a mutation
to restore the consensus amino acid is preferred, e.g. where V or M is at position 404
(to T), V at 408 (to A) or 410 (to G) or I at 414 (to N); the incidence of sequences
with these particular amino acids is very low. An overview of the mutations
described above that characterize polypeptides of the invention is given in table 6.
4. Introducing a disulfide bridge in the polypeptides of the invention, preferably
between amino acids of (the equivalent of) position 324 and 436 in H1
A/Brisbane/59/2007; SEQ ID NO: 13-16. Equivalent positions can be easily
determined by those skilled in the art by aligning the sequences using a suitable
algorithm such as Clustal, Muscle etc. Engineered disulfide bridges are created by
mutating at least one (if the other is already a cysteine), but usually two residues that
are spatially close into a cysteine, that will spontaneously or by active oxidation form
a covalent bond between the sulfur atoms of these residues.
Using the general method according to the invention, described above, polypeptides
of the invention were created based on the HA0 sequences of H1N1
A/California/04/2009 (SEQ ID NO: 159), H1N1 A/California/07/2009 (SEQ ID NO: 56),
H1N1 A/Puerto Rico/8/1934 (SEQ ID NO: 78), and H1N1 A/Texas/36/1991 (SEQ ID
NO: 64). In addition the method was applied to HA from another subtype that is part of
Group 1, i.e. H5, using HA from H5N1 A/Vietnam/1203/2004 (SEQ ID NO: 158).
H1 mini-HA A/California/07/2009 (SEQ ID NO: 160) is created from H1 FL HA
A/California/07/2009 (SEQ ID NO: 56) by
1. Removing the cleavage site: mutation R344Q (numbering refers to SEQ ID NO: 56.
2. Deleting residues K53 to P321 and introducing a GGGG linker between D52 and
K322 (numbering refers to SEQ ID NO: 56)
3. Introducing a Serine residue at position 407, 417 (F407S, L417S; numbering refers
to SEQ ID NO: 2), Threonine at position 410 (V410T; numbering refers to SEQ ID
NO: 56) and a Glycine residue at position 414 (F414G; numbering refers to SEQ ID
NO: 2) in the loop between the A-helix and the CD helix (residues 403-419 in SEQ
ID: NO: 56)
4. Introducing a disulfide bridge by mutating residues Lysine 325 and Threonine 437
into a cysteine (K325C, T437C; numbering refers to SEQ ID NO: 56)
. An additional stabilizing element was introduced by replacing
(numbering refers to SEQ ID NO: 56) with the
419KRIENLNKKVDDGFLD434
sequence RMKQIEDKIEEIESKQ.
The mini-HA sequence based on the full length HA from A/California/04/2009
(SEQ ID NO: 159) can be created in the same manner and is identical to the sequence of
H1 mini-HA A/California/07/2009 (SEQ ID NO: 160).
Similarly, H1 mini-HA A/Puerto Rico/8/1934 (SEQ ID: NO: 161) is created from
H1 FL HA A/Puerto Rico/8/1934 (SEQ ID NO: 78) by
1. Removing the cleavage site: mutation R343Q (numbering refers to SEQ ID NO: 78)
2. Deleting residues S53 to P320 and introducing a GGGG linker between D52 and
K321 (numbering refers to SEQ ID NO: 78)
3. Introducing a Serine residue at position 406, 416 (F406S, L416S; numbering refers
to SEQ ID NO: 78) Threonine at position 409 (V409T; numbering refers to SEQ ID
NO: 78) and a Glycine residue at position 413 (F413G; numbering refers to SEQ ID
NO: 78) in the loop between the A-helix and the CD helix (residues 402-418 in
SEQ ID NO: 78)
4. Introducing a disulfide bridge by mutating residues Arginine 324 and Threonine
436 into a cysteine (R324C, T436C; numbering refers to SEQ ID NO: 78)
. An additional stabilizing element was introduced by replacing
418KRMENLNNKVDDGFLD433 (numbering refers to SEQ ID NO: 78) with the
sequence RMKQIEDKIEEIESKQ.
An additional difference between H1 mini-HA A/Puerto Rico/8/1934 (SEQ ID: NO: 161)
and H1 FL HA A/Puerto Rico/8/1934 (SEQ ID NO: 78) is at position 397, which is a
Serine in the full length protein (SEQ ID: NO: 78) but a Threonine in the polypeptide of
the invention of SEQ ID: NO: 161 (S397T mutation). This is a naturally occurring
variation in the A/Puerto Rico/8/1934 sequence, and sequences containing this mutation
are therefore also included in the invention.
H1 mini-HA A/Texas/36/1991 (SEQ ID NO: 162) is created from H1 FL HA
A/Texas/36/1991 (SEQ ID NO: 64) by
1. Removing the cleavage site: mutation R344Q (numbering refers to SEQ ID NO: 64)
2. Deleting residues S53 to P321 and introducing a GGGG linker between D52 and
K322 (numbering refers to SEQ ID NO: 64)
3. Introducing a Serine residue at position 407, 417 (F407S, L417S; numbering refers
to SEQ ID NO: 64), Threonine at position 410 (V410T; numbering refers to SEQ
ID NO: 64) and a Glycine residue at position 414 (F414G; numbering refers to SEQ
ID NO: 64) in the loop between the A-helix and the CD helix (residues 403-419 in
SEQ ID: NO: 64)
4. Introducing a disulfide bridge by mutating residues Arginine 325 and Threonine
437 into a cysteine (R325C, T437C; numbering refers to SEQ ID NO: 64)
5. An additional stabilizing element was introduced by replacing
419RRMENLNKKVDDGFLD434 (numbering refers to SEQ ID NO: 64) with the
sequence RMKQIEDKIEEIESKQ.
H5 mini-HA A/Vietnam/1203/2004 (SEQ ID NO: 163) is created from H5 FL HA
A/Vietnam/1203/2004 (SEQ ID NO: 158) by
1. Removing the cleavage site. Since H5 FL HA A/Vietnam/1203/2004 (SEQ ID NO:
158) contains a polybasic cleavage site (341RRRKKR346) a single site mutation is
not enough to prevent protein cleavage. Instead 341RRRKK345 is deleted and a
R346Q mutation is introduced.
2. Deleting residues K52 to P319 and introducing a GGGG linker between K51 and
K320 (numbering refers to SEQ ID NO: 158)
3. Introducing a Serine residue at position 409, 419 (F409S, L419S; numbering refers
to SEQ ID NO: 158), Threonine at position 412 (V412T; numbering refers to SEQ
ID NO: 158) and a Glycine residue at position 416 (F416G; numbering refers to
SEQ ID NO: 158) in the loop between the A-helix and the CD helix (residues 405-
421 in SEQ ID: NO: 158)
4. Introducing a disulfide bridge by mutating residues Lysine 323 and Threonine 439
into a cysteine (K323C, T439C; numbering refers to SEQ ID NO: 158)
. An additional stabilizing element was introduced by replacing
(numbering refers to SEQ ID NO: 158) with
421RRIENLNKKMEDGFLDV437
the sequence RMKQIEDKIEEIESKQI.
The genes encoding the protein sequences of SEQ ID: NO: 56, 160, 78, 161, 162,
158 and 163 were synthesized and cloned into expression vector pcDNA2004 using
methods generally known to those skilled in the art. For reasons of comparison the full
length HA sequence of H3 A/Hong Kong/1/1968 (SEQ ID NO: 121), as well as the full
length HA sequence of H1 A/Brisbane/59/2007 (SEQ ID NO: 1) with additional
cleavage site mutation R343Q were included in the experiment.
HEK293F (Invitrogen) suspension cells (10 cells/ml, 30 ml) were transfected
with the expression vectors (1 µg/ml) using 40 µl 293transfectin as the transfection agent
and allowed to further propagate for 2 days. Cells were harvested, aliquotted (0.3 ml,
approximately 3*10 cells) and aliquots were treated with either polyclonal serum raised
against H1 HA (Sino Biological Inc. Beijing, China) to probe expression or a HA-specific
monoclonal antibody (5 microgram/ml) and a secondary antibody used for staining. The
cells were then analyzed by Fluorescence Associated Cell Sorting (FACS) for expression
of the membrane attached HA stem domain polypeptides of the invention on the cell
surface. A panel of monoclonal antibodies of known specificity that bind the stem
domain in the full length protein (CR6261, CR9114) were used to probe for the presence
of conserved epitopes and, by inference, correct folding of the full length HA and the
mini-HA polypeptides of the invention. Monoclonal antibody CR8020 (known not to
bind to H1 and H5 HA’s ) and CR9020 (binds to the head domain of HA from H1
A/Brisbane/59/2007) were also included in the experiment. Results are expressed as
percentage positive cells and Mean Fluorescence Intensity (MFI) and are shown in FIG.
Treatment of the transfected cells with polyclonal anti-H1 serum results in 20 to
80% positive cells for the full length HA (solid bars) and 40-50% positive cells for the
mini-HA’s. Negative controls FL H3 A/Hong Kong/1/1968 and cM2 only display very
low numbers of positive cells. This is mirrored by mean fluorescence intensity (bottom
panel) which shows a clearly detectable signal for all H1 full length HA proteins. The
signal for the full length H5 HA remains low; however, this can be explained by a lower
number of transfected cells in combination with a reduced recognition by the polyclonal
H1 serum. Negative controls FL A/Hong Kong/1/1968 and cM2 show intensities at
background level.
Both CR6261 and CR9114, known to be strong group 1 stem binders, recognize
all Group 1 full length HA and mini-HA proteins as indicated by high numbers of
positive cells (ca. 50 to ca. 95%) and high MFI. This is strong evidence that the
neutralizing epitopes of these antibodies are present in the mini-HA proteins, indicating a
three-dimensional structure that strongly resembles the native structure of the HA stem
domain in the full length HA. As expected, negative control CR8020 (specific for group 2
HA) does not bind to H1 and H5 Full length HA or H1 and H5 mini-HA, indicating that
the observed binding of the CR6261/CR9114 neutralizing antibodies to the mini-HA
proteins does not arise from a-specific protein-protein interactions. Binding between full
length H3 HA from A/Hong Kong/1/1968 and CR9114 or CR8020 is clearly observed
from both the percentage positive cells and the MFI, in line with earlier observations and
proving the functionality of these monoclonal antibodies. Similarly, negative control
antibody CR9020 (HA head binder for A/Brisbane/59/2007) does not recognize the mini-
HA’s or full length HA proteins, with the exception of HA from A/Brisbane/59/2007,
further underlining the specificity of the observed binding between CR6261 and CR9114.
In conclusion, four novel HA derived polypeptides of the invention have been
created that have shown to contain the epitopes recognized by the neutralizing CR6261
and CR9114 antibodies in the absence of the HA head domain.
Example 21: Protection against lethal influenza challenge in mice by polypeptides of the
invention
In order to determine whether polypeptides of the invention are capable of
inducing an immune response that protects mice from death upon an exposure to
influenza virus that would otherwise be lethal an influenza challenge experiment was
performed. Mice were immunized i.m. with expression vectors encoding SEQ ID NO:78,
161, 45 and 6, as well as Full length HA from A/Brisbane/59/2007 (SEQ ID NO: 1)
containing an additional R343Q mutation to remove the cleavage site. An expression
vector encoding cM2 was included as a negative control. Immunization was performed
using 50 mg expression construct + 50 mg adjuvant (pUMCV1-GM-CSF) according to the
study protocol below
Study Protocol
Day -1 Bleed.
Day 0 Administration of vaccine (i.m.).
Day 21 Administration of vaccine (i.m.).
Day 28 Bleed.
Day 42 Administration of vaccine (i.m.).
Day 47 Bleed.
Day 48 Measurement of weight, temperature, clinical score and lethality.
Day 49 Challenge with lethal dose of influenza viral infection (per nasal).
Day 49 Remaining inoculum is utilized for back titration of virus.
Day 49-70 Daily measurement of weight, temperature, clinical score and lethality.
Animals with clinical score ‡ 3 are monitored two times per day.
Animals with clinical score ‡4 or temperature " 32° C, whichever comes
first, are immediately removed from the study.
Day 70 Sacrifice of all mice.
Group 1-6: Challenge with PR8 (A/Puerto Rico8/34, H1N1)
Group 1: SEQ ID NO: 78
Group 2: SEQ ID NO: 161
Group 3: SEQ ID NO: 1 R343Q
Group 4: SEQ ID NO: 45
Group 5: SEQ ID NO: 6
Group 6: empty vector
10 mice per group. Total 60 mice. BALB/c.
Materials and Methods:
Virus strain and source:
Influenza virus strain PR8 (A/Puerto Rico8/34, H1N1) was sourced from Virapur (San
Diego). Stock solution 1x10e8 pfu/ml Batch #E2004B.
Storage conditions. -75 °C ± 10 °C. Freezer: -86°C UCT freezer. Thermo Form. Fisher
Scientific.
Animals:
Mouse, BALB/c (Specified Pathogen Free; SPF), female. 6 to 8 weeks old on Study Day
0 ~17-19 grams. Sourced from Charles River Laboratories and identified by ‘ear
identification’. All animals were acclimatized and maintained for 11 days before the start
of the experiment.
DNA administration
Method of inoculum reconstitution
Appropriate DNA formulations, as listed above were prepared aliquotted and stored at -
°C. Per construct one aliquot was thawed to room temperature immediately before
injection, drawn into a syringe and injected. The remainder of each aliquot was discarded
after completion of all injections of each immunization round.
Dose level and method of administration
Mice are anaesthetized by intraperitoneal injection with 9.75mg Xylasol (Graeub E Dr.
AG (www.graeub.com);Cat: 763.02) and 48.75mg Ketasol (Graeub E Dr. AG
(www.graeub.com); Cat: 668.51) per kg body weight. 50 ml DNA solution was injected
using a 0.5 ml syringe with a G29 needle intramuscularly (i.m.) in the quadriceps muscle
of each hind leg, yielding a total volume of 100 ml injected per mouse. The remainder of
each aliquot was discarded after completion of all injections of each immunization round.
Virus administration:
Method of inoculum reconstitution
The virus material was stored at -75 °C ± 10 °C and was defrosted prior to
administration. Once defrosted, the material was diluted in cold PBS (4 °C)
corresponding to 5 LD50/50 ml for the A/PR/8/34 challenges. The diluted virus was kept
on ice until administration to the mice.
Dose level and method of administration
The animals were anaesthetized by intraperitoneal injection with 9.75mg Xylasol and
48.75mg Ketasol per kg body weight and each animal received 50 ml virus solution by
intranasal. Unused material was returned to the lab for back titration.
Blood withdrawal and serum preparation
At days specified in the Study Protocol, above, blood samples were taken (intermediate
bleedings: 100-150 ml via retroorbital cannulation, terminal bleeding via cardiac
puncture: approximately 300-500 ml). Serum was isolated from this blood by
centrifugation for 5 min at 14000 g and stored at -20 °C until shipment on dry ice
Clinical scoring
Clinical signs after virus challenge were scored with a scoring system (1 point for a
healthy mouse; 2 points for a mouse showing signs of malaise, including slight
piloerection, slightly changed gait and increased ambulation; 3 points for a mouse
showing signs of strong piloerection, constricted abdomen, changed gait, periods of
inactivity, increased breathing rate and sometime râles (clicking/crackling noise); 4 points
for a mouse with enhanced characteristics of the previous group, but showing little
activity and becoming moribund; 5 points for a dead mouse). Animals were inspected
twice a day as long as they received a score of 3. Scoring was performed by a single
investigator and mice with symptoms partially represented by two scores were score +/-
0.5.
Weighing
All animals were weighed daily, starting on day 48 (authorization number 2216).
Animals were also weighed prior to the end of the study in case of death, i.e. at removal
from study. Bodyweight was recorded in grams (g)
Virus back titration
The dose of the virus administered was determined by titrating 8 replicate samples from
the inoculum remaining after inoculation of the animals was completed. For viral back
titration TCID50 measurement was utilized following the protocol outlined in ‘Current
Protocols in Immunology, Animal Models of Infectious Disease 19.11.7’.
Results:
The study was performed without technical difficulties and in line with the defined study
protocol. Back titration of the inoculums of Influenza virus strain PR8 (A/Puerto
Rico8/34, H1N1) resulted in the following TCID50: PR8 (A/Puerto Rico8/34, H1N1) :
3.2x104 TCID50/ml
Figure 24A shows the Kaplan-Meier survival curves for this experiment.
Immunization with DNA encoding polypeptides of the invention SEQ ID NO: 45, 6 and
161 results in survival of 50, 40 and 40% of mice infected with a lethal dose of influenza,
respectively, indicating that immunization with the polypeptides of the invention can
indeed induce a protective immune response. In contrast animals immunized with the
empty vector control all succumb to infection 8 days after the viral challenge.
Immunization with DNA encoding the full length HA homologous to the challenge strain
(SEQ ID NO: 78) fully protects all animals (i.e. 100% survival) from the lethal challenge,
whereas immunization with DNA encoding full length HA derived from the heterologous
strain A/Brisbane/59/2007 (SEQ ID NO: 1) containing an additional cleavage site
mutation (R343Q; numbering refers to SEQ ID NO: 1) leads to survival of 90% of the
animals infected.
The results obtained from the survival curves are also reflected in the mean body
weight change and median clinical scores for each group shown in Figure 24B and 24C.
Animals immunized with polypeptides of the invention SEQ ID NO: 45, 6 and 161
exhibit weight loss up to 25-30%, but animals surviving after day 9 post infection show
an increase in weight. For animals immunized with SEQ ID NO: 45 a drop in clinical
score from 4to 3 is also observed. Animals immunized with DNA encoding the full
length HA homologous to the challenge strain (SEQ ID NO: 78) do not show weight loss,
where as animals immunized with DNA encoding full length HA derived from the
heterologous strain A/Brisbane/59/2007 (SEQ ID NO: 1) containing an additional
cleavage site mutation (R343Q; numbering refers to SEQ ID NO: 1) experience weight
loss and clinical symptoms but survivors fully cover. The highest weight loss is and
clinical symptoms are observed for the control group immunized with an empty vector, in
line with the lack of survival of these animals.
In conclusion, polypeptides of the invention SEQ ID NO: 6, 45 and 78 are capable
of inducing a protective response against a lethal challenge with H1N1 A/Puerto
Rico/8/1934 in mice. It is of note that polypeptides of the invention SEQ ID NO: 6 and
45 are derived from an HA molecule heterologous to the challenge strain, whereas SEQ
ID NO: 78 is derived from the homologous influenza strain. So polypeptides of the
invention can induce protection against both homologous and heterologous influenza
infection.
Example 22. Selection of a panel of representative H1N1 HA sequences and design of
polypeptides of the invention based on these sequences.
In order to show the wide applicability of the design method described in example
the method was applied to a panel of selected HA0 sequences that cover a large
percentage of the natural sequence variation found in H1N1 viruses. The selection of a
panel of representative HA sequences from the pool of known human H1N1 HA
sequences in this example has the objective to select a minimum number of strains with a
maximum representativeness. To achieve this, all differences between the HA sequences
of human H1N1 influenza viruses present in the Influenza Virus Sequence Database
have been quantified, the structure in these differences has been investigated and
homogenous subgroups have been identified. From each of such groups the most
representative sequence has been selected to contribute to the panel.
The primary step in the procedure is the quantification of the difference between
each pair or sequences in the considered sequence database. The reverse PAM250
(rPAM250) matrix (Xu, 2004) is used to quantify the difference at each amino acid
position. Euclidian addition is then used to quantify the total difference for that pair. All
pair-wise differences are used to form a symmetric n×n matrix of differences, where n
equals the number virus strains considered.
Principal Coordinates Analysis (PCA) is used to structure the matrix of
differences (Higgins, 1992). PCA is based on dimension reduction. The input matrix is
considered a distribution in n dimensional space (where n equals the number of strains
considered). The variability is then analyzed and structured in such a way that a minimum
dimensionality is required to cover most (or all) variability. The result is an m
dimensional coordinate system (where m is the number dimension to cover most or all
variability) with most variation on the first axis and then decreasing. All considered
sequences are positioned within that coordinate system. In the case where only 2 or 3
dimensions are needed, the result can be plotted completely in a 2D or 3D graph,
respectively, in which the difference between the strains can be visualized. In the case
where more dimensions are needed, also a 3D plot can be constructed from the first 3
axes, but that graph does not cover all variability, since part of the variation is in the 4
and higher dimensions.
The sequences in the m dimensional space are then clustered, using both
hierarchical and k means clustering. Average linkeage within groups is used to obtain
groups with similar internal variability, and to avoid a large proportion of single strain
clusters. Clustering is done at all levels, starting at 1 (all strains in one cluster) till n (each
strain forming its own cluster). From each cluster the most central strain is selected as the
most representative. The set of most central strains then form the panel of representative
strains for that level clustering. For each level of clustering the coverage (or percentage of
variation explained) is estimated by computing the sum of squared distances of each
strain to its centre strain as compared to the sum of squared distances of each strain to the
centre of the coordinate system. A minimum level of coverage to be achieved is then set
to be the smallest required size of the representative panel.
Additionally to the Xu rPAM250 matrix, small values were assigned for the
difference when one of the two sequences had a gap on a certain position (due to inserts
or deletions). Also a weight factor was included in the procedure, to account for the large
differences in numbers of isolates through the years. This variation was considered to be
partially true variation in occurrence, partially driven by different levels of
surveillance/awareness. Therefore, the weight factor was set at one divided by the square
root of the numbers of observations in a particular year. This weight factor was taken into
consideration when constructing the m dimensional space, during the cluster analysis and
selection of centre points, and at estimation of the level of covered variation.
In this example, constructed sequences are used, consisting of the parts of HA
coding for the polypeptide of the invention. Two different sets of constructed sequences
were created. In the first set the natural sequences with the exception of the signal
sequence (e.g. amino acids 1-18), amino acids 53 to 320 (the HA head domain), the
transmembrane sequence (amino acid 530 to the C-terminal amino acid) (numbering
refers to SEQ ID NO: 1) or the equivalent of these positions in other sequences were
taken into consideration. In the second set amino acids at position (or the equivalent
position) 406, 409, 416, 324, 436, 413 were also not taken into consideration, since these
are modified according to the general method described in example 20. Furthermore, (the
equivalent of) positions 419-433 were also not taken into account in the second set
reflecting the addition of a GCN4-based stabilization sequence in polypeptides of the
invention as described in example 9.
Using the method described above 7 HA sequences were selected from
constructed sequences set 1, selected, covering 75% of the sequence variation and 8 HA
sequences from constructed sequences set 2 covering 74% of the sequence variation. The
strains are listed in table 10. Three of the selected sequences appear in both sets, so 13
unique HA sequences remain. These sequences were used to design polypeptides of the
invention according to the method described in example 20. In addition the stabilizing
GCN4 sequence MKQIEDKIEEIESKQ (SEQ ID NO: 84) is introduced at the equivalent
of position 419-433 (numbering refers to SEQ ID NO: 1), as described in example 9. The
polypeptides of the invention designed on the basis of the HA sequences of H1N1
A/Memphis/20/1978 and H1N1 A/USSR/92/1977 are identical, as are the polypeptides of
the invention designed on the basis of the HA sequences of A/Wisconsin/629-
D01415/2009 and H1N1 A/Sydney/DD3-55/2010. So in total 10 unique polypeptides of
the invention were designed, and an alignment of these sequences is shown in figure 25.
Expression vectors containing the DNA encoding polypeptides of the invention
SEQ ID NO:164 to SEQ ID NO: 173, as well as polypeptide of the invention SEQ ID
NO: 45 based on the HA sequences of A/Brisbane/59/2007 and the corresponding full
length HA SEQ ID NO: 1 with additional cleavage site mutation R343Q in expression
vector pcDNA2004 were used for transfection of HEK293F cells and the cells were
analyzed by FACS as before. In addition to human monoclonal antibodies CR6261,
CR9114 and CR8020, also mouse monoclonal antibody C179 known to neutralize
Influenza A H1 and H2 strains (Okuna et al., 1993) was included in the experiment. The
results are shown in Figure 26.
All polypeptides of the invention as well as the full length sequence of
A/Brisbane/59/2007 are expressed on the cell surface and recognized by broadly
neutralizing antibodies CR6261, CR9114 and C179, but not CR8020. The latter is known
to bind only to HA from Influenza A group 2. The binding of the antibodies CR6261,
CR9114 and C179 indicates that the broadly neutralizing epitopes are well preserved in
the polypeptides of the invention. Considering the sequence variation covered in these
sequences this is clear evidence of the general applicability of our design method to
generate polypeptides of the invention containing broadly neutralizing epitopes.
Example 23. Characterization of polypeptide of the invention s-H1-mini2-cluster1+5+6-
GCN4 (SEQ ID NO: 145)
Purified polypeptide of the invention s-H1-mini2-cluster1+5+6-GCN4 (SEQ ID
NO: 145) was obtained as described in example 13. To confirm the presence of the
conformational epitopes of CR6261 and CR9114 the binding of these antibodies with the
purified protein was studied by biolayer interferometry (Octet Red , Forte Bio). To this
end biotinylated CR6261, CR9114 and CR8020 were immobilized on streptavidin coated
sensors, the sensors were exposed first to a solution of the purified polypeptide (250 nM)
of the invention to measure the rate of association and then to a wash solution to measure
the rate of dissociation. For reasons of comparison the experiment was repeated with the
full length protein (SEQ ID NO 149) both in its trimeric and monomeric form. The
results are shown in figure 27.
The immobilized CR6261 recognizes both the monomeric and trimeric forms of
the ectodomain of full length HA from H1N1 A/Brisbane/59/2007 as evidenced by the
clear responses after exposure to these proteins in solution (Figure 27A). The response
observed for the trimeric protein is larger than observed for the monomer (ca. 1.3 nm vs
0.9) with the same sequence, an effect that is caused (at least in part) by the smaller size
of the monomer compared to the trimer. Binding of CR6261 to s-H1-mini2-cluster1+5+6-
GCN4 (SEQ ID NO: 145) results in a maximum response of approximately 0.25 nm.
Upon exposure to the wash solution dissociation of the complex is observed for all three
analytes with the fastest release observed for the polypeptide of the invention s-H1-
mini2-cluster1+5+6-GCN4 (SEQ ID NO: 145), and the slowest for the trimeric form of
the ectodomain of full length HA from H1N1 A/Brisbane/59/2007 (SEQ ID NO 149).
Similar to CR6261 immobilized CR9114 also recognizes both trimeric and
monomeric forms of the ectodomain of full length HA from H1N1 A/Brisbane/59/2007,
as well as the polypeptide of the invention s-H1-mini2-cluster1+5+6-GCN4 (SEQ ID
NO: 145). Response are stronger for all three analytes compared to CR6261 (1.5, 1.4 and
0.8 nm for trimeric, monomeric full length HA (SEQ ID NO: 149) and stem domain
polypeptide s-H1-mini2-cluster1+5+6-GCN4 (SEQ ID NO: 145), respectively) and upon
exposure of the complex to wash buffer release of the antigen is minimal or undetectable
in all three cases. For CR8020 no responses were observed for any of the analytes, in line
with the influenza group 2 stem domain specificity of this antibody.
To further characterize the binding of CR6261 and CR9114 to the purified stem
domain polypeptide a titration was performed. To this end immobilized CR6261
containing sensors were exposed to s-H1-mini2-cluster1+5+6-GCN4 (SEQ ID NO: 145)
solutions at concentrations of 500, 250, 125, 63, 31, 16 and 8 nM, respectively, and the
final response after 14000s recorded. The responses were plotted as a function of the stem
domain polypeptide concentration, and a fit to a steady state 1:1 binding model was
performed, yielding a dissociation constant K of ca 190 nM for the CR6261/stem
domain polypeptide complex FIG 28A. Similarly, sensors modified with immobilized
CR9114 were exposed to s-H1-mini2-cluster1+5+6-GCN4 (SEQ ID NO: 145) at
concentrations of 80, 40, 20, 10, 5, 2.5 and 1.3 nM, respectively, and the final response
after 10800s recorded. Fitting of the final responses as a function of stem domain
polypeptide concentration yields a K value of 5.4 nM for the CR9114/stem domain
polypeptide complex (B).
In conclusion polypeptide of the invention s-H1-mini2-cluster1+5+6-GCN4 (SEQ
ID NO: 145) is capable of binding broadly neutralizing monoclonal antibodies CR6261
and CR9114, confirming the presence of the corresponding neutralizing epitopes in this
stem domain polypeptide.
Example 24: Protection against lethal influenza challenge in mice by polypeptides of the
invention
In order to determine whether polypeptides of the invention are capable of
inducing an immune response that protects mice from death upon an exposure to
influenza virus that would otherwise be lethal an influenza challenge experiment was
performed. Mice were immunized i.m. with expression vectors encoding H3 Full length
A/Hong Kong/1/1968 (SEQ ID NO: 121), HK68 H3m2-cl9+10+11 (SEQ ID NO: 124)
and HK68 H3m2-cl9+10+11+12-GCN4 SEQ ID NO: 130. Immunization was performed
using 50 mg expression construct + 50 mg adjuvant (pUMCV1-GM-CSF) according to the
study protocol below
Study Protocol
Day -1 Bleed.
Day 0 Administration of vaccine (i.m.).
Day 21 Administration of vaccine (i.m.).
Day 28 Bleed.
Day 42 Administration of vaccine (i.m.).
Day 47 Bleed.
Day 48 Measurement of weight, temperature, clinical score and lethality.
Day 49 Challenge with lethal dose of influenza viral infection (per nasal).
Day 49 Remaining inoculum is utilized for back titration of virus.
Day 49-70 Daily measurement of weight, temperature, clinical score and lethality.
Animals with clinical score ‡ 3 are monitored two times per day.
Animals with clinical score ‡4 or temperature " 32° C, whichever comes
first, are immediately removed from the study.
Day 70 Sacrifice of all mice.
Group 7-10: Challenge with HK68 (A/Hong Kong/1/68, H3N2)
Group 7: SEQ ID NO: 121
Group 8: SEQ ID NO: 130
Group 9: SEQ ID NO: 124
Group 10: empty vector
mice per group. Total 40 mice. BALB/c.
Materials and Methods:
Virus strain and source:
Influenza virus strain HK68 (A/Hong Kong/1/68) was provided by Prof J. Katz (Center
for Disease Control and Prevention, Atlanta, GA, USA) followed by propagation by
Virapur (San Diego). The virus has been passaged multiple times in mouse lungs to
enhance virulence in mice. A suitable reference for this virus is: Frace et al., Vaccine
1999; 17:2237. Stock solution 3x10e8 pfu/ml. Batch #F1109A.
Storage conditions. -75 °C ± 10 °C. Freezer: -86°C UCT freezer. Thermo Form. Fisher
Scientific.
Animals:
Mouse, BALB/c (Specified Pathogen Free; SPF), female. 6 to 8 weeks old on Study Day
0 ~17-19 grams. Sourced from Charles River Laboratories and identified by ‘ear
identification’. All animals were acclimatized and maintained for 11 days before the start
of the experiment.
DNA administration
Method of inoculum reconstitution
Appropriate DNA formulations, as listed above were prepared aliquoted and stored at -20
°C. Per construct one aliquot was thawed to roomtemperature immediately before
injection, drawn into a syringe and injected. The remainder of each aliquot was discarded
after completion of all injections of each immunization round.
Dose level and method of administration
Mice are anaesthetized by intraperitoneal injection with 9.75mg Xylasol (Graeub E Dr.
AG (www.graeub.com);Cat: 763.02) and 48.75mg Ketasol (Graeub E Dr. AG
(www.graeub.com); Cat: 668.51) per kg body weight. 50 ml DNA solution was injected
using a 0.5 ml syringe with a G29 needle intramuscularly (i.m.) in the quadriceps muscle
of each hind leg, yielding a total volume of 100 ml injected per mouse. The remainder of
each aliquot was discarded after completion of all injections of each immunization round.
Virus administration:
Method of inoculum reconstitution
The virus material was stored at -75 °C ± 10 °C and was defrosted prior to
administration. Once defrosted, the material was diluted in cold PBS (4 °C)
corresponding to 10 LD50/50 ml for the A/HK/1/68 challenges. The diluted virus was
kept on ice until administration to the mice.
Dose level and method of administration
The animals were anaesthetized by intraperitoneal injection with 9.75mg Xylasol and
48.75mg Ketasol per kg body weight and each animal received 50 ml virus solution by
intranasal. Unused material was returned to the lab for back titration.
Blood withdrawal and serum preparation
At days specified in the Study Protocol, above, blood samples were taken (intermediate
bleedings: 100-150 ml via retroorbital cannulation, terminal bleeding via cardiac
puncture: approximately 300-500 ml). Serum was isolated from this blood by
centrifugation for 5 min at 14000 g and stored at -20 °C until shipment on dry ice
Clinical scoring
Clinical signs after virus challenge were scored with a scoring system (1 point for a
healthy mouse; 2 points for a mouse showing signs of malaise, including slight
piloerection, slightly changed gait and increased ambulation; 3 points for a mouse
showing signs of strong piloerection, constricted abdomen, changed gait, periods of
inactivity, increased breathing rate and sometime râles (clicking/crackling noise); 4 points
for a mouse with enhanced characteristics of the previous group, but showing little
activity and becoming moribund; 5 points for a dead mouse). Animals were inspected
twice a day as long as they received a score of 3. Scoring was performed by a single
investigator and mice with symptoms partially represented by two scores were score +/-
0.5.
Weighing
All animals were weighed daily, starting on day 48 (authorization number 2216).
Animals were also weighed prior to the end of the study in case of death, i.e. at removal
from study. Bodyweight was recorded in grams (g)
Virus back titration
The dose of the virus administered was determined by titrating 8 replicate samples from
the inoculum remaining after inoculation of the animals was completed. For viral back
titration TCID50 measurement was utilized following the protocol outlined in ‘Current
Protocols in Immunology, Animal Models of Infectious Disease 19.11.7’.
Results:
The study was performed without technical difficulties and in line with the defined study
protocol. Back titration of the inoculums of Influenza virus strain HK68 (A/Hong
Kong/1/68, H3N2) resulted in the following TCID50: HK68 (A/Hong Kong/1/68): 1x10
TCID50/ml.
Figure 29 shows the IgG response against the ectodomain of HA from A/Hong
Kong/1/1968 at day 49 as determined by ELISA. Immunization with DNA encoding
polypeptides of the invention SEQ ID NO: 124 and SEQ ID NO: 130 induces a clearly
detectable response against the H3 HA HK68 ectodomain, whereas no response is
detected for the empty vector negative control. As expected, the highest responses are
observed for immunization with H3 Full length A/Hong Kong/1/1968 (SEQ ID NO: 121).
Figure 30A shows the Kaplan-Meier survival curves for this experiment.
Immunization with DNA encoding polypeptides of the invention SEQ ID NO: 124 and
130 results in survival of 40 and 20% of mice infected with a lethal dose of influenza,
respectively, indicating that immunization with the polypeptides of the invention can
indeed induce a protective immune response. In contrast animals immunized with the
empty vector control all succumb to infection 10 days after the viral challenge.
Immunization with DNA encoding the full length HA (SEQ ID NO: 121) fully protects
all animals (i.e. 100% survival) from the lethal challenge.
The results obtained from the survival curves are also reflected in the mean body
weight change and median clinical scores for each group shown in Figure 30B and 30C.
Animals immunized with DNA encoding polypeptides of the invention SEQ ID NO: 124
and 130 exhibit weight loss up to 20%, but animals surviving after day 9 post infection
show an increase in weight. Animals immunized with DNA encoding the full length HA
(SEQ ID NO: 121) do not show weight loss. The highest weight loss and clinical
symptoms are observed for the control group immunized with an empty vector, in line
with the lack of survival of these animals.
In conclusion, polypeptides of the invention SEQ ID NO: 124 and 130 are
immunogenic and capable of inducing a protective response against a lethal challenge
with H3N2 A/Hong Kong/1/1968 in mice.
Example 25. Design and characterization of stem domain polypeptides based on H3 HA
To further improve the stem domain polypeptides described in example 12 an
additional set of constructs was designed. Two additional sets of cysteine mutations were
designed that will allow formation of stabilizing disulfide bridges at position 53 and 334
(T53C, G334C; cluster 16) and position 39 and 51 (G39C-E51C; cluster 17) (numbering
refers to SEQ ID NO: 121). Furthermore, two sequences to be inserted between position
420-421, i.e. at the N-terminal side of the long CD-helix (see figure 1). The insertion
sequences have been designed such that they will facilitate the formation of inter-
monomer disulfide bridges between individual monomers in the trimeric molecule. Two
different sequences have been designed, i.e. NATGGCCGG (Cluster 18) and
GSGKCCGG (Cluster 19). The sequence of cluster 18 also comprises a sequence
introducing a glycosylation site (i.e. NAT) in the stem domain polypeptide. In some cases
a glycosylation site is also introduced at position 417-419 by mutation into NAT.
Using the sequence of full length HA from A/Hong Kong/1/1968 as a starting point the
modifications described above were combined with the S62-P322 deletion to arrive at the
following stem domain polypeptides:
SEQ ID NO: 174:H3 HK mini2a-linker+cl9 +10+11+12+GCN4T-CG7-1
SEQ ID NO: 175:HK68 H3mini2a-linker+cl9_+10+12+18+GCN4T
SEQ ID NO: 176:HK68 H3mini2a-linker+cl9_+10+12+16+CG7-GCN4T
SEQ ID NO: 177:HK68 H3mini2a-linker+cl9_+10+12+19+GCN4T
SEQ ID NO: 178:HK68 H3mini2a-linker+cl9_+10+12+17+CG7-GCN4T
SEQ ID NO: 179:H3 HK68 mini2a-linker2+cl9_+10+12+GCN4T
The genes encoding the protein sequences described above were synthesized and
cloned in expression vector pcDNA2004 using methods generally known in the art.
Expression on the cell surface and binding of monoclonal antibodies was analyzed by
fluorescence associated cell sorting as described above. For reasons of comparison also
the full length HA of H3N2 A/Hong Kong/1/1968 (SEQ ID NO: 121), additionally
containing an R345Q mutation in the cleavage site, and SEQ ID NO: 130 (HK68 H3m2-
cl9+10+11+12-GCN4) were also included in the experiment as well as negative control
cM2.
Figure 31 shows the results of this experiment. All constructs are expressed on the
cell surface as evidenced by the responses (MFI, panel A; percentage positive cells, panel
B) observed for the polyclonal anti-H3 serum. Binding of CR8043 and CR8020 is
observed for SEQ ID NO: 174, 175, 176,177,178, 179, 121 and 130, indicating that the
mutations of cluster 16 do not contribute to stabilizing the conformational epitopes of
these antibodies. For mAb CR9114 binding above background can only be observed for
SEQ ID NO: 174 :H3 HK mini2a-linker+cl9 +10+11+12+GCN4T-CG7-1 and to a lesser
extent SEQ ID NO: 177 :HK68 H3mini2a-linker+cl9_+10+12+17+CG7-GCN4T. Both
sequences contain an additional glycosylation site in the B-loop, indicating the stabilizing
effect of this modification on the conformational neutralizing epitope of CR9114.
In conclusion we have shown that following the method described above stem
domain polypeptides of the invention can be obtained for serotypes of group 2, in
particular H3 subtypes. Further stabilization of these stem domain polypeptides can be
achieved by introducing a glycosylation site in the B-loop. These sequences are also
encompassed by the invention.
Example 26: Immunogenicity HA stem domain polypeptides based on H3 HA
In order to assess the immunogenicity of the stem domain polypeptides mice were
immunized with the expression vectors encoding full length H3 from A/Wisconsin/67/2005 (SEQ
ID NO: 89), SEQ ID NO: 105: H3-mini2, SEQ ID NO: 108: H3-mini2-cl9+10+11, SEQ ID NO:
112: H3-mini2-cl9+10+12, SEQ ID NO: 111: H3-mini2-cl9+10+11+12, SEQ ID NO: 114: H3-
mini2-cl9+10+11+12-tri, SEQ ID NO: 113: H3-mini2-cl9+10+11+12-GCN4, SEQ ID NO: 119:
H3-mini3-cl9+10+11+12+14, SEQ ID NO: 120: H3-mini4-cl9+10+11+12+14. An expression
vector encoding for cM2 was also included as a negative control.
Groups of 4 mice (BALB\c) were immunized with 50 µg construct + 50 µg
adjuvant (pUMCV1-GM-CSF) i.m. on day 1, 21 and 42. On day 49 a final bleed was
performed and serum collected. Negative control plasmid cM2 was administered by gene
gun, using approximately 10 µg construct + approximately 2µg adjuvant (pUMCV1-GM-
CSF) and the same immunization scheme. The sera were analyzed by ELISA using
recombinant full length HA from A/Wisconsin/67/2005 and A/Hong Kong/1/1968
(obtained from Protein Sciences Corporation, Meriden, CT, USA) as the antigen. In short,
96 wells plates were coated with 50 ng HA overnight at 4 C, followed by incubation
with block buffer (100 ml PBS, pH 7.4 + 2% skim milk) for 1h at room temperature.
Plates were washed with PBS + 0.05% Tween-20, and 100 ml of a 2-fold dilution series in
block buffer, starting from a 50 fold dilution of the serum is added. Bound antibody is
detected using HRP –conjugated goat-anti-mouse IgG, using standard protocols well-
established in the art. Titers are compared to a standard curve composed of a serial
dilution of a mouse monoclonal antibody binding to the HA antigen and expressed as
ELISA units per ml (EU/ml). Results of the ELISAs using HA from
A/Wisconsin/67/2005, A/Hong Kong/1/1968 and A/Perth/16/2009 after 49 days are
shown in Figure 32A, B and C, respectively. Sera obtained from mice immunized with
DNA encoding the stem domain polypeptides included in this experiment are capable of
recognizing the homologous full length HA from A/Wisconsin/67/2005 and to a similar
extent the heterologous full length HA from A/Hong Kong/1/1968. In contrast, serum
obtained from mice immunized with the full length HA from A/Wisconsin/67/2005 (SEQ
ID NO: 89) show a higher response towards the homologous HA than to the heterologous
HA from A/Hong Kong/1/1968 and A/Perth/16/2009.
In conclusion, the data show that polypeptides of the invention derived from H3
HA are capable of inducing an immune response directed towards full length HA.
Example 27: Immunogenicity HA stem domain polypeptides based on H3 HA of A/Hong
Kong/1/1968
In order to assess the immunogenicity of the stem domain polypeptides mice were
immunized with the expression vectors encoding full length H3 from A/Hong Kong/1/1968 (SEQ
ID NO: 121), SEQ ID NO: 124: HK68 H3m2-cl9+10+11, SEQ ID NO: 125: HK68 H3m2-
cl9+10+12, SEQ ID NO: 126: HK68 H3m2-cl9+10+11+12, SEQ ID NO: 128: HK68 H3m2-
cl9+10+11+12-tri, SEQ ID NO: 130: HK68 H3m2-cl9+10+11+12-GCN4. An expression vector
encoding for cM2 was also included as a negative control.
Groups of 4 mice (BALB\c) were immunized with 100 µg construct + 100 µg
adjuvant (pUMCV1-GM-CSF) i.m. on day 1, 21 and 42. On day 49 a final bleed was
performed and serum collected. Negative control plasmid cM2 was administered by gene
gun, using approximately 10 µg construct + approximately 2µg adjuvant (pUMCV1-GM-
CSF) and the same immunization scheme. The sera were analyzed by ELISA using
recombinant full length HA from A/Hong Kong/1/1968 (obtained from Protein Sciences
Corporation, Meriden, CT, USA) as the antigen. In short, 96 wells plates were coated
with 50 ng HA overnight at 4 C, followed by incubation with block buffer (100 ml PBS,
pH 7.4 + 2% skim milk) for 1h at room temperature. Plates were washed with PBS +
0.05% Tween-20, and 100 ml of a 2-fold dilution series in block buffer, starting from a 50
fold dilution of the serum is added. Bound antibody is detected using HRP –conjugated
goat-anti-mouse IgG, using standard protocols well-established in the art. Titers are
compared to a standard curve composed of a serial dilution of a mouse monoclonal
antibody binding to the HA antigen and expressed as ELISA units per ml (EU/ml).
Results of the ELISAs using HA from A/Hong Kong/1/1968 after 49 days are
shown in Figure 33. Sera obtained from mice immunized with DNA encoding the stem
domain polypeptides included in this experiment are capable of recognizing the
homologous full length HA from A/Hong Kong/1/1968. As expected immunization with
DNA encoding the full length HA leads to high antibody titers to the homologous HA
protein, whereas immunization with the negative control expression vector encoding cM2
does not induce anibodies that recognize the full length HA of A/Hong Kong/1/1968.
In conclusion, the data show that polypeptides of the invention derived from H3
HA are capable of inducing an immune response directed towards the full length H3 HA.
Example 28: Design of another stem-domain polypeptide based on a H1 HA capable of
eliciting antibodies neutralizing group 1 and group 2 influenza viruses
Examples 4 and 6 disclose polypeptides based on H1 sequences that stably expose the
epitope of the broadly neutralizing CR6261 antibody. Given the fact that CR6261
exclusively neutralizes influenza viruses from phylogenetic group 1, polypeptides
designed to this epitope may not elicit a strong reaction to phylogentic group 2 influenza
viruses. Another way to design polypeptides according to the invention that induce such
broadly cross-neutralizing antibodies is to use H1 HA sequence variants that more closely
resemble H3 HA sequences in terms of structural and biochemical characteristics of the
important amino acids in the epitope. Based on comparison between the structures of
group-specific antibodies and molecules (CR6261, F10 and HB36) and the crystallized
pan-influenza antibody FI6 (Corti et al, 2011), we found that the group 1-group 2 T49N
(HA2) mutation can only be accommodated by FI6 without introduction of steric clashes.
Asparagine at position 49 of HA2 exists in two group 1 viruses in the NCBI flu-database:
A/swine/Hubei/S1/2009 (ACY06623) and A/swine/Haseluenne/IDT2617/2003
(ABV60697). Therefore, in one embodiment the H1 sequences that constitute the basis of
the invention as disclosed in examples 4, 6 and 9 is one of these N49 containing HA
sequences. Alternatively, sequences according to the invention as described in examples
4, 6 and 9 have an additional mutation at position 49 in HA2 to change the T into an N
amino acid. Table 7shows a sequence alignment of exemplary H1 HA sequences that can
be used as starting sequences for the polypeptides of the invention.
SEQ ID NO: 180 is derived from SEQ ID NO: 45 by mutation T392N
(numbering refers to SEQ ID NO: 1) T392 in SEQ ID NO: 1 corresponds to Threonine at
position 49 in HA2 as described above. The gene encoding this polypeptide of the
invention was synthesized and cloned into expression vector pcDNA2004 using methods
well known to those skilled in the art. The presence of the neutralizing epitopes of
CR9114 and CR6261 was confirmed by fluorescence associated cell sorting as described
above. The results are shown in Figure 34. MFI for SEQ ID NO: 180 is comparable to
MFI observed for SEQ ID NO: 45 and SEQ ID NO: 1 for CR6261 and CR9114 binding,
whereas CR9020 (known to bind to the head region of the full length HA molecule) only
recognizes SEQ ID NO: 1, and CR8020 (specific for HA of Influenza A group 2) does
not recognize SEQ ID NO: 180, SEQ ID NO: 1 or SEQ ID NO: 45. Negative control cM2
is not recognized by any of the monoclonal antibodies used in this experiment.
In conclusion, SEQ ID NO: 180, containing mutation T392N comprises the
neutralizing epitiopes of CR6261 and CR9114.
Example 29. Design of additional polypeptides of the invention lacking the
transmembrane sequence.
Influenza HA in its native form exists as a trimer on the cell or virus membrane.
In certain embodiments the intracellular and transmembrane sequence is removed so that
a secreted (soluble) polypeptide is produced following expression in cells. Methods to
express and purify secreted ectodomains of HA have been described (see e.g. Dopheide et
al 2009; Ekiert et al 2009, 2011; Stevens et al 2004, 2006; Wilson et al 1981). A person
skilled in the art will understand that these methods can also be applied directly to stem
domain polypeptides of the invention in order to achieve expression of secreted (soluble)
polypeptide. Therefore these polypeptides are also encompassed in the invention.
For example, in the case of a polypeptide of the invention derived from a HA sequence of
group 1 influenza virus, a soluble polypeptide of the invention can be created from a by
deletion of the polypeptide sequence from residue (the equivalent of) 514 to the C-
terminus (numbering according to SEQ ID NO: 1), Alternatively, additional residues can
be included in the polypeptide of the invention, e.g. by deleting the sequence from
residue 515, 516, 517, 518, 519, 520, 521 or 522. Optionally, a his-tag sequence
(HHHHHH or HHHHHHH) may be added, for purification purposes, optionally
connected through a linker. Optionally the linker may contain a proteolytic cleavage site
to remove the his-tag after purification. The soluble polypeptide can be further stabilized
by introducing a sequence known to form trimeric structures, such as the foldon
sequence. Polypeptides obtained as described above are also encompassed in the
invention.
SEQ ID NO: 181 to 185 show sequences of soluble polypeptides of the invention
derived from the HA sequence of H1N1 A/Brisbane/59/2007. Similarly, SEQ ID NO:
186 to 187 show sequences of soluble polypeptides of the invention the HA sequence of
H3N2 A/Hong Kong/1/1968. A person skilled in the art will understand that equivalent
sequences for polypeptides of the invention derived from other HA sequences of other
influenza A vaccine strains of e.g. H1, H3, H5 subtypes can be designed. It will also be
clear to a person skilled in the art that the C-terminal 6 histidines are attached for
purification purposes. Since other purification methods that do not use this tag are in
existence, the 6 histidine sequence is optional, an sequences lacking this purification tag
are also encompassed in the invention.
Table 1. CDR regions of antibodies. The SEQ ID NO is given between brackets.
Ab HC CDR1 HC CDR2 HC CDR3 LC CDR1 LC CDR2 LC CDR3
9114 GGTSNNYA ISPIFGST (26) ARHGNYYYYSGMDV DSNIGRRS (28) SND (29) AAWDDSLKGAV
(25) (27) (30)
Table 2. Cross-binding reactivity of CR9114, as measured by ELISA and FACS.
H1=soluble recombinant A/New Caledonia/20/1999 H1 HA; H3= soluble recombinant
A/Wisconsin/67/2005 H3 HA; H5= soluble recombinant A/Vietnam/1203/04 H5 HA;
H7= soluble recombinant A/Netherlands/219/2003 H7 HA; H9= soluble recombinant
A/Hong Kong/1073/99 H9 HA; B= soluble recombinant B/Ohio/01/05 influenza B HA;
Rabies= rabies glycoprotein; PER.C6=untransfected PER.C6 cells (control);
mH1=PER.C6 expressed A/New Caledonia/20/1999 H1 HA; mH3= PER.C6 expressed
A/Wisconsin/67/2005 H3 HA; mH7= PER.C6 expressed A/Netherlands/219/2003 H7
HA; ND=not done. + = binding (>10x background); +/- = low binding (2-10x
background) - = no detectable binding.
IgG Elisa IgG Facs
H1 H3 H5 H7 H9 B Rabies PerC6 mH1 mH3 mH7
CR9114 + + + + + + - - + + +
CR4098 - - - - - - + - - - -
Table 3. Cross-neutralizing activity of CR9114; Titers (indicated in µg/ml) are geomean
IC50 values as determined according to the Spearman-Karber method of at least duplicate
experiments; >100 = not neutralizing at highest tested concentration (100 µg/ml).
Subtype Strain CR9114
Group I H1 A/WSN/33 1.1
A/New Caledonia/20/99 3.7
A/Solomon Islands/3/2006 1.8
A/Brisbane/59/2007 2.6
A/California/7/2009 0.3
H2 A/Env/MPU3156/05 8.8
H5 A/Hong Kong/156/97 0.4
A/EW/MPF461/07 10.5
H6 A/EW/MPD411/07 10.5
H8 A/EW/MPH571/08 8.8
H9 A/Hong Kong/1073/99 4.4
A/Ck/HK/SSP176/09 6.3
Group II H3 A/Hong Kong/1/68 19
A/Johannesburg/33/94 21.9
A/Panama/2007/1999 39.9
A/Hiroshima/52/2005 12.5
A/Wisconsin/67/2005 32.4
A/Brisbane/10/2007 5.6
H4 A/WF/MPA 892/06 0.8
H7 A/Mallard/Netherlands/12/2000 4.8
A/New York/107/2003 > 100
H10 A/Chick/Germany/N/49 15.7
H14 A/Mallard/Astrakhan/263/1982 > 100
Table 4. Binding of serum obtained from mice immunized with either full length HA or
mini-HA constructs as analyzed by FACS. Data are the average values (n=4) for
percentage of cells positive after staining followed by the mean fluorescence intensity (in
brackets). H1-FL (SEQ ID NO: 1), CL1 (SEQ ID NO: 3), CL1+2 (SEQ ID NO: 4) and
CL1+4 (SEQ ID NO: 6). cM2 is a negative control.
Im Imm mu un niiz za ati tio on n cM cM2 2 H H1- 1-F FL L C CL L1 1 C CL L1 1+ +2 2 C CL L1+ 1+4 4
( (s ser erum um) )
DNA DNA tra tran ns sfe fec ctte ed d
cM cM2 2 47. 47.5 ( 5 (1817 1817) ) 4 4..8 8 ( (4 404) 04) 0. 0.9 ( 9 (272 272) ) 0 0..7 7 ( (263) 263) 0. 0.7 7 ( (2 269) 69)
H1 H1-FL -FL 2. 2.1 ( 1 (389) 389) 8 84 4..1 1 ( (7 7130) 130) 40. 40.0 ( 0 (132 1324) 4) 38. 38.7 ( 7 (1195 1195) ) 4 45. 5.5 5 ( (1 1618) 618)
CL1 CL1 2. 2.1 ( 1 (368) 368) 3 39 9..1 1 ( (1 1124) 124) 43. 43.9 ( 9 (176 1763) 3) N ND D N ND D
CL1 CL1+ +2 2 1. 1.7 ( 7 (348) 348) 4 47 7..9 9 ( (1 1616) 616) N ND D 51. 51.4 ( 4 (2472 2472) ) N ND D
CL1 CL1+ +4 4 1. 1.7 ( 7 (342) 342) 19. 19.6 ( 6 (787 787) ) N ND D N ND D 3 30. 0.0 0 ( (1 1047) 047)
% PE pos (Geometric MFI, n=4)
Table 5. Standard amino acids, abbreviations and properties
Amino Acid 3-Letter 1-Letter Side chain Side chain charge (pH 7.4)
polarity
alanine Ala A nonpolar Neutral
arginine Arg R polar Positive
asparagine Asn N polar Neutral
aspartic acid Asp D polar Negative
cysteine Cys C nonpolar Neutral
glutamic acid Glu E polar Negative
glutamine Gln Q polar Neutral
glycine Gly G nonpolar Neutral
histidine His H polar positive(10%) neutral(90%)
isoleucine Ile I nonpolar Neutral
leucine Leu L nonpolar Neutral
lysine Lys K polar Positive
methionine Met M nonpolar Neutral
phenylalanine Phe F nonpolar Neutral
proline Pro P nonpolar Neutral
serine Ser S polar Neutral
threonine Thr T polar Neutral
tryptophan Trp W nonpolar Neutral
tyrosine Tyr Y polar Neutral
valine Val V nonpolar Neutral
Table 6. Consensus sequence for H1 402-418 (SEQ ID NO: 17), other natural variants
and mutations that stabilize polypeptides of the invention. One or more mutations in the
parental sequence are present in polypeptides of the invention.
Other Other Other
amino conservation other naturally preferred polar charged flexible
position acid (%) occurring a.a. mutation mutations mutations mutations
402 M 99.88 T,I
403 N 99.88 T,D
404 T 96.24 S,A,M,N,I,V
405 Q 99.92 H,K
406 F 99.92 L S T, N, QR,H,K,D,E G
407 T 99.73 A,I,K
408 A 96.71 S,G,V
409 V 99.45 Q,M,I,G,L T,Q,G S, NR,H,K,D,E
410 G 99.1 S,N,D,C,V
411 K 99.8 T,N,R,E
412 E 99.84 A.G
413 F 99.92 S,L S T,N,QR,H,K,D,E G
414 N 96.52 S,D,I
415 H/K 56.20/32.76 S,T,N,E,Q,R,D
416 L 99.8 F,S,I,P S T, N, QR,H,K,D,E G
417 E 99.84 A,D,R
418 K/R 63.95/35.69 S,Q,T,N
Table 7. Sequence alignment of H1 sequences according to particular embodiments of
the invention
1. A/Solomon Islands/6/2003 (H1N1) (SEQ ID NO: 54)
2. A/Brisbane/59/2007 (H1N1) (SEQ ID NO: 1)
3. A/New Caledonia/20/1999(H1N1) (SEQ ID NO: 55)
4. A/California/07/2009 (H1N1) (SEQ ID NO: 56)
. A/swine/Hubei/S1/2009(H1N1) (SEQ ID NO: 57)
6. A/swine/Haseluenne/IDT2617/2003(H1N1) (SEQ ID NO: 58)
7. A/NewYork/8/2006(H1N1) (SEQ ID NO: 59)
8. A/SolomonIslands/3/2006(H1N1) (SEQ ID NO: 60)
9. A/NewYork/146/2000(H1N1) (SEQ ID NO: 61)
. A/NewYork/653/1996(H1N1) (SEQ ID NO: 62)
11. A/Beijing/262/1995(H1N1) (SEQ ID NO: 63)
12. A/Texas/36/1991(H1N1) (SEQ ID NO: 64)
13. A/Singapore/6/1986(H1N1) (SEQ ID NO: 65)
14. A/Chile/1/1983(H1N1) (SEQ ID NO: 66)
. A/Baylor/11515/1982(H1N1) (SEQ ID NO: 67)
16. A/Brazil/11/1978(H1N1) (SEQ ID NO: 68)
17. A/USSR/90/1977(H1N1) (SEQ ID NO: 69)
18. A/NewJersey/8/1976(H1N1) SEQ ID NO: 70)
19. A/Denver/1957(H1N1) (SEQ ID NO: 71)
. A/Albany/4835/1948(H1N1) (SEQ ID NO: 72)
21. A/FortMonmouth/1/1947(H1N1) (SEQ ID NO: 73)
22. A/Cameron/1946(H1N1) (SEQ ID NO: 74)
23. A/Weiss/1943(H1N1) (SEQ ID NO: 75)
24. A/Iowa/1943(H1N1) (SEQ ID NO: 76)
. A/Bellamy/1942(H1N1) (SEQ ID NO: 77)
26. A/PuertoRico/8/1934(H1N1) (SEQ ID NO: 78)
27. A/WSN/1933(H1N1) (SEQ ID NO: 79)
28. A/SouthCarolina/1/1918(H1N1) (SEQ ID NO: 80)
1. MKVKLLVLLC TFTATYADTI CIGYHANNST DTVDTVLEKN VTVTHSVNLL EDSHNGKLCL 60
2. MKVKLLVLLC TFTATYADTI CIGYHANNST DTVDTVLEKN VTVTHSVNLL ENSHNGKLCL 60
3. MKAKLLVLLC TFTATYADTI CIGYHANNST DTVDTVLEKN VTVTHSVNLL EDSHNGKLCL 60
4. MKAILVVLLY TFATANADTL CIGYHANNST DTVDTVLEKN VTVTHSVNLL EDKHNGKLCK 60
. MEAKLFVLFC AFTALKADTF CVGYHANYST HTVDTILEKN VTVTHSVNLL ENSHNGKLCS 60
6. MEAKLFVLFC AFTALKADTI CVGYHANNST DTVDTILEKN VTVTHSINLL ENNHNGKLCS 60
40 7. MKVKLLVLLC TFTATYADTI CIGYHANNST DTVDTVLEKN VTVTHSVNLL EDSHNGKLCL 60
8. MKVKLLVLLC TFTATYADTI CIGYHANNST DTVDTVLEKN VTVTHSVNLL EDSHNGKLCL 60
9. MKAKLLVLLC AFTATYADTI CIGYHANNST DTVDTVLEKN VTVTHSVNLL EDSHNGKLCR 60
. MKAKLLVLLC AFTATYADTI CIGYHANNST DTVDTVLEKN VTVTHSVNLL EDSHNGKLCR 60
11. MKAKLLVLLC TFTATYADTI CIGYHANNST DTVDTVLEKN VTVTHSVNLL EDSHNGKLCL 60
45 12. MKAKLLVLLC AFTATYADTI CIGYHANNST DTVDTVLEKN VTVTHSVNLL EDSHNGKLCR 60
13. MKAKLLVLLC AFTATDADTI CIGYHANNST DTVDTVLEKN VTVTHSVNLL EDSHNGKLCR 60
14. MKAKLLVLLC ALSATDADTI CIGYHANNST DTVDTVLEKN VTVTHSVNLL EDNHNGKLCK 60
. MKAKLLVLLC ALSATDADTI CIGYHANNST DTVDTVLEKN VTVTHSVNLL EDSHNGKLCR 60
16. MKAKLLVLLC ALSATDADTI CIGYHANNST DTVDTVLEKN VTVTHSVNLL EDSHNGKLCR 60
50 17. MKAKLLVLLC ALSATDADTI CIGYHANNST DTVDTVLEKN VTVTHSVNLL EDSHNGKLCR 60
18. MKAKLLVLLC AFTATDADTI CIGYHANNST DTVDTVLEKN VTVTHSVNLL EDSHNGKLCR 60
19. MKAKLLILLC ALSATDADTI CIGYHANNST DTVDTVLEKN VTVTHSVNLL EDSHNGKLCR 60
. MKAKLLVLLC ALSATDADTI CIGYHANNST DTVDTVLEKN VTVTHSVNLL EDSHNGKLCR 60
21. MKAKLLILLC ALTATDADTI CIGYHANNST DTVDTVLEKN VTVTHSVNLL EDSHNGKLCR 60
55 22. MKAKLLILLC ALSATDADTI CIGYHANNST DTVDTVLEKN VTVTHSVNLL EDSHNGKLCR 60
23. MKARLLVLLC ALAATDADTI CIGYHANNST DTVDTILEKN VTVTHSVNLL EDSHNGKLCR 60
24. MKARLLVLLC ALAATDADTI CIGYHANNST DTVDTVLEKN VTVTHSVNLL EDSHNGKLCR 60
. MKARLLVLLC AIAATDADTI CIGYHANNST DTVDTILEKN VTVTHSVNLL EDSHNGKLCR 60
26. MKANLLVLLC ALAAADADTI CIGYHANNST DTVDTVLEKN VTVTHSVNLL EDSHNGKLCR 60
27. MKAKLLVLLY AFVATDADTI CIGYHANNST DTVDTIFEKN VAVTHSVNLL EDRHNGKLCK 60
28. MEARLLVLLC AFAATNADTI CIGYHANNST DTVDTVLEKN VTVTHSVNLL EDSHNGKLCK 60
*:. *::** :: :: ***: ********** *****::*** *:******** *: ******
1. LKGIAPLQLG NCSVAGWILG NPECELLISR ESWSYIVEKP NPENGTCYPG HFADYEELRE 120
2. LKGIAPLQLG NCSVAGWILG NPECELLISK ESWSYIVEKP NPENGTCYPG HFADYEELRE 120
3. LKGIAPLQLG NCSVAGWILG NPECELLISK ESWSYIVETP NPENGTCYPG YFADYEELRE 120
4. LRGVAPLHLG KCNIAGWILG NPECESLSTA SSWSYIVETP SSDNGTCYPG DFIDYEELRE 120
. LNGKIPLQLG NCNVAGWILG NPKCDLLLTA NSSSYIIETS KSKNGACYPG EFADYEELKE 120
6. LNGKAPLQLG NCNVAGWILG NPECDLLLTV DSWSYIIETS NSKNGACYPG EFADYEELRE 120
7. LKGIAPLQLG NCSVAGWILG NPECELLISK ESWSYIVETP NPENGTCYPG YFADYEELRE 120
8. LKGIAPLQLG NCSVAGWILG NPECELLISR ESWSYIVEKP NPENGTCYPG HFADYEELRE 120
9. LKGTAPLQLG NCSIAGWILG NPECESLFSK ESWSYIAETP NPKNGTCYPG YFADYEELRE 120
. LKGTAPLQLG NCSVAGWILG NPECESLFSK ESWSYIAETP NPENGTCYPG YFADYEELRE 120
11. LKGIAPLQLG NCSVAGWILG NPECESLISK ESWSYIVETP NPENGTCYPG YFADYEELRE 120
12. LKGIAPLQLG NCSVAGWILG NPKCESLFSK ESWSYIAETP NPENGTCYPG YFADYEELRE 120
13. LKGIAPLQLG NCSIAGWILG NPECESLFSK KSWSYIAETP NSENGTCYPG YFADYEELRE 120
14. LKGIAPLQLG KCSIAGWILG NPECESLFSK KSWSYIAETP NSENGTCYPG YFADYEELRE 120
. LKGIAPLQLG KCSIAGWILG NPECESLFSK KSWSYIAETP NSENGTCYPG YFADYEELRE 120
16. LKGIAPLQLG KCSIAGWILG NPECESLFSK KSWSYIAETP NSENGTCYPG YFADYEELRE 120
17. LKGIAPLQLG KCNIAGWILG NPECESLFSK KSWSYIAETP NSENGTCYPG YFADYEELRE 120
18. LKGIAPLQLG NCSIAGWILG NPECESLFSK KSWSYIAETP NSENGTCYPG YFADYEELRE 120
19. LKGKAPLQLG NCNIAGWVLG NPECESLLSN RSWSYIAETP NSENGTCYPG DFADYEELRE 120
. LKGIAPLQLG KCNIAGWILG NPECESLFSK KSWSYIAETP NSENGTCYPG YFADYEELRE 120
21. LKGIAPLQLG KCNIAGWILG NPECESLLSK RSWSYIAETP NSENGACYPG DFADYEELRE 120
22. LKGIAPLQLG KCNIAGWILG NPECESLLSK RSWSYIAETP NSENGACYPG DFADYEELRE 120
23. LKGIAPLQLG KCNIAGWILG NPECESLLSE RSWSYIVEIP NSENGTCYPG DFTDYEELRE 120
24. LKGIAPLQLG KCNIAGWILG NPECESLLSE RSWSYIVETP NSENGTCYPG DFIDYEELRE 120
. LKGIAPLQLG KCNIAGWILG NPECESLLSE RSWSYIVETP NSENGTCYPG DFIDYEELRE 120
26. LKGIAPLQLG KCNIAGWLLG NPECDPLLPV RSWSYIVETP NSENGICYPG DFIDYEELRE 120
27. LKGIAPLQLG KCNITGWLLG NPECDSLLPA RSWSYIVETP NSENGACYPG DFIDYEELRE 120
28. LKGIAPLQLG KCNIAGWLLG NPECDLLLTA SSWSYIVETS NSENGTCYPG DFIDYEELRE 120
*:* ***:** :*.::**:** **:*: * . *****.* . ...** **** * *******
1. QLSSVSSFER FEIFPKESSW PNHTTT-GVS ASCSHNGESS FYKNLLWLTG KNGLYPNLSK 179
2. QLSSVSSFER FEIFPKESSW PNHTVT-GVS ASCSHNGESS FYRNLLWLTG KNGLYPNLSK 179
40 3. QLSSVSSFER FEIFPKESSW PNHTVT-GVS ASCSHNGKSS FYRNLLWLTG KNGLYPNLSK 179
4. QLSSVSSFER FEIFPKTSSW PNHDSNKGVT AACPHAGAKS FYKNLIWLVK KGNSYPKLSK 180
. QLSTVSSFER FEIFPKAISW PDHDATRGTT VACSHSGVNS FYRNLLSTVK KGNSYPKLSK 180
6. QLSTVSSFER FEIFPKATSW PNHDTTRGTT ISCSHSGANS FYRNLLWIVK KGNSYPKLSK 180
7. QLSSVSSFER FEIFPKESSW PNHTVT-GVS ASCSHNGKSS FYRNLLWLTG KNGLYPNLSK 179
45 8. QLSSVSSFER FEIFPKESSW PNHTTT-GVS ASCSHNGESS FYKNLLWLTG KNGLYPNLSK 179
9. QLSSVSSFER FEIFPKDSSW PNHTVTKGVT ASCSHNGKSS FYKNLLWLTE KNGLYPNLSK 180
. QLSSVSSFER FEIFPKESSW PNHTVTKGVT ASCSHNGKSS FYKNLLWLTE KNGLYPNLSK 180
11. QLSSVSSFER FEIFPKESSW PNHTVT-GVT ASCSHNGKSS FYRNLLWLTE KNGLYPNLSN 179
12. QLSSVSSFER FEIFPKESSW PNHTVTKGVT TSCSHNGKSS FYRNLLWLTK KNGLYPNVSK 180
50 13. QLSSVSSFER FEIFPKESSW PNHTVTKGVT ASCSHKGRSS FYRNLLWLTK KNGSYPNLSK 180
14. QLSSVSSFER FEIFPKESSW PKHNVTKGVT AACSHKGKSS FYRNLLWLTE KNGSYPNLSK 180
. QLSSVSSFER FEIFPKESSW PKHSVTRGVT ASCSHKGKSS FYRNLLWLTE KNGSYPNLSK 180
16. QLSSVSSFER FEIFPKERSW PKHNITRGVT ASCSHKGKSS FYRNLLWLTE KNGSYPNLSK 180
17. QLSSVSSFER FEIFPKERSW PKHNVTRGVT ASCSHKGKSS FYRNLLWLTE KNGSYPNLSK 180
55 18. QLSSVSSFER FEIFPKESSW PNHTVTKGVT ASCSHKGRSS FYRNLLWLTK KNGSYPNLSK 180
19. QLSSVSSFER FEIFPKERSW PNHTTR-GVT AACPHARKSS FYKNLVWLTE ANGSYPNLSR 179
. QLSSVSSFER FEIFPKERSW PKHNITRGVT AACSHKGKSS FYRNLLWLTE KNGSYPNLNK 180
21. QLSSVSSFER FEIFPKERSW PKHNITRGVT AACSHAGKSS FYKNLLWLTE TDGSYPKLSK 180
22. QLSSVSSFER FEIFPKGRSW PEHNIDIGVT AACSHAGKSS FYKNLLWLTE KDGSYPNLNK 180
60 23. QLSSVSSFER FEIFPKESSW PKHNTARGVT AACSHAGKSS FYRNLLWLTE KDGSYPNLKN 180
24. QLSSVSSFER FEIFSKESSW PKHTTG-GVT AACSHAGKSS FYRNLLWLTE KDGSYPNLNN 179
. QLSSVTSFER FEIFPKETSW PKHNTTKGVT AACSHAGKCS FYRNLLWLTE KDGSYPNLNN 180
26. QLSSVSSFER FEIFPKESSW PNHNTN-GVT AACSHEGKSS FYRNLLWLTE KEGSYPKLKN 179
27. QLSSVSSLER FEIFPKESSW PNHTFN-GVT VSCSHRGKSS FYRNLLWLTK KGDSYPKLTN 179
28. QLSSVSSFEK FEIFPKTSSW PNHETTKGVT AACSYAGASS FYRNLLWLTK KGSSYPKLSK 180
*****:*:*: ****.* ** *:* **: .:*.: * **:**:**. . **::..
1. SYANNKEKEV LVLWGVHHPP NIGDQRALYH KENAYVSVVS SHYSRKFTPE IAKRPKVRDQ 239
2. SYANNKEKEV LVLWGVHHPP NIGNQKALYH TENAYVSVVS SHYSRKFTPE IAKRPKVRDQ 239
3. SYVNNKEKEV LVLWGVHHPP NIGNQRALYH TENAYVSVVS SHYSRRFTPE IAKRPKVRDQ 239
4. SYINDKGKEV LVLWGIHHPS TSADQQSLYQ NADAYVFVGS SRYSKKFKPE IAIRPKVRXX 240
5. SYTNNKGKEV LVIWGVHHPP TDSVQQTLYQ NKHTYVSVGS SKYYKRFTPE IVARPKVRGQ 240
6. SYTNNKGKEV LVIWGVHHPP TDSDQQTLYQ NNHTYVSVGS SKYYQRFTPE IVTRPKVRGQ 240
7. SYANNKEKEV LVLWGVHHPP NIGDQRALYH TENAYVSVVS SHYSRRFTPE IAKRPKVRDQ 239
8. SYANNKEKEV LVLWGVHHPP NIGDQRALYH KENAYVSVVS SHYSRKFTPE IAKRPKVRDQ 239
9. SYVNKKGKEV LVLWGVHHPS NMGDQRAIYH KENAYVSVLS SHYSRRFTPE IAKRPKVRDQ 240
10. SYVNNKEKEV LVLWGVHHPS NIGDQRAIYH TENAYVSVVS SHYSRRFTPE ITKRPKVRDQ 240
11. SYVNNKEKEV LVLWGVHHPS NIRDQRAIYH TENAYVSVVS SHYSRRFTPE IAKRPKVRGQ 239
12. SYVNNKEKEV LVLWGVHHPS NIGDQRAIYH TENAYVSVVS SHYSRRFTPE IAKRPKVRDQ 240
13. SYVNNKEKEV LVLWGVHHPS NIGDQRAIYH TENAYVSVVS SHYNRRFTPE IAKRPKVRDQ 240
14. SYVNNKEKEV LVLWGVHHPS NIEDQKTIYR KENAYVSVVS SHYNRRFTPE IAKRPKVRNQ 240
15. SYVNDKEKEV LVLWGVHHPS NIEDQKTIYR KENAYVSVVS SHYNRRFTPE IAKRPKVRDQ 240
16. SYVNNKEKEV LVLWGVHHPS NIEDQKTIYR KENAYVSVVS SNYNRRFTPE IAKRPKVRGQ 240
17. SYVNNKEKEV LVLWGVHHPS NIEDQKTIYR KENAYVSVVS SNYNRRFTPE IAERPKVRGQ 240
18. SYVNNKEKEV LVLWGVHHPS NIGDQRAIYH TENAYVSVVS SHYNRRFTPE IAKRPKVRDQ 240
19. SYVNNQEKEV LVLWGVHHPS NIEEQRALYR KDNAYVSVVS SNYNRRFTPE IAKRPKVRDQ 239
20. SYVNNKEKEV LVLWGVHHPS NIEDQKTLYR KENAYVSVVS SNYNRRFTPE IAERPKVRGQ 240
21. SYVNNKEKEV LVLWGVHHPS NIEDQKTLYR KENAYVSVVS SNYNRRFTPE IAERPKVRGQ 240
22. SYVNKKEKEV LILWGVHHPP NIENQKTLYR KENAYVSVVS SNYNRRFTPE IAERPKVRGQ 240
23. SYVNKKGKEV LVLWGVHHPS SIKEQQTLYQ KENAYVSVVS SNYNRRFTPE IAERPKVRDQ 240
24. SYVNKKGKEV LVLWGVHHPS NIKDQQTLYQ KENAYVSVVS SNYNRRFTPE IAERPKVRGQ 239
25. SYVNKKGKEV LVLWGVHHPS NIKDQQTLYQ KENAYVSVVS SNYNRRFTPE IAERPKVRGQ 240
26. SYVNKKGKEV LVLWGIHHPP NSKEQQNLYQ NENAYVSVVT SNYNRRFTPE IAERPKVRDQ 239
27. SYVNNKGKEV LVLWGVHHPS SSDEQQSLYS NGNAYVSVAS SNYNRRFTPE IAARPKVKDQ 239
28. SYVNNKGKEV LVLWGVHHPP TGTDQQSLYQ NADAYVSVGS SKYNRRFTPE IAARPKVRDQ 240
** *.: *** *:***:***. . :*: :* . :*** * : *.*.::*.** *: ****:
1. EGRINYYWTL LEPGDTIIFE ANGNLIAPRY AFALSRGFGS GIINSNAPMD ECDAKCQTPQ 299
2. EGRINYYWTL LEPGDTIIFE ANGNLIAPRY AFALSRGFGS GIINSNAPMD KCDAKCQTPQ 299
3. EGRINYYWTL LEPGDTIIFE ANGNLIAPWY AFALSRGFGS GIITSNAPMD ECDAKCQTPQ 299
40 4. EGRMNYYWTL VEPGDKITFE ATGNLVVPRY AFAMERNAGS GIIISDTPVH DCNTTCQTPK 300
. AGRMNYYWTL FDQGDTITFE ATGNLIAPWH AFALKKGSSS GIMLSDAQVH NCTTKCQTPH 300
6. AGRMNYYWTL LDQGDTITFE ATGNLIAPWH AFALNKGPSS GIMISDAHVH NCTTKCQTPH 300
7. EGRINYYWTL LEPGDTIIFE ANGNLIAPRF AFALSRGFGS GIITSNAPMD ECDAKCQTPQ 299
8. EGRINYYWTL LEPGDTIIFE ANGNLIAPRY AFALSRGFGS GIINSNAPMD ECDAKCQTPQ 299
45 9. EGRINYYWTL LEPGDTIIFE ANGNLIAPWY AFALSRGFGS GIIISNASMG ECDAKCQTPQ 300
. EGRINYYWTL LEPGDTIIFE ANGNLIAPWY AFALSRGFGS GIITSNASMG ECDAKCQTPQ 300
11. EGRINYYWTL LEPGDTIIFE ANGNLIAPWY AFALSRGFGS GIITSNAPMN ECDAKCQTPQ 299
12. EGRINYYWTL LEPGDTIIFE ANGNLIAPWY AFALSRGFGS GIITSNASMD ECDAKCQTPQ 300
13. EGRINYYWTL LEPGDTIIFE ANGNLIAPWY AFALSRGFGS GIITSNASMD ECDAKCQTPQ 300
50 14. EGRINYYWTL LEPGDTIIFE ANGNLIAPWY AFALSRGFGS GIITSNASMD ECDAKCQTPQ 300
. EGRINYYWTL LEPGDTIIFE ANGNLIAPWY AFALSRGFGS GIITSNVSMD ECDAKCQTPQ 300
16. EGRINYYWTL LEPGDTIIFE ANGNLIAPWY AFALSRGFGS GIITSNASMD ECDTKCQTPQ 300
17. AGRINYYWTL LEPGDTIIFE ANGNLIAPWH AFALNRGFGS GIITSNASMD ECDTKCQTPQ 300
18. EGRINYYWTL LEPGDTIIFE ANGNLIAPWY AFALSRGFGS GIITSNASMD ECDAKCQTPQ 300
55 19. SGRMNYYWTL LEPGDTIIFE ATGNLIAPWY AFALSRGPGS GIITSNAPLD ECDTKCQTPQ 299
. AGRINYYWTL LEPGDTIIFE ANGNLIAPWH AFALSRGFGS GIITSNASMD ECDTKCQTPQ 300
21. AGRINYYWTL LEPGDTIIFE ANGNLIAPWY AFALSRDFGS GIITSNASMD ECDTKCQTPQ 300
22. AGRINYYWTL LEPGDTIIFE ANGNLIAPWY AFALNRGIGS GIITSNASMD ECDTKCQTPQ 300
23. AGRMNYYWTL LEPGDTIIFE ANGNLIAPWY AFALSRGFGS GIITSNASMH ECDTKCQTPQ 300
60 24. AGRINYYWTL LKPGDTIMFE ANGNLIAPWY AFALSRGFGS GIITSNASMH ECDTKCQTPQ 299
. AGRMNYYWTL LEPGDTIIFE ANGNLIAPWY AFALSRGFGS GIITSNASMH ECNTKCQTPQ 300
26. AGRMNYYWTL LKPGDTIIFE ANGNLIAPMY AFALRRGFGS GIITSNASMH ECNTKCQTPL 299
27. HGRMNYYWTL LEPGDTIIFE ATGNLIAPWY AFALSRGFES GIITSNASMH ECNTKCQTPQ 299
28. AGRMNYYWTL LEPGDTITFE ATGNLIAPWY AFALNRGSGS GIITSDAPVH DCNTKCQTPH 300
**:****** ::***.* ** *.***:.* . ***: *. * *** *:..: .*::.****
1. GAINSSLPFQ NVHPVTIGEC PKYVRSAKLR MVTGLRNIPS IQSRGLFGAI AGFIEGGWTG 359
2. GAINSSLPFQ NVHPVTIGEC PKYVRSAKLR MVTGLRNIPS IQSRGLFGAI AGFIEGGWTG 359
3. GAINSSLPFQ NVHPVTIGEC PKYVRSAKLR MVTGLRNIPS IQSRGLFGAI AGFIEGGWTG 359
4. GAINTSLPFQ NIHPITIGKC PKYVKSTKLR LATGLRNIPS IQSRGLFGAI AGFIEGGWTG 360
. GALKNNLPLQ NVHLFTIGEC PKYVKSTQLR MATGLRNIPS IQSRGLFGAI AGFIEGGRTG 360
6. GALKSNLPFQ NVHPSTIGEC PKYVKSTQLR MATGLRNIPS IQSRGLFGAI AGFIEGGWTG 360
7. GAINSSLPFQ NVHPVTIGEC PKYVRSAKLR MVTGLRNIPS IQSRGLFGAI AGFIEGGWTG 359
8. GAINSSLPFQ NVHPVTIGEC PKYVRSAKLR MVTGLRNIPS IQSRGLFGAI AGFIEGGWTG 359
9. GAINSSLPFQ NVHPVTIGEC PKYVRSTKLR MVTGLRNVPS IQSRGLFGAI AGFIEGGWTG 360
. GAINSSLPFQ NVHPVTIGEC PKYVRSTKLR MVTGLRNIPS IQSRGLFGAI AGFIEGGWTG 360
11. GAINSSLPFQ NVHPVTIGEC PKYVRSTKLR MVTGLRNIPS IQSRGLFGAI AGFIEGGWTG 359
12. GAINSSLPFQ NVHPVTIGEC PKYVRSTKLR MVTGLRNIPS IQSRGLFGAI AGFIEGGWTG 360
13. GAINSSLPFQ NVHPVTIGEC PKYVRSTKLR MVTGLRNIPS IQSRGLFGAI AGFIEGGWTG 360
14. GAINSSLPFQ NVHPVTIGEC PKYVRSTKLR MVTGLRNIPS IQSRGLFGAI AGFIEGGWTG 360
. GAINSSLPFQ NVHPVTIGEC PKYVRSTKLR MVTGLRNIPS IQSRGLFGAI AGFIEGGWTG 360
16. GAINSSLPFQ NVHPVTIGEC PKYVRSTKLR MVTGLRNIPS IQSRGLFGAI AGFIEGGWTG 360
17. GAINSSLPFQ NIHPVTIGEC PKYVRSTKLR MVTGLRNIPS IQSRGLFGAI AGFIEGGWTG 360
18. GAINSSLPFQ NVHPVTIGEC PKYVRSTKLR MVTGLRNIPS IQSRGLFGAI AGFIEGGWTG 360
19. GAINSSLPFQ NIHPVTIGEC PKYVRSTKLR MVTGLRNIPS VQSRGLFGAI AGFIEGGWTG 359
. GAINSSLPFQ NIHPVTIGEC PKYVRSTKLR MVTGLRNIPS IQSRGLFGAI AGFIEGGWTG 360
21. GAINSSLPFQ NIHPVTIGEC PKYVKSTKLR MVTGLRNIPS IQSRGLFGAI AGFIEGGWTG 360
22. GAINSSLPFQ NIHPFTIGEC PKYVRSTKLR MVTGLRNIPS IQSRGLFGAI AGFIEGGWDG 360
23. GAINSSLPFQ NIHPVTIGEC PKYVRSTKLR MVTGLRNIPS IQSRGLFGAI AGFIEGGWTG 360
24. GAINSSLPFQ NIHPVTIGEC PKYVRSTKLR MVTGLRNIPS IQSRGLFGAI AGFIEGGWTG 359
. GAINSSLPFQ NIHPVTIGEC PKYVRSTKLR MVTGLRNIPS IQSRGLFGAI AGFIEGGWTG 360
26. GAINSSLPYQ NIHPVTIGEC PKYVRSAKLR MVTGLRNIPS IQSRGLFGAI AGFIEGGWTG 359
27. GSINSNLPFQ NIHPVTIGEC PKYVRSTKLR MVTGLRNIPS IQYRGLFGAI AGFIEGGWTG 359
28. GAINSSLPFQ NIHPVTIGEC PKYVRSTKLR MATGLRNIPS IQSRGLFGAI AGFIEGGWTG 360
*:**:.**:* *:**.***:* ****:*:*** :.*****:** :* ******* ******** *
1. MVDGWYGYHH QNEQGSGYAA DQKSTQNAIN GITNKVNSVI EKMNTQFTAV GKEFNKLERR 419
40 2. MVDGWYGYHH QNEQGSGYAA DQKSTQNAIN GITNKVNSVI EKMNTQFTAV GKEFNKLERR 419
3. MVDGWYGYHH QNEQGSGYAA DQKSTQNAIN GITNKVNSVI EKMNTQFTAV GKEFNKLERR 419
4. MVDGWYGYHH QNEQGSGYAA DLKSTQNAID EITNKVNSVI EKMNTQFTAV GKEFNHLEKR 420
. MIDGWYGYHH QNEQGSGYAA DQKSTQIAID GINNKANSVI GKMNIQLTSV GKEFNSLEKR 420
6. MIDGWYGYHH QNEQGSGYAA DQKSTQIAID GINNKVNSII EKMNTQFTSV GKEFNDLEKR 420
45 7. MVDGWYGYHH QNEQGSGYAA DQKSTQNAIN GITNKVNSVI EKMNTQFTAV GKEFNKLERR 419
8. MVDGWYGYHH QNEQGSGYAA DQKSTQNAIN GITNKVNSVI EKMNTQFTAV GKEFNKLERR 419
9. MIDGWYGYHH QNEQGSGYAA DQKSTQNAIN GITNKVNSII EKMNTQFTAV GKEFNKLEKR 420
. MIDGWYGYHH QNEQGSGYAA DQKSTQNAID GITNKVNSVI EKMNTQFTAV GKEFNKLERR 420
11. MMDGWYGYHH QNEQGSGYAA DQKSTQNAIN GITNKVNSVI EKMNTQFTAV GKEFNKLERR 419
50 12. MIDGWYGYHH QNEQGSGYAA DQKSTQNAIN GITNKVNSVI EKMNTQFTAV GKEFNKLERR 420
13. MIDGWYGYHH QNEQGSGYAA DQKSTQNAIN GITNKVNSVI EKMNTQFTAV GKEFNKLERR 420
14. MIDGWYGYHH QNEQGSGYAA DQKSTQNAIN GITNKVNSII EKMNTQFTAV GKEFNKLEKR 420
. MIDGWYGYHH QNEQGSGYAA DQKSTQNAIN GITNKVNSVI EKMNTQFTAV GKEFNKLEKR 420
16. MIDGWYGYHH QNEQGSGYAA DQKSTQNAIN GITNKVNSVI EKMNTQFTAV GKEFNKLEKR 420
55 17. MIDGWYGYHH QNEQGSGYAA DQKSTQNAIN GITNKVNSVI EKMNTQFTAV GKEFNKLEKR 420
18. MIDGWYGYHH QNEQGSGYAA DQKSTQNAIN GITNKVNSVI EKMNTQFTAV GKEFNKLERR 420
19. MMDGWYGYHH QNEQGSGYAA DQKSTQNAIN GITNKVNSVI EKMNTQFTAV GKEFNKLEKR 419
. MIDGWYGYHH QNEQGSGYAA DQKSTQNAIN GITNKVNSVI EKMNTQFTAV GKEFNKLEKR 420
21. MIDGWYGYHH QNEQGSGYAA DQKSTQNAIN WITNKVNSVI EKMNTQFTAV GKEFNKLEKR 420
60 22. MIDGWYGYHH QNEQGSGYAA DQKSTQNAIN GITNKVNSVI EKMNTQFTAV GKEFNKLEKR 420
23. MIDGWYGYHH QNEQGSGYAA DQKSTQNAIN GITNKVNSVI EKMNTQFTAV GKEFNNLEKR 420
24. MIDGWYGYHH QNEQGSGYAA DQKSTQNAIN GITNKVNSVI EKMNTQFTAV GKEFNNLEKR 419
. MIDGWYGYHH QNEQGSGYAA DQKSTQNAIN GITNKVNSVI EKMNTQFTAV GKEFNNLEKR 420
26. MIDGWYGYHH QNEQGSGYAA DQKSTQNAIN GITNKVNSVI EKMNIQFTAV GKEFNKLEKR 419
27. MIDGWYGYHH QNEQGSGYAA DQKSTQNAIN GITNKVNSVI EKMNTQFTAV GKEFNNLEKR 419
28. MIDGWYGYHH QNEQGSGYAA DQKSTQNAID GITNKVNSVI EKMNTQFTAV GKEFNNLERR 420
*:******** ********** * *******: *******:* **** ***** *****:**:*
1. MENLNKKVDD GFIDIWTYNA ELLVLLENER TLDFHDSNVK NLYEKVKSQL KNNAKEIGNG 479
2. MENLNKKVDD GFIDIWTYNA ELLVLLENER TLDFHDSNVK NLYEKVKSQL KNNAKEIGNG 479
3. MENLNKKVDD GFLDIWTYNA ELLVLLENER TLDFHDSNVK NLYEKVKSQL KNNAKEIGNG 479
4. IENLNKKVDD GFLDIWTYNA ELLVLLENER TLDYHDSNVK NLYEKVRSQL KNNAKEIGNG 480
5. KENLNKTVDD RFLDVWTFNA ELLVLLENQR TLEFHDLNIK SLYEKVKSHL RNNDKEIGNG 480
6. IENLNKKVDD GFLDVWTYNA ELLILLENER TLDFHDFNVK NLYEKVKSQL RNNAKEIGNG 480
7. MENLNKKVDD GFLDIWTYNA ELLVLLENER TLDFHDSNVK NLYEKVKSQL KNNAKEIGNG 479
8. MENLNKKVDD GFIDIWTYNA ELLVLLENER TLDFHDSNVK NLYEKVKSQL KNNAKEIGNG 479
9. MENLNKKVDD GFLDIWTYNA ELLVLLENER TLDFHDLNVK NLYEKVKNQL KNNAKEIGNG 480
10. MENLNKKVDD GFLDIWTYNA ELLVLLENER TLDFHDSNVK NLYEKVKTQL KNNAKEIGNG 480
11. MENLNKKVDD GFLDIWTYNA ELLVLLENER TLDFHDSNVK NLYEKVKSQL KNNAKEIGNG 479
12. MENLNKKVDD GFLDIWTYNA ELLVLLENGR TLDFHDSNVK NLYEKVKSQL KNNAKEIGNG 480
13. MENLNKKVDD GFLDIWTYNA ELLVLLENER TLDFHDSNVK NLYEKVKSQL KNNAKEIGNG 480
14. MENLNKKVDD GFLDIWTYNA ELLVLLENER TLDFHDSNVK NLYEKVKSQL KNNAKEIGNG 480
15. MENLNKKVDD GFLDIWTYNA ELLVLLENER TLDFHDSNVK NLYEKVKSQL KNNAKEIGNG 480
16. MENLNKKVDD GFLDIWTYNA ELLVLLENER TLDFHDSNVK NLYEKVKSQL KNNAKEIGNG 480
17. MENLNKKVDD GFLDIWTYNA ELLVLLENER TLDFHDSNVK NLYEKVKSQL KNNAKEIGNG 480
18. MENLNKKVDD GFLDIWTYNA ELLVLLENER TLDFHDSNVK NLYEKVKSQL KNNAKEIGNG 480
19. MENLNKKVDD GFMDIWTYNA ELLVLLENER TLDFHDSNVK NLYEKVKNQL RNNAKELGNG 479
20. MENLNKKVDD GFLDIWTYNA ELLVLLENER TLDFHDSNVK NLYEKVKSQL KNNAKEIGNG 480
21. MENLNKKVDD GFLDIWTYNA ELLVLLENER TLDFHDSNVK NLYEKVKNQL RNNAKEIGNG 480
22. MENLNKKVDD GFLDIWTYNA ELLVLLENER TLDFHDSNVK NLYEKVKNQL RNNAKEIGNG 480
23. MENLNKKVDD GFLDIWTYNA ELLILLENER TLDFHDSNVK NLYEKVKSQL RNNAKEIGNG 480
24. MENLNKKVDD GFLDIWTYNA ELLVLLENER TLDFHDSNVK NLYEKVKNQL RNNAKEIGNG 479
25. MENLNKKVDD GFLDIWTYNA ELLVLLENER TLDFHDSNVK NLYEKVKSQL RNNAKEIGNG 480
26. MENLNNKVDD GFLDIWTYNA ELLVLLENER TLDFHDSNVK NLYEKVKSQL KNNAKEIGNG 479
27. MENLNKKVDD GFLDIWTYNA ELLVLLENER TLDFHDLNVK NLYEKVKSQL KNNAKEIGNG 479
28. IENLNKKVDD GFLDIWTYNA ELLVLLENER TLDFHDSNVR NLYEKVKSQL KNNAKEIGNG 480
:****:**** **:******* ***:**** * ***:** **: ******:.** :*****:***
1. CFEFYHKCND ECMESVKNGT YDYPKYSEES KLNREKIDGV KLESMGVYQI LAIYSTVASS 539
2. CFEFYHKCND ECMESVKNGT YDYPKYSEES KLNREKIDGV KLESMGVYQI LAIYSTVASS 539
3. CFEFYHKCNN ECMESVKNGT YDYPKYSEES KLNREKIDGV KLESMGVYQI LAIYSTVASS 539
4. CFEFYHKCDN TCMESVKNGT YDYPKYSEEA KLNREEIDGV KLESTRIYQI LAIYSTVASS 540
40 5. CFEFYHKRDN ECLECVKNGT YNYPKYSEES KFNREEIVGV KLESMGIHQI LAIYSTVASS 540
6. CFEFYHKCDN ECMESVKNGT YNYPKYSEES KLNREKIDGV KLESMGVHQI LAIYSTVASS 540
7. CFEFYHKCND ECMESVKNGT YDYPKYSEES KLNRERIDGV KLESMGVYQI LAIYSTVASS 539
8. CFEFYHKCND ECMESVKNGT YDYPKYSEES KLNREKIDGV KLESMGVYQI LAIYSTVASS 539
9. CFEFYHKCNN ECMESVKNGT YDYPKYSKES KLNREKIDGV KLESMGVYQI LAIYSTVASS 540
45 10. CFEFYHKCNN ECMESVKNGT YDYPKYSEES KLNREKIDGV KLESMGVYQI LAIYSTVASS 540
11. CFEFYHKCNN ECMESVKNGT YDYPKYSEES KLNREKIDGV KLESMGVYQI LAIYSTVASS 539
12. CFEFYHKCNN ECMESVKNGT YDYPKYSEES KLNRGKIDGV KLESMGVYQI LAIYSTVASS 540
13. CFEFYHKCNN ECMESVKNGT YDYPKYSEES KLNREKIDGV KLESMGVYQI LAIYSTVASS 540
14. CFEFYHKCNN ECMESVKNGT YDYPKYSEES KLNREKIDGV KLESMGVYQI LAIYSTVASS 540
50 15. CFEFYHKCNN ECMESVKNGT YDYPKYSEES KLNREKIDGV KLESMGVYQI LAIYSTVASS 540
16. CFEFYHKCNN ECMESVKNGT YDYPKYSEES KLNREKIDGV KLESMGVYQI LAIYSTVASS 540
17. CFEFYHKCNN ECMESVKNGT YDYPKYSEES KLNREKIDGV KLESMGVYQI LAIYSTVASS 540
18. CFEFYHKCNN ECMESVKNGT YDYPKYSEES KLNREKIDGV KLESMGVYQI LAIYSTVASS 540
19. CFEFYHKCDN ECMESVKNGT YDYPKYSEES KLNREKIDGV KLESMGVYRI LAIYSTVASS 539
55 20. CFEFYHKCNN ECMESVKNGT YDYPKYSEES KLNREKIDGV KLESMGVYQI LAIYSTVASS 540
21. CFEFYHKCNN ECMESVKNGT YDYPKYSEES KLNREKIDGV KLESMGVYQI LAIYSTVASS 540
22. CFEFYHKCNN ECMESVKNGT YDYPKFSEES KLNREKIDGV KLESMGVYQI LAIYSTVASS 540
23. CFEFYHKCNN ECMESVKNGT YDYPKYSEES KLNREKIDGV KLESMGVYQI LAIYSTVASS 540
24. CFEFYHKCNN ECMESVKNGT YDYPKYSEES KLNREKIDGV KLESMGVYQI LAIYSTAASS 539
60 25. CFEFYHKCNN ECMESVKNGT YDYPKYSEES KLNREKIDGV KLESMGVYQI LAIYSTVASS 540
26. CFEFYHKCDN ECMESVRNGT YDYPKYSEES KLNREKVDGV KLESMGIYQI LAIYSTVASS 539
27. CFEFYHKCDN ECMESVRNGT YDYPKYSEES KLNREKIDGV KLESMGVYQI LAIYSTVASS 539
28. CFEFYHKCDD ACMESVRNGT YDYPKYSEES KLNREEIDGV KLESMGVYQI LAIYSTVASS 540
********:: *****:*** *****:*:*: **** .:*** **** :*:* ******.***
1. LVLLVSLGAI SFWMCSNGSL QCRICI 565
2. LVLLVSLGAI SFWMCSNGSL QCRICI 565
3. LVLLVSLGAI SFWMCSNGSL QCRICI 565
4. LVLVVSLGAI SFWMCSNGSL QCRICI 566
5. LVLLVSLGAI SFWMCSNGSL QCRVCI 566
6. LVLLVSLGAI SFWMCSNGSL QCRICI 566
7. LVLLVSLGAI SFWMCSNGSL QCRICI 565
8. LVLLVSLGAI SFWMCSNGSL QCRICI 565
9. LVLLVSLGAI SFWMCSNGSL QCRICI 566
10. LVLLVSLGAI SFWMCSNGSL QCRICI 566
11. LVLLVSLGAI SFWMCSNGSL QCRICI 565
12. LVLLVSLGAI SFWMCSNGSL QCRICI 566
13. LVLLVSLGAI SFWMCSNGSL QCRICI 566
14. LVLLVSLGAI SFWMCSNGSL QCRICI 566
15. LVLLVSLGAI SFWMCSNGSL QCRICI 566
16. LVLLVSLGAI SFWMCSNGSL QCRICI 566
17. LVLLVSLGAI SFWMCSNGSL QCRICI 566
18. LVLLVSLGAI SFWMCSNGSL QCRICI 566
19. LVLLVSLGAI SFWMCSNGSL QCRICI 565
20. LVLLVSLGAI SFWMCSNGSL QCRICI 566
21. LVLLVSLGAI SFWMCSNGSL QCRICI 566
22. LVLLVSLGAI SFWMCSNGSL QCRICI 566
23. LVLLVSLGAI SFWMCSNGSL QCRICI 566
24. LVLLVSLGAI SFWMCSNGSL QCRICI 565
25. LVLLVSLGAI SFWMCSNGSL QCRICI 566
26. LVLLVSLGAI SFWMCSNGSL QCRICI 565
27. LVLLVSLGAI SFWMCSNGSL QCRICI 565
28. LVLLVSLGAI SFWMCSNGSL QCRICI 566
***:****** ********** ******
Table 9. Consensus sequence for H3 401-421 (SEQ ID NO: 104), other natural variants
and mutations that stabilize polypeptides of the invention. One or more mutations in the
parental sequence are present in polypeptides of the invention.
amino conservation other preferred
Position acid (%) natural mutation polar charged flexible
401 I 99.26 V R K
402 E/G 56.2/40.3 K
403 K 94.85 R
404 T 99.88 A
405 N 99.88 S
406 E 100
407 K 100
408 F 100 S T,N,Q R,H,K,D,E G
409 H 100
410 Q 100
411 I 100 T S,N,Q R,H,K,D,E G
412 E 100
413 K 100
414 E 100
415 F 100 S T,N,Q R,H,K,D,E G
416 S 99.46 T,L
417 E 99.71 G,D
418 V 98.64 I G S,T,N,Q R,H,K,D,E
419 E 100
420 G 99.84 E
421 R 100
Table 10. Calculated and experimental molecular weight as determined from SEC-
MALS. The calculated molecular weight is based on the amino acid composition
of the processed polypeptide of the invention, i.e. after the leader peptide has been
cleaved of. Addtional mass arising from glycosylation ahs nopt been taken into
account.
SEQ ID NO Calculated molecular Experimental molecular
weight (Da) weight (kDa)
144 29137 75
145 29257 50
146 29203 56
147 29119 60
148 29293 66
150 29411 64
151 29283 79
Table 11.
Selected strains
Set 1 Set 2
H1N1 A/Maryland/12/1991 H1N1 A/Maryland/12/1991
H1N1 A/Henry/1936/ H1N1 A/Henry/1936/
H1N1 A/AA/Marton/1943 H1N1 A/AA/Marton/1943
H1N1 A/Memphis/20/1978 H1N1 A/USSR/92/1977
H1N1 A/New York/607/1995 H1N1 A/New York/629/1995
H1N1 A/New Jersey/11/2007 H1N1 A/Virginia/UR06-0549/2007
H1N1 A/Wisconsin/629-D01415/2009 H1N1 A/Texas/UR06-0526/2007
H1N1 A/Sydney/DD3-55/2010
REFERENCES
Bommakanti et al. (2010), PNAS 107(31): 13701-13706.
Chen et al. (1995), PNAS 92, 12205-12209.
Coffman et al. (2010), Immunity 33: 492.
Corti et al. (2011), Science 333(6044): 850-856.
Delhaise, et al. (1984), J. Mol. Graph. 2:103–106.
Devereux et al. (1984), Nucl. Acids Res. 12: 387.
Dopheide, Ward (1981), J Gen Virol. 367–370.Edgar RC (2004), Nucleic Acids Res. 32,
1792-1797.
Ekiert et al. (2009), Science 324:246.
Ekiert et al. (2011), Science 333: 844.Ferguson et al. (2003), Nature 422: 428-443.
Higgins (1992), Comput Appl Biosci 8:15-22.Lorieau et al. 2010, Proc. Natl. Acad. Sci.
USA, 107: 11341.
Okuno et al. (1993). J Virol. 67:2552-2558.Russel et al. (2004), Virology 325 : 287.
Samantha et al. (2002) Prot Eng. 15, 659-667.
Steel et al. (2010), mBio 1(1): 1-9.
Steven et al. (2004) Science 303: 1866.
Steven et al. (2006) Science 312: 404.Sun et al., (2010), J. Virol. 84: 8683
Suzuki et al. (2005), Prot Eng 11, 1051.
Throsby et al. (2008), Plos One 12(3): 1-15.
Wilson et al (1981) Nature 289: 366. Woolfson (2005), Adv Protein Chem 70: 79-112.
Xu & Miranker (2004) Bioinformatics 8: 1214-1221.
In this specification where reference has been made to patent specifications, other
external documents, or other sources of information, this is generally for the purpose of
providing a context for discussing the features of the invention. Unless specifically stated
otherwise, reference to such external documents is not to be construed as an admission
that such documents, or such sources of information, in any jurisdiction, are prior art, or
form part of the common general knowledge in the art.
In the description in this specification reference may be made to subject matter
that is not within the scope of the claims of the current application. That subject matter
should be readily identifiable by a person skilled in the art and may assist in putting into
practice the invention as defined in the claims of this application.
SEQUENCES
SEQ ID NO 1: H1 Full length (A/Brisbane/59/2007)
MKVKLLVLLC TFTATYADTI CIGYHANNST DTVDTVLEKN VTVTHSVNLL 50
ENSHNGKLCL LKGIAPLQLG NCSVAGWILG NPECELLISK ESWSYIVEKP 100
NPENGTCYPG HFADYEELRE QLSSVSSFER FEIFPKESSW PNHTVTGVSA 150
SCSHNGESSF YRNLLWLTGK NGLYPNLSKS YANNKEKEVL VLWGVHHPPN 200
IGDQKALYHT ENAYVSVVSS HYSRKFTPEI AKRPKVRDQE GRINYYWTLL 250
EPGDTIIFEA NGNLIAPRYA FALSRGFGSG IINSNAPMDK CDAKCQTPQG 300
AINSSLPFQN VHPVTIGECP KYVRSAKLRM VTGLRNIPSI QSRGLFGAIA 350
GFIEGGWTGM VDGWYGYHHQ NEQGSGYAAD QKSTQNAING ITNKVNSVIE 400
KMNTQFTAVG KEFNKLERRM ENLNKKVDDG FIDIWTYNAE LLVLLENERT 450
LDFHDSNVKN LYEKVKSQLK NNAKEIGNGC FEFYHKCNDE CMESVKNGTY 500
DYPKYSEESK LNREKIDGVK LESMGVYQIL AIYSTVASSL VLLVSLGAIS 550
FWMCSNGSLQ CRICI 565
SEQ ID NO 2: miniHA (A/Brisbane/59/2007)
MKVKLLVLLC TFTATYADTI CIGYHANNST DTVDTVLEKN VTVTHSVNLL 50
ENSHNGKLCG GGGCDAKCQT PQGAINSSLP FQNVHPVTIG ECPKYVRSAK 100
LRMVTGLRNI PSIQSQGLFG AIAGFIEGGW TGMVDGWYGY HHQNEQGSGY 150
AADQKSTQNA INGITNKVNS VIEKMNTQFT AVGKEFNKLE RRMENLNKKV 200
DDGFIDIWTY NAELLVLLEN ERTLDFHDSN VKNLYEKVKS QLKNNAKEIG 250
NGCFEFYHKC NDECMESVKN GTYDYPKYSE ESKLNREKID GVKLESMGVY 300
QILAIYSTVA SSLVLLVSLG AISFWMCSNG SLQCRICI 338
SEQ ID NO 3: miniHA cluster1 (A/Brisbane/59/2007)
MKVKLLVLLC TFTATYADTI CIGYHANNST DTVDTVLEKN VTVTHSVNLL 50
ENSHNGKTCG GGGCDAKCQT PQGAINSSLP FQNVHPTTTG ECPKYVRSAK 100
LRMVTGLRNI PSIQSQGLFG AIAGFIEGGW TGMVDGWYGY HHQNEQGSGY 150
AADQKSTQNA INGITNKVNS VIEKMNTQST ATGKEFNKSE RRMENLNKKV 200
DDGFIDIWTY NAELLVLLEN ERTLDFHDSN VKNLYEKVKS QLKNNAKEIG 250
NGCFEFYHKC NDECMESVKN GTYDYPKYSE ESKLNREKID GVKLESMGVY 300
QILAIYSTVA SSLVLLVSLG AISFWMCSNG SLQCRICI 338
SEQ ID NO 4: miniHA cluster1+2 (A/Brisbane/59/2007)
MKVKLLVLLC TFTATYADTI CIGYHANNST DTVDTVLEKN VTVTHSVNLL 50
ENSHNGKTCG GGGCDAKCQT PQGAINSSLP FQNVHPTTTG ECPCYVRSAK 100
LRMVTGLRNI PSIQSQGLFG AIAGFIEGGW TGMVDGWYGY HHQNEQGSGY 150
AADQKSTQNA INGITNKVNS VIEKMNTCST ATGKEFNKSE RRMENLNKKV 200
40 DDGFIDIWTY NAELLVLLEN ERTLDFHDSN VKNLYEKVKS QLKNNAKEIG 250
NGCFEFYHKC NDECMESVKN GTYDYPKYSE ESKLNREKID GVKLESMGVY 300
QILAIYSTVA SSLVLLVSLG AISFWMCSNG SLQCRICI 338
SEQ ID NO 5: miniHA cluster1+3 (A/Brisbane/59/2007)
45 MKVKLLVLLC TFTATYADTI CIGYHANNST DTVDTVLEKN VTVTHSVNLL 50
ENSHNGKTCG GGGCDAKCQT PQGAINSSLP FQNVHPTTTG ECPKYVRSAK 100
LRMVTGLRNI PSIQSQGLFG AIAGFIEGGW TGMVDGWYGY HHQNEQGSGY 150
AADQKSTQNA INGITNKVNS VIEKMNTQST ATGKECNKSE RRMCNLNKKV 200
DDGFIDIWTY NAELLVLLEN ERTLDFHDSN VKNLYEKVKS QLKNNAKEIG 250
50 NGCFEFYHKC NDECMESVKN GTYDYPKYSE ESKLNREKID GVKLESMGVY 300
QILAIYSTVA SSLVLLVSLG AISFWMCSNG SLQCRICI 338
SEQ ID NO 6: miniHA cluster1+4 (A/Brisbane/59/2007)
MKVKLLVLLC TFTATYADTI CIGYHANNST DTVDTVLEKN VTVTHSVNLL 50
ENSHNGKTCG GGGCDAKCQT PQGAINSSLP FQNVHPTTTG ECPKYVRSAK 100
LRMVTGLRNI PSIQSQGLFG AIAGFIEGGW TGMVDGWYGY HHQNEQGSGY 150
AADQKSTQNA INGITNKVNS VIEKMNTQST ATGKEFNKSE RRMENLNKKV 200
DDGFIDIWTY NAELLVLLEN ERTLDFHDSN VKNLYEKVKS QLKNNAKEIG 250
NGCFEFYHKC NDECMESVKN GTYDYPKYSE ESKLNREKID GVKLESMGVY 300
QILAIYSTVA SSLVLLVSLG AISFWMCSNG SLQCRICI 338
SEQ ID NO 7: miniHA cluster1+2+3 (A/Brisbane/59/2007)
MKVKLLVLLC TFTATYADTI CIGYHANNST DTVDTVLEKN VTVTHSVNLL 50
ENSHNGKTCG GGGCDAKCQT PQGAINSSLP FQNVHPTTTG ECPCYVRSAK 100
LRMVTGLRNI PSIQSQGLFG AIAGFIEGGW TGMVDGWYGY HHQNEQGSGY 150
AADQKSTQNA INGITNKVNS VIEKMNTCST ATGKECNKSE RRMCNLNKKV 200
DDGFIDIWTY NAELLVLLEN ERTLDFHDSN VKNLYEKVKS QLKNNAKEIG 250
NGCFEFYHKC NDECMESVKN GTYDYPKYSE ESKLNREKID GVKLESMGVY 300
QILAIYSTVA SSLVLLVSLG AISFWMCSNG SLQCRICI 338
SEQ ID NO 8: miniHA cluster1+2+3+4 (A/Brisbane/59/2007)
MKVKLLVLLC TFTATYADTI CIGYHANNST DTVDTVLEKN VTVTHSVNLL 50
ENSHNGKTCG GGGCDAKCQT PQGAINSSLP FQNVHPTTTG ECPCYVRSAK 100
LRMVTGLRNI PSIQSQGLFG AIAGFIEGGW TGMVDGWYGY HHQNEQGSGY 150
AADQKSTQNA INGITNKVNS VIEKMNTCST ATGKECNKSE RRMCNLNKKV 200
DDGFIDIWTY NAELLVLLEN ERTLDFHDSN VKNLYEKVKS QLKNNAKEIG 250
NGCFEFYHKC NDECMESVKN GTYDSPKYSE ESKLNREKID GVKLESMGVY 300
QILAIYSTVA SSLVLLVSLG AISFWMCSNG SLQCRICI 338
SEQ ID NO 9: mini1 cluster11 (A/Brisbane/59/2007)
MKVKLLVLLC TFTATYADTI CIGYHANNST DTVDTVLEKN VTVTHSVNLL 50
ENSHNGKTCG GGGCDAKCQT PQGAINSSLP FQNVHPTTTG ECPKYVRSAK 100
LRMVTGLRNI PSIQSQGLFG AIAGFIEGGW TGMVDGWYGY HHQNEQGSGY 150
AADQKSTQNA INGITNKVNS VIEKMNTQST ATGKEFNKSE RRIENLNKKI 200
DDGFIDIWTY NAELLVLLEN ERTLDFHDSN VKNLYEKVKS QLKNNAKEIG 250
NGCFEFYHKC NDECMESVKN GTYDYPKYSE ESKLNREKID GVKLESMGVY 300
QILAIYSTVA SSLVLLVSLG AISFWMCSNG SLQCRICI 338
SEQ ID NO 10: mini2 cluster11 (A/Brisbane/59/2007)
MKVKLLVLLC TFTATYADTI CIGYHANNST DTVDTVLEKN VTVTHSVNLL 50
40 ENGGGGKYVR SAKLRMVTGL RNIPSIQSQG LFGAIAGFIE GGWTGMVDGW 100
YGYHHQNEQG SGYAADQKST QNAINGITNK VNSVIEKMNT QSTATGKEFN 150
KSERRIENLN KKIDDGFIDI WTYNAELLVL LENERTLDFH DSNVKNLYEK 200
VKSQLKNNAK EIGNGCFEFY HKCNDECMES VKNGTYDYPK YSEESKLNRE 250
KIDGVKLESM GVYQILAIYS TVASSLVLLV SLGAISFWMC SNGSLQCRIC 300
45 I 301
SEQ ID NO 11: mini3 cluster11 (A/Brisbane/59/2007)
MKVKLLVLLC TFTATYADTI CIGYHANNST DTVDTVLEKN VTVTHSVNLL 50
ENSGGGGNSS LPFQNVHPTT TGECPKYVRS AKLRMVTGLR NIPSIQSQGL 100
FGAIAGFIEG GWTGMVDGWY GYHHQNEQGS GYAADQKSTQ NAINGITNKV 150
NSVIEKMNTQ STATGKEFNK SERRIENLNK KIDDGFIDIW TYNAELLVLL 200
ENERTLDFHD SNVKNLYEKV KSQLKNNAKE IGNGCFEFYH KCNDECMESV 250
KNGTYDYPKY SEESKLNREK IDGVKLESMG VYQILAIYST VASSLVLLVS 300
LGAISFWMCS NGSLQCRICI 320
SEQ ID NO 12: mini4 cluster11 (A/Brisbane/59/2007)
MKVKLLVLLC TFTATYADTI CIGYHANNST DTVDTVLEKN VTVTHSVNLL 50
ENSHNGGGGE CPKYVRSAKL RMVTGLRNIP SIQSQGLFGA IAGFIEGGWT 100
GMVDGWYGYH HQNEQGSGYA ADQKSTQNAI NGITNKVNSV IEKMNTQSTA 150
TGKEFNKSER RIENLNKKID DGFIDIWTYN AELLVLLENE RTLDFHDSNV 200
KNLYEKVKSQ LKNNAKEIGN GCFEFYHKCN DECMESVKNG TYDYPKYSEE 250
SKLNREKIDG VKLESMGVYQ ILAIYSTVAS SLVLLVSLGA ISFWMCSNGS 300
LQCRICI 307
SEQ ID NO 13: mini1 cluster11+5 (A/Brisbane/59/2007)
MKVKLLVLLC TFTATYADTI CIGYHANNST DTVDTVLEKN VTVTHSVNLL 50
ENSHNGKTCG GGGCDAKCQT PQGAINSSLP FQNVHPTTTG ECPKYVCSAK 100
LRMVTGLRNI PSIQSQGLFG AIAGFIEGGW TGMVDGWYGY HHQNEQGSGY 150
AADQKSTQNA INGITNKVNS VIEKMNTQST ATGKEFNKSE RRIENLNKKI 200
DDGFIDIWCY NAELLVLLEN ERTLDFHDSN VKNLYEKVKS QLKNNAKEIG 250
NGCFEFYHKC NDECMESVKN GTYDYPKYSE ESKLNREKID GVKLESMGVY 300
QILAIYSTVA SSLVLLVSLG AISFWMCSNG SLQCRICI 338
SEQ ID NO 14: mini2 cluster11+5 (A/Brisbane/59/2007)
MKVKLLVLLC TFTATYADTI CIGYHANNST DTVDTVLEKN VTVTHSVNLL 50
ENGGGGKYVC SAKLRMVTGL RNIPSIQSQG LFGAIAGFIE GGWTGMVDGW 100
YGYHHQNEQG SGYAADQKST QNAINGITNK VNSVIEKMNT QSTATGKEFN 150
KSERRIENLN KKIDDGFIDI WCYNAELLVL LENERTLDFH DSNVKNLYEK 200
VKSQLKNNAK EIGNGCFEFY HKCNDECMES VKNGTYDYPK YSEESKLNRE 250
KIDGVKLESM GVYQILAIYS TVASSLVLLV SLGAISFWMC SNGSLQCRIC 300
I 301
SEQ ID NO 15: mini3 cluster11+5 (A/Brisbane/59/2007)
MKVKLLVLLC TFTATYADTI CIGYHANNST DTVDTVLEKN VTVTHSVNLL 50
ENSGGGGNSS LPFQNVHPTT TGECPKYVCS AKLRMVTGLR NIPSIQSQGL 100
40 FGAIAGFIEG GWTGMVDGWY GYHHQNEQGS GYAADQKSTQ NAINGITNKV 150
NSVIEKMNTQ STATGKEFNK SERRIENLNK KIDDGFIDIW CYNAELLVLL 200
ENERTLDFHD SNVKNLYEKV KSQLKNNAKE IGNGCFEFYH KCNDECMESV 250
KNGTYDYPKY SEESKLNREK IDGVKLESMG VYQILAIYST VASSLVLLVS 300
LGAISFWMCS NGSLQCRICI 320
SEQ ID NO 16: mini4 cluster11+5 (A/Brisbane/59/2007)
MKVKLLVLLC TFTATYADTI CIGYHANNST DTVDTVLEKN VTVTHSVNLL 50
ENSHNGGGGE CPKYVCSAKL RMVTGLRNIP SIQSQGLFGA IAGFIEGGWT 100
GMVDGWYGYH HQNEQGSGYA ADQKSTQNAI NGITNKVNSV IEKMNTQSTA 150
TGKEFNKSER RIENLNKKID DGFIDIWCYN AELLVLLENE RTLDFHDSNV 200
KNLYEKVKSQ LKNNAKEIGN GCFEFYHKCN DECMESVKNG TYDYPKYSEE 250
SKLNREKIDG VKLESMGVYQ ILAIYSTVAS SLVLLVSLGA ISFWMCSNGS 300
LQCRICI 307
SEQ ID NO 17: H1 consensus sequence residue 402-418 (numbering
according to SEQ ID NO:1)
402 MNTQFTAVG KEFN(H/K)LE(K/R) 418
>SC09-114 VH PROTEIN (SEQ ID NO: 18)
QVQLVQSGAEVKKPGSSVKVSCKSSGGTSNNYAISWVRQAPGQGLDWMGGISPIFGSTAYAQKFQGRVTISA
DIFSNTAYMELNSLTSEDTAVYFCARHGNYYYYSGMDVWGQGTTVTVSS
>SC09-114 VL PROTEIN (SEQ ID NO: 19)
SYVLTQPPAVSGTPGQRVTISCSGSDSNIGRRSVNWYQQFPGTAPKLLIYSNDQRPSVVPDRFSGSKSGTSA
SLAISGLQSEDEAEYYCAAWDDSLKGAVFGGGTQLTVL
>CR6261 VH PROTEIN (SEQ ID NO: 20)
E V Q L V E S G A E V K K P G S S V K V S C K A S G G P F R S Y A I S W
V R Q A P G Q G P E W M G G I I P I F G T T K Y A P K F Q G R V T I T A
D D F A G T V Y M E L S S L R S E D T A M Y Y C A K H M G Y Q V R E T M
D V W G K G T T V T V S S
>CR6261 VL PROTEIN (SEQ ID NO: 21)
Q S V L T Q P P S V S A A P G Q K V T I S C S G S S S N I G N D Y V S W
Y Q Q L P G T A P K L L I Y D N N K R P S G I P D R F S G S K S G T S A
T L G I T G L Q T G D E A N Y Y C A T W D R R P T A Y V V F G G G T K L
T V L G
>SC08-057 VH PROTEIN (SEQ ID NO: 22)
EVQLVESGGGLVQPGGSLRLSCAASGFTDSVIFMSWVRQAPGKGLECVSIIYIDDSTYYADSVKGRFTISRH
NSMGTVFLEMNSLRPDDTAVYYCATESGDFGDQTGPYHYYAMDV
>SC08-057 VL PROTEIN (SEQ ID NO: 23)
QSALTQPASVSGSPGQSITISCTGSSGDIGGYNAVSWYQHHPGKAPKLMIYEVTSRPSGVSDRFSASRSGDT
ASLTVSGLQAEDEAHYYCCSFADSNILI
45 SEQ ID NO: 24 (STEEL)
MKANLLVLLC ALAAADADTI CIGYHANNST DTVDTVLEKN VTVTHSVNLL 50
EDSHNGKLCG GGGCNTKCQT PLGAINSSLP YQNIHPVTIG ECPKYVRSAK 100
LRMVTGLRNI PSIQSRGLFG AIAGFIEGGW TGMIDGWYGY HHQNEQGSGY 150
AADQKSTQNA INGITNKVNS VIEKMNIQFT AVGKEFNKLE KRMENLNNKV 200
50 DDGFLDIWTY NAELLVLLEN ERTLDFHDSN VKNLYEKVKS QLKNNAKEIG 250
NGCFEFYHKC DNECMESVRN GTYDYPKYSE ESKLNREKVD GVKLESMGIY 300
QILAIYSTVA SSLVLLVSLG AISFWMCSNG SLQCRICI 338
SEQ ID NO: 31: H7 Full length (A/Mallard/Netherlands/12/2000)
MNTQILVFAL MAIIPTNADK ICLGHHAVSN GTKVNTLTER GVEVVNATET 50
VERTNVPRIC SKGKRTVDLG QCGLLGTITG PPQCDQFLEF SADLIIERRE 100
GSDVCYPGKF VNEEALRQIL RESGGIDKET MGFTYSGIRT NGATSACRRS 150
GSSFYAEMKW LLSNTDNAAF PQMTKSYKNT RKDPALIIWG IHHSGSTTEQ 200
TKLYGSGNKL ITVGSSNYQQ SFVPSPGARP QVNGQSGRID FHWLILNPND 250
TVTFSFNGAF IAPDRASFLR GKSMGIQSGV QVDANCEGDC YHSGGTIISN 300
LPFQNINSRA VGKCPRYVKQ ESLLLATGMK NVPEIPKGRG LFGAIAGFIE 350
NGWEGLIDGW YGFRHQNAQG EGTAADYKST QSAIDQITGK LNRLIEKTNQ 400
QFELIDNEFT EVEKQIGNVI NWTRDSMTEV WSYNAELLVA MENQHTIDLA 450
DSEMNKLYER VKRQLRENAE EDGTGCFEIF HKCDDDCMAS IRNNTYDHSK 500
YREEAMQNRI QIDPVKLSSG YKDVILWFSF GASCFILLAI AMGLVFICVK 550
NGNMRCTICI 560
SEQ ID NO: 32: H7 consensus sequence residue 394-414 (numbering
according to SEQ ID NO: 31)
394 LI(E/D/G)KTNQQFELIDNEF (N/T/S) E (I/V) E (Q/K) 414
SEQ ID NO: 33: H7-mini2 (A/Mallard/Netherlands/12/2000)
MNTQILVFAL MAIIPTNADK ICLGHHAVSN GTKVNTLTER GVEVVNATET 50
VEGGGGRYVK QESLLLATGM KNVPEIPKGQ GLFGAIAGFI ENGWEGLIDG 100
WYGFRHQNAQ GEGTAADYKS TQSAIDQITG KLNRLIEKTN QQFELIDNEF 150
TEVEKQIGNV INWTRDSMTE VWSYNAELLV AMENQHTIDL ADSEMNKLYE 200
RVKRQLRENA EEDGTGCFEI FHKCDDDCMA SIRNNTYDHS KYREEAMQNR 250
IQIDPVKLSS GYKDVILWFS FGASCFILLA IAMGLVFICV KNGNMRCTIC 300
I 301
SEQ ID NO: 34: H7-mini2-cluster15
MNTQILVFAL MAIIPTNADK ICLGHHAVSN GTKVNTLTER GVEVVNATET 50
VEGGGGRYVK QESLLLATGM KNVPEIPKGQ GLFGAIAGFI ENGWEGLIDG 100
WYGFRHQNAQ GEGTAADYKS TQSAIDQITG KLNRLIEKTN QQSELTDNES 150
TEVEKQIGNV INWTRDSMTE VWSYNAELLV AMENQHTIDL ADSEMNKLYE 200
RVKRQLRENA EEDGTGCFEI FHKCDDDCMA SIRNNTYDHS KYREEAMQNR 250
IQIDPVKLSS GYKDVILWFS FGASCFILLA IAMGLVFICV KNGNMRCTIC 300
I 301
SEQ ID NO: 35: H7-mini2-cluster15+16
40 MNTQILVFAL MAIIPTNADK ICLGHHAVSN GTKVNTLTER GVEVVNATET 50
VEGGGGRYVK QESLLLATGM KNVPEIPKGQ GLFGAIAGFI ENGWEGLIDG 100
WYGFRHQNAQ GEGTAADYKS TQSAIDQITG KLNRLIEKTN QQSENTDNES 150
TENEKQIGNV INWTRDSMTE VWSYNAELLV AMENQHTIDL ADSEMNKLYE 200
RVKRQLRENA EEDGTGCFEI FHKCDDDCMA SIRNNTYDHS KYREEAMQNR 250
45 IQIDPVKLSS GYKDVILWFS FGASCFILLA IAMGLVFICV KNGNMRCTIC 300
I 301
SEQ ID NO: 36: H7-mini2-cluster17
MNTQILVFAL MAIIPTNADK ICLGHHAVSN GTKVNTLTER GVEVVNATET 50
VEGGGGRYVC QESLLLATGM KNVPEIPKGQ GLFGAIAGFI ENGWEGLIDG 100
WYGFRHQNAQ GEGTAADYKS TQSAIDQITG KLNRLIEKTN QQFELIDNEF 150
TEVEKQIGNV INWTRDSMTE VWCYNAELLV AMENQHTIDL ADSEMNKLYE 200
RVKRQLRENA EEDGTGCFEI FHKCDDDCMA SIRNNTYDHS KYREEAMQNR 250
IQIDPVKLSS GYKDVILWFS FGASCFILLA IAMGLVFICV KNGNMRCTIC 300
I 301
SEQ ID NO: 37: H7-mini2-cluster15+16+17
MNTQILVFAL MAIIPTNADK ICLGHHAVSN GTKVNTLTER GVEVVNATET 50
VEGGGGRYVC QESLLLATGM KNVPEIPKGQ GLFGAIAGFI ENGWEGLIDG 100
WYGFRHQNAQ GEGTAADYKS TQSAIDQITG KLNRLIEKTN QQSENTDNES 150
TENEKQIGNV INWTRDSMTE VWCYNAELLV AMENQHTIDL ADSEMNKLYE 200
RVKRQLRENA EEDGTGCFEI FHKCDDDCMA SIRNNTYDHS KYREEAMQNR 250
IQIDPVKLSS GYKDVILWFS FGASCFILLA IAMGLVFICV KNGNMRCTIC 300
I 301
SEQ ID NO: 38: H7-mini2-cluster15+16+17+18
MNTQILVFAL MAIIPTNADK ICLGHHAVSN GTKVNTLTER GVEVVNATET 50
VEGGGGRYVC QESLLLATGM KNVPEIPKGQ GLFGAIAGFI ENGWEGLIDG 100
WYGFRHQNAQ GEGTAADYKS TQSAIDQITG KLNRLIEKTN QQSENTDNES 150
TENEKQIGNI INWIRDIMTE IWCYNAELLV AMENQHTIDL ADSEMNKLYE 200
RVKRQLRENA EEDGTGCFEI FHKCDDDCMA SIRNNTYDHS KYREEAMQNR 250
IQIDPVKLSS GYKDVILWFS FGASCFILLA IAMGLVFICV KNGNMRCTIC 300
I 301
SEQ ID NO: 39: H7-mini2-cluster15+16+17+tri
MNTQILVFAL MAIIPTNADK ICLGHHAVSN GTKVNTLTER GVEVVNATET 50
VEGGGGRYVC QESLLLATGM KNVPEIPKGQ GLFGAIAGFI ENGWEGLIDG 100
WYGFRHQNAQ GEGTAADYKS TQSAIDQITG KLNRLIEKTN QQSENTDNES 150
TENEKQIEAI EKKIEAIMTE IWCYNAELLV AMENQHTIDL ADSEMNKLYE 200
RVKRQLRENA EEDGTGCFEI FHKCDDDCMA SIRNNTYDHS KYREEAMQNR 250
IQIDPVKLSS GYKDVILWFS FGASCFILLA IAMGLVFICV KNGNMRCTIC 300
I 301
SEQ ID NO: 40: H7-mini5
MNTQILVFAL MAIIPTNADK ICLGHHAVSN GTKVNTLTER GVEVVNATET 50
VERGGGGPRY VKQESLLLAT GMKNVPEIPK GQGLFGAIAG FIENGWEGLI 100
40 DGWYGFRHQN AQGEGTAADY KSTQSAIDQI TGKLNRLIEK TNQQFELIDN 150
EFTEVEKQIG NVINWTRDSM TEVWSYNAEL LVAMENQHTI DLADSEMNKL 200
YERVKRQLRE NAEEDGTGCF EIFHKCDDDC MASIRNNTYD HSKYREEAMQ 250
NRIQIDPVKL SSGYKDVILW FSFGASCFIL LAIAMGLVFI CVKNGNMRCT 300
ICI 303
SEQ ID NO: 41: H7-mini5-cluster15+16
MNTQILVFAL MAIIPTNADK ICLGHHAVSN GTKVNTLTER GVEVVNATET 50
VERGGGGPRY VKQESLLLAT GMKNVPEIPK GQGLFGAIAG FIENGWEGLI 100
DGWYGFRHQN AQGEGTAADY KSTQSAIDQI TGKLNRLIEK TNQQSENTDN 150
ESTENEKQIG NVINWTRDSM TEVWSYNAEL LVAMENQHTI DLADSEMNKL 200
YERVKRQLRE NAEEDGTGCF EIFHKCDDDC MASIRNNTYD HSKYREEAMQ 250
NRIQIDPVKL SSGYKDVILW FSFGASCFIL LAIAMGLVFI CVKNGNMRCT 300
ICI 303
SEQ ID NO: 42:H7-mini5-cluster17
MNTQILVFAL MAIIPTNADK ICLGHHAVSN GTKVNTLTER GVEVVNATET 50
VERGGGGPRY CKQESLLLAT GMKNVPEIPK GQGLFGAIAG FIENGWEGLI 100
DGWYGFRHQN AQGEGTAADY KSTQSAIDQI TGKLNRLIEK TNQQFELIDN 150
EFTEVEKQIG NVINWTRDSM TEVWCYNAEL LVAMENQHTI DLADSEMNKL 200
YERVKRQLRE NAEEDGTGCF EIFHKCDDDC MASIRNNTYD HSKYREEAMQ 250
NRIQIDPVKL SSGYKDVILW FSFGASCFIL LAIAMGLVFI CVKNGNMRCT 300
ICI 303
SEQ ID NO: 43:H7-mini5-cluster15+16+17+18
MNTQILVFAL MAIIPTNADK ICLGHHAVSN GTKVNTLTER GVEVVNATET 50
VERGGGGPRY VCQESLLLAT GMKNVPEIPK GQGLFGAIAG FIENGWEGLI 100
DGWYGFRHQN AQGEGTAADY KSTQSAIDQI TGKLNRLIEK TNQQSENTDN 150
ESTENEKQIG NIINWIRDIM TEIWCYNAEL LVAMENQHTI DLADSEMNKL 200
YERVKRQLRE NAEEDGTGCF EIFHKCDDDC MASIRNNTYD HSKYREEAMQ 250
NRIQIDPVKL SSGYKDVILW FSFGASCFIL LAIAMGLVFI CVKNGNMRCT 300
ICI 303
SEQ ID NO: 44: H1-mini2-cluster1+5+6-trim
MKVKLLVLLC TFTATYADTI CIGYHANNST DTVDTVLEKN VTVTHSVNLL 50
ENGGGGKYVC SAKLRMVTGL RNIPSIQSQG LFGAIAGFIE GGWTGMVDGW 100
YGYHHQNEQG SGYAADQKST QNAINGITNK VNSVIEKMNT QSTATGKEGN 150
KSEIEAIEKK IEAIEKKIEI WCYNAELLVL LENERTLDFH DSNVKNLYEK 200
VKSQLKNNAK EIGNGCFEFY HKCNDECMES VKNGTYDYPK YSEESKLNRE 250
KIDGVKLESM GVYQILAIYS TVASSLVLLV SLGAISFWMC SNGSLQCRIC 300
I 301
SEQ ID NO: 45: H1-mini2-cluster1+5+6-GCN4
MKVKLLVLLC TFTATYADTI CIGYHANNST DTVDTVLEKN VTVTHSVNLL 50
ENGGGGKYVC SAKLRMVTGL RNIPSIQSQG LFGAIAGFIE GGWTGMVDGW 100
40 YGYHHQNEQG SGYAADQKST QNAINGITNK VNSVIEKMNT QSTATGKEGN 150
KSERMKQIED KIEEIESKQI WCYNAELLVL LENERTLDFH DSNVKNLYEK 200
VKSQLKNNAK EIGNGCFEFY HKCNDECMES VKNGTYDYPK YSEESKLNRE 250
KIDGVKLESM GVYQILAIYS TVASSLVLLV SLGAISFWMC SNGSLQCRIC 300
I 301
SEQ ID NO: 46: mini2-cluster1+5+6 (A/Brisbane/59/2007)
MKVKLLVLLC TFTATYADTI CIGYHANNST DTVDTVLEKN VTVTHSVNLL 50
ENGGGGKYVC SAKLRMVTGL RNIPSIQSQG LFGAIAGFIE GGWTGMVDGW 100
YGYHHQNEQG SGYAADQKST QNAINGITNK VNSVIEKMNT QSTATGKEGN 150
KSERRMENLN KKVDDGFIDI WCYNAELLVL LENERTLDFH DSNVKNLYEK 200
VKSQLKNNAK EIGNGCFEFY HKCNDECMES VKNGTYDYPK YSEESKLNRE 250
KIDGVKLESM GVYQILAIYS TVASSLVLLV SLGAISFWMC SNGSLQCRIC 300
I 301
SEQ ID NO: 47: mini2-cluster11+5+6 (A/Brisbane/59/2007)
MKVKLLVLLC TFTATYADTI CIGYHANNST DTVDTVLEKN VTVTHSVNLL 50
ENGGGGKYVC SAKLRMVTGL RNIPSIQSQG LFGAIAGFIE GGWTGMVDGW 100
YGYHHQNEQG SGYAADQKST QNAINGITNK VNSVIEKMNT QSTATGKEGN 150
KSERRIENLN KKIDDGFIDI WCYNAELLVL LENERTLDFH DSNVKNLYEK 200
VKSQLKNNAK EIGNGCFEFY HKCNDECMES VKNGTYDYPK YSEESKLNRE 250
KIDGVKLESM GVYQILAIYS TVASSLVLLV SLGAISFWMC SNGSLQCRIC 300
I 301
SEQ ID NO: 48: mini2-cluster1+5 (A/Brisbane/59/2007)
MKVKLLVLLC TFTATYADTI CIGYHANNST DTVDTVLEKN VTVTHSVNLL 50
ENGGGGKYVC SAKLRMVTGL RNIPSIQSQG LFGAIAGFIE GGWTGMVDGW 100
YGYHHQNEQG SGYAADQKST QNAINGITNK VNSVIEKMNT QSTATGKEFN 150
KSERRMENLN KKVDDGFIDI WCYNAELLVL LENERTLDFH DSNVKNLYEK 200
VKSQLKNNAK EIGNGCFEFY HKCNDECMES VKNGTYDYPK YSEESKLNRE 250
KIDGVKLESM GVYQILAIYS TVASSLVLLV SLGAISFWMC SNGSLQCRIC 300
I 301
SEQ ID NO: 49: H1-mini2-cluster1+5+6-trim2
MKVKLLVLLC TFTATYADTI CIGYHANNST DTVDTVLEKN VTVTHSVNLL 50
ENGGGGKYVC SAKLRMVTGL RNIPSIQSQG LFGAIAGFIE GGWTGMVDGW 100
YGYHHQNEQG SGYAADQKST QNAINGITNK VNSVIEKMNT QSTATGKEGN 150
KSERIEAIEK KIEAIEKKII WCYNAELLVL LENERTLDFH DSNVKNLYEK 200
VKSQLKNNAK EIGNGCFEFY HKCNDECMES VKNGTYDYPK YSEESKLNRE 250
KIDGVKLESM GVYQILAIYS TVASSLVLLV SLGAISFWMC SNGSLQCRIC 300
I 301
SEQ ID NO: 50: H1-mini2-cluster1+5+6-trim3
MKVKLLVLLC TFTATYADTI CIGYHANNST DTVDTVLEKN VTVTHSVNLL 50
ENGGGGKYVC SAKLRMVTGL RNIPSIQSQG LFGAIAGFIE GGWTGMVDGW 100
40 YGYHHQNEQG SGYAADQKST QNAINGITNK VNSVIEKMNT QSTATGKEGN 150
KSERRIEAIE KKIEAIEKKI WCYNAELLVL LENERTLDFH DSNVKNLYEK 200
VKSQLKNNAK EIGNGCFEFY HKCNDECMES VKNGTYDYPK YSEESKLNRE 250
KIDGVKLESM GVYQILAIYS TVASSLVLLV SLGAISFWMC SNGSLQCRIC 300
I 301
SEQ ID NO: 51: H1-mini2-cluster1+5+6-GCN4t2
MKVKLLVLLC TFTATYADTI CIGYHANNST DTVDTVLEKN VTVTHSVNLL 50
ENGGGGKYVC SAKLRMVTGL RNIPSIQSQG LFGAIAGFIE GGWTGMVDGW 100
YGYHHQNEQG SGYAADQKST QNAINGITNK VNSVIEKMNT QSTATGKEGN 150
KSERRMKQIE DKIEEIESKI WCYNAELLVL LENERTLDFH DSNVKNLYEK 200
VKSQLKNNAK EIGNGCFEFY HKCNDECMES VKNGTYDYPK YSEESKLNRE 250
KIDGVKLESM GVYQILAIYS TVASSLVLLV SLGAISFWMC SNGSLQCRIC 300
I 301
SEQ ID NO: 52: H1-mini2-cluster1+5+6-GCN4t3
MKVKLLVLLC TFTATYADTI CIGYHANNST DTVDTVLEKN VTVTHSVNLL 50
ENGGGGKYVC SAKLRMVTGL RNIPSIQSQG LFGAIAGFIE GGWTGMVDGW 100
YGYHHQNEQG SGYAADQKST QNAINGITNK VNSVIEKMNT QSTATGKEGN 150
KSRMKQIEDK IEEIESKQKI WCYNAELLVL LENERTLDFH DSNVKNLYEK 200
VKSQLKNNAK EIGNGCFEFY HKCNDECMES VKNGTYDYPK YSEESKLNRE 250
KIDGVKLESM GVYQILAIYS TVASSLVLLV SLGAISFWMC SNGSLQCRIC 300
I 301
SEQ ID NO: 53: H1-mini2-cluster1+5+6-IleTri
MKVKLLVLLC TFTATYADTI CIGYHANNST DTVDTVLEKN VTVTHSVNLL 50
ENGGGGKYVC SAKLRMVTGL RNIPSIQSQG LFGAIAGFIE GGWTGMVDGW 100
YGYHHQNEQG SGYAADQKST QNAINGITNK VNSVIEKMNT QSTATGKEGN 150
KSERRIENIN KKIDDIFIDI WCYNAELLVL LENERTLDFH DSNVKNLYEK 200
VKSQLKNNAK EIGNGCFEFY HKCNDECMES VKNGTYDYPK YSEESKLNRE 250
KIDGVKLESM GVYQILAIYS TVASSLVLLV SLGAISFWMC SNGSLQCRIC 300
I 301
SEQ ID NO: 89: H3 Full length A/Wisconsin/67/2005
MKTIIALSYI LCLVFAQKLP GNDNSTATLC LGHHAVPNGT IVKTITNDQI 50
EVTNATELVQ SSSTGGICDS PHQILDGENC TLIDALLGDP QCDGFQNKKW 100
DLFVERSKAY SNCYPYDVPD YASLRSLVAS SGTLEFNDES FNWTGVTQNG 150
TSSSCKRRSN NSFFSRLNWL THLKFKYPAL NVTMPNNEKF DKLYIWGVHH 200
PVTDNDQIFL YAQASGRITV STKRSQQTVI PNIGSRPRIR NIPSRISIYW 250
TIVKPGDILL INSTGNLIAP RGYFKIRSGK SSIMRSDAPI GKCNSECITP 300
NGSIPNDKPF QNVNRITYGA CPRYVKQNTL KLATGMRNVP EKQTRGIFGA 350
IAGFIENGWE GMVDGWYGFR HQNSEGIGQA ADLKSTQAAI NQINGKLNRL 400
IGKTNEKFHQ IEKEFSEVEG RIQDLEKYVE DTKIDLWSYN AELLVALENQ 450
40 HTIDLTDSEM NKLFERTKKQ LRENAEDMGN GCFKIYHKCD NACIGSIRNG 500
TYDHDVYRDE ALNNRFQIKG VELKSGYKDW ILWISFAISC FLLCVVLLGF 550
IMWACQKGNI RCNICI 566
SEQ ID NO: 90: mini-H3
45 MKTIIALSYI LCLVFAQKLP GNDNSTATLC LGHHAVPNGT IVKTITNDQI 50
EVTNATELVQ SSSTGGICGG GGCNSECITP NGSIPNDKPF QNVNRITYGA 100
CPRYVKQNTL KLATGMRNVP EKQTQGIFGA IAGFIENGWE GMVDGWYGFR 150
HQNSEGIGQA ADLKSTQAAI NQINGKLNRL IGKTNEKFHQ IEKEFSEVEG 200
RIQDLEKYVE DTKIDLWSYN AELLVALENQ HTIDLTDSEM NKLFERTKKQ 250
50 LRENAEDMGN GCFKIYHKCD NACIGSIRNG TYDHDVYRDE ALNNRFQIKG 300
VELKSGYKDW ILWISFAISC FLLCVVLLGF IMWACQKGNI RCNICI 346
SEQ ID NO: 91: mini-H3 cluster1
MKTIIALSYI LCLVFAQKLP GNDNSTATLC LGHHAVPNGT IVKTITNDQI 50
EVTNATELVQ SSSTGGTCGG GGCNSECTTP NGSIPNDKPF QNVNRQTYGA 100
CPRYVKQNTL KLATGMRNVP EKQTQGIFGA IAGFIENGWE GMVDGWYGFR 150
HQNSEGIGQA ADLKSTQAAI NQINGKLNRL IGKTNEKTSQ IEKEFSESEG 200
RIQDLEKYVE DTKIDLWSYN AELLVALENQ HTIDLTDSEM NKLFERTKKQ 250
LRENAEDMGN GCFKIYHKCD NACIGSIRNG TYDHDVYRDE ALNNRFQIKG 300
VELKSGYKDW ILWISFAISC FLLCVVLLGF IMWACQKGNI RCNICI 346
SEQ ID NO: 92: mini-H3 cluster1+2
MKTIIALSYI LCLVFAQKLP GNDNSTATLC LGHHAVPNGT IVKTITNDQI 50
EVTNATELVQ SSSTGGTCGG GGCNSECTTP NGSIPNDKPF QNVNRQTYGC 100
CPRYVKQNTL KLATGMRNVP EKQTQGIFGA IAGFIENGWE GMVDGWYGFR 150
HQNSEGIGQA ADLKSTQAAI NQINGKLNRL IGKTNCKTSQ IEKEFSESEG 200
RIQDLEKYVE DTKIDLWSYN AELLVALENQ HTIDLTDSEM NKLFERTKKQ 250
LRENAEDMGN GCFKIYHKCD NACIGSIRNG TYDHDVYRDE ALNNRFQIKG 300
VELKSGYKDW ILWISFAISC FLLCVVLLGF IMWACQKGNI RCNICI 346
SEQ ID NO: 93: mini-H3 cluster1+3
MKTIIALSYI LCLVFAQKLP GNDNSTATLC LGHHAVPNGT IVKTITNDQI 50
EVTNATELVQ SSSTGGTCGG GGCNSECTTP NGSIPNDKPF QNVNRQTYGA 100
CPRYVCQNTL KLATGMRNVP EKQTQGIFGA IAGFIENGWE GMVDGWYGFR 150
HQNSEGIGQA ADLKSTQAAI NQINGKLNRL IGKTNEKTSQ IEKEFSESEG 200
RIQDLEKYVE DTKIALWCYN AELLVALENQ HTIDLTDSEM NKLFERTKKQ 250
LRENAEDMGN GCFKIYHKCD NACIGSIRNG TYDHDVYRDE ALNNRFQIKG 300
VELKSGYKDW ILWISFAISC FLLCVVLLGF IMWACQKGNI RCNICI 346
SEQ ID NO: 94: mini-H3 cluster1+4
MKTIIALSYI LCLVFAQKLP GNDNSTATLC LGHHAVPNGT IVKTITNDQI 50
EVTNATELVQ SSSTGGTCGG GGCNSECTTP NGSIPNDKPF QNVNRQTYGA 100
CPRYVKQNTL KLATGMRNVP EKQTQGIFGA IAGFIENGWE GMVDGWYGFR 150
HQNSEGIGQA ADLKSTQAAI NQINGKKNRL TGKTNEKTSQ IEKEFSESEG 200
RIQDLEKYVE DTKIDLWSYN AELLVALENQ HTIDLTDSEM NKLFERTKKQ 250
LRENAEDMGN GCFKIYHKCD NACIGSIRNG TYDHDVYRDE ALNNRFQIKG 300
VELKSGYKDW ILWISFAISC FLLCVVLLGF IMWACQKGNI RCNICI 346
SEQ ID NO: 95: mini-H3 cluster1+5 N60A
40 MKTIIALSYI LCLVFAQKLP GNDNSTATLC LGHHAVPNGT IVKTITNDQI 50
EVTNATELVQ SSSTGGTCGG GGCNSECTTP NGSIPNDKPF QNVNRQTYGA 100
CPRYVKQNTL KLATGMRNVP EKQTQGIFGA IAGFIENGWE GMVDGWYGFR 150
HQNSEGIGQA ADLKSTQAAI NQINGKLNRL IGKTAEKTSQ IEKEFSESEG 200
RIQDLEKYVE DTKIDLWSYN AELLVALENQ HTIDLTDSEM NKLFERTKKQ 250
45 LRENAEDMGN GCFKIYHKCD NACIGSIRNG TYDHDVYRDE ALNNRFQIKG 300
VELKSGYKDW ILWISFAISC FLLCVVLLGF IMWACQKGNI RCNICI 346
SEQ ID NO: 96: mini-H3 cluster1+5 N60D
MKTIIALSYI LCLVFAQKLP GNDNSTATLC LGHHAVPNGT IVKTITNDQI 50
50 EVTNATELVQ SSSTGGTCGG GGCNSECTTP NGSIPNDKPF QNVNRQTYGA 100
CPRYVKQNTL KLATGMRNVP EKQTQGIFGA IAGFIENGWE GMVDGWYGFR 150
HQNSEGIGQA ADLKSTQAAI NQINGKLNRL IGKTDEKTSQ IEKEFSESEG 200
RIQDLEKYVE DTKIDLWSYN AELLVALENQ HTIDLTDSEM NKLFERTKKQ 250
LRENAEDMGN GCFKIYHKCD NACIGSIRNG TYDHDVYRDE ALNNRFQIKG 300
VELKSGYKDW ILWISFAISC FLLCVVLLGF IMWACQKGNI RCNICI 346
SEQ ID NO: 97: mini-H3 cluster1+5 N60E
MKTIIALSYI LCLVFAQKLP GNDNSTATLC LGHHAVPNGT IVKTITNDQI 50
EVTNATELVQ SSSTGGTCGG GGCNSECTTP NGSIPNDKPF QNVNRQTYGA 100
CPRYVKQNTL KLATGMRNVP EKQTQGIFGA IAGFIENGWE GMVDGWYGFR 150
HQNSEGIGQA ADLKSTQAAI NQINGKLNRL IGKTEEKTSQ IEKEFSESEG 200
RIQDLEKYVE DTKIDLWSYN AELLVALENQ HTIDLTDSEM NKLFERTKKQ 250
LRENAEDMGN GCFKIYHKCD NACIGSIRNG TYDHDVYRDE ALNNRFQIKG 300
VELKSGYKDW ILWISFAISC FLLCVVLLGF IMWACQKGNI RCNICI 346
SEQ ID NO: 98: mini-H3 cluster1+6
MKTIIALSYI LCLVFAQKLP GNDNSTATLC LGHHAVPNGT IVKTITNDQI 50
EVTNATELVQ SSSTGGTCGG GGCNSECTTP NGSIPNDKPF QNVNRQTYGA 100
CPRYVKQNTL KLATGMRNVP EKQTQGIFGA IAGFIENGWE GMVDGWYGFR 150
HQNSEGIGQA ADLKSTQAAI NQINGKLNRL IGKTNEKTSQ IEKECSESEG 200
RICDLEKYVE DTKIDLWSYN AELLVALENQ HTIDLTDSEM NKLFERTKKQ 250
LRENAEDMGN GCFKIYHKCD NACIGSIRNG TYDHDVYRDE ALNNRFQIKG 300
VELKSGYKDW ILWISFAISC FLLCVVLLGF IMWACQKGNI RCNICI 346
SEQ ID NO: 99: mini-H3 cluster1+7
MKTIIALSYI LCLVFAQKLP GNDNSTATLC LGHHAVPNGT IVKTITNDQI 50
EVTNATELVQ SSSTGGTCGG GGCNSECTTP NGSIPNDKPF QNVNRQTYGA 100
CPRYVKQNTL KLATGMRNVP EKQTQGIFGA IAGFIENGWE GMVDGWYGFR 150
HQNSEGIGQA ADLKSTQAAI NQINGKLNRL IGKTNEKTSQ IEKEFSESEG 200
RIQDLEKYVE DTKIDLWSYN AELLVALENQ HTIDLTDSEM NKLFERTKKQ 250
LRENAEDMGN GCFKIYHKCD NACIESIRNG TYDHDVYRDE ALNNRFQIKG 300
VELKSGYKDW ILWISFAISC FLLCVVLLGF IMWACQKGNI RCNICI 346
SEQ ID NO: 100: mini-H3 cluster1+2+3+4+5+6+7-N405E
MKTIIALSYI LCLVFAQKLP GNDNSTATLC LGHHAVPNGT IVKTITNDQI 50
EVTNATELVQ SSSTGGTCGG GGCNSECTTP NGSIPNDKPF QNVNRQTYGC 100
CPRYVCQNTL KLATGMRNVP EKQTQGIFGA IAGFIENGWE GMVDGWYGFR 150
HQNSEGIGQA ADLKSTQAAI NQINGKKNRL TGKTECKTSQ IEKECSESEG 200
RICDLEKYVE DTKIALWCYN AELLVALENQ HTIDLTDSEM NKLFERTKKQ 250
LRENAEDMGN GCFKIYHKCD NACIESIRNG TYDHDVYRDE ALNNRFQIKG 300
40 VELKSGYKDW ILWISFAISC FLLCVVLLGF IMWACQKGNI RCNICI 346
SEQ ID NO: 101: mini-H3 cluster1+2+3+4+5+6+7-N405A
MKTIIALSYI LCLVFAQKLP GNDNSTATLC LGHHAVPNGT IVKTITNDQI 50
EVTNATELVQ SSSTGGTCGG GGCNSECTTP NGSIPNDKPF QNVNRQTYGC 100
45 CPRYVCQNTL KLATGMRNVP EKQTQGIFGA IAGFIENGWE GMVDGWYGFR 150
HQNSEGIGQA ADLKSTQAAI NQINGKKNRL TGKTACKTSQ IEKECSESEG 200
RICDLEKYVE DTKIALWCYN AELLVALENQ HTIDLTDSEM NKLFERTKKQ 250
LRENAEDMGN GCFKIYHKCD NACIESIRNG TYDHDVYRDE ALNNRFQIKG 300
VELKSGYKDW ILWISFAISC FLLCVVLLGF IMWACQKGNI RCNICI 346
SEQ ID NO: 102: mini-H3 cluster1+2+3+4+5+6+7-N405D
MKTIIALSYI LCLVFAQKLP GNDNSTATLC LGHHAVPNGT IVKTITNDQI 50
EVTNATELVQ SSSTGGTCGG GGCNSECTTP NGSIPNDKPF QNVNRQTYGC 100
CPRYVCQNTL KLATGMRNVP EKQTQGIFGA IAGFIENGWE GMVDGWYGFR 150
HQNSEGIGQA ADLKSTQAAI NQINGKKNRL TGKTDCKTSQ IEKECSESEG 200
RICDLEKYVE DTKIALWCYN AELLVALENQ HTIDLTDSEM NKLFERTKKQ 250
LRENAEDMGN GCFKIYHKCD NACIESIRNG TYDHDVYRDE ALNNRFQIKG 300
VELKSGYKDW ILWISFAISC FLLCVVLLGF IMWACQKGNI RCNICI 346
SEQ ID NO: 103: mini-H3 cluster1+8
MKTIIALSYI LCLVFAQKLP GNDNSTATLC LGHHAVPNGT IVKTITNDQI 50
EVTNATELVQ SSSTGGTCGG GGCNSECTTP NGSIPNDKPF QNVNRQTYGA 100
CPRYVKQNTL KLATGMRNVP EKQTQGICGA IAGFIENGWE GMVDGWYGFR 150
HQNSEGIGQA ADLKCTQAAI NQINGKLNRL IGKTNEKTSQ IEKEFSESEG 200
RIQDLEKYVE DTKIDLWSYN AELLVALENQ HTIDLTDSEM CKCFERTKKQ 250
LRENAEDMGN GCFKIYHKCD NACIGSIRNG TYDHDVYRDE ALNNRFQIKG 300
VELKSGYKDW ILWISFAISC FLLCVVLLGF IMWACQKGNI RCNICI 346
SEQ ID NO: 104: H3 consensus sequence residue 401-421 (numbering
according to SEQ ID No: 1)
401 I(E/G)KTNEKFHQIEKEFSEVEGR 421
SEQ ID NO: 105: H3-mini2
MKTIIALSYI LCLVFAQKLP GNDNSTATLC LGHHAVPNGT IVKTITNDQI 50
EVTNATELVQ SGGGGRYVKQ NTLKLATGMR NVPEKQTQGI FGAIAGFIEN 100
GWEGMVDGWY GFRHQNSEGI GQAADLKSTQ AAINQINGKL NRLIGKTNEK 150
FHQIEKEFSE VEGRIQDLEK YVEDTKIDLW SYNAELLVAL ENQHTIDLTD 200
SEMNKLFERT KKQLRENAED MGNGCFKIYH KCDNACIGSI RNGTYDHDVY 250
RDEALNNRFQ IKGVELKSGY KDWILWISFA ISCFLLCVVL LGFIMWACQK 300
GNIRCNICI 309
SEQ ID NO: 106: H3-mini2-cl9+10
MKTIIALSYI LCLVFAQKLP GNDNSTATLC LGHHAVPNGT IVKTITNDQI 50
EVTNATELVQ SGGGGRYVKQ NTLKLATGMR NVPEKQTQGI FGAIAGFIEN 100
GWEGMVDGWY GFRHQNSEGI GQAADLKSTQ AAINQINGKL NRLIGKTNEK 150
SHQTEKESSE GEGRIQDLEK YVEDTKIDLW SYNAELLVAL ENQHTIDLTD 200
SEMNKLFERT KKQLRENAED MGNGCFKIYH KCDNACIGSI RNGTYDHDVY 250
RDEALNNRFQ IKGVELKSGY KDWILWISFA ISCFLLCVVL LGFIMWACQK 300
GNIRCNICI 309
SEQ ID NO: 107: H3-mini2-cl9+11
40 MKTIIALSYI LCLVFAQKLP GNDNSTATLC LGHHAVPNGT IVKTITNDQI 50
EVTNATELVQ SGGGGRYVKQ NTLKLATGMR NVPEKQTQGI FGAIAGFIEN 100
GWEGMVDGWY GFRHQNSEGI GQAADLKSTQ AAINQINGKL NRLRGKTNEK 150
SHQTEKESSE VEGRIQDLEK YVEDTKIDLW SYNAELLVAL ENQHTIDLTD 200
SEMNKLFERT KKQLRENAED MGNGCFKIYH KCDNACIGSI RNGTYDHDVY 250
45 RDEALNNRFQ IKGVELKSGY KDWILWISFA ISCFLLCVVL LGFIMWACQK 300
GNIRCNICI 309
SEQ ID NO: 108: H3-mini2-cl9+10+11
MKTIIALSYI LCLVFAQKLP GNDNSTATLC LGHHAVPNGT IVKTITNDQI 50
50 EVTNATELVQ SGGGGRYVKQ NTLKLATGMR NVPEKQTQGI FGAIAGFIEN 100
GWEGMVDGWY GFRHQNSEGI GQAADLKSTQ AAINQINGKL NRLRGKTNEK 150
SHQTEKESSE GEGRIQDLEK YVEDTKIDLW SYNAELLVAL ENQHTIDLTD 200
SEMNKLFERT KKQLRENAED MGNGCFKIYH KCDNACIGSI RNGTYDHDVY 250
RDEALNNRFQ IKGVELKSGY KDWILWISFA ISCFLLCVVL LGFIMWACQK 300
GNIRCNICI 309
SEQ ID NO: 109: H3-mini2-cl9+10+11-tri
MKTIIALSYI LCLVFAQKLP GNDNSTATLC LGHHAVPNGT IVKTITNDQI 50
EVTNATELVQ SGGGGRYVKQ NTLKLATGMR NVPEKQTQGI FGAIAGFIEN 100
GWEGMVDGWY GFRHQNSEGI GQAADLKSTQ AAINQINGKL NRLRGKTNEK 150
SHQTEKESSE GEGIEAIEKK IEAIEKKIEA IEKKELLVAL ENQHTIDLTD 200
SEMNKLFERT KKQLRENAED MGNGCFKIYH KCDNACIGSI RNGTYDHDVY 250
RDEALNNRFQ IKGVELKSGY KDWILWISFA ISCFLLCVVL LGFIMWACQK 300
GNIRCNICI 309
SEQ ID NO: 110: H3-mini2-cl9+10+11-GCN4
MKTIIALSYI LCLVFAQKLP GNDNSTATLC LGHHAVPNGT IVKTITNDQI 50
EVTNATELVQ SGGGGRYVKQ NTLKLATGMR NVPEKQTQGI FGAIAGFIEN 100
GWEGMVDGWY GFRHQNSEGI GQAADLKSTQ AAINQINGKL NRLRGKTNEK 150
SHQTEKESSE GEGRMKQIED KIEEIESKQK KIENELLVAL ENQHTIDLTD 200
SEMNKLFERT KKQLRENAED MGNGCFKIYH KCDNACIGSI RNGTYDHDVY 250
RDEALNNRFQ IKGVELKSGY KDWILWISFA ISCFLLCVVL LGFIMWACQK 300
GNIRCNICI 309
SEQ ID NO: 111: H3-mini2-cl9+10+11+12
MKTIIALSYI LCLVFAQKLP GNDNSTATLC LGHHAVPNGT IVKTITNDQI 50
EVTNATELVQ SGGGGRYVCQ NTLKLATGMR NVPEKQTQGI FGAIAGFIEN 100
GWEGMVDGWY GFRHQNSEGI GQAADLKSTQ AAINQINGKL NRLRGKTNEK 150
SHQTEKESSE GEGRIQDLEK YVEDTKIDLW CYNAELLVAL ENQHTIDLTD 200
SEMNKLFERT KKQLRENAED MGNGCFKIYH KCDNACIGSI RNGTYDHDVY 250
RDEALNNRFQ IKGVELKSGY KDWILWISFA ISCFLLCVVL LGFIMWACQK 300
GNIRCNICI 309
SEQ ID NO: 112: H3-mini2-cl9+10+12
MKTIIALSYI LCLVFAQKLP GNDNSTATLC LGHHAVPNGT IVKTITNDQI 50
EVTNATELVQ SGGGGRYVCQ NTLKLATGMR NVPEKQTQGI FGAIAGFIEN 100
GWEGMVDGWY GFRHQNSEGI GQAADLKSTQ AAINQINGKL NRLIGKTNEK 150
SHQTEKESSE GEGRIQDLEK YVEDTKIDLW CYNAELLVAL ENQHTIDLTD 200
SEMNKLFERT KKQLRENAED MGNGCFKIYH KCDNACIGSI RNGTYDHDVY 250
RDEALNNRFQ IKGVELKSGY KDWILWISFA ISCFLLCVVL LGFIMWACQK 300
GNIRCNICI 309
SEQ ID NO: 113: H3-mini2-cl9+10+11+12-GCN4
MKTIIALSYI LCLVFAQKLP GNDNSTATLC LGHHAVPNGT IVKTITNDQI 50
EVTNATELVQ SGGGGRYVCQ NTLKLATGMR NVPEKQTQGI FGAIAGFIEN 100
GWEGMVDGWY GFRHQNSEGI GQAADLKSTQ AAINQINGKL NRLRGKTNEK 150
45 SHQTEKESSE GEGRMKQIED KIEEIESKLW CYNAELLVAL ENQHTIDLTD 200
SEMNKLFERT KKQLRENAED MGNGCFKIYH KCDNACIGSI RNGTYDHDVY 250
RDEALNNRFQ IKGVELKSGY KDWILWISFA ISCFLLCVVL LGFIMWACQK 300
GNIRCNICI 309
50 SEQ ID NO: 114: H3-mini2-cl9+10+11+12-tri
MKTIIALSYI LCLVFAQKLP GNDNSTATLC LGHHAVPNGT IVKTITNDQI 50
EVTNATELVQ SGGGGRYVCQ NTLKLATGMR NVPEKQTQGI FGAIAGFIEN 100
GWEGMVDGWY GFRHQNSEGI GQAADLKSTQ AAINQINGKL NRLRGKTNEK 150
SHQTEKESSE GEGIEAIEKK IEAIEKKILW CYNAELLVAL ENQHTIDLTD 200
SEMNKLFERT KKQLRENAED MGNGCFKIYH KCDNACIGSI RNGTYDHDVY 250
RDEALNNRFQ IKGVELKSGY KDWILWISFA ISCFLLCVVL LGFIMWACQK 300
GNIRCNICI 309
SEQ ID NO: 115: H3-mini2-cl9+13
MKTIIALSYI LCLVFAQKLP GNDNSTATLC LGHHAVPNGT IVKTITNDQI 50
EVTNATELVQ SGGGGRYVKQ NTLKLACGMR NVPEKQTQGI FGAIAGFIEN 100
GWEGMVDGWY GFRHQNSEGI GQAADLKSTQ AAINQCNGKL NRLIGKTNEK 150
SHQTEKESSE VEGRIQDLEK YVEDTKIDLW SYNAELLVAL ENQHTIDLTD 200
SEMNKLFERT KKQLRENAED MGNGCFKIYH KCDNACIGSI RNGTYDHDVY 250
RDEALNNRFQ IKGVELKSGY KDWILWISFA ISCFLLCVVL LGFIMWACQK 300
GNIRCNICI 309
SEQ ID NO: 116: H3-mini2-cl9+10+11+13
MKTIIALSYI LCLVFAQKLP GNDNSTATLC LGHHAVPNGT IVKTITNDQI 50
EVTNATELVQ SGGGGRYVKQ NTLKLACGMR NVPEKQTQGI FGAIAGFIEN 100
GWEGMVDGWY GFRHQNSEGI GQAADLKSTQ AAINQCNGKL NRLRGKTNEK 150
SHQTEKESSE GEGRIQDLEK YVEDTKIDLW SYNAELLVAL ENQHTIDLTD 200
SEMNKLFERT KKQLRENAED MGNGCFKIYH KCDNACIGSI RNGTYDHDVY 250
RDEALNNRFQ IKGVELKSGY KDWILWISFA ISCFLLCVVL LGFIMWACQK 300
GNIRCNICI 309
SEQ ID NO: 117: H3-mini2-cl9+10+11+13-GCN4
MKTIIALSYI LCLVFAQKLP GNDNSTATLC LGHHAVPNGT IVKTITNDQI 50
EVTNATELVQ SGGGGRYVKQ NTLKLACGMR NVPEKQTQGI FGAIAGFIEN 100
GWEGMVDGWY GFRHQNSEGI GQAADLKSTQ AAINQCNGKL NRLRGKTNEK 150
SHQTEKESSE GEGRMKQIED KIEEIESKQK KIENELLVAL ENQHTIDLTD 200
SEMNKLFERT KKQLRENAED MGNGCFKIYH KCDNACIGSI RNGTYDHDVY 250
RDEALNNRFQ IKGVELKSGY KDWILWISFA ISCFLLCVVL LGFIMWACQK 300
GNIRCNICI 309
SEQ ID NO: 118: H3-mini2-cl9+10+11+13-tri
MKTIIALSYI LCLVFAQKLP GNDNSTATLC LGHHAVPNGT IVKTITNDQI 50
EVTNATELVQ SGGGGRYVKQ NTLKLACGMR NVPEKQTQGI FGAIAGFIEN 100
GWEGMVDGWY GFRHQNSEGI GQAADLKSTQ AAINQCNGKL NRLRGKTNEK 150
SHQTEKESSE GEGIEAIEKK IEAIEKKIEA IEKKELLVAL ENQHTIDLTD 200
SEMNKLFERT KKQLRENAED MGNGCFKIYH KCDNACIGSI RNGTYDHDVY 250
40 RDEALNNRFQ IKGVELKSGY KDWILWISFA ISCFLLCVVL LGFIMWACQK 300
GNIRCNICI 309
SEQ ID NO: 119: H3-mini3-cl9+10+11+12+14
MKTIIALSYI LCLVFAQKLP GNDNSTATLC LGHHAVPNGT IVKTITNDQI 50
45 EVTNATELVQ SSGGGGNDKP FQNVNRITYG AGPRYVCQNT LKLATGMRNV 100
PEKQTQGIFG AIAGFIENGW EGMVDGWYGF RHQNSEGIGQ AADLKSTQAA 150
INQINGKLNR LRGKTNEKSH QTEKESSEGE GRIQDLEKYV EDTKIDLWCY 200
NAELLVALEN QHTIDLTDSE MNKLFERTKK QLRENAEDMG NGCFKIYHKC 250
DNACIGSIRN GTYDHDVYRD EALNNRFQIK GVELKSGYKD WILWISFAIS 300
50 CFLLCVVLLG FIMWACQKGN IRCNICI 327
SEQ ID NO: 120: H3-mini4-cl9+10+11+12+14
MKTIIALSYI LCLVFAQKLP GNDNSTATLC LGHHAVPNGT IVKTITNDQI 50
EVTNATELVQ SSSTGGGGYG AGPRYVCQNT LKLATGMRNV PEKQTQGIFG 100
AIAGFIENGW EGMVDGWYGF RHQNSEGIGQ AADLKSTQAA INQINGKLNR 150
LRGKTNEKSH QTEKESSEGE GRIQDLEKYV EDTKIDLWCY NAELLVALEN 200
QHTIDLTDSE MNKLFERTKK QLRENAEDMG NGCFKIYHKC DNACIGSIRN 250
GTYDHDVYRD EALNNRFQIK GVELKSGYKD WILWISFAIS CFLLCVVLLG 300
FIMWACQKGN IRCNICI 317
SEQ ID NO: 121: H3 Full length A/Hong Kong/1/1968
MKTIIALSYI FCLALGQDLP GNDNSTATLC LGHHAVPNGT LVKTITDDQI 50
EVTNATELVQ SSSTGKICNN PHRILDGIDC TLIDALLGDP HCDVFQNETW 100
DLFVERSKAF SNCYPYDVPD YASLRSLVAS SGTLEFITEG FTWTGVTQNG 150
GSNACKRGPG SGFFSRLNWL TKSGSTYPVL NVTMPNNDNF DKLYIWGVHH 200
PSTNQEQTSL YVQASGRVTV STRRSQQTII PNIGSRPWVR GLSSRISIYW 250
TIVKPGDVLV INSNGNLIAP RGYFKMRTGK SSIMRSDAPI DTCISECITP 300
NGSIPNDKPF QNVNKITYGA CPKYVKQNTL KLATGMRNVP EKQTRGLFGA 350
IAGFIENGWE GMIDGWYGFR HQNSEGTGQA ADLKSTQAAI DQINGKLNRV 400
IEKTNEKFHQ IEKEFSEVEG RIQDLEKYVE DTKIDLWSYN AELLVALENQ 450
HTIDLTDSEM NKLFEKTRRQ LRENAEDMGN GCFKIYHKCD NACIESIRNG 500
TYDHDVYRDE ALNNRFQIKG VELKSGYKDW ILWISFAISC FLLCVVLLGF 550
IMWACQRGNI RCNICI 566
SEQ ID NO: 122: HK68 H3m2-cl9
MKTIIALSYI FCLALGQDLP GNDNSTATLC LGHHAVPNGT LVKTITDDQI 50
EVTNATELVQ SGGGGKYVKQ NTLKLATGMR NVPEKQTQGL FGAIAGFIEN 100
GWEGMIDGWY GFRHQNSEGT GQAADLKSTQ AAIDQINGKL NRVIEKTNEK 150
SHQTEKESSE VEGRIQDLEK YVEDTKIDLW SYNAELLVAL ENQHTIDLTD 200
SEMNKLFEKT RRQLRENAED MGNGCFKIYH KCDNACIESI RNGTYDHDVY 250
RDEALNNRFQ IKGVELKSGY KDWILWISFA ISCFLLCVVL LGFIMWACQR 300
GNIRCNICI 309
SEQ ID NO: 123: HK68 H3m2-cl9+10
MKTIIALSYI FCLALGQDLP GNDNSTATLC LGHHAVPNGT LVKTITDDQI 50
EVTNATELVQ SGGGGKYVKQ NTLKLATGMR NVPEKQTQGL FGAIAGFIEN 100
GWEGMIDGWY GFRHQNSEGT GQAADLKSTQ AAIDQINGKL NRVIEKTNEK 150
SHQTEKESSE GEGRIQDLEK YVEDTKIDLW SYNAELLVAL ENQHTIDLTD 200
SEMNKLFEKT RRQLRENAED MGNGCFKIYH KCDNACIESI RNGTYDHDVY 250
RDEALNNRFQ IKGVELKSGY KDWILWISFA ISCFLLCVVL LGFIMWACQR 300
40 GNIRCNICI 309
SEQ ID NO: 124: HK68 H3m2-cl9+10+11
MKTIIALSYI FCLALGQDLP GNDNSTATLC LGHHAVPNGT LVKTITDDQI 50
EVTNATELVQ SGGGGKYVKQ NTLKLATGMR NVPEKQTQGL FGAIAGFIEN 100
45 GWEGMIDGWY GFRHQNSEGT GQAADLKSTQ AAIDQINGKL NRVREKTNEK 150
SHQTEKESSE GEGRIQDLEK YVEDTKIDLW SYNAELLVAL ENQHTIDLTD 200
SEMNKLFEKT RRQLRENAED MGNGCFKIYH KCDNACIESI RNGTYDHDVY 250
RDEALNNRFQ IKGVELKSGY KDWILWISFA ISCFLLCVVL LGFIMWACQR 300
GNIRCNICI 309
SEQ ID NO: 125: HK68 H3m2-cl9+10+12
MKTIIALSYI FCLALGQDLP GNDNSTATLC LGHHAVPNGT LVKTITDDQI 50
EVTNATELVQ SGGGGKYVCQ NTLKLATGMR NVPEKQTQGL FGAIAGFIEN 100
GWEGMIDGWY GFRHQNSEGT GQAADLKSTQ AAIDQINGKL NRVIEKTNEK 150
SHQTEKESSE GEGRIQDLEK YVEDTKIDLW CYNAELLVAL ENQHTIDLTD 200
SEMNKLFEKT RRQLRENAED MGNGCFKIYH KCDNACIESI RNGTYDHDVY 250
RDEALNNRFQ IKGVELKSGY KDWILWISFA ISCFLLCVVL LGFIMWACQR 300
GNIRCNICI 309
SEQ ID NO: 126: HK68 H3m2-cl9+10+11+12
MKTIIALSYI FCLALGQDLP GNDNSTATLC LGHHAVPNGT LVKTITDDQI 50
EVTNATELVQ SGGGGKYVCQ NTLKLATGMR NVPEKQTQGL FGAIAGFIEN 100
GWEGMIDGWY GFRHQNSEGT GQAADLKSTQ AAIDQINGKL NRVREKTNEK 150
SHQTEKESSE GEGRIQDLEK YVEDTKIDLW CYNAELLVAL ENQHTIDLTD 200
SEMNKLFEKT RRQLRENAED MGNGCFKIYH KCDNACIESI RNGTYDHDVY 250
RDEALNNRFQ IKGVELKSGY KDWILWISFA ISCFLLCVVL LGFIMWACQR 300
GNIRCNICI 309
SEQ ID NO: 127: HK68 H3m2-cl9+10+11+13
MKTIIALSYI FCLALGQDLP GNDNSTATLC LGHHAVPNGT LVKTITDDQI 50
EVTNATELVQ SGGGGKYVKQ NTLKLACGMR NVPEKQTQGL FGAIAGFIEN 100
GWEGMIDGWY GFRHQNSEGT GQAADLKSTQ AAIDQCNGKL NRVREKTNEK 150
SHQTEKESSE GEGRIQDLEK YVEDTKIDLW SYNAELLVAL ENQHTIDLTD 200
SEMNKLFEKT RRQLRENAED MGNGCFKIYH KCDNACIESI RNGTYDHDVY 250
RDEALNNRFQ IKGVELKSGY KDWILWISFA ISCFLLCVVL LGFIMWACQR 300
GNIRCNICI 309
SEQ ID NO: 128: HK68 H3m2-cl9+10+11+12-tri
MKTIIALSYI FCLALGQDLP GNDNSTATLC LGHHAVPNGT LVKTITDDQI 50
EVTNATELVQ SGGGGKYVCQ NTLKLATGMR NVPEKQTQGL FGAIAGFIEN 100
GWEGMIDGWY GFRHQNSEGT GQAADLKSTQ AAIDQINGKL NRVREKTNEK 150
SHQTEKESSE GEGIEAIEKK IEAIEKKILW CYNAELLVAL ENQHTIDLTD 200
SEMNKLFEKT RRQLRENAED MGNGCFKIYH KCDNACIESI RNGTYDHDVY 250
RDEALNNRFQ IKGVELKSGY KDWILWISFA ISCFLLCVVL LGFIMWACQR 300
GNIRCNICI 309
SEQ ID NO: 129: HK68 H3m2-cl9+10+11+13-tri
MKTIIALSYI FCLALGQDLP GNDNSTATLC LGHHAVPNGT LVKTITDDQI 50
EVTNATELVQ SGGGGKYVKQ NTLKLACGMR NVPEKQTQGL FGAIAGFIEN 100
40 GWEGMIDGWY GFRHQNSEGT GQAADLKSTQ AAIDQCNGKL NRVREKTNEK 150
SHQTEKESSE GEGIEAIEKK IEAIEKKILW SYNAELLVAL ENQHTIDLTD 200
SEMNKLFEKT RRQLRENAED MGNGCFKIYH KCDNACIESI RNGTYDHDVY 250
RDEALNNRFQ IKGVELKSGY KDWILWISFA ISCFLLCVVL LGFIMWACQR 300
GNIRCNICI 309
SEQ ID NO: 130: HK68 H3m2-cl9+10+11+12-GCN4
MKTIIALSYI FCLALGQDLP GNDNSTATLC LGHHAVPNGT LVKTITDDQI 50
EVTNATELVQ SGGGGKYVCQ NTLKLATGMR NVPEKQTQGL FGAIAGFIEN 100
GWEGMIDGWY GFRHQNSEGT GQAADLKSTQ AAIDQINGKL NRVREKTNEK 150
SHQTEKESSE GEGRMKQIED KIEEIESKLW CYNAELLVAL ENQHTIDLTD 200
SEMNKLFEKT RRQLRENAED MGNGCFKIYH KCDNACIESI RNGTYDHDVY 250
RDEALNNRFQ IKGVELKSGY KDWILWISFA ISCFLLCVVL LGFIMWACQR 300
GNIRCNICI 309
SEQ ID NO: 131: HK68 H3m2-cl9+10+11+13-GCN4
MKTIIALSYI FCLALGQDLP GNDNSTATLC LGHHAVPNGT LVKTITDDQI 50
EVTNATELVQ SGGGGKYVKQ NTLKLACGMR NVPEKQTQGL FGAIAGFIEN 100
GWEGMIDGWY GFRHQNSEGT GQAADLKSTQ AAIDQCNGKL NRVREKTNEK 150
SHQTEKESSE GEGRMKQIED KIEEIESKLW SYNAELLVAL ENQHTIDLTD 200
SEMNKLFEKT RRQLRENAED MGNGCFKIYH KCDNACIESI RNGTYDHDVY 250
RDEALNNRFQ IKGVELKSGY KDWILWISFA ISCFLLCVVL LGFIMWACQR 300
GNIRCNICI 309
SEQ ID NO: 132: B/Florida/4/2006 Full length HA
MKAIIVLLMV VTSNADRICT GITSSNSPHV VKTATQGEVN VTGVIPLTTT 50
PTKSYFANLK GTRTRGKLCP DCLNCTDLDV ALGRPMCVGT TPSAKASILH 100
EVKPVTSGCF PIMHDRTKIR QLPNLLRGYE NIRLSTQNVI DAEKAPGGPY 150
RLGTSGSCPN ATSKSGFFAT MAWAVPKDNN KNATNPLTVE VPYICTEGED 200
QITVWGFHSD DKTQMKNLYG DSNPQKFTSS ANGVTTHYVS QIGSFPDQTE 250
DGGLPQSGRI VVDYMMQKPG KTGTIVYQRG VLLPQKVWCA SGRSKVIKGS 300
LPLIGEADCL HEKYGGLNKS KPYYTGEHAK AIGNCPIWVK TPLKLANGTK 350
YRPPAKLLKE RGFFGAIAGF LEGGWEGMIA GWHGYTSHGA HGVAVAADLK 400
STQEAINKIT KNLNSLSELE VKNLQRLSGA MDELHNEILE LDEKVDDLRA 450
DTISSQIELA VLLSNEGIIN SEDEHLLALE RKLKKMLGPS AVEIGNGCFE 500
TKHKCNQTCL DRIAAGTFNA GEFSLPTFDS LNITAASLND DGLDNHTILL 550
YYSTAASSLA VTLMLAIFIV YMVSRDNVSC SICL 584
SEQ ID NO: 133: FL4-06 B-m2
MKAIIVLLMV VTSNADRICT GITSSNSPHV VKTATQGEVN VTGVIPLTTT 50
GGGGIWVKTP LKLANGTKYR PPAKLLKEQG FFGAIAGFLE GGWEGMIAGW 100
HGYTSHGAHG VAVAADLKST QEAINKITKN LNSLSELEVK NLQRLSGAMD 150
ELHNEILELD EKVDDLRADT ISSQIELAVL LSNEGIINSE DEHLLALERK 200
LKKMLGPSAV EIGNGCFETK HKCNQTCLDR IAAGTFNAGE FSLPTFDSLN 250
ITAASLNDDG LDNHTILLYY STAASSLAVT LMLAIFIVYM VSRDNVSCSI 300
40 CL 302
SEQ ID NO: 134: FL4-06 B-m2-CL1+5
MKAIIVLLMV VTSNADRICT GITSSNSPHV VKTATQGEVN VTGVIPLTTT 50
GGGGIWVCTP LKLANGTKYR PPAKLLKEQG FFGAIAGFLE GGWEGMIAGW 100
45 HGYTSHGAHG VAVAADLKST QEAINKITKN LNSLSELETK NSQRTSGAMD 150
EGHNEILELD EKVDDLRADT ICSQIELAVL LSNEGIINSE DEHLLALERK 200
LKKMLGPSAV EIGNGCFETK HKCNQTCLDR IAAGTFNAGE FSLPTFDSLN 250
ITAASLNDDG LDNHTILLYY STAASSLAVT LMLAIFIVYM VSRDNVSCSI 300
CL 302
SEQ ID NO: 135: FL4-06 B-m2-CL1+5-GCN4a
MKAIIVLLMV VTSNADRICT GITSSNSPHV VKTATQGEVN VTGVIPLTTT 50
GGGGIWVCTP LKLANGTKYR PPAKLLKEQG FFGAIAGFLE GGWEGMIAGW 100
HGYTSHGAHG VAVAADLKST QEAINKITKN LNSLSELETK NSQRTSGAMD 150
EGHRRMKQIE DKIEEILSKI ICSQIELAVL LSNEGIINSE DEHLLALERK 200
LKKMLGPSAV EIGNGCFETK HKCNQTCLDR IAAGTFNAGE FSLPTFDSLN 250
ITAASLNDDG LDNHTILLYY STAASSLAVT LMLAIFIVYM VSRDNVSCSI 300
CL 302
SEQ ID NO: 136: FL4-06 B-m2-CL1+5-GCN4b
MKAIIVLLMV VTSNADRICT GITSSNSPHV VKTATQGEVN VTGVIPLTTT 50
GGGGIWVCTP LKLANGTKYR PPAKLLKEQG FFGAIAGFLE GGWEGMIAGW 100
HGYTSHGAHG VAVAADLKST QEAINKITKN LNSLSELETK NSQRTSGAMD 150
EGHRMKQIED KIEEILSKIT ICSQIELAVL LSNEGIINSE DEHLLALERK 200
LKKMLGPSAV EIGNGCFETK HKCNQTCLDR IAAGTFNAGE FSLPTFDSLN 250
ITAASLNDDG LDNHTILLYY STAASSLAVT LMLAIFIVYM VSRDNVSCSI 300
CL 302
SEQ ID NO: 137: B/Malaysia/2506/2004 Full length HA
MKAIIVLLMV VTSNADRICT GITSSNSPHV VKTATQGEVN VTGVIPLTTT 50
PTKSHFANLK GTETRGKLCP KCLNCTDLDV ALGRPKCTGN IPSARVSILH 100
EVRPVTSGCF PIMHDRTKIR QLPNLLRGYE HIRLSTHNVI NAENAPGGPY 150
KIGTSGSCPN VTNGNGFFAT MAWAVPKNDN NKTATNSLTI EVPYICTEGE 200
DQITVWGFHS DNEAQMAKLY GDSKPQKFTS SANGVTTHYV SQIGGFPNQT 250
EDGGLPQSGR IVVDYMVQKS GKTGTITYQR GILLPQKVWC ASGRSKVIKG 300
SLPLIGEADC LHEKYGGLNK SKPYYTGEHA KAIGNCPIWV KTPLKLANGT 350
KYRPPAKLLK ERGFFGAIAG FLEGGWEGMI AGWHGYTSHG AHGVAVAADL 400
KSTQEAINKI TKNLNSLSEL EVKNLQRLSG AMDELHNEIL ELDEKVDDLR 450
ADTISSQIEL AVLLSNEGII NSEDEHLLAL ERKLKKMLGP SAVEIGNGCF 500
ETKHKCNQTC LDRIAAGTFD AGEFSLPTFD SLNITAASLN DDGLDNHTIL 550
LYYSTAASSL AVTLMIAIFV VYMVSRDNVS CSICL 585
SEQ ID NO: 138: Mal2506-04 B-m2
MKAIIVLLMV VTSNADRICT GITSSNSPHV VKTATQGEVN VTGVIPLTTT 50
GGGGIWVKTP LKLANGTKYR PPAKLLKEQG FFGAIAGFLE GGWEGMIAGW 100
HGYTSHGAHG VAVAADLKST QEAINKITKN LNSLSELEVK NLQRLSGAMD 150
ELHNEILELD EKVDDLRADT ISSQIELAVL LSNEGIINSE DEHLLALERK 200
LKKMLGPSAV EIGNGCFETK HKCNQTCLDR IAAGTFDAGE FSLPTFDSLN 250
ITAASLNDDG LDNHTILLYY STAASSLAVT LMIAIFVVYM VSRDNVSCSI 300
CL 302
40 SEQ ID NO: 139: Mal2506-04 B-m2-CL1+5
MKAIIVLLMV VTSNADRICT GITSSNSPHV VKTATQGEVN VTGVIPLTTT 50
GGGGIWVCTP LKLANGTKYR PPAKLLKEQG FFGAIAGFLE GGWEGMIAGW 100
HGYTSHGAHG VAVAADLKST QEAINKITKN LNSLSELETK NSQRTSGAMD 150
EGHNEILELD EKVDDLRADT ICSQIELAVL LSNEGIINSE DEHLLALERK 200
45 LKKMLGPSAV EIGNGCFETK HKCNQTCLDR IAAGTFDAGE FSLPTFDSLN 250
ITAASLNDDG LDNHTILLYY STAASSLAVT LMIAIFVVYM VSRDNVSCSI 300
CL 302
SEQ ID NO: 140: Mal2506-04 B-m2-CL1+5-GCN4a
50 MKAIIVLLMV VTSNADRICT GITSSNSPHV VKTATQGEVN VTGVIPLTTT 50
GGGGIWVCTP LKLANGTKYR PPAKLLKEQG FFGAIAGFLE GGWEGMIAGW 100
HGYTSHGAHG VAVAADLKST QEAINKITKN LNSLSELETK NSQRTSGAMD 150
EGHRRMKQIE DKIEEILSKI ICSQIELAVL LSNEGIINSE DEHLLALERK 200
LKKMLGPSAV EIGNGCFETK HKCNQTCLDR IAAGTFDAGE FSLPTFDSLN 250
ITAASLNDDG LDNHTILLYY STAASSLAVT LMIAIFVVYM VSRDNVSCSI 300
CL 302
SEQ ID NO: 141: Mal2506-04 B-m2-CL1+5-GCN4b
MKAIIVLLMV VTSNADRICT GITSSNSPHV VKTATQGEVN VTGVIPLTTT 50
GGGGIWVCTP LKLANGTKYR PPAKLLKEQG FFGAIAGFLE GGWEGMIAGW 100
HGYTSHGAHG VAVAADLKST QEAINKITKN LNSLSELETK NSQRTSGAMD 150
EGHRMKQIED KIEEILSKIT ICSQIELAVL LSNEGIINSE DEHLLALERK 200
LKKMLGPSAV EIGNGCFETK HKCNQTCLDR IAAGTFDAGE FSLPTFDSLN 250
ITAASLNDDG LDNHTILLYY STAASSLAVT LMIAIFVVYM VSRDNVSCSI 300
CL 302
SEQ ID NO: 142: Influenza B HA consensus sequence residue 416-436
416 LSELEVKNLQRLSGAMDELHN 436
SEQ ID NO: 144: s-H1-mini2-cluster1+5+6-trim (A/Brisbane/59/2007)
MKVKLLVLLC TFTATYADTI CIGYHANNST DTVDTVLEKN VTVTHSVNLL 50
ENGGGGKYVC SAKLRMVTGL RNIPSIQSQG LFGAIAGFIE GGWTGMVDGW 100
YGYHHQNEQG SGYAADQKST QNAINGITNK VNSVIEKMNT QSTATGKEGN 150
KSEIEAIEKK IEAIEKKIEI WCYNAELLVL LENERTLDFH DSNVKNLYEK 200
VKSQLKNNAK EIGNGCFEFY HKCNDECMES VKNGTYDYPK YSEESKLNRE 250
KIDGVKLESM GVYQIEGRHH HHHHH 275
SEQ ID NO: 145: s-H1-mini2-cluster1+5+6-GCN4 (A/Brisbane/59/2007)
MKVKLLVLLC TFTATYADTI CIGYHANNST DTVDTVLEKN VTVTHSVNLL 50
ENGGGGKYVC SAKLRMVTGL RNIPSIQSQG LFGAIAGFIE GGWTGMVDGW 100
YGYHHQNEQG SGYAADQKST QNAINGITNK VNSVIEKMNT QSTATGKEGN 150
KSERMKQIED KIEEIESKQI WCYNAELLVL LENERTLDFH DSNVKNLYEK 200
VKSQLKNNAK EIGNGCFEFY HKCNDECMES VKNGTYDYPK YSEESKLNRE 250
KIDGVKLESM GVYQIEGRHH HHHHH 275
SEQ ID NO: 146: s-H1-mini2-cluster1+5+6 (A/Brisbane/59/2007)
MKVKLLVLLC TFTATYADTI CIGYHANNST DTVDTVLEKN VTVTHSVNLL 50
ENGGGGKYVC SAKLRMVTGL RNIPSIQSQG LFGAIAGFIE GGWTGMVDGW 100
YGYHHQNEQG SGYAADQKST QNAINGITNK VNSVIEKMNT QSTATGKEGN 150
KSERRMENLN KKVDDGFIDI WCYNAELLVL LENERTLDFH DSNVKNLYEK 200
40 VKSQLKNNAK EIGNGCFEFY HKCNDECMES VKNGTYDYPK YSEESKLNRE 250
KIDGVKLESM GVYQIEGRHH HHHHH 275
SEQ ID NO: 147: s-H1-mini2-cluster11+5+6 (A/Brisbane/59/2007)
MKVKLLVLLC TFTATYADTI CIGYHANNST DTVDTVLEKN VTVTHSVNLL 50
45 ENGGGGKYVC SAKLRMVTGL RNIPSIQSQG LFGAIAGFIE GGWTGMVDGW 100
YGYHHQNEQG SGYAADQKST QNAINGITNK VNSVIEKMNT QSTATGKEGN 150
KSERRIENLN KKIDDGFIDI WCYNAELLVL LENERTLDFH DSNVKNLYEK 200
VKSQLKNNAK EIGNGCFEFY HKCNDECMES VKNGTYDYPK YSEESKLNRE 250
KIDGVKLESM GVYQIEGRHH HHHHH 275
SEQ ID NO: 148: s-H1-mini2-cluster1+5 (A/Brisbane/59/2007)
MKVKLLVLLC TFTATYADTI CIGYHANNST DTVDTVLEKN VTVTHSVNLL 50
ENGGGGKYVC SAKLRMVTGL RNIPSIQSQG LFGAIAGFIE GGWTGMVDGW 100
YGYHHQNEQG SGYAADQKST QNAINGITNK VNSVIEKMNT QSTATGKEFN 150
KSERRMENLN KKVDDGFIDI WCYNAELLVL LENERTLDFH DSNVKNLYEK 200
VKSQLKNNAK EIGNGCFEFY HKCNDECMES VKNGTYDYPK YSEESKLNRE 250
KIDGVKLESM GVYQIEGRHH HHHHH 275
SEQ ID NO 149: s-H1 Full length R343Q (A/Brisbane/59/2007)
MKVKLLVLLC TFTATYADTI CIGYHANNST DTVDTVLEKN VTVTHSVNLL 50
ENSHNGKLCL LKGIAPLQLG NCSVAGWILG NPECELLISK ESWSYIVEKP 100
NPENGTCYPG HFADYEELRE QLSSVSSFER FEIFPKESSW PNHTVTGVSA 150
SCSHNGESSF YRNLLWLTGK NGLYPNLSKS YANNKEKEVL VLWGVHHPPN 200
IGDQKALYHT ENAYVSVVSS HYSRKFTPEI AKRPKVRDQE GRINYYWTLL 250
EPGDTIIFEA NGNLIAPRYA FALSRGFGSG IINSNAPMDK CDAKCQTPQG 300
AINSSLPFQN VHPVTIGECP KYVRSAKLRM VTGLRNIPSI QSQGLFGAIA 350
GFIEGGWTGM VDGWYGYHHQ NEQGSGYAAD QKSTQNAING ITNKVNSVIE 400
KMNTQFTAVG KEFNKLERRM ENLNKKVDDG FIDIWTYNAE LLVLLENERT 450
LDFHDSNVKN LYEKVKSQLK NNAKEIGNGC FEFYHKCNDE CMESVKNGTY 500
DYPKYSEESK LNREKIDGVK LESMGVYQIE GRHHHHHHH 539
SEQ ID NO: 150: s-H1-mini2-cluster1+5+6-nl (A/Brisbane/59/2007
MKVKLLVLLC TFTATYADTI CIGYHANNST DTVDTVLEKN VTVTHSVNLL 50
ENHNGKKYVC SAKLRMVTGL RNIPSIQSQG LFGAIAGFIE GGWTGMVDGW 100
YGYHHQNEQG SGYAADQKST QNAINGITNK VNSVIEKMNT QSTATGKEGN 150
KSERRMENLN KKVDDGFIDI WCYNAELLVL LENERTLDFH DSNVKNLYEK 200
VKSQLKNNAK EIGNGCFEFY HKCNDECMES VKNGTYDYPK YSEESKLNRE 250
KIDGVKLESM GVYQIEGRHH HHHHH 275
SEQ ID NO: 151: s-H1-mini2-cluster1+5+6-nl2 (A/Brisbane/59/2007)
MKVKLLVLLC TFTATYADTI CIGYHANNST DTVDTVLEKN VTVTHSVNLL 50
ENHNGKYVCS AKLRMVTGLR NIPSIQSQGL FGAIAGFIEG GWTGMVDGWY 100
GYHHQNEQGS GYAADQKSTQ NAINGITNKV NSVIEKMNTQ STATGKEGNK 150
SERRMENLNK KVDDGFIDIW CYNAELLVLL ENERTLDFHD SNVKNLYEKV 200
KSQLKNNAKE IGNGCFEFYH KCNDECMESV KNGTYDYPKY SEESKLNREK 250
IDGVKLESMG VYQIEGRHHH HHHH 274
SEQ ID NO:152 H1mini2a-cl1+5+6_no_linker(HNGK)
MKVKLLVLLCTFTATYADTICIGYHANNSTDTVDTVLEKNVTVTHSVNLL 50
ENHNGKKYVCSAKLRMVTGLRNIPSIQSQGLFGAIAGFIEGGWTGMVDGW 100
YGYHHQNEQGSGYAADQKSTQNAINGITNKVNSVIEKMNTQSTATGKEGN 150
KSERRMENLNKKVDDGFIDIWCYNAELLVLLENERTLDFHDSNVKNLYEK 200
45 VKSQLKNNAKEIGNGCFEFYHKCNDECMESVKNGTYDYPKYSEESKLNRE 250
KIDGVKLESMGVYQILAIYSTVASSLVLLVSLGAISFWMCSNGSLQCRIC 300
I 301
SEQ ID NO:153 H1mini2a-cl1+5+6_no_linker2s
MKVKLLVLLCTFTATYADTICIGYHANNSTDTVDTVLEKNVTVTHSVNLL 50
ENHNGKYVCSAKLRMVTGLRNIPSIQSQGLFGAIAGFIEGGWTGMVDGWY 100
GYHHQNEQGSGYAADQKSTQNAINGITNKVNSVIEKMNTQSTATGKEGNK 150
SERRMENLNKKVDDGFIDIWCYNAELLVLLENERTLDFHDSNVKNLYEKV 200
KSQLKNNAKEIGNGCFEFYHKCNDECMESVKNGTYDYPKYSEESKLNREK 250
IDGVKLESMGVYQILAIYSTVASSLVLLVSLGAISFWMCSNGSLQCRICI 300
SEQ ID NO:154 H1-mini2-cl1+5+6-no_linker2s-GCN4
MKVKLLVLLCTFTATYADTICIGYHANNSTDTVDTVLEKNVTVTHSVNLL 50
ENSHNGKYVCSAKLRMVTGLRNIPSIQSQGLFGAIAGFIEGGWTGMVDGW 100
YGYHHQNEQGSGYAADQKSTQNAINGITNKVNSVIEKMNTQSTATGKEGN 150
KSERMKQIEDKIEEIESKQIWCYNAELLVLLENERTLDFHDSNVKNLYEK 200
VKSQLKNNAKEIGNGCFEFYHKCNDECMESVKNGTYDYPKYSEESKLNRE 250
KIDGVKLESMGVYQILAIYSTVASSLVLLVSLGAISFWMCSNGSLQCRIC 300
I 301
SEQ ID NO:155 H1mini2a-cl1+5+6_no_linker2s-trim3
MKVKLLVLLCTFTATYADTICIGYHANNSTDTVDTVLEKNVTVTHSVNLL 50
ENSHNGKYVCSAKLRMVTGLRNIPSIQSQGLFGAIAGFIEGGWTGMVDGW 100
YGYHHQNEQGSGYAADQKSTQNAINGITNKVNSVIEKMNTQSTATGKEGN 150
KSERRIEAIEKKIEAIEKKIWCYNAELLVLLENERTLDFHDSNVKNLYEK 200
VKSQLKNNAKEIGNGCFEFYHKCNDECMESVKNGTYDYPKYSEESKLNRE 250
KIDGVKLESMGVYQILAIYSTVASSLVLLVSLGAISFWMCSNGSLQCRIC 300
I 301
SEQ ID NO:156 H1mini2a-cl1+5+6-12
MKVKLLVLLCTFTATYADTICIGYHANNSTDTVDTVLEKNVTVTHSVNLL 50
ENGGGGKYVCSAKLRMVTGLRNNPSNQSQGLFGAIAGYIEGGWTGMVDGW 100
YGYHHQNEQGSGYAADQKSTQNAINGITNKVNSVIEKMNTQSTATGKEGN 150
KSERRMENLNKKVDDGFIDIWCYNAELLVLLENERTLDFHDSNVKNLYEK 200
VKSQLKNNAKEIGNGCFEFYHKCNDECMESVKNGTYDYPKYSEESKLNRE 250
KIDGVKLESMGVYQILAIYSTVASSLVLLVSLGAISFWMCSNGSLQCRIC 300
I301
SEQ ID NO:157 H1mini2a-cl1+5+6-12+13
MKVKLLVLLCTFTATYADTICIGYHANNSTDTVDTVLEKNVTVTHSVNLLENGGGGKYVCSAKLR
MVTGLRNNPSNQSQGLFGAIAGYNEGGWTGMVDGWYGYHHQNEQGSGYAADQKSTQNAINGITNK
40 VNSVIEKMNTQSTATGKEGNKSERRMENLNKKVDDGFIDIWCYNAELLVLLENERTLDFHDSNVK
NLYEKVKSQLKNNAKEIGNGCFEFYHKCNDECMESVKNGTYDYPKYSEESKLNREKIDGVKLESM
GVYQILAIYSTVASSLVLLVSLGAISFWMCSNGSLQCRICI
SEQ ID NO:158:H5 FL HA A/Vietnam/1203/2004
(341 RRRKK 345 is deleted and a R346Q mutation is introduced)
MEKIVLLFAIVSLVKSDQICIGYHANNSTEQVDTIMEKNVTVTHAQDILE 50
KKHNGKLCDLDGVKPLILRDCSVAGWLLGNPMCDEFINVPEWSYIVEKAN 100
PVNDLCYPGDFNDYEELKHLLSRINHFEKIQIIPKSSWSSHEASLGVSSA 150
CPYQGKSSFFRNVVWLIKKNSTYPTIKRSYNNTNQEDLLVLWGIHHPNDA 200
AEQTKLYQNPTTYISVGTSTLNQRLVPRIATRSKVNGQSGRMEFFWTILK 250
PNDAINFESNGNFIAPEYAYKIVKKGDSTIMKSELEYGNCNTKCQTPMGA 300
INSSMPFHNIHPLTIGECPKYVKSNRLVLATGLRNSPQRERRRKKRGLFG 350
AIAGFIEGGWQGMVDGWYGYHHSNEQGSGYAADKESTQKAIDGVTNKVNS 400
IIDKMNTQFEAVGREFNNLERRIENLNKKMEDGFLDVWTYNAELLVLMEN 450
ERTLDFHDSNVKNLYDKVRLQLRDNAKELGNGCFEFYHKCDNECMESVRN 500
GTYDYPQYSEEARLKREEISGVKLESIGIYQILSIYSTVASSLALAIMVA 550
GLSLWMCSNGSLQCRICI 568
SEQ ID NO:159:H1 FL HA A/California/04/2009 R343Q
MKAILVVLLYTFATANADTLCIGYHANNSTDTVDTVLEKNVTVTHSVNLL 50
EDKHNGKLCKLRGVAPLHLGKCNIAGWILGNPECESLSTASSWSYIVETP 100
SSDNGTCYPGDFIDYEELREQLSSVSSFERFEIFPKTSSWPNHDSNKGVT 150
AACPHAGAKSFYKNLIWLVKKGNSYPKLSKSYINDKGKEVLVLWGIHHPS 200
TSADQQSLYQNADTYVFVGSSRYSKKFKPEIAIRPKVRDQEGRMNYYWTL 250
VEPGDKITFEATGNLVVPRYAFAMERNAGSGIIISDTPVHDCNTTCQTPK 300
GAINTSLPFQNIHPITIGKCPKYVKSTKLRLATGLRNIPSIQSRGLFGAI 350
AGFIEGGWTGMVDGWYGYHHQNEQGSGYAADLKSTQNAIDEITNKVNSVI 400
EKMNTQFTAVGKEFNHLEKRIENLNKKVDDGFLDIWTYNAELLVLLENER 450
TLDYHDSNVKNLYEKVRSQLKNNAKEIGNGCFEFYHKCDNTCMESVKNGT 500
YDYPKYSEEAKLNREEIDGVKLESTRIYQILAIYSTVASSLVLVVSLGAI 550
SFWMCSNGSLQCRICI 566
SEQ ID NO:160:H1mini-HAA/California/07/2009
MKAILVVLLYTFATANADTLCIGYHANNSTDTVDTVLEKNVTVTHSVNLL 50
EDGGGGKYVCSTKLRLATGLRNIPSIQSQGLFGAIAGFIEGGWTGMVDGW 100
YGYHHQNEQGSGYAADLKSTQNAIDEITNKVNSVIEKMNTQSTATGKEGN 150
HSERMKQIEDKIEEIESKQIWCYNAELLVLLENERTLDYHDSNVKNLYEK 200
VRSQLKNNAKEIGNGCFEFYHKCDNTCMESVKNGTYDYPKYSEEAKLNRE 250
EIDGVKLESTRIYQILAIYSTVASSLVLVVSLGAISFWMCSNGSLQCRIC 300
I30 1
SEQ ID NO:161:H1mini-HAA/PuertoRico/8/1934
MKANLLVLLCALAAADADTICIGYHANNSTDTVDTVLEKNVTVTHSVNLL50
EDGGGGKYVCSAKLRMVTGLRNIPSIQSQGLFGAIAGFIEGGWTGMIDGW 100
YGYHHQNEQGSGYAADQKSTQNAINGITNKVNTVIEKMNTQSTATGKEGN 150
45 KSERMKQIEDKIEEIESKQIWCYNAELLVLLENERTLDFHDSNVKNLYEK 200
VKSQLKNNAKEIGNGCFEFYHKCDNECMESVRNGTYDYPKYSEESKLNRE 250
KVDGVKLESMGIYQILAIYSTVASSLVLLVSLGAISFWMCSNGSLQCRIC 300
I 301
SEQ ID NO:162:H1mini-HAA/Texas/36/1991
MKAKLLVLLCAFTATYADTICIGYHANNSTDTVDTVLEKNVTVTHSVNLL 50
EDGGGGKYVCSTKLRMVTGLRNIPSIQSQGLFGAIAGFIEGGWTGMIDGW 100
YGYHHQNEQGSGYAADQKSTQNAINGITNKVNSVIEKMNTQSTATGKEGN 150
KSERMKQIEDKIEEIESKQIWCYNAELLVLLENGRTLDFHDSNVKNLYEK 200
VKSQLKNNAKEIGNGCFEFYHKCNNECMESVKNGTYDYPKYSEESKLNRG 250
KIDGVKLESMGVYQILAIYSTVASSLVLLVSLGAISFWMCSNGSLQCRIC 300
I301
SEQ ID NO:163:H5mini-HAA/Vietnam/1203/2004
MEKIVLLFAIVSLVKSDQICIGYHANNSTEQVDTIMEKNVTVTHAQDILE 50
KGGGGKYVCSNRLVLATGLRNSPQRESQGLFGAIAGFIEGGWQGMVDGWY 100
GYHHSNEQGSGYAADKESTQKAIDGVTNKVNSIIDKMNTQSEATGREGNN 150
SERMKQIEDKIEEIESKQIWCYNAELLVLMENERTLDFHDSNVKNLYDKV 200
RLQLRDNAKELGNGCFEFYHKCDNECMESVRNGTYDYPQYSEEARLKREE 250
ISGVKLESIGIYQILSIYSTVASSLALAIMVAGLSLWMCSNGSLQCRICI 300
SEQ ID NO:164: mHA_H1N1_A_Maryland_12_1991
MKAILLVLLYTFTAANADTLCIGYHANNSTDTVDTVLEKNVTVTHSVNLLEDGGGGKYVC
STKLRMATGLRNIPSIQSQGLFGAIAGFIEGGWTGMIDGWYGYHHQNEQGSGYAADQKST
QNAIDGITNKVNSVIEKMNTQSTATGKEGNHSERMKQIEDKIEEIESKQVWCYNAELLVL
LENERTLDYHDSNVKNLYEKVRSQLKNNAKEIGNGCFEFYHKCDDTCMESVKNGTYDYPK
YSEESKLNREEIDGVKLESTRIYQILAIYSTVASSLVLLVSLGAISFWMCSNGSLQCRIC
I*
SEQ ID NO:165: mHA_H1N1_A_Henry_1936
MKARLLVLLCALAATDADTICIGYHANNSTDTVDTVLEKNVTVTHSVNLLEDGGGGKYVC
SAKLRMVTGLRNIPSIQSQGLFGAIAGFIEGGWTGMIDGWYGYHHQNEQGSGYAADQKST
QNAINGITNKVNSVIEKMNTQSTATGKEGNNSERMKQIEDKIEEIESKQIWCYNAELLVL
LENERTLDFHDSNVKNLYEKVKSQLKNNAKEIGNGCFEFYHKCDNECMESVRNGTYDYPK
YSEESKLNREKIDGVKLESMGVYQILAIYSTVASSLVLLVSLGAISFWMCSNGSLQCRIC
SEQ ID NO:166: mHA_H1N1 A/AA/Marton/1943
MKARLLVLLCALAATDADTICIGYHANNSTDTVDTVLEKNVTVTHSVNLLEDGGGGKYVC
STKLRMVTGLRNIPSIQSQGLFGAIAGFIEGGWTGMIDGWYGYHHQNEQGSGYAADQKST
QNAINGITNKVNSVIEKMNTQSTATGKEGNNSERMKQIEDKIEEIESKDIWCYNAELLVL
LENERTLDFHDSNVKNLYEKVKNQLRNNAKEIGNGCFEFYHKCNNECMESVKNGTYDYPK
40 YSEESKLNREKIDGVKLESMGVYQILAIYSTVASSLVLLVSLGAISFWMCSNGSLQCRIC
SEQ_ID_NO:_167:_mHA_H1N1_A_New_York_607_1995
MKAKLLVLLCAFTATYADTICIGYHANNSTDTVDTVLEKNVTVTHSVNLLEDGGGGKYVC
45 STKLRMVTGLRNIPSIQSQGLFGAIAGFIEGGWTGMIDGWYGYHHQNEQGSGYAADQKST
QNAIDGITNKVNSVIEKMNTQSTATGKEGNKSERMKQIEDKIEEIESKQIWCYNAELLVL
LENERTLDFHDSNVKNLYEKVKTQLKNNAKEIGNGCFEFYHKCNNECMESVKNGTYDYPK
YSEESKLNREKIDGVKLESMGVYQILAIYSTVASSLVLLVSLGAISFWMCSNGSLQCRIC
SEQ_ID_NO:_168: mHA_H1N1_A_New_Jersey_11_2007
1 MKARLLVLLCALAATDADTICIGYHANNSTDTVDTVLEKNVTVTHSVNLLEDGGGGKYVC
61 SAKLRMVTGLRNIPSIQSQGLFGAIAGFIEGGWTGMVDGWYGYHHQNEQGSGYAADQKST
121 QNAINGITNKVNSVIEKMNTQSTATGKEGNKSERMKQIEDKIEEIESKQIWCYNAELLVL
181 LENERTLDFHDSNVKNLYEKVKSQLKNNAKEIGNGCFEFYHKCNDECMESVKNGTYDYPK
241 YSEESKLNREKIDGVKLESMGVYQILAIYSTVASSLVLLVSLGAISFWMCSNGSLQCRIC
301 I*
SEQ_ID_NO:_169: mHA_H1N1_A_USSR_92_1977
1 MKAKLLVLLCALSATDADTICIGYHANNSTDTVDTVLEKNVTVTHSVNLLEDGGGGKYVC
61 STKLRMVTGLRNIPSIQSQGLFGAIAGFIEGGWTGMIDGWYGYHHQNEQGSGYAADQKST
121 QNAINGITNKVNSVIEKMNTQSTATGKEGNKSERMKQIEDKIEEIESKQIWCYNAELLVL
181 LENERTLDFHDSNVKNLYEKVKSQLKNNAKEIGNGCFEFYHKCNNECMESVKNGTYDYPK
241 YSEESKLNREKIDGVKLESMGVYQILAIYSTVASSLVLLVSLGAISFWMCSNGSLQCRIC
301 I*
SEQ_ID_NO:_170: mHA_H1N1_A_New_York_629_1995
1 MKVKLLVLLCAFTATYADTICIGYHANNSTDTVDTVLEKNVTVTHSVNLLEDGGGGKYVC
61 STKLRMVTGLRNIPSIQSQGLFGAIAGFIEGGWTGMIDGWYGYHHQNEQGSGYAADQKST
121 QNAIDGITNKVNSVIEKMNTQSTATGKEGNKSERMKQIEDKIEEIESKQIWCYNAELLVL
181 LENERTLDFHDSNVKNLYEKVKNQLKNNAKEIGNGCFEFYHKCNNECMESVKNGTYDYPK
241 YSEESKLNREKIDGVKLESMGVYQILAIYSTVASSLVLLVSLGAISFWMCSNGSLQCRIC
301 I*
SEQ_ID_NO:_171: mHA_H1N1_A_Virginia_UR06-0549_2007
1MKVKLLVLLCTFTATYADTICIGYHANNSTDTVDTVLEKNVTVTHSVNLLEDGGGGKYVC
61SAKLRMVTGLRNIPSIQSQGLFGAIAGFIEGGWTGMVDGWYGYHHQNEQGSGYAADQKST
121QNAINGITNKVNSVIEKMNTQSTATGKEGNKSERMKQIEDKIEEIESKQIWCYNAELLVL
181LENERTLDFHDSNVKNLYEKVKSQLKNNAKEIGNGCFEFYHKCNDECMESVKNGTYDYPK
241YSEESKLNREKIDGVKLESMGVYQILAIYSTVASSLVLLVSLGAISFWMCSNGSLQCRIC
301I*
SEQ_ID_NO:_172:_mHA_H1N1_A_Texas_UR0-0526_2007
1 MKVKLLVLLCTFTATYADTICIGYHANNSTDTVDTVLEKNVTVTHSVNLLEDGGGGKYVC
61 SAKLRMVTGLRNIPSIQSQGLFGAIAGFIEGGWTGMVDGWYGYHHQNEQGSGYAADQKST
121 QNAINGITNKVNSVIEKMNTQSTATGKEGNKSERMKQIEDKIEEIESKQIWCYNAELLVL
181 LENERTLDFHDSNVKNLYEKVKNQLKNNAKEIGNGCFEFYHKCNDECMESVKNGTYDYPK
241 YSEESKLNREKIDGVKLESMGVYQILAIYSTVASSLVLLISLGAISFWMCSNGSLQCRIC
40 301 I*
SEQ_ID_NO:_173:_mHA_H1N1_A_Sydney_DD3-55_2010
1 MKAILVVLLYTFATANADTLCIGYHANNSTDTVDTVLEKNVTVTHSVNLLEDGGGGKYVC
61 STKLRLATGLRNVPSIQSQGLFGAIAGFIEGGWTGMVDGWYGYHHQNEQGSGYAADLKST
45 121 QNAIDEITNKVNSVIEKMNTQSTATGKEGNHSERMKQIEDKIEEIESKQIWCYNAELLVL
181 LENERTLDYHDSNVKNLYEKVRSQLKNNAKEIGNGCFEFYHKCDNTCMESVKNGTYDYPK
241 YSEEAKLNREEIDGVKLESTRIYQILAIYSTVASSLVLVVSLGAISFWMCSNGSLQCRIC
301 I*
SEQ_ID_NO:_174 H3mini2a-linker+cl9_+10+11+12+GCN4T_CG7-1
(A/HongKong/1/1968(H3N2)
1 MKTIIALSYIFCLALGQDLPGNDNSTATLCLGHHAVPNGTLVKTITDDQIEVTNATELVQ
61 SGGGGKYVCQNTLKLATGMRNVPEKQTQGLFGAIAGFIENGWEGMIDGWYGFRHQNSEGT
121 GQAADLKSTQAAIDQINGKLNRVREKTNEKSHQTEKESSNATGRMKQIEDKIEEIESKLW
181 CYNAELLVALENQHTIDLTDSEMNKLFEKTRRQLRENAEDMGNGCFKIYHKCDNACIESI
241 RNGTYDHDVYRDEALNNRFQIKGVELKSGYKDWILWISFAISCFLLCVVLLGFIMWACQR
301 GNIRCNICI
SEQ_ID_NO:_175 H3mini2a-linker+cl9_+10+12+18+GCN4T
(A/HongKong/1/1968(H3N2))
1 MKTIIALSYIFCLALGQDLPGNDNSTATLCLGHHAVPNGTLVKTITDDQIEVTNATELVQ
61 SGGGGKYVCQNTLKLATGMRNVPEKQTQGLFGAIAGFIENGWEGMIDGWYGFRHQNSEGT
121 GQAADLKSTQAAIDQINGKLNRVIEKTNEKSHQTEKESSEGEGNATGGCCGGRMKQIEDK
181 IEEIESKLWCYNAELLVALENQHTIDLTDSEMNKLFEKTRRQLRENAEDMGNGCFKIYHK
241 CDNACIESIRNGTYDHDVYRDEALNNRFQIKGVELKSGYKDWILWISFAISCFLLCVVLL
301 GFIMWACQRGNIRCNICI
SEQ_ID_NO:_176 H3mini2a-linker+cl9_+10+12+16+CG7-GCN4T
(A/HongKong/1/1968(H3N2))]
1 MKTIIALSYIFCLALGQDLPGNDNSTATLCLGHHAVPNGTLVKTITDDQIEVCNATELVQ
61 SGGGGKYVCQNTLKLATCMRNVPEKQTQGLFGAIAGFIENGWEGMIDGWYGFRHQNSEGT
121 GQAADLKSTQAAIDQINGKLNRVIEKTNEKSHQTEKESSNATGRMKQIEDKIEEIESKLW
181 CYNAELLVALENQHTIDLTDSEMNKLFEKTRRQLRENAEDMGNGCFKIYHKCDNACIESI
241 RNGTYDHDVYRDEALNNRFQIKGVELKSGYKDWILWISFAISCFLLCVVLLGFIMWACQR
301 GNIRCNICI
SEQ_ID_NO:_177H3mini2a-linker+cl9_+10+12+19+GCN4T
(A/HongKong/1/1968(H3N2))]
1 MKTIIALSYIFCLALGQDLPGNDNSTATLCLGHHAVPNGTLVKTITDDQIEVTNATELVQ
61 SGGGGKYVCQNTLKLATGMRNVPEKQTQGLFGAIAGFIENGWEGMIDGWYGFRHQNSEGT
121 GQAADLKSTQAAIDQINGKLNRVIEKTNEKSHQTEKESSEGEGSGSGGCCGGRMKQIEDK
181 IEEIESKLWCYNAELLVALENQHTIDLTDSEMNKLFEKTRRQLRENAEDMGNGCFKIYHK
241 CDNACIESIRNGTYDHDVYRDEALNNRFQIKGVELKSGYKDWILWISFAISCFLLCVVLL
301 GFIMWACQRGNIRCNICI
SEQ_ID_NO:_178H3mini2a-linker+cl9_+10+12+17+CG7-GCN4T
40 (A/HongKong/1/1968(H3N2))]
1 MKTIIALSYIFCLALGQDLPGNDNSTATLCLGHHAVPNCTLVKTITDDQICVTNATELVQ
61 SGGGGKYVCQNTLKLATGMRNVPEKQTQGLFGAIAGFIENGWEGMIDGWYGFRHQNSEGT
121 GQAADLKSTQAAIDQINGKLNRVIEKTNEKSHQTEKESSNATGRMKQIEDKIEEIESKLW
181 CYNAELLVALENQHTIDLTDSEMNKLFEKTRRQLRENAEDMGNGCFKIYHKCDNACIESI
45 241 RNGTYDHDVYRDEALNNRFQIKGVELKSGYKDWILWISFAISCFLLCVVLLGFIMWACQR
301 GNIRCNICI
SEQ_ID_NO:_179 H3_HK68_mini2a-linker2+cl9_+10+12+GCN4T
1 LATMKTIIALSYIFCLALGQDLPGNDNSTATLCLGHHAVPNGTLVKTITDDQIEVTNATE
61 LVQSGSGSGGKYVCQNTLKLATGMRNVPEKQTQGLFGAIAGFIENGWEGMIDGWYGFRHQ
121 NSEGTGQAADLKSTQAAIDQINGKLNRVIEKTNEKSHQTEKESSEGEGRMKQIEDKIEEI
181 ESKLWCYNAELLVALENQHTIDLTDSEMNKLFEKTRRQLRENAEDMGNGCFKIYHKCDNA
241 CIESIRNGTYDHDVYRDEALNNRFQIKGVELKSGYKDWILWISFAISCFLLCVVLLGFIM
301 WACQRGNIRCNICI**
SEQ_ID_NO:_180 H1-mini2-cluster1+5+6+GCN4-T49N
MKVKLLVLLCTFTATYADTICIGYHANNSTDTVDTVLEKNVTVTHSVNLLENGGGGKYVCSAKLR
MVTGLRNIPSIQSQGLFGAIAGFIEGGWTGMVDGWYGYHHQNEQGSGYAADQKSTQNAINGINNK
VNSVIEKMNTQSTATGKEGNKSERMKQIEDKIEEIESKQIWCYNAELLVLLENERTLDFHDSNVK
NLYEKVKSQLKNNAKEIGNGCFEFYHKCNDECMESVKNGTYDYPKYSEESKLNREKIDGVKLESM
GVYQILAIYSTVASSLVLLVSLGAISFWMCSNGSLQCRICI
SEQ ID NO: 181 sH1-mini2-cl1+5+6-GCN4-Bromelain
MKVKLLVLLCTFTATYADTICIGYHANNSTDTVDTVLEKNVTVTHSVNLLENGGGGKYVCSAKLR
MVTGLRNIPSIQSQGLFGAIAGFIEGGWTGMVDGWYGYHHQNEQGSGYAADQKSTQNAINGITNK
VNSVIEKMNTQSTATGKEGNKSERMKQIEDKIEEIESKQIWCYNAELLVLLENERTLDFHDSNVK
NLYEKVKSQLKNNAKEIGNGCFEFYHKCNDECMESVKNGTYDYPKYSEESKLNREKIDGRSLVPR
GSPGHHHHHH
SEQ ID NO: 182 sH1-mini2-cl1+5+6-GCN4-Bromelain-Foldon
MKVKLLVLLCTFTATYADTICIGYHANNSTDTVDTVLEKNVTVTHSVNLLENGGGGKYVCSAKLR
MVTGLRNIPSIQSQGLFGAIAGFIEGGWTGMVDGWYGYHHQNEQGSGYAADQKSTQNAINGITNK
VNSVIEKMNTQSTATGKEGNKSERMKQIEDKIEEIESKQIWCYNAELLVLLENERTLDFHDSNVK
NLYEKVKSQLKNNAKEIGNGCFEFYHKCNDECMESVKNGTYDYPKYSEESKLNREKIDGRSLVPR
GSPGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGHHHHHH
SEQ ID NO: 183 sH1-mini2-cl1+5+6-GCN4t2
MKVKLLVLLCTFTATYADTICIGYHANNSTDTVDTVLEKNVTVTHSVNLLENGGGGKYVCSAKLR
MVTGLRNIPSIQSQGLFGAIAGFIEGGWTGMVDGWYGYHHQNEQGSGYAADQKSTQNAINGITNK
VNSVIEKMNTQSTATGKEGNKSERRMKQIEDKIEEIESKIWCYNAELLVLLENERTLDFHDSNVK
NLYEKVKSQLKNNAKEIGNGCFEFYHKCNDECMESVKNGTYDYPKYSEESKLNREKIDGVKLESM
GVYQIEGRHHHHHHH
SEQ ID NO: 184 sH1-mini2-cl1+5+6-GCN4t2-Bromelain
MKVKLLVLLCTFTATYADTICIGYHANNSTDTVDTVLEKNVTVTHSVNLLENGGGGKYVCSAKLR
MVTGLRNIPSIQSQGLFGAIAGFIEGGWTGMVDGWYGYHHQNEQGSGYAADQKSTQNAINGITNK
40 VNSVIEKMNTQSTATGKEGNKSERRMKQIEDKIEEIESKIWCYNAELLVLLENERTLDFHDSNVK
NLYEKVKSQLKNNAKEIGNGCFEFYHKCNDECMESVKNGTYDYPKYSEESKLNREKIDGRSLVPR
GSPGHHHHHH
SEQ ID NO: 185 sH1-mini2-cl1+5+6-GCN4t2-Bromelain-Foldon
45 MKVKLLVLLCTFTATYADTICIGYHANNSTDTVDTVLEKNVTVTHSVNLLENGGGGKYVCSAKLR
MVTGLRNIPSIQSQGLFGAIAGFIEGGWTGMVDGWYGYHHQNEQGSGYAADQKSTQNAINGITNK
VNSVIEKMNTQSTATGKEGNKSERRMKQIEDKIEEIESKIWCYNAELLVLLENERTLDFHDSNVK
NLYEKVKSQLKNNAKEIGNGCFEFYHKCNDECMESVKNGTYDYPKYSEESKLNREKIDGRSLVPR
GSPGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGHHHHHH
SEQ ID NO: 186 sH3 HK mini2a-linker+cl9 +10+11+12+GCN4T-CG7-His
MKTIIALSYIFCLALGQDLPGNDNSTATLCLGHHAVPNGTLVKTITDDQIEVTNATELVQSGGGG
KYVCQNTLKLATGMRNVPEKQTQGLFGAIAGFIENGWEGMIDGWYGFRHQNSEGTGQAADLKSTQ
AAIDQINGKLNRVREKTNEKSHQTEKESSNATGRMKQIEDKIEEIESKLWCYNAELLVALENQHT
IDLTDSEMNKLFEKTRRQLRENAEDMGNGCFKIYHKCDNACIESIRNGTYDHDVYRDEALNNRFQ
IKGRSLVPRGSPGHHHHHH
SEQ ID NO: 187 sH3 HK mini2a-linker+cl9 +10+11+12+GCN4T-CG7-
Foldon-His
MKTIIALSYIFCLALGQDLPGNDNSTATLCLGHHAVPNGTLVKTITDDQIEVTNATELVQSGGGG
KYVCQNTLKLATGMRNVPEKQTQGLFGAIAGFIENGWEGMIDGWYGFRHQNSEGTGQAADLKSTQ
AAIDQINGKLNRVREKTNEKSHQTEKESSNATGRMKQIEDKIEEIESKLWCYNAELLVALENQHT
IDLTDSEMNKLFEKTRRQLRENAEDMGNGCFKIYHKCDNACIESIRNGTYDHDVYRDEALNNRFQ
IKGRSLVPRGSPGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGHHHHHH
Applications Claiming Priority (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161564198P | 2011-11-28 | 2011-11-28 | |
US201161564086P | 2011-11-28 | 2011-11-28 | |
EP11191009.7 | 2011-11-28 | ||
US61/564,198 | 2011-11-28 | ||
EP11191003.0 | 2011-11-28 | ||
US61/564,086 | 2011-11-28 | ||
EP11191003 | 2011-11-28 | ||
EP11191009 | 2011-11-28 | ||
EP12166268.8 | 2012-05-01 | ||
EP12166268 | 2012-05-01 | ||
US201261720281P | 2012-10-30 | 2012-10-30 | |
US61/720,281 | 2012-10-30 | ||
PCT/EP2012/073706 WO2013079473A1 (en) | 2011-11-28 | 2012-11-27 | Influenza virus vaccines and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ625973A NZ625973A (en) | 2016-09-30 |
NZ625973B2 true NZ625973B2 (en) | 2017-01-05 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9969778B2 (en) | Influenza virus vaccines and uses thereof | |
US10328144B2 (en) | Influenza virus vaccines and uses thereof | |
EP3166963B1 (en) | Influenza virus vaccines and uses thereof | |
US10517941B2 (en) | Influenza virus vaccines and uses thereof | |
JP2018052953A (en) | Influenza vaccines and uses thereof | |
NZ625973B2 (en) | Influenza virus vaccines and uses thereof | |
NZ715583B2 (en) | Influenza virus vaccines and uses thereof |